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1 CHAPTER	  1:	  INTRODUCTION	  
	  
1.1 GENERAL	  INTRODUCTION	  	  
1.1.1 Discovery	  of	  respiratory	  syncytial	  virus	  
Acute	   respiratory	   tract	   disease	   is	   the	   leading	   cause	   of	   infectious	   disease	  mortality	   worldwide,	   and	   human	   respiratory	   syncytial	   virus	   (HRSV)	   is	  recognised	  as	  the	  primary	  viral	  agent	  in	  young	  children.	  	  In	  recent	  years,	  there	  has	  been	  increased	  focus	  on	  HRSV	  morbidity	  and	  mortality	   in	  other	  high-­‐risk	  groups,	  including	  the	  elderly	  and	  the	  immunocompromised.	  	  	  	   In	   1956,	   a	   previously	   unidentified	   virus	   was	   isolated	   from	   infants	  suffering	   from	   croup	   (or	   larynogotracheobronchitis).	   	   It	   caused	   an	   unusual	  ‘sponge-­‐like’	   cytopathic	   effect	   in	  monkey	  kidney	   tissue	   culture	   and	  was	   later	  found	   to	   be	   indistinguishable	   from	   a	   virus	   named	   chimpanzee	   coryza	   agent,	  (CCA)	   recovered	   from	   chimpanzees	   appearing	   to	   show	   symptoms	   of	   the	  ‘common	  cold’	  (rhinitis,	  coughing)	  (Chanock	  et	  al.,	  1957,	  Chanock	  and	  Finberg,	  1957).	   	  The	  virus	  was	  renamed	  respiratory	  syncytial	  virus	  (RSV)	  and	  its	  high	  prevalence	   in	   infants	  was	   realised	   soon	  after.	   	   Several	   closely	   related	   animal	  species,	   including	   bovine,	   ovine,	   and	   caprine	   RSV,	   were	   also	   discovered	   and	  they	  are	  of	  considerable	  concern	  to	  the	  livestock	  industry.	  	  As	  only	  human	  RSV	  is	  studied	  in	  this	  thesis,	  the	  acronym	  ‘RSV’	  shall	  refer	  to	  the	  human	  virus	  unless	  stated	  otherwise.	  	  	  	  	  	  
1.1.2 Classification	  
RSV	   is	   a	   member	   of	   the	   subfamily	   Pneumovirinae	   in	   the	   family	  
Paramyxoviridae,	  order	  Mononegavirales	  –	  the	  non-­‐segmented	  negative	  strand	  RNA	  viruses	  (ICTV,	  2012).	  	  This	  order	  contains	  a	  number	  of	  high	  profile	  human	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pathogens	  including	  Ebola	  and	  Marburg	  viruses	  (family	  Filoviridae),	  and	  rabies	  virus	  (family	  Rhabdoviridae).	   	  The	  family	  Paramyxoviridae	   is	  divided	  into	  two	  subfamilies:	   the	   subfamily	   Paramyxovirinae,	   featuring	   measles	   and	   mumps	  viruses,	   and	   the	   highly	   pathogenic	   Nipah	   and	   Hendra	   viruses;	   the	   subfamily	  
Pneumovirinae,	   which	   is	   further	   divided	   into	   the	   genus	   Pneumovirus,	  containing	   the	   respiratory	   syncytial	   viruses	   and	   murine	   pneumonia	   virus	  (MPV),	   and	   the	   genus	   Metapneumovirus,	   containing	   human	   and	   avian	  metapneumoviruses	  (HMPV,	  AMPV).	  The	   paramyxoviruses	   are	   a	   family	   of	   enveloped	   viruses	   with	   a	   well-­‐conserved	   gene	   order	   and	   replication	   cycle.	   	   They	   are	   defined	   by	   their	  expression	  of	  a	   fusion	  protein	  on	  the	  virion	  surface,	   their	  pleomorphic	  virion	  morphology,	   ranging	   from	   150	   to	   300	   nm	   in	   diameter,	   and	   they	   contain	  helically	   symmetric	   nucleocapsids	   comprised	   of	   a	   monopartite,	   single-­‐stranded,	  negative-­‐sense	  RNA	  genome	  and	  a	  polymerase	  complex	  featuring	  the	  RNA-­‐dependent	   RNA-­‐polymerase	   (RdRp)	   and	   its	   co-­‐factors.	   	   The	   size	   and	  shape	   of	   these	   nucleocapsids	   is	   considered	   a	   distinguishing	   feature	   of	   the	  family	   Paramyxoviridae	   subfamilies;	   the	   pneumoviruses	   have	   narrower	  nucleocapsids	  than	  the	  paramyxoviruses	  (Collins,	  2007).	   	  The	  pneumoviruses	  also	  lack	  the	  enhanced	  coding	  capacity	  of	  the	  P	  gene,	  through	  RNA	  editing	  and	  alternative	   translation	   initiation	   codons,	   that	   is	   common	   to	   the	  paramyxoviruses	   –	   with	   the	   exception	   of	   murine	   pneumonia	   virus	   (MPV),	  which	   has	   a	   second	   P	   open	   reading	   frame	   (ORF).	   	   The	   nature	   of	   the	   surface	  proteins	   is	   characteristic	   of	   each	   genus	   within	   the	   family	   Paramyxoviridae,	  with	   the	   subfamily	   Pneumovirinae	   (e.g.	   RSV	   and	   HMPV)	   lacking	   both	   the	  haemagglutinin	   and	   neuraminidase	   activities	   that	   are	   attributed	   in	   various	  combinations	   to	   other	   genera,	   expressing	   instead	   a	   glycoprotein,	   G.	   	   The	  classification	   of	   RSV	   in	   a	   separate	   genus	   (Pneumovirus)	   from	   the	  metapneumoviruses	   is	   due	   to	   the	   presence	   of	   additional	   genes	   and	   slight	  differences	  in	  genome	  organisation.	  RSV	  has	  one	  serotype	  containing	  two	  antigenically	  distinct	  subgroups,	  A	  and	   B,	   which	   share	   88	   %	   amino	   acid	   identity	   (Biacchesi	   et	   al.,	   2003).	   	   The	  majority	   of	   variation	   occurs	   within	   the	   viral	   envelope	   glycoproteins,	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particularly	  the	  attachment	  glycoprotein	  (G),	  which	  can	  vary	  by	  up	  to	  45	  %	  at	  the	  amino	  acid	  level	  between	  the	  two	  subgroups	  (Meyer	  et	  al.,	  2008).	  	  Much	  of	  our	   understanding	   of	   RSV	   molecular	   biology	   is	   based	   on	   the	   archetypal	  paramyxovirus	   Sendai	   virus	   (SeV)	   (subfamily	   Paramyxovirinae)	   and	   the	  rhabdovirus	  vesicular	  stomatitis	  virus	   (VSV),	  as	   these	  were	  easily	  adapted	   to	  tissue	   culture	   and	   grown	   to	   high	   titres.	   	   Despite	   the	   high	   conservation	   of	  genome	  organisation,	  the	  RSV	  genome	  contains	  a	  number	  of	  genes	  not	  found	  in	  these	   model	   viruses:	   non-­‐structural	   proteins	   1	   and	   2	   (NS1,	   NS2),	   small	  hydrophobic	   protein	   (SH),	   and	   the	  M2	   gene	  which	   expresses	   both	  M2-­‐1	   and	  M2-­‐2	  proteins.	  	  It	  also	  appears	  that	  the	  viral	  replication	  cycle	  is	  more	  complex	  for	  RSV,	  featuring	  overlapping	  genes	  (M2/L)	  and	  multiple	  open	  reading	  frames	  (M2-­‐1/M2-­‐2).	  Paramyxoviruses	   share	   some	   similarities	   with	   the	   family	  
Orthomyxoviridae,	  especially	  influenza	  A	  virus	  (IAV),	  who	  also	  express	  surface	  proteins	   characterised	   by	   haemagglutinin	   and	   neuraminidase	   activity.	   	   The	  requirement	  for	  a	  ribonucleocapsid	  as	  the	  template	  for	  viral	  transcription	  and	  replication	   is	  also	  a	   commonality	  between	   these	   two	   families,	  however	   there	  are	   many	   fundamental	   differences	   that	   have	   resulted	   in	   their	   separate	  classification:	   monopartite	   vs.	   segmented,	   cellular	   (paramyxo)	   vs.	   nuclear	  (orthomyxo)	  transcription	  and	  replication.	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1.1.3 Epidemiology	  
The	  most	  recent	   figures	  from	  the	  World	  Health	  Organization	  (2009)	  estimate	  that	  RSV	  infects	  64	  million	  people	  each	  year,	  killing	  160,000,	  although	  with	  95	  %	   of	   these	   cases	   occurring	   in	   developing	   countries	   these	   figures	   may	  underestimate	   the	   true	  burden	  of	  disease.	   	   In	  Europe,	  RSV	   infection	  accounts	  for	   42-­‐45	   %	   of	   hospital	   admissions	   for	   lower	   respiratory	   tract	   infection	   in	  children	  <2	  years	  of	  age,	  and	  in	  the	  USA	  in	  2005,	  2.1	  million	  children	  <5	  years	  of	  age	  required	  medical	  attention	  because	  of	  RSV	  infection	  (Hall	  et	  al.,	  2009).	  	  Consequently,	  whilst	  RSV-­‐associated	  mortality	   is	  relatively	   low,	   the	  economic	  burden	  of	  this	  virus	  is	  substantial.	  The	  majority	  of	   children	  are	   infected	  within	   the	   first	  6	  months	  of	   life,	  and	   virtually	   all	   have	   been	   infected	   with	   RSV	   by	   the	   age	   of	   2.	   	   Multiple	  infections	  throughout	  childhood,	  without	  antigenic	  variation	  by	  the	  virus,	  are	  commonplace	   despite	   there	   being	   only	   one	   serotype,	   due	   to	   inadequate	   and	  short-­‐lived	   protective	   immunity	   by	   neutralising	   antibodies,	   compounded	   by	  the	   high	   levels	   of	   exposure	   in	   schools	   and	   nurseries	   (Collins	   and	   Graham,	  2008).	  	  In	  the	  UK	  and	  other	  temperate	  countries,	  RSV	  epidemics	  occur	  annually	  and	  show	  predictable	  seasonality	  between	  October	  and	  April	   (Goddard	  et	  al.,	  2007).	   	   Both	   subgroups	   of	   the	   virus	   can	   co-­‐circulate	   during	   an	   epidemic,	  although	  one	  usually	  predominates.	  	  	  	  
1.1.4 Pathogenesis	  and	  immunology	  
Transmission	  of	  RSV,	  like	  many	  respiratory	  viruses,	  is	  via	  large-­‐droplet	  aerosol	  and	   direct	   contact.	   	   RSV	   is	   extremely	   contagious,	   with	   contamination	   of	   the	  nasal	   or	   conjunctival	   mucosa	   being	   an	   effective	   means	   of	   infection.	   	   Viral	  tropism	  is	  for	  the	  airway	  epithelium	  and	  infection	  begins	  with	  viral	  replication	  in	   the	   superficial	   cells	   of	   the	   nasopharynx.	   	   The	   initial	   host	   response	   to	  infection	  is	  mediated	  by	  the	  innate	  immune	  system,	  triggered	  by	  recognition	  of	  the	   pathogen	   by	   macrophages	   and	   toll-­‐like	   receptor	   4	   (TLR-­‐4),	   which	  recognises	   the	   RSV	   F	   protein	   (Kurt-­‐Jones	   et	   al.,	   2000).	   	   This	   results	   in	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upregulation	  of	  an	  array	  of	  pro-­‐inflammatory	  cytokines	  and	  chemokines	   that	  promote	   neutrophil	   and	   natural-­‐killer	   cell	   recruitment,	   responsible	   for	  cytotoxicity	   and	   interferon-­‐γ	   (INF-­‐γ)	   induction,	   respectively	   (reviewed	   in	  McNamara	  and	  Smyth,	  2002).	  	  The	  histology	  of	  infected	  tissues	  shows	  necrosis	  of	  the	  epithelium	  and	  accumulation	  of	  immune	  cells,	  such	  as	  monocytes	  and	  T-­‐cells,	   leading	   to	   obstruction	   of	   the	   small	   bronchioles	   by	   sloughed	   epithelial	  cells	  and	  mucus	  (Collins	  and	  Graham,	  2008).	  	  The	   adaptive	   immune	   response	   is	   responsible	   for	   both	   cell-­‐mediated	  clearance	  of	  RSV	  and	  the	  humoral	  response	  required	  for	  protective	  immunity.	  	  CD8+	  cytotoxic	  T-­‐lymphocytes	  (CTL)	  and	  CD4+	  T-­‐helper	  cells	  are	  both	  recruited	  to	   the	   sites	   of	   RSV	   infection,	   and	   they	   play	   roles	   in	   the	   pathogenesis	   of	   RSV	  disease	  as	  well	  as	  viral	  clearance.	  	  The	  balance	  between	  the	  two	  types	  of	  CD4+	  T-­‐helper	   cell	   responses	   is	   a	   recurring	   theme	   in	  RSV	  pathogenesis:	   ‘anti-­‐viral’	  Th1	  responses	  promote	  CD8+	  CTL-­‐mediated	  cytotoxicity	  of	  infected	  host	  cells;	  Th2	  responses	  promote	  the	  humoral	  adaptive	  immune	  response	  through	  B-­‐cell	  activation	   and	   production	   of	   neutralising	   antibodies,	   but	   are	   also	   associated	  with	   allergic	   responses	   such	   as	   asthma.	   	   	   It	   has	   been	   suggested	   that	   a	   bias	  towards	   a	   Th2-­‐type	   response	   may	   be	   responsible	   for	   the	   bronchiolitis	   and	  recurrent	  wheezing	   of	   severe	  RSV	   infection,	   as	   Th2-­‐bias	  was	   responsible	   for	  vaccine-­‐enhanced	  disease	   after	   the	   1960’s	   formalin-­‐inactivated	  RSV	   (FI-­‐RSV)	  vaccine	   trial:	   RSV-­‐naïve	   children	   suffered	   enhanced	   disease	   severity	   upon	  subsequent	   infection	   (Kapikian	   et	   al.,	   1969).	   	   Recently	   it	   has	   been	   suggested	  that	  poor	  stimulation	  of	  B-­‐cell-­‐associated	  TLRs	  by	   the	  FI-­‐RSV	   led	   to	  a	   lack	  of	  affinity	  maturation	  –	  the	  differentiation	  and	  proliferation	  of	  antigen-­‐specific	  B-­‐cells	   required	   to	  produce	  a	  high-­‐affinity	   antibody	   response	   –	   and	   resulted	   in	  the	  significant	  but	  non-­‐protective	  antibody	  response.	   	  These	  antibodies	  failed	  to	  neutralise	  the	  virus,	  allowing	  unrestricted	  amplification	  of	  the	  Th2	  response	  (Delgado	  et	  al.,	  2009).	  	  A	  link	  between	  recurrent	  RSV	  infection	  in	  early	  life	  and	  the	  development	  of	  allergic	  asthma	  has	  recently	  been	  shown	  to	  be	  as	  a	  result	  of	  Th2-­‐like	   inflammation	   in	   the	   lungs;	   this	   results	   in	   permanently	   biasing	   T-­‐regulatory	   cells	   (a	   T-­‐cell	   population	   involved	   in	   control	   and	   suppression	   of	  inflammatory	   responses)	   towards	   low	   antigen	   tolerance,	   and	   permits	   the	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allergic	   response	   to	   otherwise	   innocuous	   antigens	   that	   is	   characteristic	   of	  asthma	  (Krishnamoorthy	  et	  al.,	  2012).	  Data	  to	  support	  a	  Th2-­‐bias	  in	  RSV	  infection	  are	  conflicting,	  due	  in	  part	  to	  the	  fact	  that	  the	  mouse	  models	  used	  are	  poorly	  representative	  of	  the	  human	  immune	   system.	   	   A	   more	   appropriate	   theory	   may	   be	   that	   balancing	   the	  different	  CD4+	  T-­‐helper	  cell	  responses	  is	  required	  to	  manage	  the	  compromise	  between	  the	  protective	  and	  pathogenic	  effects	  of	  the	  cellular	  adaptive	  immune	  response.	  	  A	  serum	  neutralising-­‐antibody	  response	  to	  RSV,	  particularly	  against	  the	  F	  and	  G	  protein	  antigens,	  is	  induced	  during	  infection	  and	  a	  strong	  response	  is	   associated	   with	   reduced	   risk	   of	   bronchiolitis	   in	   children	   (McNamara	   and	  Smyth,	   2002).	   	   Despite	   this	   apparent	   protective	   effect,	   RSV	   is	   able	   to	   infect	  infants	   in	   the	   first	   2-­‐6	  months	   of	   life	   when	  maternal	   antibodies	   transferred	  across	   the	   placenta	   should	   still	   be	   present,	   due	   to	   the	   immunological	  immaturity	   of	   young	   infants	   preventing	   them	   from	   mounting	   a	   robust	   and	  specific	  response.	  	  	  	  The	   relative	   contributions	   of	   the	   host	   response	   and	   the	   virus	   itself	   to	  RSV	  pathogenesis	  are	  still	  debated.	  	  There	  is	  considerable	  evidence	  to	  suggest	  that	  the	  host	  response	  to	  infection	  plays	  a	  significant	  role,	  in	  particular	  the	  FI-­‐RSV	  vaccine	  disease-­‐enhancement.	   	  Additionally,	  RSV	   is	  not	  highly	  cytopathic	  and	  there	  are	  genetic	  polymorphisms	  that	  are	  linked	  to	  increased	  RSV	  disease	  severity,	  such	  as	  those	  leading	  to	  increased	  expression	  of	  cytokines	  that	  recruit	  and	  activate	  immune	  cells	  (e.g.	  IL-­‐4	  and	  IL-­‐8),	  further	  suggesting	  that	  the	  host	  response	  is	  a	  factor	  in	  the	  pathogenesis	  of	  infection	  (Collins,	  2007).	  	  However,	  in	  support	  of	  a	  direct	  role	  of	  the	  virus	  in	  RSV	  pathogenesis,	  disease	  appears	  to	  be	   more	   severe	   in	   the	   immunocompromised	   and	   some	   cytopathology	   is	  observed,	  such	  as	  disruption	  of	  ciliary	  beating	  and	  the	  sloughing	  of	  epithelial	  cells.	   Most	   paediatric	   RSV	   infections	   result	   in	   mild	   symptoms	   such	   as	  rhinorrhoea,	  fever	  and	  a	  cough.	  	  However,	  25-­‐40	  %	  of	  children	  develop	  lower	  respiratory	  tract	  diseases	  such	  as	  bronchiolitis,	  pneumonia	  or	  bronchitis,	  due	  to	   a	   number	   of	   risk	   factors:	   premature	   birth,	   male	   gender,	   lack	   of	   maternal	  antibodies,	   low	   birth	   weight,	   and	   underlying	   cardiopulmonary	   disorders	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(Olszewska	   and	   Openshaw,	   2009).	   	   This	   results	   in	   symptoms	   including	  wheezing	   and	   laboured	   breathing,	   because	   of	   increased	   airway	   resistance.	  	  Lower	  respiratory	  tract	  infection	  (LRI)	  is	  as	  a	  direct	  result	  of	  RSV	  infection	  of	  the	   bronchiolar	   and	   alveolar	   epithelium,	   rather	   than	   as	   a	   result	   of	   the	   host	  response	  to	  the	  preceding	  upper	  respiratory	  tract	  infection	  (URI).	  In	   contrast	   to	   the	   frequently	   severe	   pathogenesis	   of	   infection	   in	  children,	  most	  occurrences	  of	  RSV	  in	  adults	  go	  undiagnosed	  as	  the	  symptoms	  are	   non-­‐specific	   and	   similar	   to	   other	   respiratory	   pathogens	   (Hall,	   2001).	  	  Particularly	  severe	  RSV	  infection	  during	  the	  first	  6	  months	  of	   life	  may	  lead	  to	  childhood	  wheezing	  and	  asthma,	  as	  described	  above.	  	  In	  recent	  years	  there	  has	  been	  increased	  focus	  on	  the	  significant	  morbidity	  and	  mortality	  in	  the	  elderly,	  high-­‐risk	   adults	   (those	   with	   chronic	   heart	   or	   lung	   disease)	   and	   the	  immunocompromised,	  particularly	  bone	  marrow	  transplant	  patients	  (Falsey	  et	  al.,	  2005).	  	  	  	  
1.1.5 Treatment	  
	  
1.1.5.1 Therapeutics	  Despite	  awareness	  of	  the	  high	  prevalence	  of	  this	  virus,	  and	  continued	  research	  efforts	   over	   the	   last	   50	   years,	   there	   is	   no	   cost-­‐effective	   efficacious	   anti-­‐viral	  therapy	   for	   RSV	   infection.	   	   Current	   therapeutic	   options	   include	   prophylactic	  use	   of	   palivizumab	   (MedImmume),	   a	   humanised	   mouse	   monoclonal	  neutralising	   antibody	   (mAb)	   against	   RSV	   fusion	   protein	   (F),	   in	   high-­‐risk	  neonates;	   this	   is	   expensive	   and	   only	   acts	   to	   reduce	   disease	   severity	   by	  preventing	   viral	   spread	   to	   the	   lower	   respiratory	   tract,	   resulting	   in	   fewer	  hospitalisations	  (55	  %	  in	  a	  2004	  study)	  (Fenton	  et	  al.,	  2004).	  	  Development	  of	  motavizumab	  (AstraZeneca),	   a	   second-­‐generation	  mAb	  based	  on	  palivizumab	  with	  significantly	  higher	  neutralisation	  activity	   in	  vitro	   (Wu	  et	  al.,	  2007),	  was	  discontinued	  in	  2010	  after	  phase	  III	  trials.	  The	   use	   of	   ribavirin,	   a	   nucleoside	   analogue	   with	   broad	   anti-­‐viral	  activity,	   is	   technically	   licenced	   for	   use	   against	   RSV,	   however	   it	   is	   no	   longer	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recommended	   due	   to	   a	   lack	   of	   proven	   efficacy	   and	   possible	   toxicity.	   	   Alios	  BioPharma	  began	   a	  phase	   I	   clinical	   trial	   for	   a	   first-­‐in-­‐class	   structurally	  novel	  anti-­‐RSV	  nucleoside	  analogue	  in	  2013,	  following	  on	  from	  their	  phase	  I	  success	  with	  a	  similar	  strategy	  for	  hepatitis	  C	  virus.	  	  A	   number	   of	   fusion	   inhibitors	   have	   been	   found	   by	   high-­‐throughput	  screening	   of	   small	  molecule	   libraries,	   and	   co-­‐crystal	   structures	   revealed	   that	  these	  target	  formation	  of	  the	  six-­‐helix	  bundle	  of	  the	  fusion	  protein.	  	  However,	  development	  of	  all	  but	  one	  was	  discontinued	  by	  2009	  and	  new	  candidates	  are	  only	  in	  early	  clinical	  evaluation	  (Olszewska	  and	  Openshaw,	  2009).	  	  	  An	   antisense	   RNA	   against	   the	   RSV	   nucleocapsid	   protein,	   ALN-­‐RSV01	  (Alnylam	   Pharmaceuticals),	   has	   been	   evaluated	   in	   phase	   II	   trials	   for	   the	  prevention	   of	   a	   severe	   complication	   of	   RSV	   LRI,	   bronchiolitis	   obliterans	  syndrome	  –	  a	  permanent	  constriction	  and	  fibrosis	  of	   the	  bronchioles.	   	  This	   is	  an	  important	  proof	  of	  concept,	  as	  it	  is	  the	  first	  RNAi-­‐based	  drug	  to	  be	  tested	  in	  humans	  against	  a	  microbial	  pathogen.	  	  It	  works	  by	  binding	  N	  protein	  mRNA	  in	  the	  cytoplasm,	  preventing	  its	  expression	  and	  consequently	  stopping	  the	  virus	  from	  replicating	  (DeVincenzo	  et	  al.,	  2010).	  	  	  	  	  
1.1.5.2 Vaccine	  candidates	  A	  number	  of	  inactivated	  and	  live	  attenuated	  vaccines	  for	  bovine	  RSV	  have	  been	  available	  for	  20	  years	  (Meyer	  et	  al.,	  2008),	  but	  the	  situation	  for	  human	  RSV	  is	  very	  different.	  	  Prior	  to	  the	  last	  15	  years,	  the	  development	  of	  vaccines	  against	  human	   RSV	   has	   been	   tentative	   and	   slow.	   	   Recently	   reviewed	   by	   Collins	   and	  Molero	  (2011),	  a	  number	  of	  live-­‐attenuated	  viruses,	  initially	  produced	  by	  cold	  passage	   and	   later	   by	   reverse	   genetics,	   have	   been	   identified	   and	   evaluated	   in	  clinical	   trials	   and	  do	  not	   show	   the	   vaccine-­‐enhanced	  disease	   associated	  with	  inactivated	  RSV	  vaccines.	   	  Currently	  promising	  candidates	  are:	  RSV	  cps2	  live-­‐attentuated	   (phase	   I,	   MedImmune),	   which	   is	   a	   codon-­‐stabilised	   version	   of	  MEDI-­‐559	  –	  a	  strain	  containing	  mutations	  in	  the	  polymerase,	  the	  M2	  gene-­‐start	  signal,	  and	  the	  deletion	  of	  the	  SH	  gene,	  which	  is	  in	  phase	  II	  trials;	  MEDI-­‐ΔM2-­‐2	  live-­‐attenuated	  (phase	  I,	  MedImmune),	  a	  rationally-­‐designed	  strain	  with	  most	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of	   the	   M2-­‐2	   ORF	   removed	   to	   increase	   transcription	   and,	   thus,	   antigen	  expression.	  	  	  	   Other	   types	   of	   vaccine	   are	   also	   being	   evaluated	   for	   RSV.	   	   A	   subunit	  vaccine	   of	   baculovirus-­‐expressed	   RSV	   post-­‐fusion	   F	   protein,	   designed	   for	  maternal	   vaccination	   and	   consequent	   placental-­‐transfer	   of	   neutralising	  antibodies,	  is	  currently	  entering	  phase	  II	  trials	  (Novavax)	  (Glenn	  et	  al.,	  2013).	  	  This	   strategy	  aims	   to	   circumvent	  one	  of	   the	  most	   significant	   issues	  with	  RSV	  vaccinology	  –	  the	  very	  short	  window	  of	  opportunity	  for	  vaccination.	  	  A	  number	  of	   viral-­‐vector	   vaccines	   are	   in	   early	   stages	   of	   clinical	   testing,	   and	   a	   chimeric	  bovine	  parainfluenza	  virus	  3	  (bPIV3)	  has	  been	  successfully	  evaluated	  at	  phase	  I:	   the	   bPIV3	   F	   and	   haemagglutinin	   proteins	   are	   substituted	   for	   human	   PIV3	  proteins,	  and	  the	  vector	  additionally	  modified	  to	  express	  the	  RSV	  F	  protein.	  	  	  
1.2 THE	  VIRUS	  
1.2.1 The	  virion	  
The	   RSV	   virion	   is	   renowned	   for	   its	   pleomorphism,	   instability,	   and	   relatively	  poor	   titres	   in	   cell	   culture	   –	   features	   that	   have	   hampered	   attempts	   to	  characterise	   the	   3D	   structure	   of	   the	   whole	   virus	   until	   recently,	   when	   the	  ultrastructure	   of	   the	   RSV	   virion	  was	   confirmed	   by	   electron	   cryotomography	  (Liljeroos	   et	   al.,	   2013),	   shown	   in	   figure	   1.2.	   	   Preparations	   of	   purified	   virus	  consist	  of	  a	  mixture	  of	   spherical	  and	   filamentous	  particles,	   and	  particles	   that	  show	  both	  morphologies,	  ranging	  from	  100	  nm	  to	  1	  µm	  in	  diameter	  and	  up	  to	  2	   µm	   in	   length.	   	   Both	   spherical	   and	   filamentous	   morphologies	   have	   been	  associated	  with	   infectivity,	   although	  Liljeroos	  et	  al	   (2013)	  demonstrated	   that	  the	   loss	   of	   infectivity	   resulting	   from	   freeze-­‐thaw	  of	   the	   virus	   corresponds	   to	  loss	  of	   the	   filamentous	   form.	   	  A	  host-­‐derived	   lipid	  bilayer	   is	   studded	  with	  an	  irregular	   arrangement	   of	   the	   viral	   transmembrane	   glycoproteins,	   F	   and	   G,	  which	   are	   required	   for	   fusion	   and	   attachment,	   respectively,	   and	   are	   the	  primary	   antigenic	   components	   of	   the	   virus.	   	   The	   virion	   membrane	   also	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contains	   the	   small	   hydrophobic	   (SH)	   protein,	   which	   forms	   a	   pentameric	   ion	  channel	   (Gan	  et	  al.,	  2012),	  but	   its	   low	  abundance	  means	   it	  has	  not	  been	   fully	  characterised	   by	   cryo-­‐EM.	   	   The	   virion	   has	   an	   internal	   membrane-­‐associated	  layer	   of	  matrix,	  M,	   protein	   that	   is	   considered	   essential	   for	   particle	   assembly	  (figure	  1.2	  B).	  	  The	  left-­‐handed	  helical	  ribonucleoprotein	  (RNP)	  complex	  forms	  the	  core	  of	  the	  virion,	  and	  is	  composed	  of	  the	  genomic	  RNA	  in	  association	  with	  a	  number	  of	  proteins:	  the	  nucleocapsid,	  N,	  protein	  is	  tightly	  bound	  to	  the	  RNA	  creating	  the	  helical	  structure;	  the	  RNA-­‐dependent	  RNA-­‐polymerase	  (RdRp),	  or	  ‘large’	   L	   protein,	   is	   the	   key	   component	   of	   the	   transcription/replication	  complex;	   the	   phosphoprotein,	   P,	   protein	   is	   an	   essential	   co-­‐factor	   of	   the	   viral	  RdRp;	   the	   M2-­‐1	   protein,	   an	   additional	   RdRp	   co-­‐factor	   that	   is	   required	   for	  transcription	  of	  viral	  mRNAs.	  	  	  
	  
Figure	  1.2	  Electron	  micrographs	  of	  RSV	  virions.	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1.2.2 Genome	  organisation	  
	  
1.2.2.1 The	  Mononegavirales	  The	   RNA	   genomes	   of	   the	   order	   Mononegavirales	   are	   single-­‐stranded,	  monopartite,	   negative-­‐sense,	   vary	   in	   length	   from	   8.9	   to	   19	   kb,	   and	   are	  displayed	  3’	  to	  5’	  by	  convention.	  	  The	  general	  order	  of	  viral	  genes	  is	  conserved	  across	   the	   whole	   order:	   3’	   –	   nucleocapsid,	   P	   protein,	   matrix,	   surface	  glycoproteins	  (F/G/HN),	  and	  the	  polymerase	  –	  5’.	  	  This	  is	  shown	  in	  figure	  1.3,	  which	  compares	  the	  genomes	  of	  several	  genera	  of	  the	  family	  Paramyxoviridae	  and	  the	  rhabdovirus	  VSV.	  	  Both	  genera	  of	  the	  subfamily	  Pneumovirinae	  contain	  additional	  genes	  not	  present	  in	  the	  other	  paramyxoviruses,	  namely	  the	  SH,	  M2	  and,	   in	   the	   case	   of	   RSV,	   NS1	   and	   NS2	   genes.	   	   Table	   1	   outlines	   the	   basic	  functions	   of	   RSV	   encoded	   proteins	   and	   they	   are	   described	   in	   more	   detail	  below.	  	  	  The	   viral	   genome	   is	   flanked	  by	   3’	   leader	   and	  5’	   trailer	   regions,	  which	  show	   inverse	   complementarity	   and	   contain	   the	   promoters	   to	   drive	  mRNA/antigenome	   and	   genome	   synthesis,	   respectively.	   	   Despite	   this	  complementarity,	  none	  of	  the	  paramyxoviridae	  are	  predicted	  to	  circularise	  or	  form	   a	   panhandle	   structure,	   as	   with	   influenza	   A	   virus.	   	   Each	   viral	   gene	   is	  delineated	   by	   gene	   start	   and	   gene	   end	   cis-­‐acting	   signals,	   which	   direct	   the	  sequential	   ‘stop-­‐start’	   mechanism	   of	   transcription	   (Kuo	   et	   al.,	   1996).	   	   Gene	  start	  signals	  are	  highly	  conserved	  within	  each	  virus	  family;	  gene	  end	  sequences	  are	   less	  well	   conserved,	  but	   contain	  essential	  motifs	   including	  a	  poly-­‐uridine	  tract	  for	  the	  generation	  of	  the	  3’	  mRNA	  poly-­‐adenosine	  tail.	  	  Between	  these	  cis-­‐acting	   signals	   is	   a	   non-­‐transcribed	   intergenic	   region	   that	   can	   be	   absolutely	  conserved	   in	   length	   (3	  nucleotides	   for	   respiroviruses	  and	  morbilliviruses)	  or	  variable	  in	  length	  (1-­‐190	  for	  pneumoviruses	  and	  rubulaviruses).	   	  Many	  of	  the	  mononegaviruses	  employ	  mechanisms	  to	  increase	  the	  coding-­‐capacity	  of	  their	  genomes,	  including	  overlapping	  reading	  frames	  (ORFs),	  such	  as	  the	  M2-­‐1	  and	  M2-­‐2	   ORFs	   of	   the	   pneumovirus	   M2	   gene	   or	   the	   P/C	   ORFs	   of	   many	   of	   the	  subfamily	  Paramyxovirinae	  P	  genes.	   	  The	  latter	  also	  use	  a	  mechanism	  of	   ‘RNA	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editing’,	   where	   non-­‐templated	   insertion	   of	   guanosine	   nucleotides	   shifts	   the	  downstream	   translational	   reading	   frame	   to	   produce	   V/I/W/D	   proteins	   from	  the	  P	  gene	  (Collins	  and	  Crowe	  Jr,	  2007).	  	  Borna	  disease	  virus,	  the	  only	  current	  member	  of	  the	  family	  Bornaviridae,	  has	  many	  unique	  characteristics	  that	  set	  it	  apart	   from	   the	   other	   mononegaviruses,	   including	   its	   nuclear	   site	   of	  transcription	  and	   replication.	   	  This	   allows	   the	  virus	   to	  use	  host	  RNA	  splicing	  machinery	  to	  generate	  the	  complete	  mRNA	  transcript	  of	  the	  viral	  polymerase	  (Cubitt	  et	  al.,	  1994).	  	  
	  
	  
Table	  1	  Virally	  encoded	  proteins	  of	  RSV	  and	  their	  functions.	  
Gene Protein function 
NS1 Non-structural proteins:  inhibit interferon α/β induction and 
signalling NS2 
N Nucleocapsid:  encapsidates genomic and antigenomic RNA, component of the RNP template 
P Phosphoprotein:  essential polymerase co-factor 
M Matrix:  viral assembly 
SH Small hydrophobic: viroporin of unknown function 
G Glycoprotein: attachment, secreted form binds neutralising Abs i.e. immune evasion 
F Fusion: viral entry, syncytia formation 
M2 
‘Matrix-like’ protein 1, M2-1: transcription antitermination factor 
‘Matrix-like’ protein 2, M2-2: RNA regulatory protein, viral 
transcription/replication balance? 
L Large protein: RNA-dependent RNA polymerase 
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Figure	  1.3	  Genome	  comparisons	  of	  the	  order	  Mononegavirales.	  	  Approximately	   to	   scale	   representations	   of	   genomes	   from	   the	   subfamilies	  
Pneumovirinae	   and	   Paramyxovirinae	   and	   an	   example	   from	   the	   family	  
Rhabdoviridae.	   	   Homologous	   genes	   are	   the	   same	   colour,	   with	   the	   various	  glycoproteins	  shown	  in	  shades	  of	  purple.	  	  The	  overlap	  between	  M2/L	  of	  RSV	  is	  shown	  by	  the	  offset	  L	  gene.	  	  	  	  	  	  
1.2.2.2 RSV	  The	   genome	   of	   RSV	   is	   15.2	   kb	   in	   size	   and	   contains	   10	   genes	   that	   are	  transcribed	   into	   10	   5’-­‐capped	   and	   3’-­‐polyadenylated	  mRNAs,	   and	   translated	  into	  11	  viral	   proteins	  due	   to	   the	  overlapping	  ORFs	  of	   the	  M2	  mRNA.	   	  The	  3’	  leader	   region	   (Le)	   is	   44	   nucleotides	   long	   and	   is	   well	   conserved	   across	   the	  subfamily	  Pneumovirinae;	   in	  particular	   the	   first	  11	  nucleotides	  are	  necessary	  and	   sufficient	   for	   polymerase	   recruitment	   and	   initiation	   of	   RNA	   synthesis	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(Fearns	   et	   al.,	   2002,	   Cowton	   and	   Fearns,	   2005),	   although	   the	   5’	   end	   of	   the	  leader	   sequence	   is	   required	   for	   transcriptional	   efficiency	   (McGivern	   et	   al.,	  2005).	   The	   first	   34	   nucleotides	   are	   required	   for	   antigenome	   synthesis	   and	  encapsidation	  –	  a	  distinguishing	  characteristic	  of	  RSV	  and	  the	  pneumovirinae,	  as	   the	   subfamily	   Paramyxoviridae	   has	   a	   bipartite	   replication	   promoter	  requiring	  sequences	  in	  the	  first	  gene.	  	  	  	  The	  3’	  antigenome	  contains	  the	  155	  nt	  trailer	   complementary	   (TrC)	   region,	  which	   contains	   the	   promoter	   sequences	  for	   genome	   synthesis	   and	   the	   first	   26	   nt	   are	   highly	   conserved	   with	   the	   Le	  sequence	  (Fearns	  et	  al.,	  2000).	  The	  conserved	  gene	  start	  (GS)	  sequence	  of	  RSV	  is	  3’	  CCCCGUUUA	  5’,	  and	  differs	   only	   for	   the	   L	   gene,	  whose	   gene	   start	   sequence	   is	   3’	   CCCUGUUUU	   5’.	  	  The	  L	  gene	  is	  also	  unusual	  in	  that	  it	  overlaps	  with	  the	  previous	  M2	  gene:	  The	  L	  gene	   start	   signal	   is	   upstream	   of	   the	   M2	   gene	   end	   signal,	   creating	   a	   68	  nucleotide	   overlap	   (Collins	   et	   al.,	   1987).	   	   This	   arrangement	   is	   found	   in	   all	  respiratory	   syncytial	   viruses,	   but	   no	   other	   members	   of	   the	   subfamily	  
Pneumovirinae.	   	   RSV	   gene	   end	   signals	   vary	   in	   length	   and	   sequence	   not	   only	  between	   viral	   strains,	   but	   also	   between	   gene	   junctions	   within	   those	   strains.	  	  For	   RSV	   A2	   strain,	   the	   sequence	   consists	   of	   a	   conserved	   3’	   UCAAU	   5’	  motif,	  followed	   by	   an	   unconserved	   region	   of	   3-­‐4	   nt	   and	   a	   polyU	   tract	   of	   variable	  length.	   	   The	   efficiency	   of	   termination	   at	   a	   gene	   junction	   is	   controlled	   by	   the	  gene	  end	  sequence	  (Hardy	  et	  al.,	  1999),	  and	  results	  in	  read-­‐through	  mRNAs	  at	  a	   level	   that	  may	  be	  proportional	   to	  divergence	   from	   the	   consensus	   sequence	  (Sutherland	  et	  al.,	  2001).	  	  	  
1.3 VIRUS	  LIFE	  CYCLE	  	  
1.3.1 Entry	  
The	   life	   cycle	   of	   RSV	   begins	   at	   the	   apical	   cell	   surface	   of	   the	   nasopharyngeal	  epithelium	   (figure	   1.4).	   	   In	   vitro,	   initial	   attachment	   is	   thought	   to	   be	   by	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electrostatically	   driven	   binding	   of	   the	   G	   protein	   to	   negatively	   charged	   cell	  surface	   carbohydrates	   as,	   unlike	   the	   specific	   binding	   of	   sialic	   acid	   by	   the	  haemagglutinin	  glycoproteins	  of	  many	  of	  the	  other	  paramyxoviruses,	   the	  RSV	  G	  protein	  has	  been	  suggested	  to	  bind	  a	  range	  of	  targets,	  many	  of	  which	  are	  not	  expressed	   at	   the	   apical	   surface	   of	   the	   airway	   epithelia,	   e.g.	   heparin	  (Mastrangelo	   and	   Hegele,	   2013).	   	   In	   further	   contrast	   to	   the	   subfamily	  
Paramyxovirinae,	  the	  RSV	  G	  protein	  is	  not	  thought	  to	  bind	  to	  the	  F	  protein	  and	  regulate	  its	  fusogenic	  activity,	  as	  it	  is	  dispensable	  for	  viral	  infection	  in	  vitro;	  ΔG	  mutants	  are,	  however,	  attenuated	  in	  vivo	  (Dutch,	  2010).	  	  The	   only	   definitive	   entry	   receptor	   for	  RSV	   is	   nucleolin	   (Tayyari	   et	   al.,	  2011),	   which	   is	   found	   in	   the	   lipid	   rafts	   that	   RSV	   requires	   for	   entry,	   and	   F	  protein	   has	   been	   shown	   to	   bind	   specifically	   to	   nucleolin	   at	   the	   cell	   surface.	  	  Fusion	   proteins	   of	   the	   paramyxoviridae	   are	   highly	   conserved	   and	   require	  cleavage	   by	   cellular	   proteases	   (furin	   in	   the	   case	   of	   RSV)	   to	   induce	   extensive	  and	   irreversible	   conformational	   change,	   allowing	   fusion	  of	   the	  viral	   and	  host	  cell	  membranes	  (see	  below).	  	  The	  F	  protein	  of	  RSV	  is	  unique	  in	  that	  it	  requires	  two	   fusion	   events,	   rather	   than	   one	   as	   for	   the	   other	   paramyxoviruses	  (Gonzalez-­‐Reyes	  et	  al.,	  2001).	   	  The	  recent	  discovery	  of	  the	  mechanism	  of	  RSV	  entry	   may	   explain	   this	   requirement:	   Unlike	   other	   members	   of	   the	   family	  
Paramyxoviridae	   who	   fuse	   directly	   at	   the	   plasma	   membrane,	   RSV	   is	  endocytosed	   intact	   by	   macropinocytosis	   and	   the	   second	   F	   protein	   cleavage	  event	  occurs	  post-­‐internalisation,	  within	  the	  endosome,	  initiating	  intracellular	  membrane	  fusion	  (Krzyzaniak	  et	  al.,	  2013).	  	  Interestingly,	  macropinocytosis	  is	  also	   the	   method	   of	   entry	   for	   the	   Ebola	   filovirus.	   	   Fusion	   of	   viral	   and	   host	  membranes	  by	  the	  F	  protein	  does	  not	  require	  acidification	  of	  endosomes,	  and	  results	   in	   the	   release	  of	   the	  viral	   ribonucleoprotein	   complex	   (vRNP)	   into	   the	  cytoplasm.	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Figure	  1.4	  The	  life	  cycle	  of	  RSV.	  	  	  
1)	  Attachment	  of	  RSV	  virions	  by	  G	  protein	  to	  apical	  cell	  surface	  carbohydrates	  and	   binding	   of	   the	   F	   protein	   to	   the	   entry	   receptor	   nucleolin,	   triggers	  endocytosis	   by	  macropinocytosis.	   	  2)	   Further	   cleavage	   of	   the	   F	   protein	   and	  conformational	  change	  initiates	  fusion	  of	  viral	  and	  host	  membranes,	  releasing	  the	  vRNP.	  	  3)	  Primary	  transcription	  of	  the	  genome	  into	  10	  mRNAs	  by	  the	  viral	  transcription	  complex	  (L,	  N,	  P,	  M2-­‐1).	   	  4)	  Translation	  by	  host	  ribosomes	   into	  viral	   proteins,	   allowing	   build	   up	   of	   N	   protein	   required	   for	   replication.	   	   5)	  Replication	  (L,	  N,	  P)	  and	  concurrent	  encapsidation	  of	  antigenome	  and	  genome.	  	  
6)	   Secondary	   transcription	   of	   newly	   synthesised	   genomes	   to	   amplify	   viral	  protein	   expression.	   	   7)	   Trafficking	   of	   viral	   proteins	   and	   genomic	   vRNP	  complexes	   to	   the	   apical	   cell	  membrane	   for	   virion	   assembly	   and	  budding.	   	  8)	  Release	  of	  RSV	  virions	  from	  the	  cell	  surface	  into	  the	  nasopharyngeal	  lumen.	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1.3.1.1 G	  protein	  RSV	   G	   protein	   is	   a	   highly	   glycosylated	   transmembrane	   protein	   with	   a	  polypeptide	   molecular	   weight	   of	   32	   kDa,	   although	   the	   considerable	  carbohydrate	  content	  raises	   its	  apparent	  molecular	  weight	  to	  3	  times	  this.	   	   It	  bares	   no	   sequence	   or	   structural	   similarity	   to	   the	   HN	   proteins	   of	   the	   family	  
Paramyxovirinae,	  and	  is	  the	  least	  conserved	  protein	  amongst	  RSV	  strains.	  	  The	  hydrophobic	  C-­‐terminal	  ectodomain	  of	  G	  protein	  comprises	   two	  thirds	  of	   the	  protein,	   and	   is	   made	   up	   of	   two	   highly	   variable	   mucin-­‐like	   domains.	   	   The	  majority	  of	  G	  protein	  epitopes	  recognised	  by	  neutralising	  antibodies	  are	  in	  this	  region,	   and	   its	   variability	   and	   extensive	   glycosylation	  may	  partly	   explain	   the	  virus’	  ability	  to	  evade	  such	  a	  response	  (Collins	  and	  Melero,	  2011).	  	   G	   protein	   is	   proposed	   to	   bind	   cell	   surface	   carbohydrates	   to	   mediate	  viral	  attachment,	  however	  this	  protein	  is	  not	  essential	  for	  the	  in	  vitro	  rescue	  of	  RSV,	   or	   other	   pneumovirinae	   such	   as	   the	   metapneumovirus	   avian	  metapneumovirus	   (AMPV)	   (Naylor	   et	   al.,	   2004).	   	   The	   importance	   of	   the	   G	  protein	   in	  vivo	  may	  lie	  in	  its	  alternative	  secreted	  form,	  generated	  by	  a	  second	  translation	   initiation	   codon	   and	   resulting	   in	   an	   N-­‐terminal	   truncation	   of	   the	  transmembrane	  anchor.	   	  Soluble	  G	  protein	  accounts	  for	  ~80	  %	  of	  total	  G	  and	  acts	  as	  a	  decoy	  for	  the	  host	  adaptive	  immune	  response	  (Bukreyev	  et	  al.,	  2012).	  	  	  	  	  
1.3.1.2 F	  protein	  RSV	  F	  protein	  is	  synthesised	  as	  a	  67	  kDa	  inactive	  precursor,	  which	  is	  cleaved	  in	  the	   trans-­‐Golgi	   network	   to	   form	   two	   disulphide-­‐linked	   polypeptides.	   	   This	  creates	   the	   N-­‐terminal	   fusion	   peptide	   that	   directly	   inserts	   into	   the	   target	  membrane,	  and	  allows	  homo-­‐trimerisation	   to	   form	  the	  metastable	  pre-­‐fusion	  conformation.	  	  The	  crystal	  structure	  of	  both	  pre-­‐	  and	  post-­‐fusion	  forms	  of	  RSV	  F	  protein	  have	  allowed	   the	  process	  of	  membrane	   fusion	   to	  be	  explained,	  and	  reinterpreted	  in	  light	  of	  the	  role	  of	  endocytosis	  in	  RSV	  entry	  (Mastrangelo	  and	  Hegele,	   2013):	   Pre-­‐fusion	   F	   protein	   binds	   to	   nucleolin,	   initiating	  macropinocytosis	   and	   refolding	   the	  F	  protein	   into	  an	  extended	   intermediate;	  within	   the	   endosome,	   the	   fusion	   peptide	   is	   inserted	   into	   the	   host	   cell	  membrane	   and	   a	   second	   furin	   cleavage	   triggers	   the	   irreversible	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conformational	  change	  of	  F	  protein	  to	  the	  post-­‐fusion	  six-­‐helix-­‐bundle	  form	  –	  a	  lower	   energy	   state	   that	   drives	   the	   energetically-­‐unfavourable	   process	   of	  membrane	   fusion.	   	  This	   ‘spring-­‐loaded’	  mechanism	  of	   fusion	   is	   thought	   to	  be	  similar	   to	   influenza	   A	   virus	   haemagglutinin-­‐mediated	   fusion	   (Collins	   and	  Crowe	  Jr,	  2007).	  	  All	  other	  family	  Paramyxoviridae	  F	  proteins	  undergo	  only	  one	  cleavage	  event,	  and	  the	   triggering	  of	  conformational	  change	   is	   instead	  driven	  by	  interaction	  with	  the	  attachment	  glycoprotein.	  	  	  	  	  	  Syncytia	  formation,	  whereby	  infected	  cells	  express	  the	  F	  protein	  at	  their	  surface	  and	  fuse	  with	  their	  neighbours	  forming	  giant	  multinucleated	  cells	  and	  allowing	   viral	   spread,	   occurs	   by	   pH-­‐independent	   fusion	   at	   the	   plasma	  membrane.	   	   Although	   syncytia	   are	   a	   hallmark	   of	   infection	   in	   vitro,	   they	   are	  rarely	  seen	  in	  histological	  patient	  samples,	  except	  in	  very	  severe	  disease.	  	  	  	  	  
1.3.2 Overview	  of	  transcription	  and	  replication	  
Once	   endosomal	   fusion	   has	   occurred,	   the	   viral	   RNP	   is	   released	   into	   the	  cytoplasm	   and	   associates	   with	   lipid	   rafts	   and	   cytoskeletal	   proteins,	   such	   as	  actin	   and	   profilin,	   to	   form	   cytoplasmic	   inclusion	   bodies	   where	   viral	   RNA	  synthesis	   occurs	   (Cowton	   et	   al.,	   2006).	   	   A	   single	   promoter	   in	   the	   3’	   leader	  region	  of	  the	  genome	  drives	  both	  transcription	  and	  replication	  -­‐	  two	  mutually	  exclusive	  modes	  of	  viral	  RNA	  synthesis.	  Initially	   the	  virus	   is	   limited	   to	  a	  phase	  of	  primary	   transcription,	  when	  mRNAs	  are	  transcribed	  from	  the	  encapsidated	  genome	  by	  the	  viral	  RdRp	  and	  its	  cofactors,	  P	  and	  M2-­‐1,	  in	  a	  sequential	  ‘stop-­‐start’	  mechanism;	  this	  requires	  transcription	   termination	   of	   the	   upstream	   gene	   at	   the	   gene	   end	   sequence,	  scanning	   across	   the	   intergenic	   region,	   and	   transcription	   reinitiation	   at	   the	  downstream	   gene	   start	   sequence	   –	   all	   without	   disassociation	   from	   the	  template.	  	  RSV	  mRNAs	  and	  proteins	  can	  be	  detected	  in	  the	  cytoplasm	  4-­‐6	  hours	  post	   infection	   (Collins	   and	   Crowe	   Jr,	   2007).	   	   Host-­‐translated	   viral	   proteins	  accumulate	  in	  the	  cytoplasm	  until	  a	  concentration	  of	  free	  nucleocapsid	  protein	  is	   reached	   that	   permits	   replication	   of	   the	   genome;	   this	   process	   does	   not	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require	  M2-­‐1	  and	   is	  dependent	  on	  de	  novo	   synthesis	   of	  N	   for	   the	   concurrent	  encapsidation	   of	   both	   the	   antigenomic	   intermediate,	   and	   replicated	   genome.	  	  The	   polymerase	  must	   ignore	   the	   cis-­‐acting	   signals	   that	   directed	   termination	  and	   reinitiation	   during	   transcription,	   and	   synthesise	   a	   complete	   viral	  antigenome,	  from	  which	  the	  subsequent	  synthesis	  of	  a	  viral	  genome	  is	  initiated	  at	   the	   TrC	   promoter.	   	   	   Secondary	   transcription	   of	   these	   newly	   synthesised	  genomes	  allows	  amplification	  of	  viral	  protein	  production.	  	  	  	  
1.3.3 Transcription	  
The	  mechanism	  of	  transcription	  for	  RSV	  is	  shared	  by	  the	  three	  main	  families	  of	  the	   order	   Mononegavirales:	   Paramyxoviridae,	   Filoviridae	   and	   Rhabdoviridae.	  	  Initial	   insights	   came	   from	   UV	   target	   size	   experiments	   on	   VSV	   and	   RABV	  (Abraham	   and	   Banerjee,	   1976);	   UV-­‐induced	   lesions	   in	   upstream	   genes	  prevented	  transcription	  of	  those	  downstream,	  consistent	  with	  the	  mechanism	  of	  sequential	  transcription	  described	  above.	  	  	   	  The	   5’	   end	   of	   nascent	  mRNA	   transcripts	   is	   capped	   (i.e.	   guanylylation	  and	  methylation)	  by	  the	  viral	  RdRp	  itself	  (Liuzzi	  et	  al.,	  2005),	  and	  is	  followed	  by	   elongation	   of	   the	   mRNA	   transcript	   –	   a	   process	   that	   requires	   the	  antitermination	   ability	   of	   M2-­‐1,	   the	   subject	   of	   this	   thesis	   and	   described	   in	  detail	  below.	  	  The	  ‘stop-­‐start’	  mechanism	  of	  transcription	  links	  the	  termination	  and	  polyadenylation	  of	  the	  upstream	  gene,	  the	  latter	  of	  which	  is	  thought	  to	  be	  by	  reiterative	  transcription	  of	  a	  polyU	  tract	  in	  the	  gene	  end	  sequence	  as	  shown	  for	   VSV	   (Barr	   and	   Wertz,	   2001),	   to	   the	   transcription	   initiation	   of	   the	  downstream	   gene.	   	   After	   transcription	   of	   an	   upstream	   gene	   is	   terminated	   at	  the	  gene	  end	  signal	  and	  the	  nascent	  mRNA	  released,	  the	  polymerase	  complex	  scans	   in	  either	  direction	  until	   a	   gene	   start	   signal	   is	   encountered	   (Fearns	  and	  Collins,	   1999a).	   	   This	   bi-­‐directionality	   is	   particularly	   important	   at	   the	  M2/L	  gene	   junction,	  as	   these	   two	  genes	  overlap	  by	  68	  nt	  and	   the	  polymerase	  must	  scan	  backwards	   to	   locate	   the	  L	  gene	  GS	  signal	  upstream	  of	   the	  M2	  GE	  signal.	  	  90	  %	  of	  polymerase	  initiations	  at	  the	  L	  gene	  start	  sequence	  will	  terminate	  68	  nt	  later	  at	  the	  M2	  gene	  end	  sequence,	  producing	  a	  short	  polyadenylated	  mRNA	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of	   no	   known	   function	   (Collins	   and	   Crowe	   Jr,	   2007).	   	   Successful	   L	   mRNA	  synthesis	   requires	   read-­‐through	   of	   the	   M2	   GE	   signal.	   	   VSV,	   subfamily	  
Paramyxovirinae,	  does	  not	  have	  an	  overlapping	  L	  gene	  but	  a	  very	  high	  level	  of	  attenuation	   at	   the	   G/L	   junction	   has	   been	   observed,	   likely	   as	   a	   result	   of	   the	  polymerase	  being	   insufficiently	  processive	   to	   traverse	   the	  6,379	  nucleotide	  L	  gene	  in	  the	  absence	  of	  an	  M2-­‐1-­‐like	  protein	  (Barr	  et	  al.,	  2002).	   	  This	  suggests	  that	   downregulation	   of	   the	   RdRp	   may	   be	   essential	   to	   maintaining	   an	  appropriate	  level	  of	  viral	  transcription	  and	  replication,	  and	  may	  be	  common	  to	  all	  paramyxoviruses.	  	  Descriptions	  of	  each	  of	  the	  proteins	  required	  for	  viral	  transcription	  are	  below,	  and	  M2-­‐1	  is	  described	  in	  further	  detail	  later	  in	  the	  chapter.	  	  
1.3.3.1 N	  protein	  The	  nucleocapsid	  protein	  of	  all	  mononegaviruses	  is	  essential,	  as	  the	  complete	  encapsidation	  of	  the	  genome	  is	  required	  to	  form	  the	  RNase-­‐resistant	  template	  for	   viral	   RNA	   synthesis.	   	   RSV	  N	   is	   45	   kDa	   and	   its	   crystal	   structure	   bound	   to	  bacterial	   RNA	   revealed	   the	   oligomerisation	   of	   N	   to	   form	   the	   helical	   RNP:	   N	  protein	  monomers,	  consisting	  of	  N-­‐	  and	  C-­‐terminal	  regions	   linked	  by	  a	  hinge,	  oligomerised	   to	   form	   a	   decameric	   ring	   representing	   one	   turn	   of	   the	   helix	  (Tawar	  et	  al.,	  2009),	  shown	  in	  figure	  1.5.	  	  RNA	  was	  buried	  in	  a	  basic	  groove	  on	  the	  external	  surface	  of	  the	  ring,	  in	  contrast	  to	  similar	  structure	  of	  VSV	  N:RNA.	  	  Each	  monomer	  bound	  7	  nucleotides	  of	  RNA,	  in	  further	  contrast	  to	  many	  of	  the	  paramyxoviruses,	  such	  as	  SeV,	  whose	  genomes	  are	  obligatorily	  multiples	  of	  six	  in	  length	  to	  satisfy	  the	  binding	  of	  N	  to	  viral	  RNA.	   	  This	  structure	  also	  showed	  that	  the	  N	  protein	  C-­‐terminus	  extended	  above	  the	  ring,	  in	  line	  with	  the	  binding	  of	   this	   region	   to	   the	   viral	   phosphoprotein,	   P	   (Stokes	   et	   al.,	   2003),	   which	   is	  thought	  to	  keep	  a	  pool	  of	  soluble	  N	  available	  for	  concurrent	  encapsidation.	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Figure	  1.5	  Crystal	  structure	  of	  RSV	  N	  protein	  with	  bacterial	  RNA.	  	  	  
A)	  	  The	  decameric	  N	  ring	  structure	  mimicking	  one	  helix	  turn	  is	  shown	  in	  grey,	  with	   one	   N	   monomer	   coloured	   yellow	   (N-­‐terminal	   domain)	   and	   red	   (C-­‐terminal	  domain),	  with	  its	  termini	  in	  blue.	  	  RNA	  is	  shown	  wrapped	  around	  the	  outside	  of	  the	  N	  ring,	  with	  the	  phosphate	  backbone	  in	  cyan	  and	  bases	  in	  black.	  	  
B)	   	  A	  26	  Å	  resolution	  3D	  reconstruction	  of	  the	  helical	  RNP	  complex,	  calculated	  from	   cryo-­‐EM	   negative-­‐stain	   images	   (left),	   and	   modeling	   of	   the	   N	   crystal	  structure	  into	  the	  reconstruction	  using	  the	  crystal	  contacts	  and	  the	  pitch	  of	  the	  EM	  helix	  (right).	  Figures	  from	  Tawar	  et	  al.	  2009.	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1.3.3.2 L	  protein	  The	  large	  protein,	  L,	  is	  the	  RdRp	  component	  of	  the	  polymerase	  complex	  and	  is	  the	  5’-­‐most	  gene	   for	  all	   viruses	  of	   the	  order	  Mononegavirales.	   	  At	  250	  kDa,	  L	  comprises	  almost	  half	  of	  the	  coding	  potential	  of	  the	  RSV	  genome	  and	  is	  similar	  in	   size	   to	   the	   L	   proteins	   of	   other	   paramyxoviruses.	   	   Sequence	   alignment	   of	  paramyxovirus	  L	  proteins	  suggests	  they	  consist	  of	  6	  conserved	  regions	  (CR):	  in	  SeV,	   CRI	   appears	   to	   be	   involved	   in	  N	   recruitment	   and	  P	   binding,	   and	  CRII	   is	  involved	   in	   binding	   the	   N:RNA	   template;	   CRIII	   contains	   the	   enzymatically	  active	  site	  for	  all	  mononegaviruses;	  CRIV	  functions	  as	  the	  cap	  methylase	  in	  SeV	  and	  VSV;	  CRV	   contains	   the	   capping	   enzyme	  motif	   in	  VSV;	  CRVI	  has	  not	  been	  assigned	  (Li	  et	  al.,	  2008b).	  	  There	  are	  still	  no	  crystal	  structures	  available	  for	  a	  complete	  polymerase	  of	  any	  negative	  strand	  RNA	  virus,	  in	  stark	  contrast	  to	  the	  positive	  strand	  RNA	  viruses	  -­‐	  although	  individual	  structures	  of	  the	  component	  proteins	   of	   the	   tripartite	   influenza	   A	   polymerase	   have	   been	   built	   into	   EM	  reconstructions	   of	   the	   polymerase	   complex.	   	   Low	   resolution	   EM	   images	  averaged	  over	  many	  observations	  of	  the	  VSV	  polymerase,	  suggest	  it	  consists	  of	  a	   large	   ring	   domain	   with	   several	   smaller	   appendage	   domains	   (Morin	   et	   al.,	  2013).	  	  	  	  
1.3.3.3 P	  protein	  The	  phosphoprotein	  P	   is	   the	  essential	  co-­‐factor	  of	   the	  L	  protein,	  required	   for	  both	   transcription	   and	   replication,	   possibly	   by	   ensuring	   placement	   of	   the	  polymerase	   on	   the	   RNP	   template.	   	   The	   RSV	   P	   gene	   encodes	   a	   single	   33	   kDa	  protein,	  which	   is	   considerably	   smaller	   than	   the	   subfamily	  Paramyxovirinae	   P	  proteins	  and	  lacks	  their	  alternative	  ORFs	  and	  RNA	  editing	  mechanisms.	  	  Fellow	  pneumovirus	  murine	  pneumonia	  virus	  (MPV)	  does	  have	  an	  second	  ORF	  in	  its	  P	  gene,	   and	   the	   P-­‐2	   protein	   inhibits	   viral	   mRNA	   synthesis	   in	   a	   minigenome	  system	  (Dibben	  et	  al.,	  2008).	  	  There	  is	  little	  structural	  information	  available	  for	  P;	   it	   is	  homotetrameric	  and	  forms	  interactions	  with	  L,	  N,	  and	  M2-­‐1.	   	  RSV	  P	   is	  constitutively	  phosphorylated	  at	   five	   sites	  but	   the	   role	  of	   this	  modification	   is	  not	   known;	   unphosphorylated	   bacterially-­‐expressed	   P	   protein	   cannot	   form	  tetramers	  without	   in	  vitro	   phosphorylation,	   and	   serine	   to	   alanine	  mutants	  of	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key	   phosphorylation	   sites	   reduced	   N-­‐binding	   by	   coimmunoprecipitation.	  	  However,	  ablation	  of	  phosphorylation	  does	  not	  seem	  to	  affect	  replication	  of	  a	  minigenome	  in	  mammalian	  cells,	  and	  phosphoablatant-­‐P	  virus	  can	  be	  rescued	  by	   reverse	   genetics	   (Lu	  et	   al.,	   2002).	   	   Phosphorylation	  of	  P	   at	   threonine	  108	  has	   been	   shown	   to	   specifically	   prevent	   the	   P:M2-­‐1	   interaction	   (Asenjo	   et	   al.,	  2006).	  	  
1.3.3.4 M2	  gene	  The	  M2	  gene	  is	  unique	  to	  the	  subfamily	  Pneumovirinae	  and	  does	  not	  appear	  to	  have	  a	  homologue	  in	  the	  subfamily	  Paramyxovirinae,	  although	  VP30	  protein	  of	  the	   family	  Filoviridae	   Ebola	   virus	  has	   some	   similarities	   (see	  below).	   	  The	  M2	  gene	  is	  transcribed	  into	  a	  single	  mRNA,	  which	  is	  translated	  into	  two	  proteins	  from	  overlapping	  open	  reading	  frames:	  M2-­‐1	  and	  M2-­‐2.	  	  The	  translation	  of	  the	  3’	  M2-­‐2	   ORF,	   whose	   3	   possible	   start	   codons	   are	   upstream	   of	   the	  M2-­‐1	   stop	  codon,	   is	   by	   a	   coupled	   translation	  mechanism	   that	   had	   not	   been	   previously	  described	  in	  any	  eukaryotic	  system	  prior	  to	  its	  discovery	  in	  RSV	  (Ahmadian	  et	  al.,	  2000).	   	  M2-­‐2	  translation	  requires	  the	  termination	  of	  M2-­‐1	  translation	  and	  the	  reverse	   translocation	  of	   the	  host	   ribosome	   to	   reinitiate	   translation	  at	   the	  M2-­‐2	   AUG.	   	   Truncation	   analysis	   of	   the	   M2-­‐1	   ORF	   showed	   that	   virtually	   the	  whole	   M2-­‐1	   sequence	   was	   required	   to	   achieve	   wild-­‐type	   levels	   of	   reporter	  expression	  from	  the	  downstream	  open	  reading	  frame,	  suggesting	  that	  an	  RNA	  secondary	  structure	  requiring	  most	  of	  the	  M2-­‐1	  mRNA	  may	  be	  involved	  in	  the	  coupling	   process	   (Gould	   and	   Easton,	   2005).	   This	   was	   supported	   by	   Mfold	  predictions	   and	   the	   observation	   that	   moving	   the	   M2-­‐1	   stop	   codon	   further	  downstream	  of	  the	  M2-­‐2	  AUG	  codons	  prevents	  M2-­‐2	  translation,	  possibly	  as	  a	  ribosomal	  interaction	  with	  an	  M2-­‐1	  mRNA	  secondary	  structure	  element	  is	  no	  longer	   sterically	   favourable	   (Ahmadian	   et	   al.,	   2000).	   	   A	   similar	   process	   has	  been	  demonstrated	  in	  the	  pneumovirus	  MPV	  and	  the	  metapneumovirus	  AMPV	  (Gould	  and	  Easton,	  2007),	  and	  the	  variation	  in	  M2-­‐2	  expression	  levels	  appears	  to	  be	  determined	  by	  the	  secondary	  structure	  imparted	  by	  the	  upstream	  M2-­‐1	  sequence.	   	   Coupled	   translation	  has	   also	  been	   reported	   in	   two	   caliciviruses,	   a	  positive	  strand	  RNA	  virus	  family.	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   The	  protein	  products	  of	  the	  two	  overlapping	  M2	  ORFs	  are	  M2-­‐1,	  a	  22.15	  kDa	  transcriptional	  antiterminator	  that	  increases	  polymerase	  processivity	  and	  is	  essential	  for	  transcription	  but	  dispensable	  for	  replication	  (described	  it	  detail	  below),	  and	  M2-­‐2,	  a	  11	  kDa	  protein	  that	  was	  proposed	  to	  regulate	  the	  balance	  between	   viral	   transcription	   and	   replication	   (Bermingham	  and	  Collins,	   1999).	  	  Expression	   of	   M2-­‐2	   in	   vitro	   was	   found	   to	   increase	   viral	   replication	   and	  decrease	   transcription,	   although	   data	   on	   the	   precise	   role	   of	   M2-­‐2	   are	  conflicting	  and	  ΔM2-­‐2	  viruses	  are	  still	   viable,	   if	   attenuated,	   in	   cell	   culture.	   	  A	  regulatory	   role	   for	   M2-­‐2	   is	   in	   line	   with	   the	   control	   over	   its	   expression	   that	  results	   from	   the	   inefficient	   nature	   of	   coupled	   translation	   (Gould	   and	   Easton,	  2007),	   and	  a	   similar	   role	  has	  been	   identified	   for	  M2-­‐2	  of	  MPV	   (Dibben	  et	  al.,	  2008).	  	  	  	  
1.3.4 Replication	  and	  its	  differentiation	  from	  transcription	  
Replication	   of	   the	   RSV	   genome	   is	   via	   a	   full	   genomic-­‐length,	   encapsidated,	  positive-­‐sense	   antigenomic	   intermediate,	   from	   which	   an	   encapsidated	  negative-­‐sense	  genome	  is	  synthesised;	  both	  antigenome	  and	  genome	  synthesis	  require	  de	  novo	  synthesis	  of	  the	  N	  protein	  for	  concurrent	  encapsidation	  of	  the	  nascent	  RNA.	  	  The	  5’	  genomic	  trailer	  region	  contains	  the	  reverse	  complement	  of	  the	  3’	  leader	  promoter,	  resulting	  in	  a	  trailer	  complementary	  (TrC)	  promoter	  at	   the	   3’	   end	   of	   the	   antigenomic	   intermediate.	   	   The	   TrC	   promoter	   directs	   a	  higher	   rate	   of	   replication	   than	   the	   leader	   region	   promoter,	   resulting	   in	   an	  increased	  ratio	  of	  genome	  to	  antigenome	  synthesis	  (Fearns	  et	  al.,	  2000).	  	  This	  difference	  in	  promoter	  strength	  may	  be	  important	  for	  ensuring	  the	  majority	  of	  progeny	   virions	   contain	   negative	   sense	   genomes,	   as	   is	   the	   case	   with	   rabies	  virus.	  	  	  Most	  importantly,	  replication	  differs	  from	  transcription	  in	  that	  the	  viral	  polymerase	   complex	   must	   bypass	   the	   cis-­‐acting	   signals	   for	   termination	   and	  synthesise	   a	   copy	   of	   the	   entire	   genome	   –	   a	   process	   that,	   counter-­‐intuitively,	  does	   not	   require	   the	   polymerase	   processivity	   factor,	   M2-­‐1.	   	   How	   the	   same	  promoter	  and	  RdRp	  achieve	  both	  of	  these	  mutually	  exclusive	  processes	  is	  still	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debated.	   	   Historically,	   there	   are	   two	   proposed	  models	   for	   how	   transcription	  and	  replication	  are	  differentiated:	  	  Model	  1	  suggests	  that	  the	  polymerase	  complex	  initiates	  RNA	  synthesis	  at	   the	   first	   3’	   nucleotide	   and	   transcribes	   the	   leader	   region.	   	   During	  transcription	   this	   sequence	   will	   be	   terminated	   and	   released,	   allowing	   the	  polymerase	   to	   reinitiate	  at	   the	   first	  gene	  start	   signal.	   	  During	   replication,	   the	  leader	  RNA	  is	  concurrently	  encapsidated	  and	  is	  not	  terminated,	  thus	  synthesis	  continues	  along	  the	  whole	  length	  of	  the	  genome.	   	  The	  presence	  or	  absence	  of	  sufficient	   soluble	   N	   protein	   is	   thought	   to	   be	   the	   ‘switch’	   between	   the	   two	  modes.	  	  	  Model	   2	   suggests	   that	   there	   are	   two	   pools	   of	   polymerase:	   a	  ‘transcriptase’	   composed	   of	   L,	   P	   and	  M2-­‐1	  which	   scans	   along	   to	   the	   first	   GS	  signal	  and	  initiates	  mRNA	  synthesis	  independently	  of	  leader	  transcription;	  and	  a	   ‘replicase’	   composed	   of	   L	   and	   P,	  which	   initiates	   at	   the	   first	   nucleotide	   and	  transcribes	   the	   whole	   genome,	   including	   the	   leader	   sequence	   (Curran	   and	  Kolakofsky,	  2008,	  Whelan,	  2008,	  Banerjee,	  2008).	  There	  is	  evidence	  to	  support	  both	  models.	  	  Other	  members	  of	  the	  family	  
Paramyxoviridae	   have	   demonstrated	   distinct	   pools	   of	   polymerase	   complexes	  (model	  2)	  that	  vary	  in	  their	  composition	  and	  post-­‐translational	  modifications,	  such	  as	  VSV	  (Qanungo	  et	  al.,	  2004).	  	  The	  crystal	  structure	  of	  RSV	  N:RNA	  shows	  that	  the	  3’	  polymerase	  recruitment	  sequence	  and	  the	  first	  gene	  start	  signal	  are	  spatially	   close	   together	   (figure	   1.5),	   adding	   support	   to	   the	   idea	   of	   leader-­‐independent	   initiation	   (model	   1).	   	   However,	   recent	   developments	   in	   the	  methods	   of	   analysing	   RNA	   synthesis	   initiation	   in	   vitro	   provide	   new	   insights	  into	  a	  model	  1-­‐type	  mechanism:	  	  	  Since	   the	   successful	   expression	   of	   recombinant	   RSV	   L	   protein,	   an	   in	  
vitro	   RNA	   synthesis	   assay	  has	  been	  developed	  based	  on	   the	   assumption	   that	  the	  N	  protein	   flexes	   to	   temporarily	   expose	   the	  viral	   genome	   to	   the	  RdRp	   (as	  was	  revealed	  by	  the	  N:RNA	  crystal	  structure	  for	  RSV,	  Tawar	  et	  al.,	  2009),	  and	  that	  this	  action	  can	  be	  recapitulated	  using	  a	  naked	  RNA	  oligonucleotide	  (Noton	  et	   al.,	   2012).	   	  Data	   from	   this	   system	  are	   recent	  and	  constantly	   changing,	   and	  the	  latest	  publications	  indicate	  that	   initiation	  of	  RNA	  synthesis	  at	  both	  leader	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and	   trailer	   complementary	   promoters	   is	   significantly	   more	   complex	   than	  previously	  thought.	   	  The	  RSV	  polymerase	  is	  able	  to	  not	  only	  initiate	  at	  the	  1+	  position	  of	  the	  Le	  promoter,	  but	  also	  at	  3+	  position	  in	  response	  to	  a	  gene-­‐start-­‐like	   sequence	  within	   the	   promoter	   (Tremaglio	   et	   al.,	   2013).	   	   This	   is	   the	   first	  example	  of	  non-­‐1+	  transcription	  initiation	  in	  a	  non-­‐segmented	  negative	  strand	  RNA	   virus,	   and	   has	   led	   to	   the	   suggestion	   that	   these	   different	   initiation	   sites	  may	   differentiate	   transcription	   from	   replication	   as	   follows	   (possible	   model	  outlined	  in	  figure	  1.6):	  during	  replication,	  the	  RdRp	  initiates	  at	  1+	  and	  becomes	  concurrently	   encapsidated,	   synthesising	   a	   full	   genomic	   length	   RNA;	   during	  transcription,	   the	  RdRp	   initiates	   at	   3+	   and	  begins	   transcription	  of	   the	   leader	  region,	  which	  is	  prematurely	  terminated	  at	  an	  uncharacterised	  signal	  in	  the	  5’	  of	   the	   leader	   (possibly	   explaining	   the	   requirement	   of	   this	   region	   for	  transcriptional	   efficiency),	   allowing	   the	   RdRp	   to	   scan	   along	   to	   the	   first	   gene	  start	   sequence	  and	   reinitiate	   transcription	   (figure	  1.6).	   	  This	   is	   supported	  by	  the	   identification	   of	   abortive	   Le	   transcripts	   by	   primer	   extension	   of	   RNA	  purified	   from	  RSV	   infected	   cells.	   	   There	   is	   also	   evidence	   to	   suggest	   that	  RNA	  synthesis	   from	   the	  TrC	  promoter	   in	   the	  3’	   antigenome	  can	  also	   initiate	  at	  3+	  position	  during	   replication,	   and	   that	   the	   viral	   polymerase	   can	   add	  additional	  nucleotides	   to	   the	   3’	   antigenome	   in	   a	   back-­‐priming	   mechanism	   similar	   to	  Borna	  disease	  virus	  (Noton	  et	  al.,	  2012).	  	  The	  implication	  of	  either	  of	  these	  two	  mechanisms	  is	  not	  currently	  understood.	  Taken	   together,	   the	   newly	   discovered	   complexity	   of	   RSV	   polymerase	  interactions	  with	  the	  viral	  promoters	  provides	  an	  attractive	  theory	  for	  how	  the	  mutually	  exclusive	  processes	  of	  transcription	  and	  replication	  are	  differentiated	  on	   a	   molecular	   level,	   and	   the	   functional	   data	   presented	   in	   this	   thesis	   may	  support	  this	  mechanism	  and	  suggest	  an	  integral	  role	  for	  M2-­‐1	  in	  the	  process.	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Figure	  1.6	  Model	  for	  transcription	  and	  RNA	  replication.	  	  	  
A)	  Transcription:	   the	   transcriptionally	  competent	  polymerase	  complex	  (blue;	  L,	  P	  and	  M2-­‐1	  proteins)	  enters	   the	  genome	  at	   the	  3’	  end	  of	   the	   template	  and	  binds	  to	  nucleotides	  3	  to	  12.	  	  RNA	  synthesis	  is	  initiated	  opposite	  position	  +3	  of	  the	   Le	   (1)	   at	   a	   gene	   start-­‐like	   sequence	   (underlined).	   After	   the	   synthesis	   of	  approximately	   25	  nt,	   the	  RdRp	   reaches	   a	   checkpoint	   and	   aborts	   synthesis	   of	  the	  Le	  RNA	  (2).	  The	  RdRp	  is	  now	  poised	  to	  scan	  the	  template	  to	  locate	  the	  first	  gene	  start	  signal	  at	  position	  +45	  (red)	  and	  reinitiate	  RNA	  synthesis	  (3).	  B)	  RNA	  replication	   occurs	   if	   the	   RdRp	   initiates	   at	   +1	   (4)	   and	   the	   RNA	   becomes	  concurrently	   encapsidated	   with	   N	   protein	   (orange)	   before	   the	   ~25	   nt	  checkpoint	  (5).	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1.3.5 Assembly	  
The	   release	   of	   progeny	   virus	   can	   be	   detected	   10	   to	   12	   hours	   post	   infection,	  implying	  that	  assembly	  begins	  not	  long	  after	  viral	  proteins	  are	  detected	  in	  the	  cytoplasm	   (4-­‐6	   hours	   p.i.).	   	   Release	   peaks	   after	   24	   hours,	   and	   continues	   in	  tissue	  culture	  until	  cell	  death	  by	  30	  to	  48	  hours	  p.i.	  (Collins,	  2007). Assembly	   of	   progeny	   virions	   occurs	   at	   the	   apical	   surface	   of	   the	  polarised	  epithelial	  cells,	  using	  the	  host	  apical	  recycling	  endosome	  to	  transport	  the	   matrix	   protein	   and	   RNPs	   to	   the	   viral	   glycoproteins	   at	   the	   plasma	  membrane.	   	   RSV	   proteins	   can	   be	   seen	   to	   localise	   at	   cell	   surface	   lipid	  microdomains	  linked	  to	  the	  cortical	  actin	  network,	  and	  the	  finding	  that	  cellular	  actin	   is	  packaged	   in	  RSV	  virions	  (Radhakrishnan	  et	  al.,	  2010)	  supports	  a	  role	  for	  actin	  in	  assembly,	  although	  this	  is	  not	  well	  defined	  (Shaikh	  et	  al.,	  2012).	  	  A	  popular	  mechanism	   for	   enveloped	  virus	   assembly	  and	   release	   is	   through	   the	  host	   cell	   ESCRT	   pathway	   that	   regulates	   vesicle	   budding	   into	   endosomes:	  retroviruses	  (e.g.	  HIV),	   the	  segmented	  negative	  strand	  RNA	  arenaviruses	  (e.g.	  LCMV),	   and	   most	   of	   the	   order	  Mononegavirales,	   including	   filoviruses,	   some	  rhabdoviruses,	  and	  some	  paramyxoviruses	  (e.g.	  PIV5	  and	  MuV),	  are	  all	  ESCRT-­‐dependent.	   	  However	  other	  paramyxoviruses,	   including	  NiV	  and	  RSV	  itself,	  as	  well	  as	  the	  rhabdovirus	  VSV	  and	  the	  orthomyxovirus	   influenza	  A,	  are	  ESCRT-­‐independent	  and	  rely	  on	  as	  yet	  undefined	  mechanisms	  (reviewed	  in	  Harrison	  et	   al.,	   2010).	   	   The	   RSV	   matrix	   protein	   is	   assumed	   to	   be	   central	   to	   the	  coordination	  of	  virion	  assembly,	  binding	  the	  glycoproteins,	  viral	  RNPs	  and	  the	  lipid	  membrane	  (Ghildyal	  et	  al.,	  2002,	  Ghildyal	  et	  al.,	  2005b).	  	  	  
1.3.5.1 M	  protein	  The	  RSV	  matrix	  protein,	  M,	   is	  25	  kDa	  hydrophobic	  protein	  that	  is	  essential	  to	  virion	  morphogenesis.	   	  The	  crystal	  structure	  of	  RSV	  M	  (figure	  1.7)	  shows	  two	  compact	   N-­‐	   and	   C-­‐terminal	   domains	   with	   a	   linker	   region,	   and	   an	   extensive	  continuous	  patch	  of	  positive	  electrostatic	  surface	  potential	  covering	  one	  whole	  face	  of	  the	  monomer,	  which	  likely	  mediates	  the	  membrane	  association	  (Money	  et	  al.,	  2009).	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M	  has	  been	  shown	  to	  silence	  viral	  transcription	  in	  preparation	  for	  RNP	  packaging	   –	   a	   role	   that	   has	   been	   demonstrated	   for	   other	   M	   proteins	   of	   the	  family	   Paramyxoviridae	   (Ghildyal	   et	   al.,	   2002);	   transcription	   of	   purified	   RSV	  RNPs	  in	  the	  presence	  of	  M	  protein	  was	   increased	  upon	  addition	  of	  M-­‐specific	  antibodies	  that	  render	  M	  non-­‐functional.	   	  The	   interaction	  between	  M	  and	  the	  RNPs	   is	   also	   suggested	   to	   recruit	   the	   RNPs	   to	   the	   plasma	   membrane	   for	  inclusion	  in	  nascent	  virions	  (Ghildyal	  et	  al.,	  2002),	  and	  has	  been	  proposed	  to	  be	  mediated	  by	  an	  M:M2-­‐1	  interaction.	  	  This	  is	  based	  on	  immunofluorescence	  co-­‐localisation	   of	   M	   and	   viral	   inclusion	   bodies	   in	   transfected	   cells	   being	  dependent	   on	   M2-­‐1	   expression	   (Li	   et	   al.,	   2008a),	   and	   is	   supported	   by	   the	  suggestion	   of	   an	   additional	   matrix-­‐like	   layer	   below	   the	   M	   layer	   in	   virions	  visualised	   by	   cryo-­‐EM	   (figure	   1.2)	   (Liljeroos	   et	   al.,	   2013).	   	   However	   this	  interaction	  could	  not	  be	  shown	  by	  co-­‐immunoprecipitation	  in	  transfected	  cells	  and	  the	  assignment	  of	  M2-­‐1	  to	  the	  second	  matrix	  layer	  is	  speculative,	  due	  to	  a	  lack	  of	  immunogold	  staining.	  	  Residues	   120-­‐170	   of	   M	   are	   required	   for	   non-­‐specific	   RNA	   binding	  (Rodríguez	   et	   al.,	   2004),	   and	   this	   has	   been	   linked	   to	   its	   nuclear	   localisation.	  	  The	   M	   protein	   has	   been	   detected	   in	   the	   nucleus	   during	   early	   infection	   by	  confocal	   microscopy,	   like	   other	   paramyxovirus	   M	   proteins	   (VSV,	   NDV,	   SeV),	  and	   has	   been	   linked	   to	   a	   decrease	   in	   host	   cell	   transcription	   (Ghildyal	   et	   al.,	  2003).	   	   The	   transport	   of	  RSV	  M	   to	   the	  nucleus	   is	   thought	   to	   be	  mediated	  by	  direct	  binding	  to	  importin	  β1	  (a	  host	  protein	  responsible	  for	  transport	  through	  nuclear	   pores)	   by	   the	   M	   protein	   RNA	   binding	   region,	   which	   is	   sufficient	   to	  relocalise	  GFP	  in	  transfected	  cells	  (Ghildyal	  et	  al.,	  2005a).	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Figure	  1.7	  Crystal	  structure	  of	  RSV	  M	  protein.	  	  	  
Top,	  ribbon	  structure	  displaying	  the	  two	  β-­‐sheet	  domains,	  N-­‐terminal	  in	  blue	  and	  C-­‐terminal	   in	  yellow.	   	  The	  linker	  domain	  is	   in	  red.	   	  Bottom,	  approximate	  electrostatic	  surface	  potential	  of	  M	  with	  charge	  coloured	  blue	  (positive)	  to	  red	  (negative),	  generated	  in	  PyMOL.	  PDB	  2VQP.	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1.3.6 Other	  viral	  proteins	  
	  
1.3.6.1 SH	  protein	  The	   small	   hydrophobic	   (SH)	   protein	   of	   RSV	   is	   the	   third	   transmembrane	  glycoprotein,	  encoded	  by	  all	  pneumovirinae	  and	  some	  paramyxovirinae	   from	  the	  Rubulavirus	  genus	  –	  parainfluenza	  virus	   type	  5	  and	  mumps	  virus	  (Collins	  and	  Crowe	   Jr,	  2007).	   	   In	  RSV,	   the	  SH	  polypeptide	   is	  7.5	  kDa	  but	  has	  multiple	  glycosylated	   and	   N-­‐linked-­‐sugar	   forms.	   	   An	   SH	   solution	   NMR	   structure	   has	  recently	   shown	   that	   the	   protein	   forms	   pentameric	   ion	   channels	   with	   non-­‐specific	  cation	  channel	  activity,	  demonstrated	  with	  whole-­‐cell	  patch	  clamping	  (Gan	   et	   al.,	   2012),	   and	   so	   SH	   is	   now	   classed	  with	   other	   viroporins	   –	   such	   as	  HCV	  p7	  and	   IAV	  M2	  –	  characterised	  by	   their	   transmembrane	  amphipathic	  α-­‐helices	   that	   form	  channel	  pores.	   	  Regulation	  of	   this	  channel	  activity	   in	  RSV	   is	  likely	  to	  be	  by	  pH-­‐dependent	  protonation	  of	  a	  conserved	  luminal	  histidine,	  as	  with	   influenza	  A	  M2	  (figure	  1.8).	   	  The	  role	  of	  RSV	  SH	   in	  viral	   infection	   is	  not	  clear,	   as	   ΔSH	   viruses	   are	   viable	   in	   vitro	   and	   are	   the	   focus	   of	   several	   live-­‐attenuated	  vaccine	  candidates.	   	   In	   infected	  cells,	  SH	  accumulates	  at	   the	  Golgi,	  endoplasmic	   reticulum	   and	   the	   plasma	   membrane,	   and	   is	   capable	   of	  permeabilising	   such	  membranes	   in	  vitro.	   	   Paramyxovirus	  SH	  proteins	  appear	  to	  inhibit	  apoptosis	  in	  mammalian	  cell	  lines,	  in	  direct	  contrast	  to	  the	  caspase	  3-­‐mediated	  apoptosis	  induced	  by	  other	  viroporins,	  e.g.	  IAV	  M2	  and	  poliovirus	  2B	  (Madan	  et	  al.,	  2008).	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Figure	  1.8	  NMR	  structure	  of	  SH	  protein.	  	  	  Solution	   NMR	   structure	   of	   the	   SH	   monomer,	   modelled	   in	   the	   most	   likely	  pentameric	   complex,	   shows	   the	   formation	  of	  an	   ion	  channel	   structure	  with	  a	  pore	  of	  ~3.5	  Å	  at	  its	  narrowest.	  	  Figure	  from	  Gan	  et	  al.	  2012.	  	  	  	  	  
1.3.6.2 NS1	  and	  NS2	  proteins	  Non-­‐structural	  proteins	  1	  and	  2	  are	  the	  3’-­‐most	  genes	  of	  RSV	  and	  are	  unique	  to	  the	   Pneumovirus	   genus.	   	   They	   are	   not	   essential	   for	   virus	   growth,	   but	   their	  deletion	  results	  in	  attenuation	  as	  their	  role	  is	  in	  immune	  evasion;	  NS1	  appears	  to	   have	   a	   variety	   of	   effects	   on	   the	   host	   immune	   system,	  many	   of	   which	   are	  augmented	   by	  NS2.	   	   In	   transfected	   cells,	  NS1	   and	  NS2	   form	  both	   homo-­‐	   and	  hetero-­‐mers	  of	  unknown	  stoichiometry,	  and	  these	  oligomers	  appear	  to	  change	  the	   localisation	  of	   the	  proteins:	  NS1	  alone	   is	   found	  diffusely	   in	   the	  cytoplasm	  and	   in	   nuclear	   puncta,	   but	   when	   co-­‐expressed	   with	   NS2	   it	   relocates	   to	   the	  mitochondria	  (Swedan	  et	  al.,	  2011).	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NS1	   and	   NS2	   are	   known	   to	   inhibit	   interferon-­‐α/β:	   NS2	   prevents	   the	  nuclear	  translocation	  of	  IRF3,	  a	  transcription	  factor	  for	  interferon	  expression;	  NS1	   supresses	   IFN-­‐induced	   signalling	   by	   targeting	   components	   of	   the	   signal	  transduction	  pathway	  for	  proteasomal	  degradation,	  and	  has	  been	  suggested	  to	  act	   as	   a	   ubiquitin	   E3	   ligase	   (Collins	   and	  Melero,	   2011).	   	   A	   similar	   interferon	  antagonism	  is	  assigned	  to	  the	  C	  protein	  of	  the	  subfamily	  Paramyxoviridae,	  such	  as	  for	  SeV.	   	  A	  role	  for	  NS1	  in	  suppressing	  the	  CD8+	  cytotoxic	  T-­‐cell	  response,	  whilst	  simultaneously	  promoting	  the	  proliferation	  of	  IL-­‐4-­‐producing	  Th2-­‐type	  CD4+	  T-­‐cells	  (creating	  a	  positive	  feedback	  amplification	  of	  the	  Th2	  response),	  confirms	   that	   NS1	   promotes	   the	   immune-­‐mediated	   pathogenesis	   that	   is	  characteristic	  of	  RSV	  infection	  (Munir	  et	  al.,	  2011).	  	  	  	   Interestingly,	  expression	  of	  NS1	  has	  an	  inhibitory	  effect	  on	  transcription	  and	  replication	  of	  the	  minigenome	  system	  (Atreya	  et	  al.,	  1998).	  	  How	  and	  why	  NS1	  might	  mediate	   this	   role	   is	   unknown,	   although	   an	   NS1:P	   interaction	   has	  been	  suggested	  by	  yeast-­‐two-­‐hybrid	  experiments.	  	  	  	  	  	  	  
1.4 M2-­‐1	  PROTEIN	  
1.4.1 Discovery	  
The	  protein	  product	  of	   the	  5’	  ORF	  of	   the	  RSV	  M2	  gene	  was	   first	  predicted	   to	  encode	   a	   small,	   basic	   polypeptide	   of	   22.15	   kDa.	   	   Early	   virion	   dissociation	  experiments	   found	   it	   co-­‐purified	   in	   the	   envelope	   fraction	   with	   the	   matrix	  protein	  and	  so	  was	  named	  ‘envelope-­‐associated	  22K	  protein’,	  later	  the	  ‘matrix-­‐like	   protein	   1’	   or	   M2-­‐1	   (Collins	   and	   Wertz,	   1985),	   and	   proposed	   to	   be	   a	  structural	   membrane	   protein.	   	   Initially,	   characterisation	   of	   M2-­‐1	   proved	  difficult	  due	  to	  its	  heterogeneity	  when	  analysed	  by	  reducing	  and	  non-­‐reducing	  SDS-­‐PAGE;	   at	   least	   five	   species	   between	   14	   and	   24	   kDa	   can	   be	   visualised	   in	  lysates	   of	   RSV-­‐infected	   cells	   using	   specific	  monoclonal	  M2-­‐1	   antibodies,	   and	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their	   electrophoretic	   mobilities	   vary	   depending	   on	   the	   conditions	   of	  electrophoresis	  and	  the	  cell	  type	  (Routledge	  et	  al.,	  1987).	  	  This	  was	  suggested	  to	   be	   caused	   by	   incomplete	   reduction	   of	   intra-­‐molecular	   disulphide	   bridges	  between	  the	  4	  cysteines	  in	  M2-­‐1.	  	  	  Sequence	  alignments	  show	  M2-­‐1	  has	  92	  %	  amino	  acid	  identity	  between	  RSV	   subgroups	   A	   and	   B	   (Collins	   et	   al.,	   1990),	   making	   it	   one	   of	   RSV’s	   more	  highly	   conserved	  proteins,	  but	  only	  43	  %	  and	  36	  %	   identity	  with	  M2-­‐1	   from	  the	  pneumovirus	  MPV	  and	  the	  metapneumovirus	  HMPV,	  respectively.	  	  	  	  	  	  	  The	   first	   indications	   that	   M2-­‐1	   was	   actually	   involved	   in	   viral	   RNA	  synthesis,	  as	  opposed	  to	  being	  a	  structural	  membrane	  protein,	  came	  from	  early	  minigenome	   experiments.	   	   The	   established	   reverse	   genetics	   system	   for	   RSV,	  termed	   the	   minigenome	   system,	   recapitulates	   viral	   transcription	   and	  replication	  of	  a	  bi-­‐	  or	  tri-­‐cistronic	  subgenomic	  replicon:	  3’	  leader	  and	  5’	  trailer	  regions	  flank	  two/three	  transcriptional	  units	  (viral	  proteins	  or	  reporters	  such	  as	   luciferase)	   separated	  by	   authentic	   viral	   gene	   junctions,	   containing	   the	   cis-­‐acting	   gene	   end	   and	   gene	   start	   signals.	   	   This	   minigenome	   is	   cloned	   in	  antigenome	  sense	  into	  a	  cDNA	  under	  the	  control	  of	  T7	  promoter,	  meaning	  that	  primary	   T7	   RNA	   polymerase	   transcription	   results	   in	   genome	   sense	   RSV	  minigenome	   synthesis.	   	   Transfection	   of	   this	   construct	   into	   mammalian	   cells	  expressing	   T7	   RNA	   polymerase,	   along	  with	   support	   plasmids	   coding	   for	   the	  viral	   proteins	   required	   for	   replication	   and	   transcription,	   results	   in	  amplification	  of	  the	  minigenome	  and	  expression	  of	  its	  encoded	  proteins	  (Yu	  et	  al.,	   1995).	   	   Supplying	   the	   full-­‐length	  RSV	   genome	   allows	   rescue	   of	   infectious	  virus	  by	  this	  method.	  Support	   plasmids	   expressing	   L,	   N	   and	   P	   proteins	   were	   found	   to	   be	  necessary	   and	   sufficient	   to	   support	   replication,	   but	   analysis	   of	   the	   RNA	  products	  of	  transcription	  revealed	  a	  smear	  of	  prematurely	  terminated	  species.	  	  Single,	   discrete	   products	   of	   transcription	   could	   only	   be	   achieved	   by	  superinfection	  with	  RSV,	  implying	  that	  another	  viral	  protein	  was	  necessary	  for	  processive	  transcription	  (Grosfeld	  et	  al.,	  1995).	  	  Then	  it	  was	  found	  that	  rescue	  of	   viable	   RSV	   virions	   from	   cDNA	   co-­‐transfection	   required	   M2-­‐1	   in	   trans	  (Collins	  et	  al.,	  1995).	  	  Omission	  of	  M2-­‐1	  from	  the	  minigenome	  system	  did	  not,	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however,	  reduce	  the	  number	  of	  transcription	  initiation	  events,	  as	  determined	  by	  northern	  blot	  against	  the	  5’	  mRNA	  (Collins	  et	  al.,	  1996).	  	  Consequently,	  M2-­‐1	   protein	   was	   termed	   a	   transcriptional	   elongation	   or	   antitermination	   factor	  required	   for	   complete	   and	   efficient	   viral	   mRNA	   transcription,	   but	   not	   for	  replication	  or	  transcription	  initiation.	  	  
1.4.2 Transcription	  antitermination	  
M2-­‐1	   promotes	   processive	   transcription	   through	   two	   distinct	  manifestations	  of	  its	  antitermination	  ability:	  prevention	  of	  premature	  intragenic	  termination,	  and	  the	  read-­‐through	  of	  gene	  end	  signals.	  	  	  The	  polymerisation	  of	  nucleic	  acid	   is	  probabilistic	  by	  nature,	  and	  both	  eukaryotic	  and	  prokaryotic	  polymerases	  have	  evolved	  mechanisms	  to	  increase	  their	  processivity,	  thus	  reducing	  the	  probability	  of	  premature	  polymerase	  ‘fall-­‐off’:	   DNA-­‐dependent	   RNA	   polymerase	   II	   –	   responsible	   for	   synthesis	   of	   all	  mRNAs	   in	  eukaryotes	  –	  employs	  a	  complex	  array	  of	  co-­‐factors	   to	  enable	   it	   to	  transition	  to	  its	  stable	  elongation	  phase,	  and	  an	  equally	  complex	  set	  of	  proteins	  to	   regulate	   its	   termination	   activities	   (Kuehner	   et	   al.,	   2011);	   E.	   coli	   RNA	  polymerase	  combats	  premature	  termination	  of	  its	  ribosomal	  RNAs	  by	  binding	  a	   number	   of	   antitermination	   factors	   (Greenblatt	   et	   al.,	   1993).	   	   Intragenic	  antitermination	   by	   M2-­‐1	   is	   RSV’s	   mechanism	   for	   improving	   transcriptional	  processivity	  of	  the	  viral	  polymerase	  L,	  and	  is	  particularly	  important	  for	  longer	  genes,	  such	  as	  the	  L	  gene	  itself.	  	  The	  second	  aspect	  of	  M2-­‐1	  antitermination	  is	  the	  read-­‐through	  of	  gene	  end	   sequences.	   	   By	   preventing	   termination	   at	   a	   gene	   end,	   the	   polymerase	  complex	   continues	   transcribing	   the	   intergenic	   region	   and	   the	   downstream	  gene,	   synthesising	   ‘read-­‐through	   mRNAs’	   (Hardy	   and	   Wertz,	   1998).	   	   These	  products	  of	  gene	  end	  antitermination	  have	  been	  identified	  in	  RSV	  infected	  cells	  and	   it	   is	   estimated	   that	   read-­‐through	   transcription	   occurs	   10	  %	   of	   the	   time	  during	  natural	  infection.	  	  This	  is	  a	  significantly	  higher	  abundance	  compared	  to	  other	   paramyxoviruses,	   and	   allowed	   them	   to	   be	   used	   to	   map	   the	   RSV	   gene	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order	   (Collins	   and	  Wertz,	   1983),	   but	   whether	   these	   mRNA	   products	   have	   a	  function	  during	  infection	  is	  unknown.	  	  	  The	   process	   of	   reinitiating	   transcription	   after	   scanning	   across	   an	  intergenic	   region	   is	   inefficient:	   For	   VSV,	   only	   ~70	   %	   of	   viral	   polymerases	  reinitiate,	   leading	   to	   a	   gradient	   of	   mRNA	   abundance	   (Barr	   et	   al.,	   2002).	  	  Therefore,	   it	   is	   likely	   that	   read-­‐through	   mRNAs	   created	   by	   M2-­‐1	  antitermination	   at	   gene	   end	   sequences	   serve	   to	   increase	   access	   to	   the	   5’	  genome	   by	   the	   polymerase,	   alleviating	   the	   transcriptional	   gradient.	   	   Similar	  read-­‐through	  mRNAs	  are	  found	  in	  the	  vesiculovirus	  VSV,	  despite	  this	  virus	  not	  encoding	  M2-­‐1	   or	   a	   homologue	   (Masters	   and	   Samuel,	   1984),	   suggesting	   that	  read-­‐through	   of	   gene	   end	   sequences	   is	   intrinsic	   to	   the	   paramyxovirus	  polymerase	   and	   that	   RSV	  M2-­‐1	   acts	   to	   promote	   and	   regulate	   its	   occurrence.	  	  For	   the	   subfamily	  Paramyxovirinae,	   transcriptional	   regulation	   is	  primarily	  by	  taking	  advantage	  of	  the	  polar	  attenuation	  inherent	  in	  sequential	  transcription;	  gene	  order	  has	  evolved	  to	  place	  genes	  required	  in	  highest	  abundance	  at	  the	  5’	  end	  of	  the	  genome.	  How	  M2-­‐1	  prevents	  intra-­‐	  or	  inter-­‐genic	  termination	  is	  not	  known,	  but	  it	   is	   assumed	   that	   M2-­‐1	   somehow	   allows	   the	   polymerase	   complex	   (L-­‐P)	   to	  bypass	  destabilising	  cis-­‐acting	  signals	  within	  the	  genome	  (Fearns	  and	  Collins,	  1999b).	  	  One	  possible	  theory	  suggests	  M2-­‐1	  binds	  to	  L	  and	  directly	  modifies	  its	  processivity,	   however	   given	   that	   M2-­‐1	   is	   dispensable	   for	   replication,	   during	  which	   the	   polymerase	   must	   be	   processive	   enough	   to	   synthesise	   the	   entire	  genome,	   and	   that	  no	  M2-­‐1:L	   interaction	  has	  been	   found,	   this	   seems	  unlikely.	  	  Further	  to	  this,	  supplying	  increasing	  levels	  of	  M2-­‐1	  in	  trans	  in	  the	  minigenome	  system	   did	   not	   affect	   the	   levels	   of	   genome/antigenome	   vs.	   mRNA	  accumulation,	   confirming	   that	   M2-­‐1	   does	   not	   regulate	   the	   role	   of	   the	  polymerase	   between	   replication	   and	   transcription	   (Hardy	   and	   Wertz,	   1998,	  Collins	  et	  al.,	  1996,	  Fearns	  and	  Collins,	  1999b).	  	  A	  role	  for	  temporal	  regulation	  of	  gene	  expression	  has	  also	  been	  discounted	  for	  M2-­‐1,	  as	  the	  relative	  ratios	  of	  viral	  mRNAs	  did	  not	  change	  during	  the	  course	  of	  RSV	  infection	  in	  cell	  culture,	  despite	   an	   increase	   in	   M2-­‐1	   expression	   throughout	   infection	   (Fearns	   and	  Collins,	  1999b)	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   Different	  gene	   junctions	  appear	   to	  have	  different	   sensitivities	   towards	  the	   antitermination	   effects	   of	   M2-­‐1	   (Hardy	   et	   al.,	   1999),	   and	   this	   may	   be	  determined	   by	   the	   level	   of	   deviation	   from	   the	   gene	   end	   consensus	   sequence	  (Sutherland	  et	  al.,	  2001).	  	  Mutation	  of	  gene	  end	  sequences	  to	  be	  less	  ‘gene	  end-­‐like’,	  i.e.	  decreasing	  the	  length	  of	  the	  polyU	  tract	  to	  3	  Us,	  had	  little	  effect	  on	  the	  intrinsic	   level	  of	   termination	   in	   the	  absence	  of	  M2-­‐1,	  but	  caused	  a	  significant	  decrease	   in	   termination	   in	   the	   presence	   of	   M2-­‐1.	   	   This	   suggests	   that	  termination	  efficiency	  is	  regulated	  not	  by	  polymerase	  recognition	  of	  gene	  ends,	  but	  by	  M2-­‐1	  recognition.	  	  	  Events	   at	   the	   leader-­‐NS1	   and	   NS1-­‐NS2	   gene	   junctions,	   the	   first	   two	  junctions	  in	  the	  RSV	  genome,	  appear	  to	  be	  different	  from	  other	  gene	  junctions;	  not	   only	   are	   levels	   of	   read-­‐through	   up	   to	   3	   times	   higher	   in	   natural	   RSV	  infection	   at	   these	   junctions,	   but	   processive	   transcription	   appears	   to	  be	  M2-­‐1	  independent,	   as	   significant	   synthesis	   of	   NS1	   and	   NS2	   mRNAs	   has	   been	  observed	  in	  the	  absence	  of	  M2-­‐1	  (Fearns	  and	  Collins,	  1999b).	  	  This	  had	  led	  to	  the	  suggestion	  that	  this	  may	  represent	  a	  low-­‐grade	  transcription	  program	  that	  allows	   the	   virus	   to	   persist,	   particularly	   in	   light	   of	   the	   immune	   evasion	  functions	  of	  NS1	  and	  NS2.	   	  However,	   it	   is	  not	  known	   if	   transcription	  at	   these	  junctions	  is	  truly	  M2-­‐1	  independent	  in	  the	  context	  of	  viral	  infection	  and	  there	  is	  no	  evidence	  of	  persistent	  RSV	  infection	  in	  humans.	  	  
1.4.3 Binding	  partners	  
	  
1.4.3.1 Proteins	  During	   infection,	  M2-­‐1	  localises	  to	  the	  cytoplasmic	   inclusion	  bodies	  with	  P,	  N	  and	  L	  proteins,	  where	  viral	  transcription	  and	  replication	  are	  thought	  to	  occur	  (Carromeu	   et	   al.,	   2007,	   Garcia	   et	   al.,	   1993).	   	   A	   specific	  M2-­‐1:P	   interaction	   is	  necessary	   for	   M2-­‐1-­‐dependent	   transcription	   (Mason	   et	   al.,	   2003),	   and	   has	  recently	  been	  described	  as	  a	  high-­‐affinity	  interaction	  between	  tetrameric	  P	  and	  tetrameric	  M2-­‐1,	   binding	   in	   1:1	   stoichiometry	   (Esperante	   et	   al.,	   2012).	   	   It	   is	  thought	   that	   binding	   to	   P	   may	   determine	   the	   incorporation	   of	   M2-­‐1	   in	   the	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polymerase	   complex.	   	   The	   interaction	   is	   ablated	   by	   phosphorylation	   of	   P	  protein	   at	   threonine	   108,	   consequently	   abolishing	   M2-­‐1	   transcriptional	  antitermination	   (Asenjo	   et	   al.,	   2006).	   	   The	   residues	   required	   for	   this	  interaction	  have	  not	  been	  precisely	  determined	  for	  either	  protein,	  although	  a	  number	   of	   M2-­‐1	   residues	   have	   been	   proposed	   by	   observing	   NMR	   chemical	  shifts	   when	  monomeric	   M2-­‐158-­‐177	   and	   tetrameric	   P	   were	   mixed	   in	   solution	  (Blondot	  et	  al.,	  2012).	  	   Binding	   of	   M2-­‐1	   to	   the	   M	   protein,	   determined	   in	   a	   cell-­‐free	   binding	  assay,	   has	   been	   suggested	   to	   mediate	   the	   link	   between	   viral	   RNPs	   and	   the	  matrix	  during	  virion	  assembly	  (Li	  et	  al.,	  2008a),	  although	  this	  interaction	  could	  not	  be	  detected	  by	  coimmunoprecipitation	  from	  transfected	  cells.	  	  	   A	  previously	  suggested	  M2-­‐1:N	  interaction	  was	  found	  to	  be	  mediated	  by	  RNA,	  due	  to	  its	  sensitivity	  to	  disruption	  by	  RNase	  A	  (Cartee	  and	  Wertz,	  2001).	  	  
1.4.3.2 RNA	  M2-­‐1	  has	  been	  observed	  to	  bind	  RNA	  in	  vitro	  in	  gel-­‐retardation	  assays	  (Cuesta	  et	  al.,	  2000),	  and	  by	  coimmunoprecipitation	  of	  M2-­‐1	  and	  RNA	  in	  RSV	  infected	  cells	   (Cartee	   and	   Wertz,	   2001).	   	   The	   specificity	   of	   this	   RNA	   binding	   is	   still	  debated:	   	  M2-­‐1	  has	   been	  proposed	   to	   bind	   to	   long	  RNAs	   (>700	  nts)	  with	  no	  sequence	   specificity	   and	   short	   RNAs	   (<80	   nts)	   containing	   the	   antigenomic	  leader	  sequence	  (Cuesta	  et	  al.,	  2000),	  RSV-­‐specific	  mRNAs	  (Cartee	  and	  Wertz,	  2001),	  and	  A-­‐rich	  RNAs	  (Tran	  et	  al.,	  2009).	   	  The	  role	  of	  RNA	  binding	  in	  M2-­‐1	  transcription	  antitermination	  is	  not	  clear,	  but	  it	  may	  be	  that	  binding	  of	  M2-­‐1	  to	  viral	   RNA	   (genome,	   antigenome	   or	   mRNA)	   may	   signal	   the	   polymerase	   to	  ignore	  cis-­‐acting	  signals.	  	  	  	   The	   region	  of	  M2-­‐1	   responsible	   for	  RNA	  binding	  was	   first	   assigned	   to	  residues	  59-­‐153,	  by	  observing	   the	  ability	  of	   truncation	  mutants	   to	  pull-­‐down	  RNA	   in	   cell-­‐free	   assays	   (Tran	   et	   al.,	   2009).	   	   This	   assignment	   also	   led	   to	   the	  suggestion	   that	   RNA	   and	   P	   binding	   by	   M2-­‐1	   are	   mutually	   exclusive	   as	   they	  involve	   the	   same	   regions	   -­‐	   a	   fact	   which	   was	   later	   confirmed	   when	   residues	  involved	  in	  RNA	  and	  P	  binding	  were	  more	  precisely	  mapped	  by	  NMR	  chemical	  shift	   perturbations,	   using	   a	   monomeric	   truncated	   M2-­‐158-­‐177	   (Blondot	   et	   al.,	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2012).	   	  This	  study	  suggested	  that	  RNA	  binding	  was	  indeed	  mediated	  by	  M2-­‐1	  residues	  between	  59	  and	  153,	  particularly	  arginines	  and	  lysines	  located	  within	  a	  region	  of	  positive	  charge.	  	  Interestingly,	  this	  is	  the	  latest	  in	  several	  studies	  to	  conclude	   that	   the	   predicted	   zinc	   finger	   motif	   at	   the	   N-­‐terminus	   of	   M2-­‐1	  (described	  below)	   is	   not	   required	   for	  RNA	  binding	   (Cartee	   and	  Wertz,	   2001,	  Tran	   et	   al.,	   2009),	   despite	   such	  motifs	   frequently	  mediating	   the	   nucleic	   acid	  binding	  ability	  of	  a	  range	  of	  eukaryotic	  proteins,	  e.g.	  transcription	  factors,	  and	  even	  other	  viral	  proteins,	  e.g.	  HIV-­‐1	  nucleocapsid.	  	  	  	  
1.4.4 Phosphorylation	  
M2-­‐1	   is	   known	   to	   require	   phosphorylation	   for	   efficient	   antitermination	  function,	   as	   phosphoablatant	   serine	   to	   alanine	   mutations	   are	   deleterious	   to	  transcription	  in	  the	  minigenome	  system	  (Cartee	  and	  Wertz,	  2001).	   	  However,	  this	   loss	  of	  antitermination	  function	   is	  not	  due	  to	  prevention	  of	  RNA	  binding.	  	  Equally,	   M2-­‐1	   phosphorylation	   does	   not	   appear	   to	   regulate	   the	   interaction	  with	  P	  protein	  (Mason	  et	  al.,	  2003),	  and	  so	  the	  role	  of	  phosphorylation	  is	  not	  known.	  	  M2-­‐1	  purified	  from	  transfected	  cells,	  or	  from	  RSV	  infection,	  is	  resolved	  by	  SDS-­‐PAGE	  as	  two	  electrophoretically	  distinct	  species	  –	  the	  slower	  of	  which	  is	   doubly	   phosphorylated	   (Hardy	   and	   Wertz,	   2000).	   	   The	   sites	   of	  phosphorylation	  have	  separately	  been	  identified	  as	  Thr56	  and	  Ser58	  (Cuesta	  et	  al.,	  2000),	  and	  Ser58	  and	  Ser61	  (Cartee	  and	  Wertz,	  2001).	  	  The	  mechanism	  of	  M2-­‐1	   phosphorylation	   is	   also	   unknown,	   although	   it	   is	   dependent	   on	   the	  predicted	   zinc	   finger	   and	   can	   be	   achieved	   in	  vitro	   by	   casein	   kinase	   I	   (Cartee	  and	  Wertz,	  2001).	  	  	  	  	  
1.4.5 Structure	  
At	   the	  beginning	  of	   this	  project,	  very	   little	  was	  known	  about	   the	  structure	  of	  RSV	  M2-­‐1.	   	   It	   is	  a	  194	  amino	  acid	  (22.15	  kDa)	  basic	  protein	  that	  forms	  stable	  homo-­‐tetramers	   in	   solution,	   determined	   by	   size	   exclusion	   chromatography,	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dynamic	   light	   scattering	   and	   analytical	   ultracentrifugation	   (Tran	   et	   al.,	   2009,	  Esperante	  et	  al.,	  2011).	  	  These	  analyses	  also	  suggest	  that	  M2-­‐1	  has	  an	  extended	  globular	  conformation,	   indicated	  by	   its	   larger	   than	  anticipated	  hydrodynamic	  volume,	   and	   that	   M2-­‐1	   is	   predominantly	   alpha-­‐helical	   by	   circular	   dichroism	  spectroscopy.	   	   The	   M2-­‐1	   tetramer	   was	   found	   to	   be	   strongly	   pH-­‐dependent,	  dissociating	   into	   partially	   folded	  monomeric	   intermediates	   at	   pH	   5,	   with	   no	  significant	  dimeric	  or	  trimeric	  unfolding	   intermediates	  seen	  (Esperante	  et	  al.,	  2011).	  	  	   The	   N-­‐terminus	   of	   all	   M2-­‐1	   proteins	   of	   the	   subfamily	   Pneumovirinae	  contains	  four	  highly	  conserved	  residues,	  3	  cysteines	  and	  a	  histidine,	  that	  have	  been	   predicted	   to	   form	   a	   zinc	   finger	   motif.	   	   This	   motif	   is	   essential	   for	  transcription	   antitermination	   by	   M2-­‐1	   (Esperante	   et	   al.,	   2011,	   Cartee	   and	  Wertz,	  2001,	  Tran	  et	  al.,	  2009)	  and	  it	  is	  thought	  that	  co-­‐ordination	  of	  1	  atom	  of	  zinc	   per	   monomer	   is	   required	   for	   correct	   folding	   and	   stability	   of	   M2-­‐1	  (Esperante	  et	   al.,	   2011).	   	  The	  putative	  Cys3-­‐His1	  motif	  has	  been	   compared	   to	  that	  of	  the	  mammalian	  protein	  Nup475	  (also	  called	  tristetraprolin	  or	  ZFP36),	  which	   regulates	  mRNA	   turnover	   by	   binding	  AU-­‐rich	   regions	   of	  mRNA	  via	   its	  tandem	  Cys3-­‐His1	  zinc	  finger	  motifs	  (discussed	  in	  more	  detail	  in	  Chapter	  4).	  The	   combination	   of	   past	   loss-­‐of-­‐function	   mutants	   and	   truncation	  analyses	   has	   resulted	   in	   the	   assignment	   of	   4	   putative	   M2-­‐1	   domains:	   a	  predicted	   Cys3-­‐His1	   zinc	   finger	   (residues	   7-­‐25);	   an	   oligomerisation	   domain	  between	  amino	  acids	  33	  and	  62;	  a	  globular	  α-­‐helical	  domain	  capable	  of	  binding	  to	   P	   and	   RNA	   (residues	  ~58-­‐177);	   and	   a	   predicted	   unstructured	   C-­‐terminus	  containing	  the	  last	  ~20	  residues	  (Tran	  et	  al.,	  2009,	  Cuesta	  et	  al.,	  2000).	  	  	  Towards	   the	   end	   of	   this	   project,	   a	   solution	   NMR	   structure	   of	   M2-­‐1	  residues	   58-­‐177	   was	   published,	   corresponding	   to	   the	   predicted	   globular	   α-­‐helical	   domain	   (Blondot	   et	   al.,	   2012,	   Dubosclard	   et	   al.,	   2011).	   	   It	   revealed	   a	  single	   globular	   α-­‐helical	   fold	   with	   6	   helices	   and	   extensive	   positive	   surface	  charge	  that	  could	  mediate	  RNA	  or	  P	  binding	  (figure	  1.9).	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Figure	  1.9	  NMR	  structure	  of	  RSV	  M2-­‐158-­‐177.	  	  	  A	   ribbon	   representation	   of	   the	   average	   of	   the	   20	   lowest	   energy	   models.	  	  Residues	  58-­‐177	  of	  M2-­‐1	  formed	  a	  monomeric	  globular	  alpha-­‐helical	  domain,	  coloured	  blue	  through	  to	  red	  (N	  to	  C	  terminus).	  	  	  	  	  
1.4.6 Related	  proteins	  
	  
1.4.6.1 Other	  M2-­‐1	  proteins	  The	   M2	   gene	   is	   unique	   to	   the	   genus	   Pneumovirus	   amongst	   the	   family	  
Paramyxoviridae.	  	  However,	  there	  is	  evidence	  to	  suggest	  that	  the	  M2-­‐1	  protein	  of	  pneumovirus	  murine	  pneumonia	  virus	   (MPV,	  or	  pneumonia	  virus	  of	  mice)	  does	  not	  perform	  the	  same	  function	  in	  its	  cognate	  virus	  life	  cycle	  as	  RSV	  M2-­‐1.	  	  MPV	  M2-­‐1	  is	  expressed	  as	  the	  first	  of	  two	  overlapping	  ORFs	  in	  the	  M2	  mRNA,	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as	  with	  RSV,	  shares	  ~40	  %	  amino	  acid	   identity,	  and	   is	   functionally	  similar	  at	  low	   concentrations.	   	   At	   high	   concentrations,	   however,	   MPV	   M2-­‐1	   has	   an	  inhibitory	   effect	   on	   viral	   replication	   –	   not	   seen	  with	   RSV	  M2-­‐1	   or	   the	  M2-­‐1	  protein	  of	  metapneumovirus	  AMPV,	  which	  has	  RSV-­‐like	  function	  (Dibben	  et	  al.,	  2008,	  Naylor	  et	  al.,	  2004).	  	  There	  has	  been	  no	  biophysical	  analysis	  of	  either	  of	  these	  proteins,	  however.	  	  
1.4.6.2 Ebola	  VP30	  Ebola	  virus,	  a	  filovirus	  of	  the	  order	  Mononegavirales,	  encodes	  a	  protein	  called	  VP30,	   described	   as	   a	   minor	   nucleoprotein	   as	   it	   forms	   part	   of	   the	   viral	   RNP	  complex.	  	  VP30	  appears	  to	  share	  many	  of	  the	  same	  properties	  are	  RSV	  M2-­‐1:	  it	  is	  predominantly	  basic,	  with	  clusters	  of	  arginine	  and	  lysine	  residues	  suggested	  to	   bind	   RNA;	   it	   has	   a	   highly	   conserved	   Cys3-­‐His1	   zinc	   finger	   motif;	   it	   is	  phosphorylated	   and	   this	   plays	   a	   role	   in	   regulating	   VP30	   function;	   and	   it	  functions	   as	   a	   transcriptional	   regulator	   that	   is	   not	   required	   for	   replication	  (Biedenkopf	  et	  al.,	  2013).	  	  There	  are	  some	  differences,	  however,	  as	  VP30	  forms	  hexamers	   in	   solution,	   binds	   the	   L	   protein	   directly,	   and	   is	   suggested	   to	   be	  involved	   in	   transcription	   at	   the	   level	   of	   initiation,	   a	   role	   that	   has	   been	  discounted	  for	  RSV	  M2-­‐1.	  	  	  The	   two	   proteins	   have	   only	   9	  %	   sequence	   conservation,	   but	   an	   X-­‐ray	  crystal	  structure	  of	  the	  VP30	  C-­‐terminal	  domain	  (Hartlieb	  et	  al.,	  2007)	  revealed	  similarities	  to	  the	  helical	  arrangement	  of	  the	  RSV	  M2-­‐158-­‐177	  core	  domain,	  with	  a	   route-­‐mean-­‐square	   deviation	   (rmsd)	   of	   3.9	   Å	   for	   the	   carbon	   alphas	   of	   92	  aligned	  residues	  (Blondot	  et	  al.,	  2012).	  	  This	  has	  led	  to	  the	  suggestion	  that	  the	  reflection	   of	   functional	   similarity	   in	   structural	   identity,	   may	   result	   in	   a	  common	   mechanism	   of	   transcriptional	   regulation	   for	   RSV	   M2-­‐1	   and	   EBOV	  VP30.	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1.5 MACROMOLECULAR	  X-­‐RAY	  CRYSTALLOGRAPHY	  
1.5.1 Introduction	  and	  comparable	  techniques	  
High	   resolution	   X-­‐ray	   crystallography	   is	   a	   technique	   for	   probing	  macromolecular	  structures,	  and	  accounts	  for	  ~90	  %	  of	  all	  structures	  deposited	  in	  the	  Protein	  Data	  Bank	  (PDB).	   	   It	  uses	  the	  diffraction	  of	  X-­‐rays	  by	  electrons	  within	   a	   crystal	   to	   calculate	   an	   electron	   density	   map,	   into	   which	   an	   atomic	  model	  of	  the	  molecule	  can	  be	  built.	  	  There	  are	  a	  number	  of	  difficulties	  with	  X-­‐ray	   crystallography,	   some	   of	   which	   are	   practical	   (e.g.	   crystal	   growth	   and	  manipulation)	  and	  others	  are	  fundamental	  (e.g.	  the	  ‘phase	  problem’	  described	  in	   Section	   1.5.4),	   however	   the	   ability	   to	   achieve	   resolutions	   that	   are	  theoretically	  only	  limited	  by	  X-­‐ray	  wavelength	  and	  crystal	  quality	  (the	  current	  record	  for	  a	  protein	  structure	  is	  0.48	  Å	  for	  crambin,	  a	  small	  plant	  antimicrobial,	  Schmidt	   et	   al.,	   2011)	   means	   it	   is	   currently	   the	   preferred	   choice	   for	   high	  resolution	  structure	  solution.	  	  	  	   There	   are	   several	   other	   methods	   for	   determining	   protein	   structure,	  each	   of	   which	   have	   their	   advantages	   and	   disadvantages	   over	   X-­‐ray	  crystallography.	   	  The	  most	  popular	  alternative	   is	  nuclear	  magnetic	  resonance	  spectroscopy	   (NMR),	   which	   uses	   the	   fact	   that	   certain	   NMR-­‐active	   magnetic	  nuclei	   (particularly	   1H,	   15N	   and	   13C)	   absorb	   electromagnetic	   radiation	   at	   the	  resonant	  frequency	  determined	  by	  the	  isotope,	  exciting	  these	  nuclei	  to	  a	  high	  energy	   state.	   	   When	   these	   nuclei	   relax	   back	   to	   their	   equilibrium	   state	   they	  release	   radiation,	   the	   frequency	   of	   which	   is	   characteristic	   of	   their	   chemical	  environment	  and	  allows	  the	  mapping	  of	  interatomic	  distances	  (through	  bonds	  and	   through	   space).	   	   This	   results	   in	   an	   ensemble	   of	   possible	   structures	   and	  typically	   the	   quality	   of	   the	   20	  most	   probable	   structures	   is	   assessed	   by	   their	  root	  mean	  square	  deviation	  (rmsd).	  	  NMR	  has	  the	  advantage	  that	  proteins	  are	  observed	   in	   solution	   and	   flexible	   regions	   that	  may	   not	   be	   resolved	   by	   X-­‐ray	  crystallography	   can	   be	   sampled	   in	   multiple	   conformations,	   providing	  information	   about	   the	   dynamics	   of	   protein	   folding.	   	   NMR	   also	   requires	   less	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protein	   at	   lower	   purity,	   and	   samples	   can	   be	   reused	   for	   several	   experiments	  (Egli,	  2010).	  	  However	  there	  are	  several	  disadvantages	  to	  using	  NMR,	  the	  most	  important	  of	  which	  are	  the	  size	  limitation	  (current	  technology	  means	  solution	  NMR	   is	   restricted	   to	   proteins	   <30	   kDa	   in	   the	   majority	   of	   cases)	   and	   the	  resolution;	  NMR	  structures	  are	  not	  assigned	  a	  resolution	  in	  the	  same	  way	  X-­‐ray	  crystal	  structures	  are,	  but	  a	  good	  NMR	  structure	  is	  considered	  to	  equate	  to	  a	  3-­‐3.5	   Å	   X-­‐ray	   crystal	   structure	   i.e.	   inadequate	   resolution	   for	   structure-­‐guided	  drug	  design.	  	  Proteins	  must	  also	  be	  labelled	  with	  15N	  or	  13C,	  which	  can	  result	  in	  altered	  expression	  and	  purification	  requirements,	   and	   they	  must	  be	  stable	  at	  room	  temperature	  in	  buffers	  that	  are	  typically	  below	  physiological	  pH	  (5-­‐6).	  	  In	  the	  case	  of	  RSV	  M2-­‐1,	  the	  large	  size	  of	  the	  physiologically	  relevant	  tetramer	  (90	  kDa),	  its	  poor	  stability	  at	  room	  temperature,	  and	  its	  characterised	  unfolding	  at	  acidic	   pH	   (Esperante	   et	   al.,	   2011),	   meant	   X-­‐ray	   crystallography	   was	   the	  obvious	  choice	  over	  solution	  NMR	  spectroscopy.	  	  	  	  	  	  Single-­‐particle	   reconstruction	   from	   cryo-­‐electron	   microscopy	   (EM)	  images	   can	   provide	   low	   resolution	   information	   about	   the	   general	   shape	   of	  molecules	  (e.g.	  VSV	  polymerase,	  Rahmeh	  et	  al.,	  2010)	  and	  tomography	  allows	  3D	   reconstruction	   by	   combining	   a	   series	   of	   2D	   images	   at	   a	   wide	   range	   of	  viewing	  angles.	  	  However,	  EM	  analysis	  alone	  is	  limited	  to	  molecules	  >150-­‐300	  kDa	  and	  achieves	  resolutions	  lower	  than	  10	  Å;	  the	  power	  of	  EM	  now	  lies	  in	  its	  complementarity	  with	  X-­‐ray	  crystallography,	  as	  crystal	  structures	  of	  subunits	  can	   be	   modelled	   into	   EM	   densities	   (e.g.	   the	   rotavirus	   double-­‐layer	   particle,	  Zhang	  et	   al.,	   2008),	   and	   its	   ability	   to	   simultaneously	   sample	  multiple	  protein	  conformations	  within	  a	  population	  of	  molecules.	  	  	  New	   techniques	   for	   macromolecular	   structure	   determination	   are	  constantly	  being	  developed.	  	  One	  option	  that	  is	  already	  beginning	  to	  contribute	  structural	   data	   to	   the	   PDB	   is	   neutron	   diffraction.	   	   In	   contrast	   to	   X-­‐ray	  crystallography,	   this	  makes	  use	  of	  neutrons	  diffracted	   from	  protons	  within	   a	  crystal,	   instead	  of	   electrons.	   	   This	   has	   the	   advantage	  of	   causing	   considerably	  less	   radiation	   damage	   to	   the	   crystal	   and	   allows	   hydrogens	   to	   be	   visualised,	  providing	   information	   about	   protonation	   states	   and	   hydrogen	   bonding.	  	  However,	   this	   technique	   is	   currently	   not	   widely	   available	   due	   to	   the	   lack	   of	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neutron	   sources	   and	   the	   often-­‐prohibitive	   experimental	   requirements	   (large	  crystals,	   1-­‐7	   day	   data	   collection	   compared	   to	   minutes	   with	   synchrotron	   X–rays).	   	  X-­‐ray	  free-­‐electron	  lasers	  (X-­‐FEL)	  have	  been	  described	  as	  the	  future	  of	  X-­‐ray	   crystallography.	   	   Able	   to	   produce	   ultrashort	   intensely	   brilliant	   X-­‐ray	  pulses	  (10x	  brightness	  of	  synchrotron	  radiation),	  it	  is	  thought	  they	  could	  allow	  the	   collection	   of	   diffraction	   data	   from	   single	   crystals	   before	   the	   onset	   of	  radiation	   damage	   -­‐	   ‘diffraction-­‐before-­‐destruction’	   –	   a	   considerable	   problem	  with	  current	  X-­‐ray	  methodologies	  (Schlichting	  and	  Miao,	  2012).	  	  	  	  
1.5.2 Crystallisation	  
	  
1.5.2.1 Crystal	  growth	  Once	   a	   high-­‐yield	   (mg/mL)	   source	   of	   homogeneous,	   >95	   %	   pure,	   soluble	  protein	  has	  been	  optimised,	  an	  X-­‐ray	  crystallography	  experiment	  begins	  with	  crystallisation.	   	   The	   requirement	   for	   well-­‐ordered,	   high	   quality	   (i.e.	   well-­‐diffracting)	  protein	   crystals	   is	   the	   remaining	  bottleneck	   to	   structure	   solution	  by	   X-­‐ray	   crystallography.	   	   Crystals	   are	   necessary	   because	   the	   intensity	   of	  diffracted	  X-­‐rays	  from	  a	  single	  protein	  molecule	  would	  be	  very	  weak;	  multiple	  copies	  of	  a	  protein	  arranged	  in	  a	  periodic,	  ordered	  lattice	  allows	  amplification	  of	  this	  signal.	  	  To	  grow	  protein	  crystals,	  an	  undersaturated	  solution	  of	  protein	  and	   precipitant	   must	   be	   concentrated	   to	   supersaturation,	   beyond	   the	  concentration	   where	   the	   protein	   is	   soluble	   in	   the	   defined	   mixture	   of	   other	  solutes	  (the	  solubility	  line),	  but	  not	  allowed	  to	  reach	  the	  point	  of	  precipitation	  (disordered	   aggregation).	   	   The	   concentration	   of	   precipitant	   changes	   the	  position	   of	   the	   solubility	   line	   at	   a	   given	   protein	   concentration.	   	   Figure	   1.10	  shows	  a	  solubility	  phase	  diagram,	  illustrating	  the	  relationship	  between	  protein	  and	   precipitant	   concentrations	   –	   which	   varies	   depending	   on	   the	   specific	  protein.	   	   Spontaneous	   nucleation	   (ordered	   aggregation)	   of	   crystals	   occurs	   in	  the	  labile	  zone,	  which	  reduces	  the	  protein	  concentration	  and	  moves	  the	  phase	  back	   into	   the	   metastable	   zone,	   where	   sustained	   crystal	   growth	   can	   occur.	  	  Crystals	  will	  continue	  to	  grow	  in	  the	  metastable	  zone	  until	  either	  the	  protein	  is	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depleted,	  or	  until	  impurities	  are	  incorporated	  into	  the	  lattice	  at	  the	  surfaces	  of	  the	  growing	  crystal.	  	  The	   most	   common	   method	   of	   growing	   protein	   crystals	   is	   vapour-­‐diffusion:	   The	   evaporation	   of	   water	   from	   a	   protein:crystallant	   drop	   as	   it	  approaches	   equilibrium	  with	   a	   reservoir	   of	   crystallant	   (in	   a	   closed	   system),	  concentrates	   both	   protein	   and	   crystallant	   to	   the	   point	  where	   nucleation	   and	  crystal	   growth	   can	   occur.	   	   Crystallant	   solutions	   (or	   ‘mother	   liquor’)	   typically	  contain	   combinations	   of	   precipitants	   (organic	   polyalcohols	   e.g.	   polyethylene	  glycol	   (PEG)),	   salts	   (e.g.	   ammonium	   sulphate	   or	   sodium	   chloride),	   additives	  (e.g.	   detergents,	   metal	   ions,	   reducing	   agents	   etc.)	   and	   buffers.	  	  Protein:crystallant	  drops	  are	  either	   sat	  on	  platforms	  over	  a	   reservoir	   (sitting	  drop)	   or	   suspended	   below	   a	   coverslip	   over	   a	   reservoir	   (hanging	   drop)	   and	  sealed.	  	  Sufficiently	  large	  protein	  crystals	  can	  take	  hours	  or	  weeks	  to	  grow,	  but	  on	  average	  it	  takes	  3-­‐7	  days.	  	  Manipulation	  of	  these	  crystals	  is	  with	  small	  loops,	  in	  which	  the	  crystal	  is	  suspended	  in	  its	  mother	  liquor.	  	  To	  reduce	  the	  radiation	  damage	  induced	  by	  X-­‐rays,	  crystals	  are	  cryo-­‐cooled	  in	  liquid	  nitrogen.	  	  This	  can	  be	   done	   directly	   from	   drops	   if	   sufficient	   cryo-­‐protectant	   is	   present	   in	   the	  mother	   liquor,	  or	  by	   first	  placing	  crystals	   in	   cryo-­‐protectant	   solution	  such	  as	  dimethyl	  sulfoxide	  (DMSO),	  low	  molecular	  weight	  PEG,	  or	  glycerol.	   	  The	  cryo-­‐protectant	  allows	  water	  in	  and	  around	  the	  crystal	  to	  cool	  into	  vitreous	  ice	  (an	  amorphous	   glass)	   rather	   than	   freezing	   as	   ice	   crystals,	  which	   can	   disrupt	   the	  crystal	  lattice	  and	  cause	  high	  background	  diffraction.	  	  
Chapter	  1:	  Introduction	  
	   48	  
Figure	  1.10	  A	  solubility	  phase	  diagram.	  	  	  As	   concentrations	   of	   free	   protein	   and	   precipitant	   increase,	   the	   phase	  moves	  from	  undersaturated	  to	  supersaturated.	  The	  supersaturated	  labile	  zone,	  where	  spontaneous	   nucleation	   occurs,	   is	   followed	   by	   the	   metastable	   zone,	   which	  supports	   sustained	   crystal	   growth.	   	   The	   precipitation	   zone	   results	   in	  disordered	  aggregation	  and	  no	  crystal	  growth.	  	  	  	  
	  
Figure	  1.11	  The	  unit	  cell.	  	  	  The	  minimum	  unit	  that	  describes	  a	  crystal	  lattice	  only	  in	  terms	  of	  translational	  symmetry,	  and	  is	  annotated	  by	  vectors	  a,	  b	  and	  c	  along	  axes	  x,	  y,	  z,	  and	  angles	  α,	  β	  and	  γ.	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1.5.2.2 Crystal	  lattices	  and	  space	  groups	  Protein	   crystals	   are	  made	   of	   periodically	   arranged,	   identical	   repeating	   units	  that	   create	   a	  weakly-­‐interacting	   3D	   lattice	   of	   protein	   and	   solvent	  molecules.	  	  The	  minimum	  unit	  of	  volume	  that	  can	  describe	  the	  crystal	  lattice	  only	  in	  terms	  of	  translational	  symmetry,	  i.e.	  the	  repeating	  unit	  of	  the	  crystal,	  is	  called	  the	  unit	  cell	   and	   is	   described	   in	   figure	   1.11.	   	   The	   unit	   cell	   is	   further	   divided	   into	  asymmetric	   units	   (AU),	   which	   define	   the	   smallest	   unit	   of	   volume	   that	   can	  describe	   the	   unit	   cell	   in	   terms	   of	   translational	   and	   rotational	   symmetry.	   	   In	  terms	  of	  a	  protein	  crystal,	  the	  asymmetric	  unit	  contains	  the	  smallest	  object	  that	  can	   be	   repeated	   to	   make	   the	   entire	   crystal	   and	   the	   unit	   cell	   describes	   how	  multiple	   asymmetric	   units	   are	   symmetrically	   related	   so	   that	   they	   form	   a	  building	   block	   that	   can	   be	   simply	   ‘stacked’	   to	   describe	   the	   entire	   crystal.	  	  Asymmetric	   units	   often	   contain	   oligomers	   of	   proteins	   and	   the	   relationship	  between	  these	  molecules	  is	  called	  non-­‐crystallographic	  symmetry	  (NCS),	  as	  the	  symmetry	   axis	   does	   not	   extend	   throughout	   the	   whole	   unit	   cell.	   	   The	  relationship	  between	  the	  asymmetric	  units	  and	  the	  unit	  cell	   is	  determined	  by	  the	  space	  group	  of	  the	  crystal,	  described	  below.	  	   The	   chirality	   of	   proteins	   means	   only	   translation,	   rotation,	   and	   screw	  axes	  can	  describe	  their	  symmetry,	  not	  mirror	  planes	  or	  inversions.	  	  There	  are	  14	  possible	   crystal	   lattices	   (Bravais	   lattices)	   that	  describe	   the	   crystal	   system	  (the	   relationship	   between	   axis	   lengths	   and	   angles	   in	   the	   unit	   cell)	   and	   their	  centering	   (whether	   they	   have	   lattice	   points	   at	   their	   vertices,	   faces,	   or	  internally).	   	   	   Combined	   with	   the	   11	   chiral	   Laue	   groups	   that	   describe	   1-­‐3	  intersecting	   perpendicular	   axes	   of	   symmetry	   within	   the	   unit	   cell,	   and	   any	  possible	   screw	   axes	   generated	   by	   combined	   translation	   and	   rotation,	   this	  results	   in	   65	   possible	   space	   groups	   for	   protein	   crystals.	   	   Consequently,	   the	  space	  group	  of	  a	  protein	  crystal	  defines	  all	  the	  symmetry	  operations	  needed	  to	  describe	   the	   crystal	   in	   terms	   of	   the	   asymmetric	   unit.	   	   Knowing	   the	   correct	  space	  group	  for	  a	  crystal	  is	  essential	  to	  correctly	  indexing	  the	  diffraction	  data	  (see	  Chapter	  4).	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1.5.3 Crystal	  diffraction	  	  
X-­‐ray	  diffraction	  data	   is	  collected	  by	  placing	  a	  protein	  crystal	   in	  the	  path	  of	  a	  beam	  of	  monochromatic	  (of	  equal	  wavelength)	  X-­‐rays,	  either	  from	  a	  laboratory	  source	   (a	   rotating	   anode,	   usually	   copper)	   or	   from	   a	   synchrotron	   (a	   high-­‐brilliance,	  tuneable	  source).	  	  X-­‐rays	  are	  used	  because	  their	  wavelength	  is	  in	  the	  same	  order	  of	  magnitude	  as	  the	  interatomic	  distances	  we	  are	  trying	  to	  resolve	  (1	  Å	  =	  0.1	  nm).	  	  A	  photon	  from	  the	  incident	  X-­‐rays	  interacts	  with	  the	  electron	  density	  around	  atoms	  and	  is	  scattered	  by	  each	  electron	  it	  encounters,	  resulting	  in	   emerging	   partial	   X-­‐ray	  waves	  with	   different	   scattering	   angles	   and	   phases.	  	  The	  way	  in	  which	  these	  waves	  combine	  either	  constructively	  or	  destructively	  has	   an	   additive	   or	   subtractive	   affect,	   respectively,	   on	   the	   amplitude	   of	   the	  resultant	  X-­‐ray	  wave	  and	  results	  in	  recording	  a	  pattern	  of	  discrete	  intensities	  on	  the	  detector	  in	  front	  of	  the	  crystal;	  these	  are	  known	  as	  reflections	  and	  they	  form	  the	  diffraction	  pattern	  –	  the	  raw	  data	  of	  an	  X-­‐ray	  diffraction	  experiment.	  	  	  	   The	  relationship	  defining	  when	  a	  particular	  set	  of	  waves	  will	   combine	  constructively	  to	  produce	  a	  reflection	  is	  described	  by	  Bragg’s	  Law.	  	  Imagine	  a	  set	  of	  parallel	  planes	   that	   intersect	  each	  unit	   cell	  of	   a	   crystal	   at	   a	   fixed	  point	  along	   their	   axes:	   if	   these	   planes	   are	   a	   distance	   (d)	   apart,	   with	   an	   angle	   of	  incidence	   (θ)	   for	   two	   incoming	   X-­‐ray	   waves	   of	   wavelength	   λ,	   then	   the	   two	  waves	   will	   only	   remain	   in	   phase	   after	   reflecting	   from	   these	   planes	   if	   the	  additional	  distance	  the	  second	  wave	  must	  travel	  (d	  sinθ)	  is	  a	  multiple	  (n)	  of	  the	  wavelength:	  	  
nλ	  =	  2d	  sinθ	  This	  is	  also	  depicted	  in	  figure	  1.12.	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Figure	  1.12	  	  Bragg’s	  Law.	  	  	  This	   defines	   the	   diffraction	   angle	   (θ)	   and	   lattice	   spacing	   (d)	   required	   for	  scattered	   X-­‐rays	   to	   remain	   in	   phase	  with	   each	   other.	   	   The	   resultant	   X-­‐ray	   is	  generated	   by	   constructive	   interference	   and	   results	   in	   a	   diffraction	   spot,	   or	  reflection.	  	  	  	  	  	  This	  relationship	  also	  explains	  why	  the	  highest	  resolution	  (smallest	  d)	  data	  is	  observed	  at	  the	  largest	  scattering	  angle	  (θ)	  i.e.	  at	  the	  edge	  of	  the	  detector.	  	  Each	  unit	   cell	   contributes	  equivalent	  constructive	   interference	  as	   the	  Bragg	  planes	  intersect	   every	   unit	   cell	   in	   the	   same	  way,	   creating	   a	   resultant	  wave	   that	   has	  contributions	   from	  each	  diffracting	  electron	   in	  every	  unit	  cell	   throughout	   the	  whole	   crystal.	   	   These	   planes	   are	   assigned	   Miller	   indices	   (hkl)	   according	   to	  where	   they	   intersect	   the	   unit	   cell,	   and	   matching	   indices	   are	   given	   to	   the	  corresponding	  reflections	  during	   indexing	  of	  diffraction	  data	  (see	  Chapter	  4).	  	  The	   summation	   of	   all	   contributing	   waves	   across	   the	   whole	   crystal	   for	   a	  particular	   reflection	   is	   called	   a	   structure	   factor,	   Fhkl,	   and	   the	   structure	   factor	  amplitude	  (|Fhkl|)	  is	  proportional	  to	  the	  square	  root	  of	  the	  reflection	  intensity.	  	  A	   single	   diffraction	   pattern	   provides	   information	   about	   the	   lattice	   from	   one	  direction	  only,	  and	  so	  the	  crystal	  must	  be	  rotated	  to	  observe	  the	  lattice	  from	  all	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angles;	   at	   each	   angle,	   a	   different	   set	   of	   planes	  will	   satisfy	   Bragg’s	   law	   and	   a	  different	  set	  of	  resultant	  waves	  will	  be	  diffracted.	  	  	  	   However,	  not	  all	  scattering	  electrons	  lie	  directly	  on	  these	  planes	  –	  many	  are	   in	   between	   them	  at	   fractional	   values	   of	  d.	   	   These	   electrons	  will	   result	   in	  diffracted	   waves	   that	   are	   out	   of	   phase,	   causing	   a	   degree	   of	   destructive	  interference	  that	  will	  result	  in	  a	  decrease	  in	  the	  amplitude	  of	  the	  emerging	  X-­‐ray	  and,	  consequently,	  the	  intensity	  of	  the	  reflection.	  	  In	  this	  way,	  the	  intensity	  of	  a	  reflection	  provides	  information	  about	  the	  arrangement	  of	  atoms	  in	  a	  unit	  cell	   relative	   to	   the	   Bragg	   planes.	   	   Equally,	   the	   symmetry	   of	   reflections	   in	   a	  diffraction	   pattern	   provides	   information	   about	   how	   asymmetric	   units	   are	  related	  to	  each	  other	  i.e.	  the	  space	  group.	  	  Together	  we	  have	  all	  the	  information	  required	  to	  recreate	  the	  structure	  of	  our	  crystal,	  except	  for	  one	  vital	  piece:	  To	  translate	   the	   information	   encoded	   in	   the	   diffraction	   pattern	   into	   an	   electron	  density	  map,	  a	  Fourier	  transformation	  is	  required.	  	  A	  Fourier	  transformation	  is	  a	  way	  of	  describing	  a	  wave	  as	  a	  sum	  of	  its	  component	  waves,	  but	  the	  relative	  phases	  of	   these	  waves	   are	   required	   to	   ensure	   they	  are	   added	   correctly.	   	  The	  way	   diffraction	   data	   is	   currently	   recorded,	   i.e.	   photon	   counts	   on	   a	   detector,	  results	  in	  the	  loss	  of	  this	  phase	  information	  and	  causes	  the	  fundamental	  ‘phase	  problem’	  that	  must	  be	  solved	  in	  any	  X-­‐ray	  diffraction	  experiment.	  	  	  	  
1.5.4 Solving	  the	  phase	  problem	  
There	  is	  no	  formal	  relationship	  between	  phases	  and	  the	  amplitudes	  recorded	  in	   the	  X-­‐ray	  diffraction	  experiment	  –	  except	   through	  the	  molecular	  structure,	  which	  is	  unknown.	   	  Recovering	  the	  lost	  phase	  information	  can	  be	  achieved	  in	  one	   of	   two	   ways:	   experimental	   phasing,	   where	   the	   phases	   for	   a	   small	  substructure	   of	   atoms	   are	   calculated,	   then	   used	   to	   estimate	   phases	   for	   the	  whole	   molecule;	   or	   molecular	   replacement,	   where	   the	   phases	   from	   a	  previously	   known	   similar	   structure	   are	   used	   as	   a	   starting	   estimate	   for	   the	  unknown	   structure.	   	   Both	   methods	   were	   used	   in	   this	   work,	   however	   the	  primary	  method	  used	  was	  experimental	  phasing	  and	  so	  this	  will	  be	  described	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Figure	  1.13	  Argand	  diagrams	  of	  reflection	  pairs.	  	  	  Vector	  representation	  of	  diffracted	  X-­‐ray	  waves,	  with	  length	  FPA	  (equivalent	  to	  structure	   factor	  amplitude)	  and	  phase	  φ,	   and	  comprised	  of	   a	  non-­‐anomalous	  component	  (FProt)	  and	  an	  anomalous	  component	  (FAnom).	  	  The	  paired	  reflection	  is	  denoted	  by	  a	  minus	  sign.	  	  A)	  In	  the	  absence	  of	  anomalous	  scatterers,	  vectors	  FPA	  and	  F-­‐PA	  are	  of	  equal	  length	  i.e.	  reflections	  have	  equal	  intensities.	  	  B)	  At	  the	  absorption	  edge,	  the	  phase	  of	  the	  anomalous	  component	  F-­‐Anom	  is	  shifted,	  and	  vector	   F-­‐PA	   has	   a	   different	   length,	   and	   thus	   the	   reflection	   has	   a	   different	  intensity.	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where	  ρ(x,y,z)	   is	   the	   electron	   density	   at	   a	   point	   x,y,z,	  V	   is	   the	   volume	   of	   the	  repeating	  unit	  of	  the	  crystal	  lattice,	  Fhkl	   is	  the	  structure	  factor	  of	  the	  scattered	  wave	  summed	  over	  all	  reflections	  (contains	  amplitude	  and	  phase	  of	  resultant	  X-­‐ray	  wave),	  and	  the	   final	   term	  is	  an	  operator	  of	   the	  Fourier	  summation	  that	  relates	   real	   space	   (electron	   density)	   to	   reciprocal	   space	   (the	   diffraction	  pattern).	   	   The	   heavy	   atom	   phases,	   φA,	   are	   then	   used	   to	   estimate	   the	   initial	  phases	   for	   the	   rest	   of	   the	   protein	   structure,	   φP,	   using	   the	   following	  relationship:	   φP	  =	  φA	  +	  α	  where	  α	   is	   the	  shift	   in	  phase	  from	  heavy	  atom	  phase	  to	  protein	  phase,	  and	   is	  related	   to	   the	   anomalous	   difference	   and	   heavy	   atom	   structure	   factor	  magnitude	   (Dauter	   et	   al.,	   2002).	   	  However,	   Patterson	  maps	   are	   symmetrical,	  and	   the	   possible	   substructure	   solutions	   do	   not	   distinguish	   between	  enantiomorphic	   structures,	   i.e.	   you	   cannot	   tell	   which	   solution	   provides	   the	  correct	  protein	   ‘handedness’.	   	  This	   ambiguity	   is	   solved	  during	   the	  process	  of	  density	  modification,	  described	  in	  Chapter	  4.2.6,	  as	  only	  one	  enantiomorph	  will	  result	   in	  electron	  density	   that	   is	   ‘protein-­‐like’	   in	   its	  distribution.	   	  Once	   initial	  phase	   estimates	   for	   the	   whole	   protein	   have	   been	   calculated,	   the	   process	   of	  model	  building	  and	  refinement	  begins,	  as	  described	  in	  Chapter	  4.2.7.	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1.6 PROJECT	  AIMS	  
The	  essential	  nature	  of	  M2-­‐1	  protein	  to	  the	  RSV	  life	  cycle	  warrants	  continued	  investigation	   of	   its	   role.	   	   A	   lack	   of	   biophysical	   or	   structural	   information	   is	   a	  significant	   barrier	   to	   the	   understanding	   of	   how	   M2-­‐1	   functions,	   and	   the	  primary	   aim	   of	   this	   project	   was	   to	   address	   this	   by	   determining	   the	   X-­‐ray	  crystal	   structure	   of	   RSV	   M2-­‐1	   protein.	   	   This	   would	   allow	   us	   to	   infer	  mechanisms	   of	   action	   through	   structural	   homology	   with	   domains	   of	   known	  function,	  and	  to	  interpret	  the	  extensive	  mutagenesis	  of	  M2-­‐1	  performed	  in	  the	  literature.	  	   A	   key	   function	   of	  M2-­‐1	   protein	   is	   RNA	   binding,	   but	  whether	   this	   is	   a	  specific	   interaction,	   what	   sequence	   or	   secondary	   structure	   this	   specificity	  consists	  of,	  and	  what	  the	  purpose	  of	  an	  M2-­‐1:RNA	  interaction	  might	  be,	  are	  all	  unknown.	  	  This	  project	  aimed	  to	  assess	  the	  RNA	  binding	  ability	  of	  purified	  RSV	  M2-­‐1	  protein,	  both	  in	  terms	  of	  sequence	  specificity	  and	  residues	  of	  the	  protein	  responsible	  for	  the	  interaction,	  and	  relate	  this	  function	  to	  the	  crystal	  structure.	  	  Development	   of	   an	   in	   vitro	   binding	   assay	   using	   fluorescence	   polarisation	  anisotropy	  (FPA)	  would	  allow	  high-­‐throughput	  analysis.	  	   M2-­‐1	   protein	   is	   phosphorylated	   during	   viral	   infection,	   although	   the	  implications	   of	   this	   post-­‐translational	   modification	   are	   not	   understood.	  	  Phosphorylation	   sites	   have	   been	   reported	   differently	   by	   two	   groups,	   and	  clarification	  of	   the	  residues	   involved	  was	  an	  early	   target	   for	   this	  project.	   	  We	  aimed	   to	   express	   and	   purify	   physiologically-­‐relevant	   protein	   for	   analysis	   by	  mass	   spectrometry.	   	   The	   knowledge	   of	   the	   correct	   phosphorylation	   sites	   of	  M2-­‐1	   would	   direct	   X-­‐ray	   crystallographic	   analysis	   of	   a	   phosphomimetic	  mutant,	  to	  determine	  if	  the	  result	  of	  phosphorylation	  is	  conformational	  change.	  	  We	  also	  aimed	  to	  assess	  the	  consequences	  of	  phosphorylation	  on	  RNA	  binding	  using	  the	  FPA	  assay.	  	   To	  relate	  our	  in	  vitro	  functional	  analysis	  to	  the	  viral	  life	  cycle,	  we	  aimed	  to	   complement	   our	   findings	   on	   RNA	   binding	   and	   phosphorylation	   with	   an	  assessment	   of	   their	   roles	   in	  M2-­‐1	   function	   in	   a	  minigenome	   system:	   	   M2-­‐1-­‐
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dependent	  transcription	  is	  reconstituted	  in	  mammalian	  tissue	  culture	  and	  the	  phenotypic	   impact	   of	   M2-­‐1	   mutagenesis	   observed.	   	   This	   would	   allow	   us	   to	  further	  interpret	  our	  structural	  findings	  in	  terms	  of	  the	  contribution	  of	  certain	  residues	  to	  M2-­‐1	  activity.	  	  	  	   In	  summary,	  the	  aims	  of	  this	  project	  were	  to	  combine	  structural	  studies	  with	   functional	   analysis	   to	   create	   a	  model	   for	  M2-­‐1	   function	   in	   the	   RSV	   life	  cycle,	   thus	   allowing	   structure-­‐guided	   drug	   design	   to	   inhibit	   M2-­‐1	   action	   –	   a	  potential	  therapeutic	  avenue	  for	  the	  treatment	  of	  RSV	  infection.	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A	  cDNA	  of	  the	  RSV	  A2	  strain	  M2-­‐1	  open	  reading	  frame	  (ORF)	  in	  pGEM3	  was	  a	  kind	   gift	   from	   Gail	   Wertz	   and	   was	   described	   previously	   (Hardy	   and	   Wertz,	  1998).	  	  See	  Appendix	  III	  for	  sequence.	  	  This	  ORF	  was	  subcloned	  into	  a	  range	  of	  vectors:	  	  
pTriEx1.1	  Neo	   (Novagen)	   -­‐	   contains	   promoter	   sequences	   for	  mammalian	   cell	  expression,	  mediated	  by	  a	  hybrid	  promoter	  composed	  of	  the	  cytomegalovirus	  (CMV)	   immediate	   early	   enhancer	   fused	   to	   the	   chicken	  β-­‐actin	  promoter,	   and	  baculovirus-­‐infected	   insect	   cell	   expression,	   as	   it	   contains	   both	   the	   sequences	  required	  to	  generate	  recombinant	  baculovirus	  and	  the	  very	  late	  p10	  promoter	  for	  expression	  of	  the	  ORF	  of	  interest.	  	  Results	  in	  the	  addition	  of	  a	  C-­‐terminal	  8x	  histidine	   tag	   (His-­‐tag).	   	  This	  vector	  also	  has	  T7	  RNA	  promoter	   sequences	   for	  IPTG-­‐induced	  bacterial	  expression	  
pETSUMO	  28a	  –	  a	  derivative	  of	  pET28a	  (Novagen)	  that	  creates	  an	  N-­‐terminal	  6x	   histidine-­‐SUMO	   protein	   tag,	   expressed	   from	   the	   SMT3	   gene	   (Life	  Technologies).	  
pGEX6P2	   (GE	   Healthcare)	   –	   glutathione	   S-­‐transferase	   (GST)	   fusion	   vectors	  used	  to	  N-­‐terminally	  tag	  the	  ORF	  of	  interest	  with	  GST	  and	  PreScission	  protease	  (GST-­‐tagged	  human	  rhinovirus	  3C	  protease,	  GE	  Healthcare)	  cleavage	  site.	  	  All	   RSV	   nucleotide	   sequences	   were	   confirmed	   by	   DNA	   sequencing	   and	  compared	  to	  RSV	  A2	  strain	  (accession	  number:	  M74568).	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2.1.2 Bacterial	  strains	  
Amplification	  of	  plasmid	  DNA	  constructs	  or	  expression	  of	  recombinant	  protein	  was	  by	  transformation	  of	  competent	  Escherichia	  coli	  (E.coli)	  cells.	  	  Strains	  used	  were:	   Subcloning	   Efficiency	   DH5α	   Competent	   Cells	   (Life	   Technologies)	   for	  initial	   transformation	  of	   ligation	   reactions;	  DH5α,	  prepared	   in	   the	   laboratory	  using	   the	   standard	   Inoue	  method	   for	   routine	   re-­‐transformation;	   BL21	   (DE3)	  derivatives	  for	  isopropyl	  β-­‐D-­‐1-­‐thiogalactopyranoside	  (IPTG)	  inducible	  protein	  expression,	   including	   Gold,	   Star,	   Rosetta,	   Rosetta	   II,	   and	   OverExpress	   C41	  (Lucigen);	   B834(DE3)	   cells,	   a	  methionine	   auxotroph	   strain	   for	   production	   of	  selenomethionine	  protein.	  	  	  	  	  	  	  
2.2 METHODS	  
2.2.1 Manipulation	  of	  recombinant	  DNA	  
	  
2.2.1.1 Polymerase	  chain	  reaction	  (PCR)	  PCR	   was	   used	   to	   amplify	   the	   M2-­‐1	   ORF	   whilst	   incorporating	   terminal	  restriction	   sites	   for	   further	   subcloning.	   	   Reactions	  were	   performed	   in	   50	  µL	  volumes	  and	  contained	  10	  x	  Thermopol	  buffer	  (New	  England	  Biolabs),	  0.3	  mM	  of	   each	   deoxyribonucleotide	   triphosphate	   (dNTPs;	   Roche),	   0.4	   µM	   of	   each	  forward	   and	   reverse	   primer,	   100	   ng	   of	   template	   DNA	   and	   1	   unit	   Vent	  polymerase	   (New	   England	   Biolabs).	   	   Reaction	   cycles	   were	   performed	   in	   a	  thermocycler	   (Eppendorf)	   as	   follows:	   initial	   denaturation	   95	   °C	   2	   min;	   22	  cycles	  of	  denaturation	  at	  95	  °C	  30	  sec,	  annealing	  at	  50-­‐65	  °C	  30	  sec	  (dependent	  on	  primer	  sequence),	  and	  elongation	  at	  72	  °C	  for	  1	  min;	  final	  extension	  at	  72	  °C	  for	   5	   min.	   	   PCR	   products	   were	   isolated	   and	   purified	   by	   agarose	   gel	  electrophoresis	  followed	  by	  gel	  extraction	  (see	  below).	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2.2.1.2 Site	  directed	  mutagenesis	  Complementary	  mutagenic	  primers	  were	  designed	  manually	  and	  consisted	  of	  10-­‐15	  nucleotides	  either	  side	  of	  the	  encoded	  mutation,	  with	  terminal	  guanine	  (G)	   or	   cytosine	   (C)	   nucleotides	  where	   possible,	   and	   are	   listed	   in	  Appendix	   I.	  	  Reactions	   were	   performed	   in	   50	  µL	   volumes	   and	   contained	   10	   x	   Pfu	   Turbo	  reaction	   buffer	   (Agilent),	   0.2	   mM	   of	   each	   deoxyribonucleotide	   triphosphate	  (dNTPs;	   Roche),	   0.2	   µM	   of	   each	   forward	   and	   reverse	   primer,	   100	   ng	   of	  template	   DNA,	   5	   %	   dimethyl	   sulfoxide	   (DMSO),	   5	   mM	   magnesium	   chloride	  (MgCl2),	   and	   2.5	   unit	   Pfu	   Turbo	   polymerase	   (Agilent).	   	   Reaction	   cycles	  were	  performed	  in	  a	  thermocycler	  (Eppendorf)	  as	  follows:	  initial	  denaturation	  95	  °C	  50	  sec;	  18	  cycles	  of	  denaturation	  at	  95	   °C	  50	  sec,	   annealing	  at	  45-­‐47.5	   °C	  60	  sec,	  and	  elongation	  at	  72	  °C	  for	  60	  sec	  per	  kb	  DNA;	  final	  extension	  at	  72	  °C	  for	  8	  min.	  	   Immediately	  following	  completion,	  1	  uL	  DpnI	  restriction	  enzyme	  (New	  England	  Biolabs)	  was	  added	  to	  the	  reaction	  and	  incubated	  at	  37	  °C	  for	  1	  hour	  to	   digest	   methylated	   template	   DNA.	   	   Reactions	   were	   then	   transformed	   into	  DH5α	  cells	  and	  plated	  out	   (see	  below);	  a	  minimum	  of	  3	   single	   colonies	  were	  picked	   and	   screened	   for	   the	   correct	   mutation	   using	   a	   Spin	   Miniprep	   kit	  (Qiagen)	  followed	  by	  DNA	  sequencing.	  	  	  
2.2.1.3 Restriction	  digest	  Restriction	   enzyme	  digests	  were	  performed	  on	  plasmid	  DNA	   for	   cloning	   and	  diagnostic	   purposes.	   In	   a	   50	   µl	   volume,	   reactions	   contained	   1	   µg	   DNA,	   1x	  compatible	  NEBuffer	  (New	  England	  Biolabs),	  ±1x	  bovine	  serum	  albumin	  (BSA;	  enzyme	  dependent)	  and	  2	  units	  of	  each	  enzyme.	  Reactions	  were	  incubated	  at	  37°C	  for	  2-­‐3	  hours.	  	   Purification	  of	  the	  products	  of	  digestion	  was	  either	  by	  gel	  extraction	   after	   agarose	   gel	   electrophoresis	   (see	   2.2.1.4)	   using	   QIAquick	   Gel	  Extraction	  Kit	  (Qiagen),	  or	  by	  removal	  of	  short	  polynucleotides	  from	  digestion	  of	   linear	  DNA	  using	  a	  QIAquick	  Nucleotide	  Removal	  Kit	   (Qiagen).	   	  Both	  were	  used	  as	  per	  the	  manufacturer’s	  protocol.	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2.2.1.4 Agarose	  gel	  electrophoresis	  Size	   and	   integrity	   of	   plasmid	   DNA,	   PCR	   products,	   restriction	   digests	   and	  ligations	  was	  determined	  using	  1%	  agarose	  gels:	  0.5	  g	  analytical	  grade	  agarose,	  50	  mL	  1x	  TAE	  buffer	   [40	  mM	  Tris-­‐acetate,	  1	  mM	  EDTA],	  1:10,000	  SYBR	  Safe	  DNA	   stain	   (Life	   Technologies).	   	   Samples	   were	   mixed	   with	   1x	   GelPilot	   DNA	  Loading	  Dye	   (Qiagen)	   and	   run	   on	   gels	   at	   100V	   for	   40-­‐60	  minutes	   in	   1x	  TAE	  buffer,	   alongside	   molecular	   marker	   Hyperladder	   I	   (Bioline).	   	   DNA	   was	  visualised	  by	  UV	  transillumination.	  	  	  
2.2.1.5 Ligations	  Ligations	   were	   performed	   in	   20	   µL	   volumes	   containing	   1x	   Ligase	   Reaction	  Buffer	  (Life	  Technologies),	  3:1	  or	  10:1	  molar	  ratio	  of	  insert:vector	  DNA,	  and	  1	  unit	  T4	  DNA	  Ligase	  (Life	  Technologies).	   	  Reactions	  were	   incubated	  overnight	  at	  16	  °C	  then	  transformed	  into	  DH5α	  cells.	  	  	  	  
2.2.1.6 Bacterial	  transformation	  Transformations	  were	  performed	  as	  per	   the	  manufacturers’	   guidelines,	   or	   as	  follows	  for	  laboratory-­‐made	  cells:	  50	  µL	  E.	  coli	  cells	  were	  thawed	  on	  ice	  and	  1	  μL	   of	   either	   25-­‐50	   ng/μL	   plasmid	   DNA,	   ligation	   mix,	   or	   site	   directed	  mutagenesis	   reaction,	   was	   added.	   	   Samples	   were	   incubated	   on	   ice	   for	   30	  minutes,	   followed	  by	  heat	  shock	  at	  42°C	   for	  45	  sec,	   then	  rapid	  cooling	  on	   ice	  for	   2	  mins.	   	   450	  µL	  pre-­‐warmed	  Luria-­‐Bertani	   (LB)	  medium	   [in	  1	   liter:	   10	   g	  tryptone,	  10	  g	  NaCl,	  5	  g	  yeast	  extract]	  was	  added	  and	  samples	  were	  incubated	  at	  37	  °C	  for	  1	  hour	  with	  shaking.	  	  100	  µL	  of	  the	  transformation	  was	  spread	  onto	  antibiotic-­‐selective	  LB	  agar	  plates	  and	  incubated	  at	  37	  °C	  overnight.	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2.2.1.7 Starter	  cultures	  Single	   colonies	   were	   picked	   from	   transformation	   plates	   and	   used	   to	   grow	  starter	   cultures	   in	   LB	   medium	   containing	   appropriate	   antibiotic	   (final	  concentration	  50	  µg/mL	  kanamycin,	  or	  100	  µg/mL	  ampicillin)	  overnight	  at	  37	  
°C.	   	   Small-­‐scale	   cultures	  were	  5	  mL,	   large	   scale	   cultures	  were	  50	  mL.	   	  These	  were	   then	   used	   to	   inoculate	   overnight	   cultures	   for	   either	   plasmid	   DNA	  amplification	   or	   protein	   expression.	   	   Aliquots	   of	   starter	   cultures	  were	  mixed	  1:1	  with	  40	  %	  sterile-­‐filtered	  glycerol	  and	  frozen	  at	  -­‐80	  °C	  as	  glycerol	  stocks.	  	  	  
2.2.1.8 Plasmid	  DNA	  amplification	  Starter	   cultures	   were	   used	   to	   inoculate	   overnight	   cultures	   of	   appropriate	  volume	  in	  LB	  medium	  containing	  antibiotics,	  and	  DNA	  isolated	  using	  Plasmid	  Maxiprep	   or	   Spin	  Miniprep	   kits	   (Qiagen)	   based	   on	   the	   alkaline-­‐lysis	  method	  followed	   by	   ethanol	   precipitation	   (maxiprep)	   or	   adsorption	   to	   a	   silica	  membrane	   under	   high-­‐salt	   conditions	   (miniprep).	   	   DNA	   was	   quantified	   by	  spectrophotometry	  using	  a	  NanoDrop	  1000	  (Thermo	  Scientific).	  	  	  
2.2.2 Protein	  expression	  in	  E.coli	  
	  
2.2.2.1 Culture	  growth,	  IPTG	  induction	  and	  lysis	  5	   or	   50	   mL	   starter	   cultures	   were	   grown	   from	   stabs	   of	   glycerol	   stocks	   of	  transformed	  E.	  coli	  BL21-­‐derivative	  cells,	  and	  used	  to	  inoculate	  100	  mL	  (small	  scale)	  or	  1L	  (large	  scale)	  LB	  overnight	  cultures	  with	  appropriate	  antibiotic.	  Cultures	   were	   grown	   to	   OD600	   0.6-­‐0.8	   at	   37	   °C	   and	   induced	   with	   0.1-­‐1	   mM	  IPTG,	   ±0.05-­‐1	  mM	   zinc	   sulphate	   (ZnS04),	   for	   6-­‐16	   hours	   at	   18-­‐37	   °C.	   	   	   Cells	  were	   recovered	   by	   centrifugation	   at	   4,000	   xg	   for	   30	   mins	   and	   either	  resuspended	  immediately,	  or	  frozen	  at	  -­‐20	  °C	  until	  lysis.	  	  Resuspension	  was	  in	  5	  mL	  lysis	  buffer	  per	  100	  mL	  pelleted	  culture.	   	  Lysis	  buffer	  contained	  50	  mM	  Tris-­‐Cl	   pH	   7-­‐8	   or	   10	   mM	   sodium	   phosphate	   dibasic/1.8	   mM	   potassium	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phosphate	   monobasic,	   0.1-­‐1	   M	   NaCl,	   1-­‐2	   %	   (v/v)	   Triton-­‐X100,	   1x	   complete	  protease	   inhibitor	   cocktail	   EDTA-­‐free	   (Roche),	   1	   mg/mL	   chicken	   egg	   white	  lysozyme,	   ±1	  mM	   dithiothreitol	   (DTT),	   ±1	  mM	   calcium	   chloride	   (CaCl2),	   ±10	  mM	  magnesium	  sulphate	   (MgS04),	  ±	  10	  %	  (v/v)	  glycerol,	  ±	  50mM	  L-­‐arginine	  and	  50	  mM	  L-­‐glutamic	  acid.	  	  Cells	  were	  incubated	  on	  ice	  for	  30	  mins,	  then	  lysis	  was	  completed	  by	  sonication	  on	  ice	  with	  8	  cycles	  of	  20	  sec	  on,	  30	  sec	  off	  at	  10	  micron	  amplitude.	  	  Lysates	  were	  clarified	  by	  centrifugation	  at	  18,000	  xg	  for	  30	  mins	  and	  the	  supernatant	  retained	  for	  purification	  by	  affinity	  chromatography.	  	  	  
2.2.2.2 Autoinduction	  5	   mL	   starter	   cultures	   were	   grown	   overnight	   at	   37	   °C	   in	   minimal	   medium	  containing	  the	  following:	  2mM	  MgS04	  1	  µL	  1000x	  trace	  elements	  [stock	  concentrations:	  50	  mM	  FeCl3,	  20	  mM	  CaCl2,	  10	  mM	  MnCl2,	   2	  mM	  CoCl2,	   2	  mM	  CuCl2,	   2	  mM	  NiCl2,	   2	  mM	  Na2MoO4,	   2	  mM	  Na2SeO3,	  2	  mM	  H3Bo3]	  0.5	  %	  (w/v)	  glucose	  0.25	  %	  (w/v)	  aspartate	  	  100	  µL	  50x	  M	  [stock	  concentrations:	  1.25	  M	  Na2HPO4,	  1.25	  M	  KH2PO4,	  2.5	  M	  NH4Cl,	  0.25	  M	  Na2SO4]	  50	  mg/mL	  kanamycin	  	  50	  µL	  of	   starter	   culture	  was	  used	   to	   inoculate	  50	  mL	  autoinduction	  medium	  growth	  cultures	  containing:	  47.85	  mL	  ZY	  medium	  [5	  g/L	  yeast	  extract,	  10	  g/L	  tryptone]	  2	  mM	  MgSO4	  10	  µL	  1000x	  trace	  elements	  (as	  above)	  1	   mL	   50x	   5052	   [stock	   concentrations:	   25	   %	   (w/v)	   glycerol,	   2.5	   %	   (w/v)	  glucose,	  10	  %	  (w/v)	  lactose]	  1	  mL	  50x	  M	  (as	  above)	  50	  mg/mL	  kanamycin	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  Cultures	  were	  grown	  at	  37	  °C	  for	  24	  hours.	  	  Cells	  were	  recovered	  and	  lysed	  as	  above	  (2.2.2.1).	  	  
2.2.3 Purification	  by	  glutathione	  affinity	  chromatography	  
Clarified	   supernatant	   containing	   soluble	   GST-­‐M2-­‐1	   protein	   was	   applied	   in	  batch	  to	  glutathione	  sepharose	  4B	  resin	  (GE	  Healthcare)	  at	  4	  °C	  overnight	  with	  rotation.	   	  Resin	  was	  pelleted	  at	  700	  xg	  for	  5	  mins	  and	  washed	  3	  times	  for	  15	  mins	  at	  4	  °C	  with	  4	  volumes	  of	  lysis	  buffer.	  	  Additional	  washes	  (2x	  30	  mins)	  in	  10	  mM	  Tris-­‐Cl	  pH	  7.4,	  1	  M	  NaCl	  were	  performed	  to	  remove	  M2-­‐1-­‐bound	  RNA	  from	   the	   expression	   host	   (Tran	   et	   al.	   2009).	   Resin	   was	   then	   washed	   and	  equilibrated	   in	  an	  equal	  volume	  of	  protease	  cleavage	  buffer	   [50	  mM	  Tris-­‐HCl	  pH	  7.5,	  150	  mM	  NaCl,	  1	  mM	  DTT]	  and	  M2-­‐1	  was	  cleaved	  from	  GST	  on	  the	  resin	  overnight	   at	  4	   °C	  by	  HRV-­‐3C	  protease,	  which	  was	  expressed	  and	  purified	   in-­‐house	  from	  glycerol	  stocks.	  	  Cleaved	  M2-­‐1	  was	  eluted	  by	  pelleting	  the	  resin	  at	  700	  xg	  for	  5	  mins	  and	  collecting	  the	  supernatant.	  	  Resin	  was	  then	  washed	  twice	  for	   10	   mins	   at	   4	   °C	   in	   1	   volume	   of	   protease	   cleavage	   buffer,	   pelleted	   by	  centrifugation,	  and	  the	  supernatant	  collected.	   	  Supernatants	  were	  pooled	  and	  M2-­‐1	   concentration	   determined	   by	   adding	   1-­‐20	   µL	   (depending	   on	  concentration	  range)	  protein	  to	  1:5	  dilution	  of	  Protein	  Assay	  reagent	  (Bio-­‐Rad)	  and	  reading	  the	  absorbance	  at	  595	  nm.	  	  
2.2.4 Size	  exclusion	  chromatography	  
Size	  exclusion	  chromatography	  was	  used	  initially	  analytically	  to	  determine	  the	  oligomeric	  status	  of	  M2-­‐1	  expressed	  in	  this	  system,	  and	  then	  preparatively	  to	  isolate	  tetrameric	  M2-­‐1.	  	  A	  320	  mL	  HiLoad	  26/600	  Superdex	  75	  pg	  column	  (GE	  Healthcare)	  was	  used	  with	  an	  Akta	  prime	  pump	  system	  at	  4	  °C,	  and	  absorbance	  at	  280	  nM	  was	  used	  to	  monitor	  protein	  elution.	  	  All	  buffers	  used	  were	  0.2	  µm	  filtered	  and	  degassed.	   	  The	  column	  was	  equilibrated	  with	   running	  buffer	   [50	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mM	  Tris-­‐HCl	  pH	  7.5,	  150	  mM	  NaCl,	  1	  mM	  DTT],	  and	  the	  protein	  (concentrated	  to	   just	   over	   5	  mL)	  was	   0.2	  µm	   filtered	   and	   injected	  using	   a	   5	  mL	   loop.	   	   The	  column	  was	  run	  at	  approximately	  2	  mL/min	  and	  3	  mL	  fractions	  collected	  once	  the	  void	  volume	  had	  eluted	  (~100	  mL).	  	  The	  column	  was	  calibrated	  using	  a	  gel	  filtration	   standard	   kit	   (Bio-­‐Rad)	   containing	   thyroglobulin	   670,000	   Da,	   γ-­‐globulin	  158,000	  Da,	  ovalbumin	  44,000	  Da,	  myoglobin	  17,000	  Da,	  vitamin	  B12	  1,350	  Da.	  	   Appropriate	  fractions	  were	  pooled	  at	  concentrated	  to	  approximately	  12	  mg/mL	  using	  10,000	  Dalton	  molecular	  weight	  cut-­‐off	  centrifugal	  concentrators	  (Sartorius)	  and	  stored	  at	  4	  °C.	  	  
2.2.5 Ion	  exchange	  chromatography	  
A	  1	  mL	  Resource	  S	  cation	  exchange	  column	  (GE	  Healthcare)	  was	  used	  at	  pH	  7.5	  	  (below	   the	   isoelectric	   point	   (pI)	   of	   M2-­‐1:	   9.1),	   with	   an	   Akta	   Purifier	   pump	  system	  at	  4	  °C,	  and	  absorbance	  at	  280	  nM	  was	  used	  to	  monitor	  protein	  elution.	  	  All	   buffers	   used	   were	   0.2	   µm	   filtered	   and	   degassed.	   	   The	   column	   was	  equilibrated	   in	   buffer	   A	   [20	   mM	   Tris-­‐Cl	   pH	   7.5,	   50	   mM	   NaCl]	   and	   protein	  sample	  diluted	   into	   the	   same	  buffer.	   	  Protein	  was	  applied	   to	   the	   column	  and	  run	  until	  the	  280	  nM	  trace	  returned	  to	  baseline.	  	  A	  20	  CV	  gradient	  was	  applied	  with	   0-­‐100%	  buffer	  B	   [20	  mM	  Tris-­‐Cl	   pH	  7.5,	   1	  M	  NaCl]	   and	   1	  mL	   fractions	  collected.	  	  	  	  
2.2.6 SDS-­‐polyacrylamide	  gel	  electrophoresis	  (SDS-­‐PAGE)	  
5	  mL	   SDS-­‐PAGE	   gels	   were	  made	  with	   a	   12	  %	   resolving	   gel	   [4	  mL	   30%	   bis-­‐acrylamide,	  2.5	  mL	  1.5	  M	  Tris-­‐HCl	  pH	  8.8,	  3.3	  mL	  ddH20,	  100	  µL	  10	  %	  SDS,	  100	  µL	  10	  %	  ammonium	  per	  sulphate	  (APS),	  10	  µl	  TEMED]	  and	  a	  5	  %	  stacking	  gel	  [0.83	  mL	  30	  %	  bis-­‐acrylamide,	  0.63	  mL	  1	  M	  Tris-­‐HCl	  pH	  6.8,	  3.4	  mL	  ddH20,	  50	  µL	  10	  %	  SDS,	  50	  µL	  10	  %	  APS,	  5	  µL	  TEMED].	  	  Samples	  were	  mixed	  1:1	  with	  2x	  denaturing	  sample	  buffer	  [60	  mM	  Tris	  pH	  6.8,	  25	  %	  (v/v)	  glycerol,	  2	  %	  (w/v)	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SDS,	  5	  %	  β-­‐mercaptoethanol,	  0.01	  %	  (w/v)	  bromophenol	  blue]	  and	  heated	  at	  95	   °C	   for	   5	  mins	   immediately	   prior	   to	   loading	   onto	   the	   gel.	   	   Electrophoresis	  was	  performed	  in	  1x	  SDS	  running	  buffer	  [25	  mM	  Tris,	  192	  mM	  glycine,	  0.1	  %	  (w/v)	  SDS]	  at	  200V	  for	  40-­‐60	  minutes.	  	  Broad	  range	  molecular	  weight	  markers	  (New	   England	   Biolabs),	   covering	   7-­‐175	   kDa,	   were	   used.	   	   Unless	   western	  blotting	  was	  required,	  proteins	  were	  visualised	  using	  Coomassie	  stain.	  	  
2.2.7 Protein	   identification,	   accurate	   mass	   and	   oligomeric	   state	  
determination	  by	  mass	  spectrometry	  
The	   lack	   of	   an	   M2-­‐1	   antibody	   resulted	   in	   the	   use	   of	   mass	   spectrometry	   to	  confirm	   the	   identity	   of	   bacterially	   expressed	   M2-­‐1	   protein.	   	   Protein	   was	  separated	  by	  SDS-­‐PAGE	  and	  the	  appropriate	  band	  excised	  from	  the	  gel	  into	  30	  %	   (v/v)	   ethanol.	   	   The	   sample	  was	   given	   to	   the	  mass	   spectrometry	   facility	   at	  University	  of	  Leeds	  for	  in-­‐gel	  trypsin	  digestion	  and	  peptide	  sequencing	  by	  LC-­‐MS/MS.	   	   The	   analysis	  was	   performed	   as	   a	   service	   by	   facility	  manager	   James	  Ault.	  	  	   Denaturing	   mass	   spectrometry	   was	   used	   to	   determine	   the	   accurate	  mass	   of	   monomeric	   M2-­‐1.	   	   Protein	   was	   diluted	   to	   10-­‐20	   µM	   in	   50	  %	   (v/v)	  acetonitrile,	   10	   %	   (v/v)	   acetic	   acid.	   	   Intact	   mass	   analysis	   by	   native	   mass	  spectrometry	  was	  used	  to	  determine	  the	  oligomeric	  state	  of	  M2-­‐1.	  	  Protein	  was	  buffer	  exchanged	  into	  10	  mM	  ammonium	  acetate	  pH	  7.5.	   	  Both	  analyses	  were	  conducted	  by	  Helen	  Beeston	  (Alison	  Ashcroft	  group,	  University	  of	  Leeds)	  using	  nano-­‐electrospray-­‐ionization	   mass	   spectrometry	   (nanoESI-­‐MS)	   with	   an	   LCT	  premier	   (Waters	  UK	  Ltd.)	  mass	   spectrometer.	  	   Samples	  were	   infused	  using	   a	  Nanomate	   (Advion)	   using	   the	   following	   instrument	   parameters:	  	   ionization	  voltage	  +1.75	  kV	  and	  sample	  cone	  voltage	  30	  V.	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2.2.8 Baculovirus	  expression	  system	  
	  
2.2.8.1 Insect	  cell	  culture	  The	   insect	   cell	   line	   Sf9,	   derived	   from	   pupal	   ovarian	   tissue	   of	   the	   moth	  
Spodoptera	   frugiperda,	   is	   highly	  susceptible	   to	   baculovirus	   infection.	   	   Cells	  were	   maintained	   in	   TC-­‐100	   Insect	   Medium	   (GIBCO®	   Invitrogen)	   with	   L-­‐glutamine,	   supplemented	  with	  10	  %	   fetal	   bovine	   serum	   (FBS)	   and	  100	  unit/	  mL	  penicillin	  and	  0.1	  mg/mL	  streptomycin	  (Sigma)	  (‘complete’	  TC-­‐100	  media),	  at	  27	  °C.	  	  Cells	  were	  grown	  in	  adherent	  culture	  immediately	  after	  thawing,	  with	  passaging	  at	  70-­‐80	  %	  confluency	  and	  renewing	  the	  media	  every	  3-­‐4	  days	  due	  to	   toxicity	  of	  waste	  products.	   	  Once	  adherent	  culture	  had	  produced	  sufficient	  viable	   cells,	   they	   were	   adapted	   to	   suspension	   culture:	   cultures	   were	  maintained	  in	  50	  mL	  volumes	  in	  125	  mL	  volume	  spinner	  flasks,	  with	  stirring	  at	  75	   rpm.	   	   Once	   cells	   reached	   a	   density	   of	   ~	   2x106	   cells/mL,	   cultures	   were	  diluted	  with	  fresh,	  room	  temperature	  medium	  1:10.	  	  	  
2.2.8.2 Bacmid	  linearization	  BAC10:KO1629	   bacmid	  DNA	   used	  was	   kindly	   donated	   by	   Professor	   Ian	   Jones’	  group	   from	   the	   University	   of	   Reading,	   and	   consisted	   of	   the	   genome	   of	  baculovirus	   strain	   Autographa	   californica	  Multicapsid	   Nucleopolyhedrovirus	  (AcMNPV)	  with	  a	   targeted	  gene	  knock-­‐out	  of	   the	  essential	  ORF1629	  adjacent	  to	  the	  polyhedrin	  recombination	  locus	  (polh),	  in	  an	  E.coli:BAC10	  vector	  (Zhao	  et	  al.,	  2003).	   	   	  When	  transfected,	  this	  creates	  a	  virus	  that	   is	  non-­‐viable	  unless	  the	   ORF1629	   sequence	   is	   supplied	   by	   homologous	   recombination	   with	   the	  pTriEx1.1	  Neo	  transfer	  vector,	  removing	  the	  need	  for	  several	  time-­‐consuming	  rounds	   of	   plaque-­‐assay	   purification.	   	   Bacmid	   DNA	   was	   linearised	   before	  transfection	  to	  increase	  recombination	  efficiency.	  	  	  A	  restriction	  digest	  using	  5	  units	  Bsu361	  (New	  England	  Biolabs)	  with	  2	  µg	  bacmid	  DNA	  and	  1x	  BSA	  was	  performed	  as	  previously	  described,	   followed	  by	  heat	   inactivation	  at	  80	  °C	   for	  20	  mins	  and	  storage	  at	  -­‐20	  °C.	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2.2.8.3 Generation	  of	  a	  P0	  generation	  recombinant	  baculovirus	  Suspension	   culture	   of	   Sf9	   cells	   was	   diluted	   to	   0.5	   x	   106	   cells/mL	   and	   2	   mL	  added	   to	  a	   single	  well	  of	   a	  6-­‐well	   tissue	  culture	  plate.	   	  Cells	  were	  allowed	   to	  settle	   and	   were	   checked	   for	   50	   %	   confluency.	   	   Transfection	   mixes	   were	  prepared	  by	  incubating	  500	  ng	  linearised	  bacmid,	  500	  ng	  pTriex1.1	  Neo	  M2-­‐1,	  8	   µL	   Lipofectin	   (Life	   Technologies)	   and	   sterile	   water	   to	   24	   µL,	   at	   room	  temperature	   for	   20	  minutes.	   	  Media	  was	   removed	   from	   the	   settled	   cells	   and	  replaced	  with	   the	   transfection	  mix	   plus	   1	  mL	   serum-­‐free,	   antibiotic-­‐free	   TC-­‐100	  medium.	  	  The	  plate	  was	  placed	  inside	  a	  plastic	  bag	  to	  prevent	  drying-­‐out	  and	  incubated	  for	  16	  hours	  at	  27	  °C.	  	  Media	  was	  changed	  for	  serum-­‐containing	  media	   and	   cells	   incubated	   for	  3	  days.	   	   Cells	  were	   scraped	  and	   centrifuged	  at	  13,000	   rpm	   for	   2	   minutes,	   and	   the	   supernatant	   (containing	   P0	   baculovirus)	  was	  retained	  in	  a	  sterile	  tube	  and	  stored	  at	  4	  °C	  in	  foil,	  to	  prevent	  degradation.	  	  	  
2.2.8.4 Infections	  and	  virus	  amplification	  Small-­‐scale	   infections	   to	   confirm	   expression	   of	  M2-­‐1-­‐His	  were	   performed	   as	  follows:	  0.5	  x	  106	   cells	  per	  well	  were	  seeded	   into	  a	  6-­‐well	  plate	  and	   infected	  with	  0.5	  mL	  P0	  virus	  for	  1	  hour	  at	  27	  °C,	  with	  gentle	  rocking	  to	  prevent	  drying	  out.	  	  Virus	  was	  replaced	  with	  fresh	  ‘complete’	  TC-­‐100	  media	  and	  the	  plate	  was	  incubated	  for	  3	  days	  at	  27	  °C.	  	   	  To	  amplify	   the	  virus	  stock,	  subsequent	  generations	  of	  virus	  (P1,	  P2	  etc.)	  were	  produced	  by	  reinfecting	  15	  x	  106	  Sf9	  cells	   in	  a	  T175	  tissue	  culture	   flask	  with	  0.5	  mL	  P0	  generation	  virus	  for	  1	  hour	  at	  27	  °C,	  followed	  by	  removal	  of	  the	  virus	  and	   incubation	   in	   fresh	  media	   for	   5	   days	   at	   27	   °C.	   	   P1	   generation	   virus	  was	  recovered	  from	  the	  supernatant	  of	  pelleted	  cells.	  Large-­‐scale	   infections	  were	  performed	  in	  200	  mL	  Sf9	  suspension	  culture	  (1	  x	  106	  cells/mL)	  with	  3	  mL	  P1	  baculovirus	  and	  incubation	  at	  27	  °C	  for	  3	  days,	  with	  stirring.	  	  	  	  	  	  
Chapter	  2:	  Materials	  and	  Methods	  
	   69	  
2.2.8.5 Harvesting	  whole	  cell	  lysates	  To	   assess	   overall	   expression	   during	   optimisation	   stages,	   whole	   cell	   lysates	  were	  prepared.	  	  Infected	  cells	  were	  recovered	  by	  centrifugation	  at	  2000	  xg	  20	  mins	   and	   a	   sample	   of	   the	   supernatant	   was	   retained	   for	   SDS-­‐PAGE	   analysis.	  	  Whole	  cell	  lysates	  were	  prepared	  by	  resuspension	  of	  pelleted	  cells	  in	  100	  µL	  or	  10	   mL	   (small-­‐	   and	   large-­‐scale	   infections,	   respectively)	   RIPA	   buffer	   [50	   mM	  Tris-­‐Cl	  pH	  7.5,	  150	  mM	  NaCl,	   1	  %	  NP-­‐40,	  0.5	  %	  sodium-­‐deoxycholate,	  0.1	  %	  SDS,	  1x	  complete	  protease	  inhibitor	  cocktail	  EDTA-­‐free	  (Roche)].	  	  
2.2.9 Purification	  of	  M2-­‐1-­‐His	  by	  cobalt	  affinity	  chromatography	  	  	  
Protocol	   is	   adapted	   from	   Mason	   et	   al.	   (Mason	   et	   al.,	   2003).	   Cells	   were	  recovered	  by	   centrifugation	   at	   2000	   xg	  20	  mins	   and	   resuspended	   in	   binding	  buffer,	   5	  mL	   per	   gram	  wet-­‐weight	   of	   pellet	   [20	  mM	  Tris-­‐Cl	   pH	   7.9,	   500	  mM	  NaCl,	   5	   mM	   imidazole,	   1x	   complete	   protease	   inhibitor	   cocktail	   EDTA-­‐free	  (Roche)].	   	  Cells	  were	  lysed	  by	  sonication	  on	  ice	  with	  5	  cycles	  of	  10	  sec	  on,	  10	  sec	  off,	  and	  lysates	  were	  clarified	  by	  centrifugation	  at	  100,000	  xg	  30	  mins.	  	   A	   HiTrap	   IMAC	   FF	   1	   mL	   column	   (GE	   Healthcare)	   was	   washed	   and	  charged	  with	  0.1	  M	  colbalt	  chloride,	  as	  per	  the	  manufacturer’s	  guidelines	  using	  a	  manual	  syringe	  method.	  	  The	  column	  was	  equilibrated	  in	  5	  column	  volumes	  (CV)	   binding	   buffer	   and	   the	   supernatant	   applied,	   collected,	   and	   reapplied	   to	  ensure	   maximum	   binding.	   	   A	   10	   CV	   wash	   with	   binding	   buffer,	   followed	   by	  stepwise	  elution	  with	  5	  CV	  steps	  of	  elution	  buffer	  [20	  mM	  Tris-­‐Cl	  pH	  7.9,	  500	  mM	  NaCl,	   increasing	   concentrations	  of	   imidazole:	   50	  mM,	  100	  mM,	  150	  mM,	  250	  mM,	  500	  mM].	  	  Eluted	  protein	  was	  stored	  at	  4	  °C.	  	  
2.2.10 Calf	  intestinal	  alkaline	  phosphatase	  (CIP)	  treatment	  
CIP	   treatment	   was	   used	   to	   observe	   dephosphorylation	   of	   cobalt-­‐affinity	  purified	   M2-­‐1-­‐His	   protein.	   	   A	   volume	   of	   50	   µL	   contained	   8	   units	   CIP	   (New	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England	  Biolabs),	  1x	  NEBuffer	  3	  (New	  England	  Biolabs),	  44	  µL	  eluted	  protein.	  	  Reactions	  were	  incubated	  for	  2	  hours	  at	  37	  °C.	  	  	  
2.2.11 Western	  blotting	  
Proteins	  were	  transferred	  from	  SDS-­‐PAGE	  gels	  (see	  2.2.2.6)	  to	  polyvinylidene	  fluoride	   (PVDF)	   membrane	   (Immobilon-­‐P	   Transfer	   Membrane;	   Millipore)	  using	  a	  Trans-­‐Blot	  semi-­‐dry	  cell	  (Bio-­‐Rad)	  in	  Towbin	  buffer	  [25	  mM	  Tris,	  192	  mM	  glycine,	  20	  %	  (v/v)	  methanol].	  	  Membranes	  were	  blocked	  overnight	  at	  4	  °C	  in	  10	  %	  (w/v)	  non-­‐fat	  powdered	  milk	  in	  1x	  Tris-­‐buffered	  saline	  with	  Tween-­‐20	  (TBS-­‐T)	  [50mM	  Tris-­‐HCl	  pH	  7.6,	  150mM	  NaCl,	  1	  %	  Tween-­‐20].	  	  Blocking	  buffer	  was	  then	  replaced	  with	  primary	  antibody	  (rabbit	  polyclonal	  anti-­‐His	  probe	  G-­‐18:sc-­‐804,	   Santa	   Cruz	   Biotechnology	   Inc.)	   diluted	   1:500-­‐1000	   in	   5	   %	   (w/v)	  non-­‐fat	   powdered	   milk	   in	   1x	   TBS-­‐T	   for	   1	   hour	   at	   room	   temperature.	  	  Membranes	  were	  washed	  twice	  for	  5	  minutes	  in	  1x	  TBS-­‐T,	  then	  incubated	  with	  horseradish	  peroxidise	  (HRP)	  conjugated	  goat	  anti-­‐rabbit	  secondary	  antibody	  (A6154	   Sigma),	   under	   the	   same	   conditions	   and	   dilution	   as	   for	   the	   primary	  incubation,	  followed	  by	  4	  washes	  in	  1x	  TBS-­‐T.	  Proteins	   were	   visualised	   using	   enhanced	   chemiluminescence	   on	  photographic	   film.	   	   Enhanced	   chemiluminescence	   solution	   (ECL)	   was	   made	  with	  1:1	  mix	  of	  each	  of	  the	  following	  solutions	  and	  applied	  to	  the	  membrane:	  solution	  1,	  25	  mM	  Luminol	  (3-­‐aminophthalydazide),	  0.3	  mM	  p-­‐coumaric	  acid,	  100	  mM	  Tris-­‐HCl	  pH	  8.5;	  solution	  2,	  0.01	  %	  (v/v)	  hydrogen	  peroxide,	  100	  mM	  Tris-­‐HCl	  pH	  8.5.	   	  Membranes	  were	   incubated	   for	  1	  min,	   then	  exposed	   to	   film	  and	  developed	  with	  a	  Konica	  SRX-­‐101A	  processor.	  	  	  
2.2.12 Phosphopeptide	  mapping	  by	  mass	  spectrometry	  
Identification	  of	  phosphorylated	  residues	  in	  M2-­‐1	  was	  by	  mass	  spectrometric	  analysis	   performed	   by	   Kevin	   Tipping	   (Sheena	   Radford	   group,	   University	   of	  Leeds)	   and	   James	   Ault	   (Mass	   Spectrometry	   Facility	   Manager,	   University	   of	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Leeds).	   	   Briefly,	   M2-­‐1	   protein	   purified	   from	   baculovirus-­‐infected	   insect	   cells	  was	  separated	  into	  phosphorylated	  and	  unphosphorylated	  species	  using	  SDS-­‐PAGE.	  	  Both	  bands	  were	  excised	  and	  analysed	  separately.	  	  Proteins	  were	  in-­‐gel	  digested	   with	   trypsin,	   eluted	   in	   acetonitrile:water:formic	   acid	   (60:35:5	   v/v)	  and	   lyophilised	   by	   vacuum	   centrifugation.	   	   Samples	   were	   then	   enriched	   for	  phosphorylated	   peptides	   using	   titanium	   oxide	   (TiO2)	   beads	   (GL	   Sciences,	  Japan)	   and	   desalted	   into	   50	   %	   (v/v)	   acetonitrile.	   	   Mass	   analysis	   was	   by	  nanoESI-­‐MS	   and	   peptide	   sequencing	   by	   tandem	   mass	   spectrometry	   using	   a	  quadrupole-­‐IMS-­‐orthogonal	   time-­‐of-­‐flight	  MS	  (Synapt	  HDMS,	  Waters	  UK	  Ltd.)	  with	   ionization	  voltage	  of	  +1.5	  kV	  and	  cone	  voltage	  of	  20	  V.	   	  Data	  processing	  was	   performed	   using	   the	  MassLynx	   v4.1	   suite	   of	   software	   supplied	  with	   the	  mass	  spectrometer.	  	  	  
2.2.13 Crystallographic	  techniques	  
	  
2.2.13.1 Sparse	  matrix	  screening	  Commercially	   available	   sparse	   matrix	   screens	   were	   used	   for	   initial	   crystal	  trials.	  	  The	  following	  kits	  were	  used:	  Crystal	  Screen	  I	  and	  II,	  Matrix,	  Index,	  Salt	  RX	  (Hampton	  Research);	  Wizard	  I	  and	  II	  (Emerald	  Biosystems).	  	  Sitting	  drops	  were	   set	   up	   in	   96-­‐well	  MRC	   2-­‐drop	   plates	   (Molecular	   Dimensions)	   using	   an	  Oryx	  6	  robot	  (Douglas	  Instruments)	  with	  60	  µL	  reservoir	  solution.	  	  1	  µL	  drops	  at	  50:50	  or	  70:30	  protein:reservoir	  ratios	  were	  dispensed,	  using	  protein	  at	  10-­‐20	  mg/mL.	   	   Plates	   were	   sealed	  with	   Viewseal	   pressure	   adhesive	   clear	   seals	  (Greiner	  Bio-­‐One)	  and	  incubated	  at	  4	  °C,	  18	  °C	  or	  25	  °C.	  	  	  	  	  
2.2.13.2 Crystal	  optimisation	  Screening	   drops	   were	   monitored	   for	   crystal	   growth	   after	   24	   hours,	   and	  periodically	  for	  two	  weeks	  thereafter.	  	  Hits	  were	  optimised	  in	  both	  sitting	  drop	  (96-­‐well	   plate)	   and	   hanging	   drop	   (24-­‐well	   plate)	   orientations	   using	   1-­‐2	   µL	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drops	   at	   50:50	   and	   70:30	   protein:reservoir	   ratios.	   	   Matrices	   were	   set	   up	   to	  vary,	  typically,	  concentration	  of	  precipitant	  and	  pH	  of	  buffer.	  	  Temperature	  and	  protein	   concentration	   were	   also	   varied,	   and	   Hampton	   Research	   Additive	  Screen	  used	  to	  further	  improve	  optimised	  hits.	  	  	  
2.2.13.3 Crystal	  harvesting	  and	  data	  collection	  Crystals	   were	   picked	   in	   appropriately	   sized	   loops	   (Hampton	   Research)	   and	  cryo-­‐cooled	   in	   liquid	  nitrogen,	  either	  straight	   from	  drops	  when	  grown	  in	   low	  molecular	  weight	  polyethylene	  glycol	  (PEG),	  or	  by	  first	  transferring	  the	  crystal	  into	  a	  1:1	  drop	  of	  reservoir	  and	  cryoprotectant	  [5	  %	  glycerol,	  5	  %	  PEG-­‐400,	  5	  %	  2-­‐Methyl-­‐2,	  4-­‐pentanediol	  (MPD),	  5	  %	  ethylene	  glycol].	  	   All	  data	  were	  collected	  at	  100	  K	  at	  Diamond	  Light	  Source	  on	  beamlines	  I24,	  I02	  and	  I04.	  	  Crystals	  were	  screened	  for	  diffraction	  by	  taking	  test	  images	  at	  ϕ	  =	  0°	  and	  90°,	  using	  12,658	  eV	  X-­‐rays	  (0.9795	  Å).	  	  Crystals	  that	  diffracted	  to	  better	  than	  4	  Å	  were	  fluorescence	  scanned	  to	  identify	  the	  presence	  of	  any	  zinc	  (from	  the	  zinc	  finger	  motif)	  or	  other	  atoms	  (either	  naturally	  occurring	  or	  from	  crystallisation	  conditions),	  and	  their	  absorption	  edges	  calculated	  for	  SAD	  data	  collection	  (approximately	  9658	  eV	  for	  zinc	  K-­‐edge).	  	  	  
2.2.13.4 Data	  processing	  and	  structure	  solution	  X-­‐ray	  data	  were	   integrated	  using	   iMOSFLM	  (Battye	  et	  al.,	  2011,	  Leslie,	  2006)	  from	   the	   Collaborative	   Computer	   Project	   4	   (CCP4)	   suite	   (Winn	   et	   al.,	   2011,	  Potterton	  et	  al.,	  2003)	  or	  XDS	  (Kabsch,	  2010).	  POINTLESS	  was	  used	  to	  test	  for	  twinning,	   confirm	   the	   space	   group	   identity,	   and	   provide	   statistics	   for	   the	  significance	  of	  any	  anomalous	  signal	  (Evans,	  2006,	  Evans,	  2011)	  and	  reduced	  data	   from	   all	   crystals	   were	   then	   scaled	   with	   AIMLESS	   (Evans,	   2006).	  Experimental	   phasing	   of	   the	   M2-­‐1	   WT-­‐P422	  data	   using	   the	   naturally-­‐bound	  zinc	   and	   cadmium	   atoms,	  was	   carried	   out	  with	   AUTOSOL	   (Terwilliger	   et	   al.,	  2009)	   using	   the	   single-­‐wavelength	   anomalous	   dispersion	   (SAD)	   method.	   A	  density-­‐modified	   map	   was	   produced	   using	   RESOLVE	   (Terwilliger	   and	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Berendzen,	   1999)	   and	   was	   then	   used	   with	   BUCCANEER	   (Cowtan,	   2006)	   to	  build	   an	   initial	   model.	   This	   was	   followed	   by	   consecutive	   cycles	   of	   manual	  building	   in	   COOT	   (Emsley	   and	   Cowtan,	   2004)	   and	   structure	   refinement	   in	  REFMAC5	   (Murshudov	   et	   al.,	   2011).	   	   Molecular	   replacement	   into	   other	  datasets	  was	   performed	   using	   PHASER	   (McCoy	   et	   al.,	   2007)	   	   The	   structures	  were	  fully	  refined	  following	  cycles	  of	  manual	  building	  in	  COOT	  and	  refinement	  cycles	   in	   REFMAC5,	   coupled	   with	   automatically	   generated	   local	   non-­‐crystallographic	   symmetry	   restraints.	   Intermolecular	   interactions	   were	  analysed	  using	  PISA	  (Krissinel	  and	  Henrick,	  2007)	  and	  the	  MolProbity	  server.	  	  Models	  were	  examined	  in	  COOT	  and	  figures	  made	  using	  PyMOL	  (Schrödinger)	  and	  CCP4mg	  (McNicholas	  et	  al.,	  2011).	  	  	  	  
2.2.14 RNA	  binding	  	  
	  
2.2.14.1 Phenol-­‐chloroform	  extraction	  of	  nucleic	  acid	  To	   visualise	   any	   nucleic	   acid	   bound	   to	   purified	   protein	   phenol-­‐chloroform	  extraction,	   followed	  by	  ethanol	  precipitation	  and	  agarose	  gel	  electrophoresis,	  was	  used.	  	  Protein	  was	  mixed	  with	  1	  volume	  TE	  buffer-­‐equilibrated	  phenol	  [TE	  buffer:	   10	   mM	   Tris-­‐Cl	   pH	   8,	   1	   mM	   EDTA]	   and	   vortexed.	   	   Samples	   were	  centrifuged	   at	   21,000	   xg	  10	  mins,	   the	  nucleic	   acid-­‐containing	   aqueous	  phase	  was	  removed,	  and	  the	  above	  procedure	  repeated.	  	  The	  aqueous	  layer	  was	  then	  vortexed	  with	   an	   equal	   volume	   of	   chloroform,	   centrifuged,	   and	   the	   aqueous	  layer	  retained	  as	  above.	   	  Ethanol	  precipitation	  of	  nucleic	  acid	  was	  performed	  by	  adding	  NaCl	  to	  a	  final	  concentration	  of	  0.1	  M	  to	  the	  aqueous	  phase,	  followed	  by	  2.5	  volumes	  of	  96	  %	   ice-­‐cold	  ethanol,	   and	   incubation	  at	   -­‐20	   °C	  overnight.	  	  Samples	  were	   centrifuged	   at	   21,000	   xg	   for	   30	  mins	   at	   4	   °C,	   the	   supernatant	  decanted,	  and	  the	  pellet	  washed	  in	  2	  volumes	  of	  70	  %	  ice-­‐cold	  ethanol.	  	  Pellets	  were	   air-­‐dried	   and	   resuspended	   in	   10-­‐20	  µL	  water	  with	   0.1	  %	   (v/v)	   diethyl	  pyrocarbonate	  (DEPC).	  	  Addition	  of	  RNase	  A	  was	  used	  to	  distinguish	  RNA	  from	  DNA.	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   Samples	  were	  added	  to	  5	  µL	  2x	  RNA	  ladder	  loading	  dye	  (New	  England	  Biolabs)	   and	   electrophoresed	   in	   1.5	   %	   agarose	   gels	   made	   with,	   and	   run	   in,	  Tris-­‐borate-­‐EDTA	   buffer	   [TBE:	   89	   mM	   Tris,	   89	   mM	   Borate,	   2	   mM	   EDTA,	   in	  DEPC-­‐treated	  water]	   and	  3	  µL	  ethidium	  bromide,	  with	  a	   single-­‐stranded	   low	  range	  RNA	  marker	  (New	  England	  Biolabs)	  at	  100	  V	  for	  40	  mins.	  	  Nucleic	  acids	  were	  visualised	  with	  UV	  transillumination.	  	  	  	  	  
2.2.14.2 Mass	  spectrometry	  Mass	   spectrometry	   was	   used	   to	   determine	   if	   short	   synthetic	   RNAs	   could	   be	  bound	   to	   purified,	   RNA-­‐free	   tetrameric	   M2-­‐1.	   	   Protein	   and	   RNA	   was	   buffer	  exchanged	   into	   100	   mM	   ammonium	   acetate	   pH	   7,	   and	   40	   µM	   protein	   was	  mixed	   with	   10	   µM	   RNA	   (a	   number	   of	   sequences	   were	   used).	   	   Analysis	   was	  performed	  by	  Helen	  Beeston	  (Alison	  Ashcroft	  group,	  University	  of	  Leeds)	  using	  nano-­‐electrospray-­‐ionization	   mass	   spectrometry	   (nanoESI-­‐MS)	   with	   an	   LCT	  premier	   time-­‐of-­‐flight	   mass	   spectrometer	   (Waters	   UK	   Ltd.).	  	   Samples	   were	  infused	   using	   a	   Nanomate	   (Advion)	   using	   the	   following	   instrument	  parameters:	  	  ionization	  voltage	  +1.75	  kV	  and	  sample	  cone	  voltage	  30	  V.	  	  	  	  
2.2.14.3 Fluorescence	  polarisation	  anisotropy	  Binding	   of	   M2-­‐1	   to	   short	   RNAs	   (8-­‐44	   nucleotides)	   was	   tested	   using	  fluorescence	   polarisation	   anisotropy	   (FPA).	   	   3’-­‐fluorescein	   (3’-­‐Fl)-­‐labelled	  RNAs	   representing	   a	   number	   of	   RSV	   cis-­‐acting	   signals	   in	   both	   positive	   and	  negative	   senses,	   as	   well	   as	   poly-­‐G,	   -­‐A,	   -­‐U	   or	   –C	   8mers,	   were	   synthesised	  (Thermo	  Scientific).	  	  Reactions	  were	  carried	  out	  in	  96-­‐	  and	  384-­‐well	  format,	  in	  20	  mM	  Tris-­‐Cl	  pH	  7.5,	  150	  mM	  NaCl	  and	  0.01	  %	  (v/v)	  Triton	  X-­‐100,	  with	  20	  nM	  3’-­‐Fl-­‐labelled	   RNA	   and	   increasing	   concentrations	   of	   protein	   (0.1	   nM	   to	   300	  
µM).	  	  Plates	  were	  allowed	  to	  equilibrate	  at	  room	  temperature	  for	  30	  mins	  and	  polarisation	   measured	   using	   an	   EnVision	   Multilabel	   Plate	   Reader	  (PerkinElmer)	  with	   a	   480	  nm	  excitation	   filter,	   and	  530	  nm	  S-­‐	   and	  P-­‐channel	  emission	  filters.	  	  Polarisation	  (mP)	  is	  defined	  as	  follows:	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  where	   S	   and	   P	   are	   background	   subtracted	   fluorescence	   count	   rates	   and	   G	  (grating)	  is	  an	  instrument	  and	  fluorophore	  dependent	  factor.	  Experiments	   were	   performed	   in	   triplicate	   and	   data	   were	   expressed	   as	   the	  fraction	   of	   RNA	   bound,	   plotted	   against	   protein	   concentration	   and	   fitted	   by	  standard	  logistic	  regression	  using	  OriginPro	  8.6	  (Origin	  Lab)	  according	  to	  the	  following	  equation:	  
    where	  y	   is	   the	   fraction	   of	  RNA	  bound,	  x	   is	   protein	   concentration,	  A1	  is	   initial	  value	  of	  y	  (0	  %	  RNA	  bound),	  A2	  is	  the	  final	  value	  of	  y	  (100	  %	  RNA	  bound),	  x0	  is	  the	  centre	  of	  the	  curve	  (Kd),	  and	  p	  is	  the	  Hill	  coefficient.	  	  Dissociation	  constants	  (Kd)	  were	  averaged	  from	  the	  Kd	  calculated	  from	  each	  triplicate	  dataset.	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3 CHAPTER	  3:	  MULTISYSTEM	  EXPRESSION	  AND	  CHARACTERISATION	  OF	  
M2-­‐1	  	  
	  
3.1 CHAPTER	  INTRODUCTION	  
This	   chapter	  describes	   the	  development	  of	  high-­‐yield	  expression	   systems	   for	  full-­‐length	  RSV	  M2-­‐1,	  as	  an	  optimised	  method	  had	  not	  been	  published	  prior	  to	  the	  start	  of	  this	  project.	  The	   first	   sections	   (3.2	   to	   3.4)	   discuss	   a	   recombinant	   baculovirus-­‐assisted	   insect	   cell	   expression	   system,	   and	   how	   this	   system	   was	   used	   to	  confirm	  the	  phosphorylation	  status	  of	  the	  M2-­‐1	  protein	  and	  accurately	  assign	  the	   residues	   involved.	   	   This	   system	  was	   found	   to	   be	  unsuitable	   for	   the	   large	  scale,	  homogeneous	  M2-­‐1	  expression	  required	  for	  crystallographic	  studies,	  and	  so	  the	  remainder	  of	  the	  chapter	  (sections	  3.5	  to	  3.8)	  outline	  the	  optimisation	  of	  bacterially	  expressed	  M2-­‐1	  protein	  for	  downstream	  use	  in	  structural	  and	  RNA	  binding	  studies.	  	  	  
3.2 INTRODUCTION	   TO	   PHOSPHORYLATION	   OF	   RSV	   M2-­‐1	   IN	   A	  
BACULOVIRUS-­‐ASSISTED	  INSECT	  CELL	  EXPRESSION	  SYSTEM	  
M2-­‐1	  protein	  has	  long	  been	  observed	  as	  heterogeneous	  when	  resolved	  by	  SDS-­‐PAGE	  (Routledge	  et	  al.,	  1987),	  with	  as	  many	  as	  five	  different	  molecular	  weight	  forms	   being	   detected	   by	   SDS-­‐PAGE	   analysis.	   	   When	   over-­‐expressed	   in	  mammalian	   cells	   or	   by	   in	   vitro	   transcription/translation,	   as	   well	   as	   in	   the	  context	  of	  viral	  infection,	  M2-­‐1	  appears	  predominantly	  as	  two	  distinct	  species:	  phosphorylated	   and	   unphosphorylated	   protein,	   with	   lower	   and	   higher	  electrophoretic	  mobility,	  respectively	  (Lambert	  et	  al.,	  1988,	  Hardy	  and	  Wertz,	  2000).	   	   The	   function	   of	   this	   post-­‐translational	   modification	   is	   unknown,	  although	  it	  is	  necessary	  for	  efficient	  M2-­‐1	  anti-­‐termination	  (Cartee	  and	  Wertz,	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2001).	  	  The	  phosphorylated	  residues	  have	  been	  separately	  reported	  as	  follows:	  threonine	   56	   and	   serine	   58	   (Cuesta	   et	   al.,	   2000),	   by	   determining	   [32]P-­‐orthophosphate	   incorporation	   into	   peptide	   fragments	   of	   mammalian	   cell-­‐expressed	  M2-­‐1,	   followed	  by	   site	  directed	  mutagenesis;	   serine	  58	  and	   serine	  61	   (Cartee	   and	   Wertz,	   2001),	   using	   protease	   digestion	   of	   mammalian	   cell-­‐expressed	   protein	   followed	   by	   mass	   spectrometric	   analysis	   by	   MALDI-­‐TOF	  MS/MS.	   	   To	   confirm	  which,	   if	   either,	   assignment	   is	   accurate,	  we	   optimised	   a	  recombinant	   baculovirus	   expression	   system	   and	   used	   the	   phosphopeptide	  mapping	  service	  at	  the	  mass	  spectrometry	  facility	  of	  the	  University	  of	  Leeds.	  	  	   Using	   insect	   cell	   culture,	   a	   eukaryotic	   expression	   system,	   greatly	  increases	   the	   likelihood	  of	  producing	  appropriately	   folded	  protein	  due	   to	   the	  expression	   of	   molecular	   chaperones	   and	   the	   mammalian-­‐like	   cytoplasmic	  environment,	  in	  terms	  of	  pH	  and	  compartmentalisation	  (Sokolenko	  et	  al.,	  2012,	  Kost	  et	  al.,	  2005).	  	  There	  is	  also	  extensive	  precedent	  for	  the	  expression	  of	  post-­‐translationally	   modified	   and	   immunologically	   relevant	   proteins	   using	  baculovirus-­‐infected	   insect	   cells,	   including	   the	   virus-­‐like	   particle	   human	  papilloma	   virus	   (HPV)	   vaccine	   (Harper	   et	   al.,	   2004),	   and	   a	   panel	   of	   human	  cellular	   kinases	   where	   a	   99	   %	   success	   rate	   in	   expressing	   soluble,	   folded	  proteins	  was	  achieved	  in	  Sf9	  cells	  compared	  to	  54	  %	  in	  E.	  coli	  (Chambers	  et	  al.,	  2004).	  	  	  Generation	   of	   a	   recombinant	   baculovirus	   used	   to	   rely	   solely	   on	  inefficient	  homologous	  recombination	  between	  the	  baculovirus	  genome	  and	  a	  transfer	   vector,	   co-­‐transfected	   into	   insect	   cells,	   with	   a	   recombination	  frequency	  of	  0.1	  %	  (Kost	  et	  al.,	  2005).	  	  This	  frequency	  was	  gradually	  improved	  with	   the	   addition	   of	   improvements	   to	   the	   baculovirus	   construct,	   such	   as	   a	  unique	  Bsu36I	  restriction	  site	  to	  linearise	  the	  genome,	  and	  further	  Bsu36I	  sites	  that	   knocked	   out	   the	   essential	   baculoviral	   gene	   ORF1629,	   preventing	   the	  replication	  of	  parental	  baculovirus	  and	  resulting	   in	  100	  %	  recombinant	  virus	  (Zhao	  et	   al.,	   2003).	   	   This	   is	   the	  method	  used	  here,	   although	   there	   are	  others	  based	   around	   site-­‐specific	   bacterial	   transposition	   (Bac-­‐to-­‐Bac,	   Life	  Technologies)	   where	   the	   gene	   of	   interest	   is	   transposed	   into	   the	   baculoviral	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genome	   in	   E.	   coli	   cells	   and	   a	   single	   plasmid	   is	   transfected	   into	   insect	   cell	  culture	  (Luckow	  et	  al.,	  1993).	  	  	  	  	  
3.3 RESULTS	  
3.3.1 Optimisation	  of	  pTriEx1.1	  Neo	  M2-­‐1	  construct	  
Subcloning	  of	  the	  M2-­‐1	  ORF	  cDNA	  into	  NcoI	  and	  EcoRI	  sites	  of	  pTriEx1.1	  Neo,	  the	   transfer	   vector	   required	   for	   recombinant	   baculovirus	   formation,	   was	  performed	  previously	   in	  our	  group.	   	  However,	   the	   resulting	  plasmid	  was	  not	  optimally	  constructed;	   it	   contained	  extraneous	  vector	  sequences	  encoding	  an	  additional	   40	   amino	   acids,	   including	   a	   redundant	   HSV-­‐tag	   (11	   amino	   acids	  from	  Herpes	  Simplex	  Virus	  glycoprotein	  D),	  prior	   to	  the	  C-­‐terminal	  8xHis-­‐tag	  (figure	   3.1	   B).	   	   This	   region	   of	   the	   vector	   was	   removed	   and	   replaced	   with	   a	  thrombin	  cleavage	  site	   [L-­‐V-­‐P-­‐R-­‐G-­‐S],	   resulting	   in	  expression	  of	  a	  M2-­‐1	   fused	  to	  a	  minimal	  number	  of	  non-­‐native	  amino	  acids	  and	  with	  provision	   for	  post-­‐expression	  removal	  of	  the	  His-­‐tag	  (figure	  3.1	  C).	  	   Optimisation	   of	   the	   vector	   construction	   was	   achieved	   using	   two	  complementary	  oligonucleotides	  designed	  to	   form	  the	  thrombin	  cleavage	  site	  flanked	  by	  EcoRI	  and	  XhoI	  restriction	  sites	  (Appendix	  I).	  	  Equimolar	  amounts	  of	  each	  oligonucleotide	  were	  annealed	   together	  at	  95	  °C	   for	  5	  minutes	   followed	  by	  slow	  cooling	  to	  room	  temperature.	  	  Both	  this	  insert	  and	  pTriEx1.1	  Neo	  M2-­‐1	  were	   digested	   with	   EcoRI	   and	   XhoI,	   and	   the	   desired	   fragments	   purified	   by	  agarose	  gel	  electrophoresis	  and	  gel	  extraction	  (figure	  3.1	  A).	  	  Vector	  and	  insert	  were	  ligated	  overnight,	  transformed	  into	  DH5α	  cells,	  DNA	  isolated	  from	  single	  colonies	   by	   miniprep	   purification,	   and	   successful	   recombinant	   plasmids	  identified	  by	  DNA	  sequencing.	  	  This	  construct	  was	  renamed	  ‘pST01’	  (figure	  3.1	  C).	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Figure	  3.1	  Optimisation	  of	  pTriEx1.1	  Neo	  M2-­‐1	  clone.	  	  
A)	   shows	  results	  of	  a	  double	  EcoRI/XhoI	   restriction	  digest	  on	  both	  pTriEx1.1	  Neo	   M2-­‐1	   and	   the	   thrombin	   site-­‐containing	   insert	   created	   by	   annealing	  complementary	   oligonucleotides.	   	   The	   vector+M2-­‐1	   ORF	   and	   insert	   bands	  were	  isolated	  by	  gel	  extraction.	   	  B)	  and	  C)	  The	  arrangement	  of	  the	  M2-­‐1	  ORF	  (585bp	   cloned	   between	   NcoI	   and	   EcoRI	   downstream	   of	   the	   expression	  promoters	  and	  ribosome	  binding	  site)	  in	  pTriEx1.1	  Neo	  before	  B)	  and	  after	  C)	  removal	  of	  extraneous	  sequence	  (multiple	  cloning	  site	  and	  HSV-­‐tag	  sequences)	  and	   insertion	   of	   thrombin	   cleavage	   site.	   	   The	   construct	   shown	   in	   C)	   was	  successfully	  generated	  and	  referred	  to	  as	  ‘pST01’.	  	  	  	  	  	  
3.3.2 Generating	  recombinant	  baculovirus	  
Initial	  recombinant	  baculovirus,	  P0,	  for	  use	  in	  small	  scale	  expression	  trials,	  was	  generated	   by	   co-­‐transfection	   by	   lipofection	   of	   Sf9	   insect	   cells	   with	   the	  linearised	   BAC10:KO1629	   	   bacmid,	   containing	   the	   AcMNPV	   genome,	   and	   the	  transfer	  vector	  pST01	  containing	   the	  M2-­‐1	  ORF.	   	  Virus	  was	  harvested	  3	  days	  post	  infection	  (p.i.)	  and	  used	  to	  infect	  small-­‐scale	  adherent	  cultures	  to	  confirm	  expression	  of	  M2-­‐1-­‐His.	  	  At	  3	  days	  p.i.	  virus	  infected	  cells	  were	  harvested	  and,	  to	  confirm	  that	  M2-­‐1	  protein	  was	  not	  secreted	  from	  insect	  cells	  in	  this	  system,	  a	  sample	  of	  the	  supernatant	  was	  also	  retained	  for	  SDS-­‐PAGE	  analysis.	   	  Whole	  cell	   lysates	   were	   prepared	   and	   analysed	   by	   SDS-­‐PAGE	   alongside	   the	  supernatant,	   followed	   by	   western	   blotting	   using	   an	   anti-­‐His-­‐tag	   primary	  antibody.	   	   Blots	   showed	   the	   presence	   of	   a	   ~26	   kDa	   band	   in	   the	   whole	   cell	  lysate	   but	   not	   the	   supernatant,	   suggesting	   the	   M2-­‐1	   fusion	   protein	   was	  expressed	  in	  these	  cultures,	  but	  was	  not	  secreted	  into	  the	  supernatant	  (figure	  3.2).	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3.3.3 Purification	  of	  M2-­‐1	  from	  large-­‐scale	  infections	  
Due	   to	   the	   lack	   of	   an	   adequate	   M2-­‐1-­‐specific	   antibody	   and	   the	   high	   non-­‐specific	   binding	   of	   anti-­‐His-­‐tag	   antibodies,	   we	   used	   cobalt	   affinity	  chromatography	   to	   purify	   the	   8x-­‐His-­‐tagged	   M2-­‐1	   protein	   and	   confirm	   its	  identity.	  	  P1	  generation	  baculovirus	  was	  created	  by	  amplification	  of	  P0	  virus	  via	  a	   round	   of	   infection	   and	   replication.	   	   This	   virus	   was	   used	   to	   infect	   200	  mL	  suspension	  cultures	  of	  Sf9	  cells	  for	  3	  days,	  and	  cells	  were	  recovered	  and	  lysed	  in	  binding	  buffer	  containing	  5	  mM	  imidazole	  to	  prevent	  non-­‐specific	  binding	  to	  the	  HiTrap	   IMAC	  FF	  column.	   	  Protein	  was	  bound	  to	   the	  column,	  washed,	  and	  eluted	  by	  stepwise	   imidazole	  gradient.	   	  Samples	  were	  taken	  at	  each	  stage	   for	  analysis	  by	  SDS-­‐PAGE	  followed	  by	  Coomassie	  staining	  (figure	  3.3	  A)	  and	  anti-­‐His-­‐tag	   western	   blotting	   (figure	   3.3	   B).	   	   Both	   analyses	   show	   a	   doublet	   of	  protein,	   presumably	   M2-­‐1,	   was	   successfully	   purified	   at	   ~26-­‐27	   kDa,	   eluting	  primarily	  between	  150	  mM	  and	  250	  mM	  imidazole,	  although	  the	  presence	  of	  two	  species	  is	  very	  difficult	  to	  resolve	  by	  western	  blot	  with	  this	  antibody.	  	  	  	  
	  
Figure	  3.2	  P0	  baculovirus	  expression	  trial.	  	  	  Anti-­‐His-­‐tag	  western	  blot	  of	  supernatant	  and	  whole	  cell	  lysate	  shows	  that	  M2-­‐1	  (red	  arrow)	  is	  present	  only	  in	  whole	  cell	  lysates	  i.e.	  it	  is	  not	  secreted.	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Figure	  3.3	  Cobalt	  affinity	  purification	  of	  M2-­‐1	   from	  baculovirus	   infected	  
cells.	  	  	  (Above)	   Samples	   from	  multiple	   steps	   throughout	   purification	  were	   analysed	  by	   SDS-­‐PAGE	   followed	   by	   A)	   Coomassie	   staining,	   or	   B)	   anti-­‐His-­‐tag	   western	  blotting.	  	  M2-­‐1	  appears	  as	  a	  doublet	  of	  approximately	  26-­‐27	  kDa;	  although	  the	  two	  species	  are	  difficult	  to	  distinguish	  in	  this	  blot,	  they	  were	  visible	  at	  shorter	  exposures.	  	  	  	  	  	  
3.3.4 Insect	  cell	  expressed	  M2-­‐1	  is	  phosphorylated	  
To	  confirm	  that	  the	  presence	  of	  a	  doublet	  on	  SDS-­‐PAGE	  was	  due	  to	  differential	  phosphorylation,	   as	   has	   been	   shown	   in	   the	   literature	   for	   mammalian	   cell	  expressed	  protein	  (Cartee	  and	  Wertz,	  2001),	  purified	  M2-­‐1	  was	  calf	  intestinal	  alkaline	   phosphatase	   (CIP)	   treated	   to	   remove	   any	   phosphorylation	   present.	  	  Samples	  were	  taken	  before	  and	  after	  CIP	  treatment	  and	  analysed	  by	  SDS-­‐PAGE	  and	  Coomassie	   staining.	   	  The	  gel	   showed	  CIP	   treatment	   resulted	   in	  a	   shift	   in	  protein	   abundance	   to	   the	   species	   with	   higher	   electrophoretic	   mobility,	  assumed	   to	   be	   unphosphorylated	   protein,	   suggesting	   that	   the	   species	   with	  lower	   electrophoretic	   mobility	   was	   indeed	   phosphorylated	   in	   this	   system	  (figure	  3.4).	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Figure	  3.4	  Phosphorylation	  of	  insect	  cell	  expressed	  M2-­‐1.	  	  	  CIP	   treatment	  of	  purified	  M2-­‐1	  shows	  the	  expected	  shift	   in	  abundance	   to	   the	  higher	  electrophoretic	  mobility	  species	  of	  the	  M2-­‐1	  doublet	  (26-­‐27	  kDa).	  	  	  
3.3.5 Confirmation	   of	   protein	   ID	   and	   identification	   of	   phosphorylation	  
sites	  by	  mass	  spectrometry	  
Both	  bands	   from	  the	  purified	  M2-­‐1	  doublet	  were	  excised	   from	  100,	  150,	  and	  250	  mM	   imidazole	   elutions	   and	   pooled	   as	   two	   samples:	   phosphorylated	   and	  unphosphorylated	   protein.	   	   Samples	   were	   analysed	   as	   a	   service	   by	   the	  University	  of	  Leeds	  mass	  spectrometry	   facility,	  by	   the	   facility	  manager	   James	  Ault	  and	  a	  PhD	  student	  Kevin	  Tipping	  (Prof	  Sheena	  Radford	  group)	  who	  was	  developing	  an	  in-­‐house	  phosphopeptide	  mapping	  protocol.	  	  	  	   Firstly,	  protein	  from	  both	  bands	  was	  identified	  as	  M2-­‐1	  by	  in-­‐gel	  trypsin	  digestion	   followed	   by	   analysis	   of	   the	   peptides	   by	   LC-­‐MS/MS.	   	   The	   primary	  database	  ‘hit’	  for	  both	  species	  was	  RSV	  M2-­‐1,	  with	  sequence	  coverage	  of	  over	  50	  %	  for	  both	  samples.	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Secondly,	   peptides	   were	   prepared	   for	   phosphomapping	   by	   first	  enriching	   for	  phosphorylated	  peptides	  using	   titanium	  oxide	  chromatography.	  	  Peptides	   were	   then	   analysed	   by	   tandem	   mass	   spectrometry	   using	   a	  quadrupole-­‐IMS-­‐orthogonal	   time-­‐of-­‐flight	   MS.	   	   The	   mass/charge	   spectrum	  shows	   the	   presence	   of	   a	   doubly	   phosphorylated	   peptide,	   as	   indicated	   by	   the	  two	  neutral	   loss	  peaks	   from	  the	  parent	   ion	  (figure	  3.5).	   	  The	  sequence	  of	   the	  phosphopeptide	  was	  calculated	  from	  the	  mass	  difference	  between	  peaks	  of	  the	  y-­‐ion	  series,	  generated	  by	  retention	  of	  protonation	  on	  the	  C-­‐terminal	  end	  of	  a	  fragmented	  CO-­‐NH	  bond.	  	  Analysis	  indicated	  phosphorylation	  events	  at	  serine	  58	   and	   serine	   61.	   	   This	   is	   in	   line	   with	   the	   previously	   published	   result	   from	  Cartee	  et	  al.	  (Cartee	  and	  Wertz,	  2001)	  and	  not	  from	  Cuesta	  et	  al.	  (Cuesta	  et	  al.,	  2000),	  who	  reported	  threonine	  56	  and	  serine	  58.	  	  
Figure	  3.5	  	  Phosphopeptide	  mapping	  mass	  spectrum.	  	  	  (Below)	  MSMS	  acquisition	  of	   [918.8947]2+	   parent	   ion	   from	  direct	   infusion	  of	  tryptically	   digested	   RSV	   M2-­‐1	   protein	   enriched	   for	   phosphopeptides	   using	  TiO2	   chromatography.	   	   The	   two	   neutral	   loss	   peaks	   (~49Da	   each)	   from	   the	  parent	   ion	   (green	   arrows)	   indicate	   the	   presence	   of	   a	   doubly-­‐phosphorylated	  peptide.	   The	   following	   sequence	   was	   determined	   from	   the	   y-­‐ion	   series	   by	  following	   the	   addition	   of	   mass	   from	   y1	   Arg,	   as	   indicated	   by	   the	   light	   blue	  numbers:	   1)	   	   114.9532,	  D.	   2)	  113.0754,	  L.	   3)	  129.0457,	  E.	   4)	  71.0364,	  A.	   5)	  	  128.0508,	  A	  &	  G.	  6)	  167.0003,	  Sp.	  7)	  113.0926,	  I.	  8)	  129.0398,	  E.	  9)	  167.0114,	  
Sp.	  10)	  113.0662,	  L.	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3.4 SECTION	  SUMMARY	  
This	   section	   has	   confirmed	   that	   the	  M2-­‐1	   species	   that	   resolves	  with	   a	   lower	  electrophoretic	   mobility	   is	   a	   doubly	   phosphorylated	   protein	   with	   phospho-­‐serines	  at	  positions	  58	  and	  61.	  	  These	  sites	  match	  those	  published	  by	  Cartee	  et	  al.	  (Cartee	  and	  Wertz,	  2001).	  The	  baculovirus	  system	  of	  expression	  was	  chosen	  for	  this	  section	  of	  the	  project	   for	   its	  ease	  of	   scale-­‐up	  relative	   to	  mammalian	  cell	   culture,	  and	   for	   its	  physiologically	   similar	   post-­‐translational	   modifications	   to	   mammalian	   tissue	  culture	  systems.	  	  Phosphopeptide	  mapping	  by	  tandem	  mass	  spectrometry	  was	  used	   for	   its	   ability	   to	   accurately	   pinpoint	   post-­‐translational	   modifications	  without	   the	   need	   for	   time	   consuming	   site	   directed	   mutagenesis	   and	   loss	   of	  phenotype	  analysis.	   	  This	   is	   the	  same	   technique	  used	  by	  Cartee	  et	  al.,	   and	   its	  superior	  accuracy	  when	  compared	  to	  the	  techniques	  employed	  by	  Cuesta	  et	  al.,	  namely	   [32]P-­‐orthophosphate	   incorporation	   and	   site	   directed	  mutagenesis,	   is	  why	   serines	   58	   and	   61	   are	   more	   frequently	   quoted	   in	   the	   literature	   as	   the	  phosphorylation	  sites	  of	  M2-­‐1.	  	  Confirmation	  of	  these	  sites	  from	  an	  orthogonal	  expression	  system	  settles	  any	  remaining	  doubt	  over	  their	  assignment.	  Knowledge	  of	  the	  residues	  involved	  in	  phosphorylation	  is	  important	  for	  our	  understanding	  of	   the	  possible	   roles	   of	   this	  modification	  during	   the	   virus	  life	  cycle.	  	  Cellular	  kinases	  involved	  may	  be	  predicted	  by	  consensus	  sequence;	  serine	  58	  lies	  within	  a	  casein	  kinase	  I	  (CKI)	  sequence,	  and	  phosphorylation	  at	  this	   site	   forms	   a	   consensus	   sequence	   for	   CKI	   phosphorylation	   at	   serine	   61.	  	  Cartee	  et	  al.	  showed	  that	  CKI	  could	  phosphorylate	  bacterially-­‐expressed	  M2-­‐1	  
in	   vitro	   (Cartee	   and	   Wertz,	   2001).	   	   More	   importantly	   for	   this	   research,	  interpretation	  of	  the	  location	  of	  the	  exact	  residues	  involved	  in	  phosphorylation	  in	  terms	  of	  a	  crystal	  structure	  may	  indicate	  a	  role	  in	  conformational	  change	  or	  regulation	  of	  access	   to	  nucleic	  acid	  or	  protein	  binding	  sites.	   	   It	  was	  based	  on	  this	   information	   that	   expression	   of	   both	   wild	   type	   and	   phosphomimetic	  (S58DS61D)	   M2-­‐1	   was	   optimised	   for	   structural	   analysis	   and	   RNA	   binding	  studies	  in	  the	  remainder	  of	  this	  project.	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Although	   we	   have	   presented	   a	   system	   for	   large-­‐scale	   expression	   of	  functionally	   relevant	   M2-­‐1	   protein,	   several	   factors	   made	   this	   method	  impractical	  for	  further	  structural	  studies.	  	  Homogeneous	  protein	  was	  required	  for	  crystallisation,	  and	  separation	  of	  the	  different	  phospho-­‐species	  of	  M2-­‐1	  on	  a	   large	   scale	   was	   not	   easily	   achievable.	   	   Equally,	   bulk	   dephosphorylation	   of	  insect	   cell	   expressed	   protein	   to	   create	   a	   homogeneous	   sample	   was	   not	   an	  option	   due	   to	   incomplete	   removal	   of	   phosphorylation	   and	   the	   cost-­‐ineffectiveness	   of	   this	   process.	   	   Finally,	   whilst	   yield	   was	   high	   relative	   to	  mammalian	  cell	  expression,	  the	  time	  scales	  involved	  in	  culturing	  large	  volumes	  of	   insect	   cell	   suspension	   culture	   prohibit	   the	   high-­‐throughput	   expression	  possible	   with	   a	   bacterial	   system.	   	   As	   a	   result,	   optimisation	   of	   bacterial	  expression	  of	  RSV	  M2-­‐1	  was	  performed	  for	  crystallographic	  studies.	  	  	  	  	  
3.5 INTRODUCTION	  TO	  BACTERIAL	  EXPRESSION	  OF	  M2-­‐1	  
Over-­‐expression	   in	   prokaryotic	   E.	   coli	   cells	   is	   the	   most	   common	   method	   of	  producing	   high-­‐yield,	   homogeneous	   protein	   for	   structural	   studies.	   	   The	   two	  vectors	   used	   here	   use	   different	   promoter	   systems:	   pET28a-­‐SUMO	  places	   the	  target	   protein	   under	   the	   control	   of	   a	   T7	   RNA	   polymerase	   promoter	   and	  requires	   DE3	   E.coli,	   which	   have	   a	   chromosomally-­‐integrated	   phage	   (λDE3)	  encoding	   the	   T7	   RNA	   polymerase	   gene	   under	   the	   control	   of	   the	   lacUV5	  promoter;	   pGEX	   vectors	   use	   the	   tac	   promoter,	   a	   strong	   hybrid	   promoter	  containing	  lacUV5	  elements,	  meaning	  the	  protein	  of	  interest	  itself	  is	  under	  lac	  repression.	   	   IPTG	   induction	   either	   allows	   T7	   RNA	   polymerase	   expression,	  which	  in	  turn	  transcribes	  the	  target	  gene	  (pET),	  or	  directly	  relieves	  repression	  of	  the	  target	  gene	  allowing	  transcription	  by	  the	  E.coli	  RNA	  polymerase	  (pGEX).	  	  	  	   Advantages	   of	   bacterial	   protein	   expression	   include	   homogeneity,	   high	  yield,	   low	   cost,	   and	   ease	   of	   scale-­‐up.	   	   However,	   these	   advantages	   are	   at	   the	  expense	   of	   correct	   post-­‐translational	  modifications,	   such	   as	   phosphorylation,	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and	  this	  must	  be	  taken	  into	  account	  when	  analysing	  the	  structure	  or	  function	  of	  proteins	  expressed	  this	  way.	  	  This	  section	  outlines	  the	  process	  of	  optimising	  bacterial	  expression	  of	  RSV	  M2-­‐1	  protein.	  	  	  	  	  	  
3.6 RESULTS	  
3.6.1 Cloning	  of	  M2-­‐1	  ORF	  into	  His-­‐SUMO-­‐tag	  expression	  vector	  
To	  improve	  bacterial	  expression	  of	  RSV	  M2-­‐1	  the	  ORF	  was	  subcloned	  into	  pET-­‐28aSUMO,	  a	  vector	   that	  encodes	  an	  N-­‐terminal	  6xHis-­‐SUMO.	   	  This	   tag	  allows	  for	   nickel	   affinity	   chromatography	   for	   purification,	   whilst	   the	   SUMO	   protein	  has	  been	  shown	  to	  aid	   in	  solubility,	   folding,	  and	  prevention	  of	  degradation	  of	  recombinant	  protein.	  	  	   Forward	  and	  reverse	  primers	  were	  designed	  to	  amplify	   the	  M2-­‐1	  ORF	  from	  pST01,	   flanking	  it	  N-­‐terminally	  with	  BamHI	  site	  and	  C-­‐terminally	  with	  a	  TAA	  stop	  codon	  followed	  by	  XhoI	  site	  (Appendix	  I).	   	  PCR	  was	  performed	  with	  these	  primers	  and	  both	  the	  PCR	  product	  (the	  insert)	  and	  pET-­‐28aSUMO	  vector	  were	   digested	  with	  BamHI	   and	   XhoI	   restriction	   enzymes.	   	   Insert	   and	   empty	  vector	   fragments	   were	   purified	   by	   agarose	   gel	   electrophoresis	   and	   gel	  extraction.	  	  Fragments	  were	  ligated	  together	  and	  transformed	  into	  DH5α	  cells,	  before	  isolating	  9	  single	  colonies	  for	  DNA	  purification	  by	  miniprep.	   	  Presence	  of	   the	  M2-­‐1	  ORF	  was	  confirmed	  by	  diagnostic	  restriction	  enzyme	  digest	  with	  
BamHI	   and	   XhoI	   (figure	   3.6).	   	   	   All	   9	   clones	   produced	   a	   609	   bp	   fragment	  corresponding	   to	   the	   PCR	   product.	   	   The	   clone	   with	   the	   highest	   yield	   was	  amplified	   by	   maxiprep	   and	   sent	   for	   DNA	   sequencing	   to	   confirm	   correct	  insertion	  of	  the	  M2-­‐1	  ORF.	  	  This	  construct	  is	  called	  ‘pETSUMO-­‐M2-­‐1’.	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Figure	  3.6	  Identification	  of	  M2-­‐1	  ORF	  subcloned	  into	  pET-­‐28aSUMO.	  Double	  restriction	  enzyme	  digests	  were	  performed	  for	  all	  9	  clones	  with	  BamHI	  and	  XhoI.	  3	  clones	  are	  shown	  here	  as	  examples,	  and	  uncut	  vector	  is	  shown	  for	  reference.	   	   All	   clones	   produced	   the	   expected	   609	   bp	   fragment	   for	   the	  M2-­‐1	  ORF.	  	  	  
3.6.2 Preliminary	  expression	  and	  purification	  of	  His-­‐SUMO-­‐M2-­‐1	  	  
pETSUMO-­‐M2-­‐1	  was	  transformed	  into	  Rosetta	  and	  Rosetta	  2	  cells,	  BL21(DE3)	  derivatives	  designed	   to	   supply	   additional	   tRNAs	   for	   codons	   rarely	   used	   in	  E.	  
coli	   and	  remove	   the	  need	   for	  codon	  optimisation	  of	   the	  recombinant	  protein,	  which	  is	  often	  necessary	  when	  attempting	  to	  express	  viral	  proteins	  in	  bacterial	  systems.	   	   Empty	   pET28aSUMO	   vector	   was	   also	   transformed	   as	   a	   negative	  control.	   	  Overnight	  cultures	  of	  LB	  with	  kanamycin	  and	  chloramphenicol	  were	  inoculated	  with	  starter	  cultures	  for	  empty	  vector	  and	  pETSUMO-­‐M2-­‐1,	  grown	  to	  OD600	  0.6-­‐0.8,	  then	  induced	  with	  100	  µM	  IPTG	  overnight	  at	  either	  18	  °C,	  30	  
°C,	  or	  37	  °C.	  	  Cells	  were	  pelleted	  by	  centrifugation,	  resuspended	  in	  20	  mM	  Tris	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pH	   7.8,	   500	   mM	   NaCl,	   and	   lysed	   by	   sonication.	   	   Lysates	   were	   clarified	   by	  centrifugation	  and	  samples	  of	  insoluble	  and	  soluble	  fractions	  were	  analysed	  by	  SDS-­‐PAGE.	   	   The	   abundance	   of	   bacterial	   proteins,	   and	   either	   low	   or	   no	  expression	   of	   M2-­‐1,	   resulted	   in	   being	   unable	   to	   identify	   a	   band	   uniquely	  expressed	  by	  pETSUMO-­‐M2-­‐1.	  	  	  	  	   100	   µM	   IPTG	   was	   a	   relatively	   mild	   induction	   condition,	   and	   so	  increased	   IPTG	   concentrations	  were	   tried.	   	  Additionally,	   ZnSO4	  was	  added	  at	  induction,	  as	  supplementing	  cultures	  with	  zinc	  has	  been	  proposed	  to	  help	  M2-­‐1	   expression	   by	   aiding	   folding	   of	   the	   predicted	   N-­‐terminal	   zinc	   finger	  motif	  (Tran	  et	  al.,	  2009).	   	   Inductions	  were	  performed	  with	  300	  µM	  IPTG	  and	  1	  mM	  ZnSO4	   overnight	   at	   18	   °C,	   30	   °C,	   or	   37	   °C	   in	   Rosetta	   and	   Rosetta	   2	   cells.	  	  Samples	   of	   insoluble	   and	   soluble	   fractions	  were	   analysed	   by	   SDS-­‐PAGE,	   and	  samples	  from	  the	  30	  °C	  induction	  are	  shown	  in	  figure	  3.7.	   	  For	  both	  bacterial	  strains	  a	  band	  with	  an	  apparent	  molecular	  weight	  of	  43	  kDa	  could	  be	  seen	  in	  M2-­‐1	  lanes	  (indicated	  by	  triangles	  in	  figure	  3.7),	  in	  all	  fractions,	  but	  not	  empty	  vector	   lanes.	   	  Although	  His-­‐SUMO-­‐M2-­‐1	  had	  an	  expected	  molecular	  weight	  of	  35	  kDa,	  both	  published	   literature	   and	  our	   insect	   cell	   expression	   suggest	   that	  M2-­‐1	   may	   have	   a	   higher	   apparent	   molecular	   weight	   than	   predicted	   when	  analysed	  by	  SDS-­‐PAGE,	  as	  does	  SUMO	  itself.	  	  This	  species	  was	  expressed	  at	  all	  induction	   temperatures,	   but	  with	  higher	   solubility	   at	   temperatures	  below	  30	  
°C	  –	  little	  difference	  was	  observed	  between	  18	  °C	  and	  30	  °C.	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A	  Rosetta, 300 µM IPTG 
	  
B Rosetta 2, 300 µM IPTG 	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  3.7	  Preliminary	  expression	  of	  His-­‐SUMO-­‐M2-­‐1.	  	  	  Cultures	  were	  induced	  overnight	  at	  30	  °C	  with	  300	  µM	  IPTG	  and	  1mM	  ZnSO4	  in	  
A)	   Rosetta	   and	   B)	   Rosetta	   2	   cells.	   	   Triangles	   indicate	   the	   43	   kDa	   species	  suspected	   to	   be	   His-­‐SUMO-­‐M2-­‐1.	   	   Lane	   labels:	   vector,	   empty	   pET28aSUMO;	  M2-­‐1,	  pETSUMO-­‐M2-­‐1	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   The	   43	   kDa	   species	   could	   be	   enriched	   by	  Ni-­‐affinity	   chromatography.	  	  	  	  Purification	   was	   as	   in	  Methods	   2.2.9,	   except	   that	   the	   HiTrap	   IMAC	   FF	   1	  mL	  column	   (GE	  Healthcare)	  was	   charged	  with	   0.1	  M	  nickel	   chloride.	   	   Inductions	  were	   performed	  with	   300	  µM	   IPTG	   and	   1	  mM	  ZnSO4	  overnight	   at	   30	   °C,	   for	  pETSUMO-­‐M2-­‐1	   and	   empty	   vector	   transformed	  Rosetta	   2	   cells.	   	   Pellets	  were	  resuspended	  in	  20	  mM	  Tris	  pH	  7.8,	  500	  mM	  NaCl,	  and	  the	  soluble	  fraction	  was	  applied	   to	   the	   column.	   	  6xHis-­‐tagged	  protein	  was	  eluted	   from	   the	  column	  by	  stepwise	   imidazole	   gradient.	   	   Figure	   3.8	   shows	   the	   elutions	   from	   both	  inductions:	  	  the	  empty	  vector	  purification	  showed	  a	  protein	  of	  ~20	  kDa	  eluting	  between	  50	  and	  150	  mM	  imidazole	  (figure	  3.8	  left),	  likely	  to	  be	  the	  His-­‐SUMO-­‐tag	  fused	  to	  the	  multiple	  cloning	  site;	  the	  M2-­‐1	  purification	  showed	  a	  protein	  of	  ~43	  kDa	  eluting	  between	  150	  and	  250	  mM	  imidazole	  that	  was	  not	  present	  in	  the	  empty	  vector	  purification.	   	  This	  molecular	  weight	  corresponded	  to	  the	  43	  kDa	  band	  suspected	  to	  be	  His-­‐SUMO-­‐M2-­‐1	  in	  figure	  3.7	  and	  confirmed,	  at	  least,	  that	  this	  species	  was	  His-­‐tagged.	  	  	  	  
	  
Figure	  3.8	  Enrichment	  of	  6xHis-­‐tagged	  proteins	  by	  Ni-­‐chromatography.	  	  The	  gel	  shows	  the	  stepwise	  imidazole	  elution	  of	  protein	  expressed	  from	  empty	  pET28aSUMO	   vector	   and	   pETSUMO-­‐M2-­‐1:	   His-­‐SUMO-­‐M2-­‐1	   elutes	   between	  150	  and	  250	  mM	  imidazole	  at	  ~43	  kDa	  (right),	  His-­‐SUMO	  fused	  to	  the	  multiple	  cloning	  site	  elutes	  between	  50	  and	  150	  mM	  imidazole	  at	  ~20	  kDa	  (left).	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   To	   confirm	   that	   M2-­‐1	   expressed	   from	   the	   pET28SUMO	   vector	   was	  folded	  and	  formed	  the	  tetramer	  predicted	   in	  the	   literature,	   the	  His-­‐SUMO-­‐tag	  was	   first	   removed	   from	   the	   N-­‐terminus	   of	   M2-­‐1.	   	   The	   elution	   from	   the	   Ni-­‐chromatography	   was	   incubated	   with	   SUMO-­‐protease;	   a	   tertiary	   structure-­‐specific	   cysteine	  protease	   that	   cleaves	  SUMO	  without	   leaving	  any	  extraneous	  residues	   and	   does	   not	   demonstrate	   erroneous	   cleavage	   (Butt	   et	   al.,	   2005).	  	  Figure	  3.9	  shows	  that	  addition	  of	  SUMO	  protease	  resulted	  in	  cleavage	  of	  the	  43	  kDa	  species	  into	  a	  28	  kDa	  species,	  suspected	  to	  be	  M2-­‐1,	  and	  a	  20	  kDa	  species,	  suspected	   to	   be	   the	   His-­‐SUMO	   tag	   as	   this	   matched	   the	   protein	   expressed	  during	  vector	  only	  inductions.	  	  This	  reaction	  was	  then	  further	  purified	  by	  size	  exclusion	  chromatography	  using	  a	  Superdex	  S75	  column.	  	  Figure	  3.10	  shows	  a	  representative	  trace	  monitoring	  the	  elution	  from	  the	  size	  exclusion	  column	  by	  absorbance	  at	  280	  nm	  (figure	  3.10	  A)	  and	  SDS-­‐PAGE	  analysis	  of	  the	  fractions	  collected	  during	  the	  purification	  (figure	  3.10	  B).	   	  M2-­‐1	  protein	  eluted	   in	  both	  peaks	   1	   and	   2,	   however	   the	   SDS-­‐PAGE	   gels	   showed	   that	   fractions	  corresponding	   to	  peak	  1	  also	   contained	  additional	  bands;	  possibly	   co-­‐eluting	  contaminants	  or	  higher	  order	  oligomers	   that	  have	  not	  been	  disrupted	  by	   the	  denaturing	   gel	   conditions.	   	   Comparison	   with	   the	   absorbance	   trace	   showed	  considerably	  higher	  absorbance	  for	  peak	  1,	  despite	  the	  similar	  distribution	  of	  protein	  according	  to	  SDS-­‐PAGE.	  	  This	  may	  indicate	  the	  presence	  of	  nucleic	  acid,	  which	  also	  absorbs	  near	  280	  nm	  wavelengths,	  and	  this	  may	  be	  mediating	  some	  of	  the	  higher	  order	  species	  seen.	  The	  His-­‐SUMO	  tag	  eluted	  at	  185	  mL.	  	  Using	  a	  calibration	  curve	  for	  the	  size	  exclusion	  column,	  generated	  by	  running	  a	  set	  of	  standards	  with	   known	  molecular	  weights,	   the	   elution	   volumes	   for	   peaks	   1-­‐3	  were	  equated	   to	  approximate	  molecular	  weights.	   	  Peak	  1	  was	  ~150	  kDa	  and	  peak	  2	  was	  ~107	  kDa,	   and	  whilst	   both	  of	   these	   values	  were	  higher	   than	   the	  predicted	   90	   kDa	   for	   an	   M2-­‐1	   tetramer,	   they	   agreed	   with	   the	   higher-­‐than-­‐expected	   values	   seen	   with	   techniques	   such	   as	   dynamic	   light	   scattering	   and	  analytical	   ultracentrifugation	   which	   have	   previously	   suggested	   an	   extended	  conformation	  is	  responsible	  for	  the	  high	  observed	  molecular	  weights	  (Tran	  et	  al.,	   2009).	   	   Peak	   3	   was	   ~	   20	   kDa,	   which	   corresponded	   to	   the	   expected	  molecular	  weigh	  for	  His-­‐SUMO	  and	  the	  size	  of	  the	  band	  observed	  by	  SDS-­‐PAGE.	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Figure	  3.9	  Removal	  of	  His-­‐SUMO-­‐tag	  by	  SUMO	  protease	  cleavage.	  	  Ni-­‐chromatography	   purified	   His-­‐SUMO-­‐M2-­‐1	   was	   incubated	   without	   (-­‐)	   and	  with	  (+)	  SUMO	  protease.	  	  Cleavage	  of	  His-­‐SUMO-­‐M2-­‐1	  (43	  kDa)	  results	  in	  M2-­‐1	  (~28	  kDa)	  and	  His-­‐SUMO	  (~20	  kDa).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  





Figure	  3.10	  Size	  exclusion	  chromatography	  of	  cleaved	  His-­‐SUMO-­‐M2-­‐1.	  	  Size	  exclusion	  chromatography	  (SEC)	  using	  a	  Superdex	  S75	  column.	   	  A)	  A280	  trace	  of	  eluting	  protein	  from	  size	  exclusion	  column.	  V0	  indicates	  void	  volume.	  	  
B)	   	   SDS-­‐PAGE	  analysis	  of	  SEC	   fractions	   labelled	  with	   the	  corresponding	  peak	  from	  A)	  and	  the	  elution	  volume.	  	  A	  28	  kDa	  protein	  (M2-­‐1)	  eluted	  in	  peaks	  1	  and	  2	  at	  113	  and	  125	  mL,	  respectively,	  and	  a	  20	  kDa	  protein	  (His-­‐SUMO-­‐tag)	  eluted	  in	  peak	  3	  at	  185	  mL.	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3.6.3 Optimising	  expression	  of	  His-­‐SUMO-­‐M2-­‐1	  
Induction	  with	  500	  µM	  and	  1	  mM	  IPTG	  was	  also	  tested,	  with	  only	  1	  mM	  IPTG	  resulting	  in	  slightly	  higher	  levels	  of	  soluble	  M2-­‐1	  expression	  compared	  to	  300	  
µM	  IPTG	  induction	  as	  determined	  by	  gel	  band	  size	  (comparing	  figures	  3.7	  and	  3.11	  A).	  	  Slightly	  more	  His-­‐SUMO-­‐M2-­‐1	  could	  be	  seen	  in	  the	  soluble	  fraction	  of	  Rosetta	  2	  cells	   induced	  at	  1	  mM	  IPTG,	  than	  with	  Rosetta	  cells	  (figure	  3.11	  A).	  	  	  Multiple	   induction	   temperatures,	   late-­‐log	   phase	   induction	   (OD600	   1-­‐1.2),	   and	  various	  molarities	  of	  IPTG	  (100	  µM	  to	  1	  mM)	  and	  ZnSO4	  (50	  µM	  to	  1	  mM)	  were	  all	   tested	   to	   increase	   total	   expression	   levels	   of	   His-­‐SUMO-­‐M2-­‐1.	   	   High-­‐level	  expression,	  i.e.	  the	  predominant	  species	  in	  the	  total	  induced	  sample,	  could	  not	  be	  achieved	  in	  Rosetta	  or	  Rosetta	  2	  cells.	  	  Next,	   pETSUMO-­‐M2-­‐1	   was	   then	   retransformed	   into	   two	   other	   E.	   coli	  expression	   strains:	   OverExpress	   C41	   (DE3)	   (‘C41’),	   engineered	   to	   withstand	  over	   expression-­‐induced	   toxicity;	   BL21	   (DE3)	  Gold	   (‘BL21	  Gold’),	   a	   standard	  protease-­‐deficient	   expression	   strain.	   	  Work	   using	   C41	   cells	   to	   express	  M2-­‐1	  was	  published	  during	   this	  project	   (Esperante	   et	   al.,	   2011)	   and	   so	   expression	  was	  tested	  as	   in	  this	  publication:	  18	  hour	  37	  °C	  induction	  with	  300	  µM	  IPTG.	  	  Low	  expression	  levels	  required	  Ni-­‐chromatography	  purification	  before	  a	  band	  presumably	   corresponding	   to	   His-­‐SUMO-­‐M2-­‐1	   could	   be	   identified	   by	   SDS-­‐PAGE	  analysis	   (figure	  3.11	  B),	   and	  so	   these	   cells	  were	  not	  optimised	   further.	  	  Expression	  in	  BL21	  Gold	  cells	  was	  tested	  by	  inducing	  at	  30	  °C	  overnight	  or	  for	  6	  hours,	  with	  1	  mM	  IPTG	  and	  1	  mM	  ZnSO4	  (the	  conditions	  optimal	  up	   to	   this	  point).	   	   Cells	  were	  pelleted	  and	   resuspended	   in	  20	  mM	  Tris	  pH	  7.8,	  500	  mM	  NaCl,	   and	   lysed	   by	   sonication.	   	   Considerably	   higher	   total	   expression	   of	   His-­‐SUMO-­‐M2-­‐1	  was	  observed	  (figure	  3.11	  C)	  although	  the	  majority	  of	  protein	  was	  insoluble.	  	  It	  was	  noted	  that	  this	  E.	  coli	  strain	  was	  significantly	  more	  difficult	  to	  sonicate,	   and	   so	   incomplete	   lysis	   may	   have	   been	   responsible	   for	   low	  abundance	  of	  M2-­‐1	  in	  the	  soluble	  fraction.	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A Rosetta and Rosetta 2, 1 mM IPTG 
B C41, 300 µM IPTG 
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C BL21 Gold, 1 mM IPTG 
Figure	  3.11	  Expression	  optimisation	  for	  His-­‐SUMO-­‐M2-­‐1.	  	  	  
A)	   Slightly	   improved	   expression	  was	   achieved	   in	   Rosetta	   2	   cells	  with	   1	  mM	  IPTG	  induction	  in.	  	  B)	  Low	  expression	  and	  poor	  solubility	  was	  seen	  using	  C41	  cells.	  	  	  C)	  Highest	  levels	  of	  total	  expression	  were	  achieved	  with	  BL21	  Gold	  cells,	  however	  protein	  is	  mostly	  insoluble.	  	  Lane	  labels:	  vector,	  empty	  pET28aSUMO;	  M2-­‐1,	  pETSUMO-­‐M2-­‐1.	  	  Triangles	  indicate	  His-­‐SUMO-­‐M2-­‐1	  at	  ~43	  kDa.	  	  
	  
	  
3.6.4 Confirmation	  of	  His-­‐SUMO-­‐M2-­‐1	  identity	  
Confirmation	   of	   the	   identity	   of	   M2-­‐1	   expressed	   in	   this	   system	  was	   by	  mass	  spectrometric	  analysis.	  	  Protein	  identification	  by	  LC-­‐MS/MS	  was	  performed	  as	  a	  service	  by	  James	  Ault	  (MS	  Facility,	  University	  of	  Leeds).	  	  A	  SDS-­‐PAGE	  band	  of	  His-­‐SUMO-­‐M2-­‐1	   was	   excised	   and	   subjected	   to	   in-­‐gel	   trypsin	   cleavage.	  	  Identification	   was	   made	   by	   database	   searching	   for	   proteins	   containing	   the	  peptides	   identified	   in	   the	  mass	   spectrometry.	   	   Figure	  3.12	   shows	  a	   sequence	  coverage	  map	  for	  both	  HRSV	  strain	  A	  M2-­‐1	  protein	  and	  SMT3	  SUMO	  protein.	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Figure	  3.12	  Sequence	  coverage	  maps	  for	  LC-­‐MS/MS	  protein	  identification.	  	  Mass	  spectrometry	  confirmed	  the	  identity	  of	  the	  43	  kDa	  species	  as	  His-­‐SUMO-­‐M2-­‐1.	   	   Peptides	   from	   both	   HRSV	   strain	   A	   M2-­‐1	   and	   SMT3	   (SUMO)	   from	   S.	  
cerevisiae	  were	  identified.	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3.6.5 Increasing	  solubility	  of	  His-­‐SUMO-­‐M2-­‐1	  in	  BL21	  Gold	  cells	  
Higher	   total	   expression	   of	   His-­‐SUMO-­‐M2-­‐1	   had	   been	   observed	   in	   BL21	   Gold	  cells	   and	   so,	   despite	   poor	   solubility,	   this	   strain	   was	   used	   for	   further	  optimisation.	  	  	  	   	  
3.6.5.1 Additives	  to	  induction	  and	  buffers	  The	   issue	   of	   insufficient	   lysis	   was	   addressed	   first,	   by	   adding	   1	   mg/mL	  lysozyme	   to	   the	   lysis	   buffer	   and	   incubating	   on	   ice	   for	   30	   mins,	   as	   well	   as	  increasing	   sonication.	   	   A	   number	   of	   solubility	   aids	  were	   tested:	   0.1	  %	   (v/v)	  Triton	   X-­‐100	   and	   10	   %	   (v/v)	   glycerol	   in	   the	   lysis	   buffer	   (figure	   3.13	   A)	  improved	   solubility,	   as	  did	   adding	  1	  mM	  DTT	   (figure	  3.13	  B);	  10	  mM	  MgSO4	  and	   1	  mM	  CaCl2	   in	   the	   lysis	   buffer	   did	   not	   improve	   solubility,	   however	   they	  were	   found	   to	   improve	   stability	   of	   M2-­‐1	   through	   the	   purification	   process.	  	  Reducing	  ZnSO4	  at	  induction	  to	  50	  µM	  also	  increased	  the	  proportion	  of	  M2-­‐1	  in	  the	   soluble	   fraction	   (figure	   3.13	   B).	   	   Finally,	   optimisation	   of	   IPTG	   levels	   for	  BL21	   Gold	   cell	   inductions	   showed	   that	   a	   lower	   concentration,	   340	   µM,	  increased	  solubility	  of	  His-­‐SUMO-­‐M2-­‐1.	  Several	   changes	   to	   the	   expression	   or	   purification	   of	   His-­‐SUMO-­‐M2-­‐1	   were	  found	   to	  have	  no	  positive	  effect:	   substituting	  Triton-­‐X100	   for	  10	  mM	  CHAPS;	  adding	  10	  mM	  MgSO4	  to	  LB	  medium	  during	  culture	  growth;	  adding	  50	  mM	  free	  L-­‐arginine	  and	  L-­‐glutamine,	  which	  have	  been	  shown	  to	  improve	  solubility	  for	  some	  proteins	  (Golovanov	  et	  al.,	  2004).	  	  	  	   	  
3.6.5.2 Autoinduction	  Autoinduction,	   a	   technique	   commonly	   used	   to	   increase	   solubility	   of	  recombinant	   proteins,	  was	   attempted	   as	   in	  Methods	   2.2.2.2.	   	  Minimal	  media	  starter	   cultures	  were	   used	   to	   inoculate	   autoinduction	  media	   cultures	   1:1000	  and	  these	  were	  grown	  for	  24	  hours	  at	  37	  °C.	  	  Cultures	  were	  processed	  as	  IPTG-­‐induced	   cultures	   and	   samples	   from	   insoluble	   and	   soluble	   fractions	   were	  analysed	   by	   SDS-­‐PAGE.	   	   His-­‐SUMO-­‐M2-­‐1	  was	   found	   to	   be	  more	   insoluble	   by	  this	  method	  than	  standard	  IPTG-­‐induced	  expression	  (figure	  3.14).	  





Figure	  3.13	  Improving	  His-­‐SUMO-­‐M2-­‐1	  solubility.	  	  	  
A)	  Addition	  of	  0.1	  %	  (v/v)	  Triton-­‐X100	  and	  10	  %	  (v/v)	  glycerol	   increase	  the	  proportion	   of	   M2-­‐1	   found	   in	   the	   soluble	   fraction,	   however	   glycerol	   caused	  smearing	   of	   SDS-­‐PAGE	   gels.	   	   B)	   Reducing	   ZnSO4	   levels	   at	   induction	   and	  including	  1	  mM	  DTT	  both	  improved	  M2-­‐1	  solubility.	  	  10	  mM	  MgSO4	  and	  1	  mM	  CaCl2	  did	  not	  affect	  solubility,	  but	  were	  found	  to	  improve	  long-­‐term	  stability	  of	  M2-­‐1.	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Figure	  3.14	  Expression	  of	  His-­‐SUMO-­‐M2-­‐1	  by	  autoinduction.	  	  	  Induction	   of	   protein	   expression	   follows	   exhaustion	   of	   the	   limited	   glucose	  supply	   and	   metabolism	   of	   lactose	   instead,	   relieving	   repression	   of	   the	   lac	  operator	  element	  in	  the	  promoter.	  	  This	  method	  reduced	  solubility	  of	  M2-­‐1	  in	  BL21	   Gold	   cells,	   as	   shown	   by	   the	  majority	   of	   protein	   found	   in	   the	   insoluble	  fraction.	  	  Triangle	  indicates	  His-­‐SUMO-­‐M2-­‐1.	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3.6.5.3 C96S	  mutant	  RSV	  M2-­‐1	  contains	  four	  conserved	  cysteine	  residues,	  only	  one	  of	  which	  is	  not	  assigned	  to	  the	  Cys3-­‐His1	  zinc	  finger	  motif;	  C96.	  	  This	  unpaired	  cysteine	  may	  be	  capable	  of	  forming	  disulphide	  bonds	  with	  either	  other	  M2-­‐1	  monomers	  or	  host	  cell	   proteins.	   	   Mutation	   of	   unpaired	   cysteine	   has	   been	   shown	   to	   improve	  solubility	   of	   recombinant	   proteins	   in	   some	   instances,	   and	   so	   a	   C96	   to	   serine	  mutant	  was	  cloned	  into	  pETSUMO-­‐M2-­‐1	  (mutant	  referred	  to	  as	  ‘C96S’).	   	  C96S	  expressed	   to	   similar	   levels	   as	   wild	   type	   (WT)	   M2-­‐1	   but	   did	   not	   show	   a	  significant	  increase	  in	  solubility.	  	  The	  protein	  could	  be	  successfully	  purified	  by	  Ni-­‐chromatography	   (figure	   3.15	  A)	   but	   the	  mutation	   conferred	  no	   additional	  long-­‐term	   stability,	   as	   C96S	   precipitated	   after	   3-­‐5	   days	   at	   4	   °C.	   	   Further	  purification	  of	  C96S	  by	  size	  exclusion	  chromatography	  showed	  that	  all	  protein	  eluted	   at	   ~113	   mL	   (figure	   3.15	   B)	   and	   SDS-­‐PAGE	   analysis	   of	   the	   fractions	  collected	   show	   significant	   contaminants,	   including	   an	   unknown	  band	   of	  ~33	  kDa	  present	  in	  all	  fractions	  (figure	  3.15	  C).	  	  C96S	  M2-­‐1	  was	  therefore	  deemed	  to	  be	  unsuitable	  for	  further	  optimisation.	  	   This	   result	   is	   unsurprising	   in	   light	   of	   the	   M2-­‐1	   crystal	   structure	  presented	   in	   Chapter	   4,	   which	   revealed	   that	   C96	   is	   buried	   within	   the	   core	  domain.	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Figure	  3.15	  	  C96S	  M2-­‐1	  expression	  and	  size	  exclusion	  chromatography.	  	  
A)	   BL21	   Gold	   expression	   of	   C96S,	   overnight	   at	   30	   °C	  with	   1	  mM	   IPTG,	   and	  purification	  by	  Ni-­‐chromatography.	  B)	  and	  C)	  Size	  exclusion	  chromatography	  using	   a	   Superdex	   S75	   column:	   B)	   shows	   the	   280	   nm	   absorbance	   trace,	  with	  C96S	  M2-­‐1	  eluting	  after	  113	  mL.	  V0	  indicates	  void	  volume;	  C)	  shows	  SDS-­‐PAGE	  analysis	   of	   the	   corresponding	   fractions,	   and	   highlights	   the	   considerable	  contaminants	   including	   an	   unknown	   species	   ‘X’	   of	   33kDa	   eluting	   in	   all	  fractions.	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3.6.6 Improving	  purification	  of	  His-­‐SUMO-­‐M2-­‐1	  
Increasing	  the	  proportion	  of	  soluble	  His-­‐SUMO-­‐M2-­‐1	  that	  was	  purified	  by	  Ni-­‐affinity	   chromatography	  was	   first	   addressed	  by	   trying	   to	   increase	  binding	   to	  the	  Ni	  column.	  	  Passing	  clarified	  lysates	  through	  the	  column	  multiple	  times	  had	  no	   affect	   on	   increasing	   binding	   of	   M2-­‐1.	   	   Ammonium	   sulphate	   precipitation	  was	   used	   to	   try	   and	   reduce	   the	   amount	   of	   bacterial	   protein	   present	   in	   the	  lysate,	  to	  prevent	  any	  possible	  competition	  from	  histidine-­‐rich	  proteins.	   	  0.67	  volumes	   of	   saturated	   ammonium	   sulphate	   solution	  were	   added	   dropwise	   to	  the	  clarified	  lysate	  at	  4	  °C	  with	  stirring	  for	  2	  hours.	   	  Precipitated	  protein	  was	  pelleted	  by	  centrifugation	  and	  SDS-­‐PAGE	  analysis	  revealed	  that	  His-­‐SUMO-­‐M2-­‐1	  had	  been	   successfully	  precipitated.	   	  The	  pellet	  was	   resuspended	   in	  50	  mM	  Tris	  pH	  7,	  200	  mM	  NaCl,	  1	  mM	  DTT,	  and	  dialysed	  against	   the	  same	  buffer	   to	  remove	  ammonium	  sulphate.	   	   This	   caused	  a	   significant	   amount	  of	  protein	   to	  precipitate	  during	  dialysis,	  and	  analysis	  by	  SDS-­‐PAGE	  showed	  that	  His-­‐SUMO-­‐M2-­‐1	  was	  insoluble	  as	  a	  result	  of	  this	  process	  (figure	  3.16).	  	  Another	  technique	  used	   to	   increase	   His-­‐SUMO-­‐M2-­‐1	   binding	   to	   the	   Ni	   column	   was	   partial	  unfolding	   with	   urea.	   	   200	   mM	   urea	   was	   added	   to	   clarified	   lysates	   and	  incubated	  at	  4	  °C	  for	  30	  mins	  before	  being	  applied	  to	  a	  Ni	  column.	  	  This	  did	  not	  increase	  binding	  of	  His-­‐SUMO-­‐M2-­‐1	  to	  the	  column,	  however.	  	  	  	  	   Purity	   and	   yield	   of	   cleaved,	   eluted	   M2-­‐1	   protein	   were	   poor	   after	   Ni-­‐affinity	   chromatography.	   	   The	   addition	   of	   5	   mM	   imidazole	   to	   lysates	   before	  binding	   reduced	   some	   non-­‐specific	   binding	   of	   bacterial	   proteins,	   as	   did	  additional	  washes	  of	   the	  column,	  however	  some	  contaminants	  remained	   that	  could	   not	   be	   removed	   even	   with	   further	   purification	   by	   size	   exclusion	  chromatography	  (figure	  3.10	  B).	   	  Typical	  yields	  of	  cleaved,	  SEC	  purified	  M2-­‐1	  expressed	  from	  pETSUMO-­‐M2-­‐1	  in	  BL21	  Gold	  cells	  were	  0.5-­‐1	  mg/L	  bacterial	  culture,	  which	  was	  insufficient	  for	  structural	  analysis.	  	   Another	  considerable	  barrier	  to	  further	  use	  of	  His-­‐SUMO-­‐M2-­‐1	  was	  the	  stability	  of	  the	  eluted	  protein	  when	  imidazole	  was	  removed	  by	  dialysis.	   	  Both	  the	   fusion	   and	   cleaved-­‐M2-­‐1	   precipitated	   upon	   removal	   of	   imidazole,	   when	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lysis	   and	   Ni-­‐affinity	   purification	  were	   performed	   in	   Tris/NaCl-­‐based	   buffers.	  	  The	  proportion	  of	  M2-­‐1	  protein	   that	   precipitated	  was	  decreased	  when	  using	  phosphate-­‐based	   buffers	   [1x	   phosphate-­‐buffered	   saline,	   10	  %	   (v/v)	   glycerol,	  0.1	   %	   Triton	   X-­‐100],	   however	   this	   buffer	   system	   is	   not	   ideal	   for	  crystallographic	  studies	  due	  to	  the	  formation	  of	  salt	  crystals.	  	  	   It	  was	  decided	  at	  this	  point	  that	  no	  further	  optimisation	  was	  reasonably	  possible	  with	  M2-­‐1	   in	   pET28aSUMO,	   and	   so	   the	   ORF	  was	   subcloned	   into	   an	  alternative	  vector	  system.	  	  	  	  	  	  
	  
Figure	   3.16	   Solubility	   of	   His-­‐SUMO-­‐M2-­‐1	   post-­‐ammonium	   sulphate	  
precipitation.	  	  	  Dialysis	   of	   ammonium	   sulphate	   from	   precipitated	   and	   resuspended	   protein	  caused	  His-­‐SUMO-­‐M2-­‐1	  to	  be	  predominantly	  insoluble	  (43	  kDa).	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3.6.7 Subcloning	  of	  M2-­‐1	  ORF	  into	  GST-­‐tag	  vector	  
To	  test	  expression	  of	  M2-­‐1	  with	  an	  alternative	  affinity	  tag,	  the	  M2-­‐1	  ORF	  was	  subcloned	  into	  a	  pGEX	  vector	  that	  would	  express	  M2-­‐1	  as	  an	  N-­‐terminal	  fusion	  with	  glutathione	  S-­‐transferase	  (GST)	  –	  an	  alternative	   tag	  known	  to	  aid	   in	   the	  solubility	   of	   recombinant	   proteins	   that	   allows	   purification	   by	   glutathione	  affinity	  chromatography.	  	   M2-­‐1	   ORF	   was	   subcloned	   by	   directly	   digesting	   the	   fragment	   from	  pETSUMO-­‐M2-­‐1	   and	   ligating	   into	   pGEX4T2	   and	   pGEX6P2,	   vectors	   with	  thrombin	  and	  HRV	  3C	  protease	  cleavage	  sites,	  respectively.	  	  Double	  restriction	  digest	  with	  BamHI	  and	  XhoI	  of	  both	  pETSUMO-­‐M2-­‐1	  and	  empty	  pGEX6P2/4T2	  vectors	  was	  performed	  and	  the	  appropriate	  fragments	  purified	  by	  agarose	  gel	  electrophoresis	  and	  gel	  extraction.	  	  M2-­‐1	  ORF	  was	  ligated	  into	  the	  empty	  pGEX	  vectors	   and	   transformed	   into	   DH5α	   cells.	   	   6	   colonies	   for	   each	   vector	   were	  minipreped	   and	   diagnostically	   digested	  with	  BamHI	   and	  XhoI	   to	   confirm	   the	  presence	  of	  the	  M2-­‐1	  ORF.	  	  Results	  for	  pGEX6P2	  are	  shown	  in	  figure	  3.17;	  5	  of	  the	  6	  colonies	  were	  positive	   for	   the	   insert,	  and	  orientation	  was	  confirmed	  by	  DNA	  sequencing.	  	  This	  construct	  is	  referred	  to	  as	  pGEX-­‐M2-­‐1	  and	  resulted	  in	  N-­‐terminally	  GST-­‐tagged	  M2-­‐1,	  with	  5	  non-­‐native	  residues	  (Gly-­‐Pro-­‐Leu-­‐Gly-­‐Ser)	  remaining	   after	   GST	   cleavage	  with	   HRV	   3C	   protease.	   	   pGEX4T2	   cloning	  was	  also	   successful,	   but	   was	   deemed	   not	   cost-­‐effective	   and	   expression	   was	   not	  optimised	  with	  this	  construct.	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Figure	  3.17	  Identification	  of	  pGEX	  6P2	  clones	  containing	  M2-­‐1	  ORF.	  	  6	   clones	  were	  minipreped	   and	   diagnostically	   digested	  with	  BamHI	   and	  XhoI,	  with	   single	   digests	   and	   uncut	   vector	   shown	   here	   for	   clone	   1	   as	   controls	   for	  enzyme	  activity.	  	  5	  of	  6	  clones	  contained	  the	  M2-­‐1	  ORF	  (609	  bp).	  	  	  	  	  	  
3.6.8 Optimising	  GST-­‐M2-­‐1	  expression	  and	  purification	  
Initial	   expression	   of	   GST-­‐M2-­‐1	   from	   pGEX-­‐M2-­‐1	   was	   tested	   using	   the	   best	  conditions	  achieved	  for	  His-­‐SUMO-­‐M2-­‐1	  expression:	  overnight	  induction	  at	  30	  
°C	   in	   BL21	  Gold	   cells	  with	   340	  µM	   IPTG	   and	   50	  µM	  ZnSO4;	   cell	   recovery	   by	  centrifugation	   and	   resuspension	   in	   1x	   PBS,	   0.1	   %	   (v/v)	   Triton-­‐X100,	   10	   %	  (v/v)	  glycerol,	  1	  mM	  DTT,	  1	  mg/mL	   lysozyme;	   incubation	  on	   ice	   for	  30	  mins	  followed	   by	   final	   lysis	   by	   sonication	   and	   clarification	   of	   lystes	   by	  centrifugation.	   	   Cells	  were	   also	   resuspended	   in	   a	   Tris	   buffer	   reported	   in	   the	  literature	  for	  comparison;	  this	  buffer	  contained	  many	  of	  the	  components	  found	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Figure	  3.18	  	  Expression	  of	  GST-­‐M2-­‐1	  and	  solubility	  in	  two	  buffer	  systems.	  	  	  Expression	  from	  pGEXM2-­‐1	  in	  BL21	  Gold	  cells	  overnight	  at	  30	  °C	  with	  340	  µM	  IPTG	  and	  50	  µM	  ZnSO4,	  followed	  by	  pellet	  resuspension	  in	  PBS	  buffer	  [1x	  PBS,	  0.1	  %	  (v/v)	  Triton-­‐X100,	  10	  %	  (v/v)	  glycerol,	  1	  mM	  DTT,	  1	  mg/mL	  lysozyme]	  or	  Tris/NaCl	  buffer	  [50	  mM	  Tris	  pH	  7.4,	  1	  M	  NaCl,	  1	  mM	  DTT,	  2	  %	  (v/v)	  Triton	  X-­‐100,	   10	   mM	   MgSO4,	   1	   mM	   CaCl2,	   1	   mg/mL	   lysozyme].	   	   GST-­‐M2-­‐1	   has	   a	  molecular	  weight	  of	  48	  kDa.	  
Figure	  3.19	  	  Purification	  of	  GST-­‐M2-­‐1.	  	  	  GST-­‐M2-­‐1	  appears	  as	  a	  48	  kDa,	  predominantly	  soluble	  species.	  	  GST-­‐M2-­‐1	  was	  bound	  to	  resin	  overnight,	  however	  a	  significant	  proportion	  of	  protein	  remains	  in	  the	  unbound	  fraction.	  	  Resin	  was	  washed	  and	  GST	  cleaved	  from	  M2-­‐1	  on	  the	  resin	  by	  HRC	  3C	  protease,	  resulting	  elution	  of	  M2-­‐1	  at	  ~26	  kDa.	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3.6.9 Size	  exclusion	  chromatography	  
Further	   purification	   of	   M2-­‐1	   was	   required	   after	   proteolytic	   GST	   removal,	   to	  isolate	  the	  tetramer	  with	  GST	  fully	  cleaved	  from	  each	  monomer.	  	  Size	  exclusion	  chromatography	   was	   used	   as	   in	   Methods	   2.2.4.	   	   Briefly,	   the	   column	   was	  equilibrated	  and	  run	  in	  50	  mM	  Tris	  pH	  7.5,	  150	  mM	  NaCl,	  1	  mM	  DTT	  (the	  3C	  protease	   cleavage	   buffer),	   the	   protein	   injected	   with	   a	   5	   mL	   loop,	   and	   the	  column	  run	  at	  2	  mL/min	  until	  a	  full	  column-­‐volume	  of	  buffer	  had	  eluted	  (320	  mL).	   	  Fractions	  were	  collected	   from	  the	  void	  volume	  (~100	  mL)	  onwards.	   	  A	  typical	   A280	   trace	   is	   shown	   in	   figure	   3.20	   A	   and	   SDS-­‐PAGE	   analysis	   of	   the	  corresponding	  fractions	  is	  shown	  in	  figure	  3.20	  B.	   	  M2-­‐1	  appeared	  to	  elute	  in	  all	   fractions	   analysed	  between	  113	   and	  160	  mLs,	   although	  predominantly	   in	  peak	  2	   at	   128	  mLs,	  which	   corresponds	   to	   a	  90	  kDa	   species	   as	   the	  molecular	  weight	   predicts.	   	   The	   presence	   of	   M2-­‐1	   across	   multiple	   peaks	   is	   likely	   as	   a	  result	   of	   incomplete	   cleavage	   of	   GST	   from	   all	   4	   monomers	   of	   the	   tetramer,	  creating	  a	  heterogeneous	  population	  of	  GST-­‐M2-­‐1	  oligomers.	   	  There	   is	   also	  a	  48	  kDa	  species	  co-­‐eluting	  in	  peak	  2,	  which	  is	  likely	  uncleaved	  GST-­‐M2-­‐1.	  	  Some	  cleaved	  GST	  that	  has	  eluted	  from	  the	  resin	  can	  be	  seen	  in	  peak	  3	  at	  150	  mLs,	  corresponding	  to	  52	  kDa	  as	  expected	  for	  a	  GST	  dimer.	  	  	  	   The	  ratio	  of	  HRV	  3C	  protease	  to	  GST-­‐M2-­‐1	  was	  increased	  from	  1:100	  to	  1:25,	   volume	   to	   volume	  of	   a	   4	  mg/mL	   solution	   of	   protease,	   in	   an	   attempt	   to	  reduce	   the	   heterogeneity	   of	   species	   present	   in	   the	   size	   exclusion	  chromatography.	   	   Increasing	   incubation	   to	   24	   hours	   at	   4	   °C	   was	   also	   tried.	  	  	  Whilst	   complete	   cleavage	   could	   not	   be	   achieved,	   the	   proportion	   of	   protein	  present	  in	  peak	  2	  of	  the	  size	  exclusion	  was	  increased	  to	  >95	  %	  (figure	  3.20	  C).	  	  	  	  	  	  	  	  	  	  





	  	  	  	  	  	  	  	  





Figure	   3.20	   Size	   exclusion	   chromatography	   of	   pGEX-­‐M2-­‐1	   expressed,	  
cleaved	  M2-­‐1.	  	  	  A)	  A280	  absorbance	  trace	  shows	  protein	  eluting	  in	  3	  peaks,	  with	  most	  protein	  in	  peak	  2	  at	  128	  mLs,	  90	  kDa.	   	  B)	  SDS-­‐PAGE	  analysis	  of	  fractions	  from	  SEC	  with	  the	   corresponding	  peaks	   labelled.	   	  M2-­‐1,	  26	  kDa,	   appears	   in	  all	   fractions.	   	  C)	  The	  proportion	  of	  peak	  2	  protein	  attributed	  to	  cleaved	  M2-­‐1	  was	  increased	  by	  optimising	  HRV	  3C	  protease	  cleavage.	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3.6.10 Ion	  exchange	  chromatography	  
GST	  and	  M2-­‐1	  have	  significantly	  different	  pIs,	  ~6	  and	  9.1	  respectively,	  and	  so	  should	   be	   separated	   by	   ion	   exchange	   chromatography.	   	   A	   cation	   exchange	  column	  was	   used	  with	   all	   buffers	   at	   pH	  7.5	   so	   that	   negatively	   charged	  M2-­‐1	  would	   bind	   the	   column,	   whilst	   positively	   charged	   GST	   would	   pass	   through.	  	  However,	  comparison	  of	  M2-­‐1	  before	  and	  after	  ion	  exchange	  revealed	  that	  very	  few	  contaminants	  had	  been	  removed	  (figure	  3.21),	  despite	  the	  fact	  that	  M2-­‐1	  clearly	   bound	   the	   column	   and	   eluted	   at	   ~300	   mM	   NaCl.	   	   In	   addition	   to	  providing	  no	  purification	  benefit,	  approximately	  30	  %	  of	  M2-­‐1	  was	  lost	  during	  this	  process,	  possibly	  due	  to	  column	  saturation.	  	  	  	  	  
	  
Figure	   3.21	   Further	   purification	   of	   M2-­‐1	   by	   ion	   exchange	  
chromatography.	  	  	  Comparing	   the	   IEX	   column	   load	   and	   pooled	   elution	   fractions,	   shows	   little	  difference	  i.e.	  very	  few	  contaminants	  have	  been	  removed.	  	  Cleaved	  M2-­‐1	  at	  26	  kDa.	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3.6.11 Characterisation	  of	  pGEX-­‐expressed	  M2-­‐1	  protein	  
Expression	   and	   purification	   of	   M2-­‐1	   by	   the	   above	   method	   (pGEXM2-­‐1	  expression	  in	  BL21	  Gold	  cells,	  glutathione	  sepharose	  affinity	  chromatography	  followed	   by	   size	   exclusion	   chromatography)	   yielded	   ~5	   mg	   of	   >95	   %	   pure	  tetrameric	  M2-­‐1	  per	  litre	  of	  bacterial	  culture.	  	  Confirmation	  of	  accurate	  mass	  of	  monomer	  and	  tetramer	  were	  acquired	  by	  mass	  spectrometry,	  and	  the	  removal	  of	   bacterially-­‐derived	   RNA	   bound	   to	   M2-­‐1	   confirmed	   by	   agarose	   gel	  electrophoresis.	  	  
3.6.11.1 Mass	  spectrometry	  Accurate	  mass	  determination	  of	  M2-­‐1	  eluting	  in	  ‘peak	  2’	  during	  size	  exclusion	  chromatography	  (i.e.	  the	  90	  kDa	  species	  assumed	  to	  be	  tetrameric	  M2-­‐1)	  was	  performed	   using	   nano-­‐electrospray-­‐ionization	  mass	   spectrometry	   in	   positive	  ionization	  mode,	  by	  Helen	  Beeston	  (Alison	  Ashcroft	  group,	  University	  of	  Leeds)	  as	   in	   Methods	   2.2.7.	   	   Denaturing	   MS	   of	   M2-­‐1	   in	   acetonitrile	   was	   used	   to	  determine	   the	  mass	   of	   the	  monomer,	  whilst	   the	   intact	  mass	   of	   the	   tetramer	  was	   determined	   in	   ammonium	   acetate	   at	   pH	   7.5.	   	   Examples	   of	   the	   spectra	  obtained	   are	   shown	   below	   (figure	   3.22).	   	   The	   denaturing	   mass	   spectrum	   is	  presented	  in	  green	  and	  shows	  peaks	  for	  protonated	  molecular	  ions	  (M+nH)n+,	  labelled	  up	  to	  n	  =	  21,	  giving	  a	  monomeric	  mass	  of	  22,565.5	  ±1	  Da;	  this	  is	  within	  0.2	  Da	  of	  the	  mass	  predicted	  for	  Gly-­‐Pro-­‐Leu-­‐Gly-­‐Ser-­‐M2-­‐1.	  	  The	  native,	  intact	  mass	   spectrum	   is	   presented	   in	   purple	   and	   shows	   peaks	   for	   protonated	  molecular	   ions	   (M+nH)n+,	   labelled	   up	   to	   n	   =	   21,	   giving	   a	   tetrameric	  mass	   of	  90,528	   ±5	   Da.	   	   There	   is	   a	   266	   Da	   disparity	   between	   the	   observed	   native	  tetrameric	  mass	  and	  four	  times	  the	  denatured	  monomeric	  mass	  (4	  x	  22,565.5	  =	  90,262	  Da),	  which	   is	   likely	  attributable	  to	  4	  atoms	  of	  zinc	  coordinated	  by	  the	  natively	  folded	  zinc	  finger	  motifs	  of	  M2-­‐1;	  266	  divided	  by	  the	  atomic	  mass	  of	  zinc	  (65.39	  Da)	  is	  4.07.	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Figure	  3.22	  Mass	  spectrometric	  analysis	  of	  M2-­‐1.	  	  	  Accurate	  mass	  spectra	  are	  shown	  for	  denaturing	  MS	  (monomeric	  mass;	  green)	  and	   native	   MS	   (intact	   tetrameric	   mass;	   purple).	   	   Spectra	   show	   the	   relative	  abundance	  (%)	  of	  peaks	  for	  a	  given	  mass	  to	  charge	  ration	  (m/z).	   	  Protonated	  molecular	   ions	   (M+nH)n+	   are	   labelled	   with	   their	   m/z	   and	   the	   number	   of	  charges.	  	  	  	  
3.6.11.2 Binding	  of	  bacterially-­‐derived	  nucleic	  acid	  Both	   crystal	   trials	   and	   RNA	   binding	   assays	   require	   a	   source	   of	   RNA-­‐free	  purified	   protein.	   	   Given	   that	   M2-­‐1	   is	   an	   established	   RNA	   binding	   protein,	  phenol-­‐chloroform	   extraction	   and	   agarose	   gel	   electrophoresis	   were	   used	   to	  identify	  any	  bacterially-­‐derived	  nucleic	  acid	  that	  had	  remained	  bound	  to	  M2-­‐1	  during	   the	  purification	  process.	   	  Tetrameric	  M2-­‐1	   from	  peak	  2	  size	  exclusion	  chromatography	  fractions,	  and	  purified	  tomato	  spotted	  wilt	  virus	  nucleocapsid	  protein	  as	  a	  known	  RNA-­‐binder,	  were	  treated	  as	  in	  Methods	  2.2.14.1.	  	  Nucleic	  acid	  was	  incubated	  with	  or	  without	  RNase	  A	  for	  1	  hour	  at	  37	  °C	  and	  samples	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analysed	  by	  1.5	  %	  agarose-­‐Tris-­‐borate-­‐EDTA	  buffer	  (TBE)	  gel	  electrophoresis.	  	  RNase	   A-­‐sensitive	   nucleic	   acid	   was	   present	   in	   both	   samples,	   showing	   that	  tetrameric	   M2-­‐1	   was	   still	   bound	   to	   bacterial	   RNA	   after	   both	   affinity	  chromatography	   and	   size	   exclusion	   chromatography	   (figure	   3.23).	   	   The	  260nm:280nm	   ratio	   for	   RNA-­‐bound	   M2-­‐1	   was	   >1,	   as	   determined	   by	  spectrophotometry,	   and	   future	   assessment	   of	   RNA	   content	   was	   made	   by	  comparing	  260nm:280nm	  measurements	  to	  this	  value.	  	   To	  remove	  the	  RNA	  present	  in	  purified	  M2-­‐1,	  two	  methods	  were	  used:	  RNase	  A	  treatment	  of	  all	  purified	  protein	  successfully	  removed	  RNA,	  however	  it	   caused	  some	  precipitation	  of	  M2-­‐1	  and	  reduced	   its	   long-­‐term	  stability	  at	  4	  
°C;	   introducing	   additional	   high	   salt	   washes	   during	   glutathione	   affinity	  purification,	   between	  washing	  with	   lysis	  buffer	   and	  equilibrating	   in	  protease	  cleavage	   buffer,	   removed	   RNA	   contamination,	   as	   determined	   by	   a	  260nm:280nm	   ratio	   of	   <0.6.	   	   Future	   purifications	   all	   contained	   thorough	  washes	  with	  20	  mM	  Tris	  pH	  7.4,	  1	  M	  NaCl.	  	  	  
Figure	  3.23	  Visualising	  RNA	  bound	  to	  purified	  M2-­‐1.	  	  	  Phenol-­‐chloroform	   was	   used	   to	   extract	   total	   nucleic	   acid	   from	   ‘peak	   2’	  fractions	  of	  pGEXM2-­‐1-­‐expressed	  M2-­‐1.	  	  Nucleic	  acid	  was	  treated	  with	  RNase	  A	  to	  distinguish	  DNA	  from	  RNA	  and	  samples	  electrophoresed	  in	  a	  1.5	  %	  agarose-­‐TBE	   gel.	   	   Tomato	   spotted	   wilt	   virus	   nucleocapsid	   protein,	   was	   used	   as	   a	  positive	  control.	  	  A	  low	  range	  single	  stranded	  RNA	  ladder	  is	  shown.	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3.6.12 Final	  optimal	  expression	  and	  purification	  of	  RSV	  M2-­‐1	  
Final	   optimal	   expression	   and	   purification	   conditions	   of	   RSV	   M2-­‐1	   were	   as	  follows	  (figure	  3.24):	  	   BL21	  Gold	  cells	  transformed	  with	  pGEXM2-­‐1	  were	  induced	  at	  OD600	  0.6-­‐0.8	  with	  340	  µM	  IPTG	  and	  50	  µM	  ZnSO4	  overnight	  at	  30	  °C.	  	  Cells	  were	  lysed	  in	  45	  mL	  lysis	  buffer	  per	  1	  L	  pellet	  [50	  mM	  Tris	  pH	  7.4,	  1	  M	  NaCl,	  1	  mM	  DTT,	  2	  %	  (v/v)	   Triton	   X-­‐100,	   10	   mM	   MgSO4,	   1	   mM	   CaCl2,	   1	   mg/mL	   lysozyme,	   1x	  complete	  protease	   inhibitors	  EDTA-­‐free	   (Roche)]	   for	  30	  minutes	  on	   ice,	  with	  further	   lysis	   by	   sonication.	   	   Lysates	   were	   clarified	   by	   centrifugation	   and	  applied	  in	  batch	  to	  glutathione	  sepharose	  overnight	  at	  4	  °C.	  	  Resin	  was	  pelleted	  and	  washed	  in	  lysis	  buffer,	  followed	  by	  extensive	  washing	  in	  high	  salt	  buffer	  to	  remove	  RNA.	   	   Resin	  was	   then	   equilibrated	   in	   1	   volume	   of	   protease	   cleavage	  buffer	   and	   incubated	   overnight	   at	   4	   °C	   with	   a	   1:25	   HRV	   3C	   protease	   to	  equilibrated	   resin	   ratio.	   	   Cleaved	  M2-­‐1	  was	   eluted	   from	   resin	   by	   washing	   3	  times	  with	  1	  volume	  of	  protease	  cleavage	  buffer	  and	  elutions	  were	  pooled	  for	  size	   exclusion	   chromatography	   purification.	   	   Tetrameric	   M2-­‐1	   eluted	   at	   128	  mL	  as	  a	  ~90	  kDa	  species.	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  3.24	  Final	  optimised	  GST-­‐M2-­‐1	  expression	  and	  purification.	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3.7 SECTION	  SUMMARY	  
This	  section	  has	  presented	  the	  optimisation	  of	  RSV	  M2-­‐1	  bacterial	  expression,	  providing	   a	   protocol	   for	   expression	   and	   purification	   of	   ~5	   mg	   >95	   %	   pure	  tetrameric	  M2-­‐1	  protein	  per	  litre	  of	  bacterial	  culture.	  Initially,	  to	  increase	  the	  likelihood	  of	  optimally	  expressing	  recombinant	  M2-­‐1	   in	  E.coli,	   a	  N-­‐terminal	   SUMO	   fusion	  was	  made	  as	   this	   system	  had	  been	  successfully	  used	  both	  within	  our	  group	  (Jenkins	  et	  al.,	  2011,	  Ariza	  et	  al.,	  2013)	  and	  for	  many	  published	  difficult-­‐to-­‐express	  proteins	  (Butt	  et	  al.,	  2005).	  	  SUMO-­‐tags	   have	   been	   shown	   to	   increase	   solubility,	   improve	   folding,	   and	   decrease	  proteolytic	   degradation	   of	   recombinant	   proteins.	   	   SUMO	   proteins,	   or	   small	  ubiquitin-­‐like	  modifier,	   are	   a	   family	  ubiquitous	   to	   eukaryotes	   that	   covalently	  modify	   cellular	   proteins	   to	   affect	   their	   role	   in	   a	   variety	   of	   cellular	   pathways,	  including	  prevention	  of	  ubiquitin-­‐mediated	  degradation	  and	  nuclear	  transport.	  	  The	   SUMO	   encoded	   in	   the	   pET-­‐28a	   vector	   is	   SMT3	   from	   Saccharomyces	  
cerevisiae.	   	  Despite	   the	   recent	   emergence	  of	   SUMO	   fusion	  as	  one	  of	   the	  most	  successful	  ways	   to	   express	   recombinant	   protein	   in	  E.	   coli,	   robust	   expression	  and	   purification	   of	   M2-­‐1	   in	   pET28aSUMO	   was	   not	   achieved;	   extensive	  optimisation	  of	   induction	  conditions,	  buffer	  components,	  and	   the	  purification	  process,	   in	   addition	   to	   a	   free-­‐cysteine	  mutant	   to	   reduce	  possible	   aggregation	  by	  disulphide	  bonds,	  all	  failed	  to	  improve	  M2-­‐1	  expression.	  	  	  At	   this	   point,	  M2-­‐1	  was	   subcloned	   and	   expressed	   as	   a	   GST-­‐fusion,	   an	  older	   but	   well-­‐documented	   solubility	   aid	   for	   recombinant	   proteins.	   	   GST	  proteins	  are	  a	   family	  of	  enzymes	   that	  covalently	  modify	   toxic	  molecules	  with	  their	   substrate	   glutathione,	   a	   tripeptide	   of	   glutamine-­‐cysteine-­‐glycine	  with	   a	  non-­‐canonical	  peptide	  linkage	  between	  the	  cysteine	  amine	  group	  and	  the	  side	  chain	   carboxyl	   group	  of	   the	  glutamine.	   	   It	   is	   the	  high	  affinity,	   specificity,	   and	  reversibility	  of	  this	  reaction	  that	  makes	  GST	  ideal	  for	  affinity	  chromatography,	  and	  gives	  glutathione	  affinity	  chromatography	  its	  reputation	  for	  yielding	  high	  purity	  protein.	  	  GST	  also	  aids	  in	  correct	  translation	  and	  folding	  of	  recombinant	  protein,	  and	  offers	  some	  protection	  from	  enzymatic	  degradation	  in	  cells	  (Walls	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and	   Loughran,	   2010).	   	   pGEX	   vectors	   encode	   a	   26	   kDa	   GST	   derived	   from	  
Schistosoma	  japonicum	  (Smith	  and	   Johnson,	  1988),	  which	   forms	  homodimers	  in	   solution	   –	   one	   of	   the	   downsides	   of	   using	   a	   GST-­‐tag	   for	   purification	   of	  oligomeric	  proteins,	  as	  GST	  dimerization	  can	  cause	  higher	  order	  oligomers	  of	  fusion	  protein	  to	  form.	  	  Due	  to	  the	  similarity	  in	  molecular	  weight	  between	  M2-­‐1	   (22.5	   kDa)	   and	   GST	   (26	   kDa),	   and	   their	   virtually	   identical	   electrophoretic	  mobilities,	   removal	   of	   the	   GST-­‐tag	   by	   proteolysis	   was	   performed	   on	   resin-­‐bound	   GST-­‐M2-­‐1.	   	   Cleavage	   by	   this	   method	   was	   inefficient,	   however,	   as	   the	  protease	  was	  sterically	  hindered	  by	  the	  orientation	  of	  the	  fusion	  protein	  on	  the	  resin.	  	  Additional	  inefficiency	  was	  introduced	  by	  the	  oligomeric	  nature	  of	  M2-­‐1;	  as	  a	  tetramer,	  all	  four	  GST-­‐M2-­‐1	  monomers	  must	  be	  successfully	  cleaved	  for	  the	   resulting	   M2-­‐1	   tetramer	   to	   be	   isolated	   as	   the	   correct	   species	   by	   size	  exclusion	  chromatography.	  	  	  Although	   there	   appear	   to	   be	   several	   advantages	   to	   His-­‐SUMO	   fusion	  over	  GST	   fusion,	   including	  a	   lack	  of	  oligomerisation	  and	   the	  use	  of	   a	   tertiary	  structure-­‐specific	  protease,	  significantly	  higher	  levels	  of	  M2-­‐1	  expression	  were	  achieved	  with	   the	  GST	   system	   and	   the	   stability	   in	   solution	   of	   GST-­‐expressed	  protein	   was	   also	   improved	   over	   the	   His-­‐SUMO	   protein.	   	   When	   the	   size	  exclusion	   chromatography	   profiles	   of	  M2-­‐1	   produced	   by	   both	  methods	  were	  compared,	   a	   difference	   in	   elution	   volumes	  was	   noticed.	  His-­‐SUMO-­‐expressed	  M2-­‐1	  eluted	  at	  ~113	  mLs,	  which	  corresponded	   to	  a	  molecular	  weight	  of	  150	  kDa,	  and	  GST-­‐expressed	  M2-­‐1	  eluted	  at	  ~128	  mLs,	  ~90	  kDa.	  	  Although	  there	  is	  precedent	  for	  M2-­‐1	  protein	  appearing	  to	  have	  a	  hydrodynamic	  volume	  larger	  than	  its	  molecular	  weight	  would	  suggest	  (Esperante	  et	  al.	  2011),	  the	  elution	  of	  His-­‐SUMO-­‐expressed	  M2-­‐1	  so	  close	  to	  the	  void	  volume	  of	  the	  column,	  added	  to	  its	   instability	   in	   solution	   upon	   dialysis	   of	   imidazole	   and	   significant	   losses	  during	   concentration,	   suggested	   that	   this	   protein	   may	   have	   been	  predominantly	  aggregated.	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3.8 CHAPTER	  SUMMARY	  
This	   chapter	   has	   outlined	   the	   optimisation	   of	   RSV	   M2-­‐1	   expression	   in	   two	  systems:	  recombinant	  baculovirus-­‐assisted	  insect	  cells	  and	  bacterial	  cells.	  	  Prior	   to	   this	  work	   there	  was	   published	  precedent	   for	   expression	   of	  M2-­‐1	  by	  both	  methods,	  however	  neither	  had	  been	  optimised	  for	  the	  kind	  of	  large	  scale	  required	  for	  structural	  studies.	   	  During	  this	  project,	  a	  number	  of	  publications	  also	  presented	  methods	  for	  high-­‐yield	  bacterial	  expression	  of	  M2-­‐1:	  Tran	  et	  al	  (2009)	  published	  an	  expression	  method	  also	  using	  a	  GST	  fusion	  and	  a	  similar	  buffer	  to	  that	  arrived	  at	  by	  the	  optimisation	  presented	  here	  –	  elements	  of	  their	  method	  were	  used	  to	  improve	  purification	  in	  this	  work,	  including	  the	  addition	  of	  1	  M	  NaCl	  washes	  to	  remove	  bacterially-­‐derived	  RNA;	  Esperante	  et	  al	  (2011)	  published	  a	  method	  of	  expressing	  M2-­‐1	  using	  C41	  (DE3)	  cells	  without	  a	  fusion	  tag,	  followed	  by	  heparin	  affinity	  chromatography	  as	  a	  form	  of	  cation	  exchange	  –	  although	  we	  did	  not	  replicate	  this	  method	  exactly,	  as	  we	  did	  not	  have	  access	  to	   the	   unusual	   bicistronic	   vector	   they	   used,	   we	   did	   not	   see	   an	   increase	   in	  expression	  using	  the	  C41	  strain.	  	  	  	  Whilst	  both	  expression	  systems	  have	  previously	  been	  extensively	  used	  for	   producing	   crystallography-­‐quality	   protein,	   the	   expression	   of	   M2-­‐1	   as	   a	  doublet	  in	  insect	  cells	  as	  a	  result	  of	  phosphorylation,	  now	  confirmed	  to	  involve	  serines	  58	  and	  61,	  and	  the	  difficulty	  of	  separating	  the	  two	  phospho-­‐species	  on	  a	   large	   scale,	   meant	   that	   this	   protein	   was	   unsuitable	   for	   structural	   studies.	  	  Successful	   optimisation	   of	   the	   bacterial	   expression	   of	   M2-­‐1	   as	   a	   GST	   fusion	  provided	  a	  high-­‐yield	  source	  of	  homogeneous	  protein	  appropriate	   for	  crystal	  trials	   and	   RNA	   binding	   studies,	   and	   these	   experiments	   are	   presented	   in	   the	  remaining	  chapters	  of	  this	  thesis.	  	  	  	  	  	  	  	  	  	  
Chapter	  4:	  Determining	  the	  X-­‐ray	  crystal	  structure	  of	  M2-­‐1	  
124	  
	  
4 CHAPTER	   4:	   DETERMINING	   THE	   X-­‐RAY	   CRYSTAL	   STRUCTURE	   OF	  
M2-­‐1	  
	  
4.1 CHAPTER	  INTRODUCTION	  
This	  chapter	  describes	   the	  process	  of	  determining	   the	  X-­‐ray	  crystal	  structure	  of	   both	   wild	   type	   (WT)	   and	   phosphomimetic	   (S58DS61D)	   M2-­‐1	   protein;	  outlining	  the	  initial	  screening	  and	  optimisation	  of	  crystallisation	  conditions,	  X-­‐ray	   data	   collection,	   multiple	   strategies	   used	   to	   address	   the	   ‘phase	   problem’,	  and	   the	   data	   reduction	   and	   structure	   solution.	   	   The	   structure	   itself	   is	   then	  described,	  and	  the	  new	  and	  unique	  insights	  into	  M2-­‐1	  structure	  and	  function	  it	  provides	  are	  summarised.	  	   	  	  	  
4.2 RESULTS	  
4.2.1 Initial	  crystallisation	  screens	  	  Purified	   RSV	   M2-­‐1	   protein	   was	   produced	   as	   described	   in	   Chapter	   3	   and	  screened	   for	   initial	   crystallisation	   conditions	   using	   commercially	   available	  sparse	   matrix	   screens.	   	   These	   were	   designed	   to	   sample	   a	   wide	   range	   of	  precipitants,	   salts,	   buffers,	   pH,	   polymers	   and	   organic	   molecules,	   in	   a	   high-­‐throughput	   96-­‐well	   format,	   and	   were	   biased	   towards	   previously	   successful	  crystallisation	   conditions	   for	  macromolecules.	   	   The	   screens	  were	   compatible	  with	   an	   automated	   robot	   system,	   which	   was	   used	   in	   these	   initial	   trials	   to	  quickly	   and	   reproducibly	   set	   up	   sitting-­‐drops	   with	   various	   protein:mother	  liquor	  ratios	  across	  all	  conditions	  and	  at	  a	  range	  of	  temperatures,	  amounting	  to	  2,880	  combinations	  (see	  Methods	  2.2.13.1).	  	  	  	   Several	  conditions	  resulted	  in	  initial	  ‘hits’	  that	  appeared	  within	  2-­‐3	  days	  and	   ranged	   from	  10-­‐20	   small	   crystals	   (20-­‐40	  µm)	   to	  2-­‐5	   larger	   crystals	   (50-­‐
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100	  µm)	  within	   a	   drop.	   	   A	   number	   of	   other	   conditions	   showed	   signs	   of	   the	  potential	   to	   be	   optimised	   for	   crystal	   growth:	   birefringent	   precipitate,	   a	  crystalline	   precipitate	   that	   is	   able	   to	   polarize	   light	   due	   to	   the	   anisotropy	  inherent	  in	  an	  ordered,	  crystalline	  material;	  phase	  separation,	  the	  formation	  of	  liquid-­‐liquid	   interface	   droplets	   that	   are	   metastable,	   i.e.	   unable	   to	   nucleate;	  showers	  of	  microcrystals	  due	  to	  excessive	  nucleation.	  	  However,	  the	  growth	  of	  crystals	   in	   multiple	   conditions	   meant	   optimisation	   of	   these	   potential	  conditions	  was	  not	  required.	  	  	   Initial	   hits,	   although	   from	   different	   screens,	   all	   centred	   around	   a	  common	  theme:	  20-­‐30	  %	  (v/v)	  low	  molecular	  weight	  PEG	  (PEG	  400,	  PEG	  MME	  550,	  PEG	  MME	  2000),	  ±0.05-­‐0.2	  M	  salt	  (NaCl,	  MgCl2,	  CaCl2),	  and	  a	  wide	  range	  of	  pHs	   from	  7-­‐10.5.	   	  Crystals	  of	   sufficient	  size	   (>20	  µm)	  and	  quality	   (few	  splits,	  single	  crystals,	  no	  plates)	  were	  picked	  from	  drops	  using	  nylon	  loops	  and	  cryo-­‐cooled	  directly	   from	  drops	   in	   liquid	   nitrogen;	   the	   low	  molecular	  weight	   PEG	  provided	   cryo-­‐protection.	   	   Crystals	   were	   screened	   for	   diffraction	   at	   the	  Diamond	   Light	   Source	   synchrotron,	   by	   taking	   test	   images	   at	  ϕ	   =	   0°	   and	   90°	  using	  12,658	  eV	  X-­‐rays	  (0.9795	  Å).	   	  All	  crystals	  were	  found	  to	  be	  protein	  and	  diffracted	   to	  3.5-­‐6	  Å.	   	  Two	  conditions	  were	  selected	   for	   further	  optimisation,	  based	  on	  diffraction	  quality,	  visual	  appearance	  of	  crystals,	  and	  reproducibility	  of	   crystals	   across	   multiple	   pHs	   and	   temperatures:	   	   Index	   G7	   -­‐	   0.05	   M	  magnesium	  chloride	  hexahydrate,	  0.1	  M	  HEPES	  pH	  7.5,	  30	  %	  (v/v)	  PEG	  MME	  550;	  Wizard	  E1	  -­‐	  0.1	  M	  CAPS	  pH	  10.5,	  30	  %	  (v/v)	  PEG	  400.	  	  	  
4.2.2 Crystal	  optimisation	  	  
4.2.2.1 Index	  G7	  optimisation	  Crystals	  directly	  from	  Index	  G7	  (IG7)	  in	  the	  initial	  screen	  diffracted	  to	  ~3.5	  Å,	  space	  group	  P2	  with	  unit	  cell	  dimensions	  of	  a	  =	  89.6	  Å,	  b	  =	  140.8	  Å,	  c	  =	  140.6	  Å,	  α	   =	   γ	   =	   90	   °,	   β	   =	   96.3	   °.	   	   However,	   these	   crystals	   were	   highly	   anisotropic,	  diffracting	  as	  well	  as	  2.8	  Å	  at	   some	  angles,	  but	  as	  poorly	  as	  5	  Å	   in	  others	   -­‐	   a	  characteristic	   that	   was	   highlighted	   visually	   by	   the	   wedge-­‐like	   shape	   of	   the	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crystals	  (figure	  4.1).	  	  These	  crystals	  were	  also	  split	  or	  formed	  of	  stacks	  of	  thin	  plates.	   	   Matrices	   were	   set	   up	   manually	   in	   24-­‐well	   hanging-­‐drop	   format	   to	  optimise	  %	  PEG	  and	  pH,	  at	  12	  °C,	  16	  °C	  and	  25	  °C.	  	  Crystals	  were	  grown	  at	  all	  temperatures	   and	   at	   several	   pHs	   and	   concentrations	   of	   PEG,	   however	   there	  was	   no	   discernable	   pattern	   of	   improvement	   when	   altering	   any	   of	   these	  parameters,	  either	  visually	  (figure	  4.1,	  right)	  or	  when	  screened	  for	  diffraction.	  	   	  	  	  
Figure	  4.1	  Index	  G7	  crystals.	  	  	  Crystals	   from	   Index	  G7	   condition	   in	   initial	   screen	  were	  wedge-­‐like	   and	   split,	  polarised	   light	   (left)	   and	  diffracted	   to	  3.5	  Å	  although	  with	   severe	  anisotropy.	  	  24-­‐well	   hanging	   drop	   optimisation	   of	   pH	   and	   %	   PEG	   did	   not	   reproducibly	  improve	  crystals	  (right).	  	   	  A	   problem	   encountered	   during	   optimisation	   was	   batch-­‐to-­‐batch	  variability.	   	   Relatively	   low	   yields,	   in	   terms	   of	   crystallographic	   studies,	   were	  achieved	   during	   optimisation	   of	   GST-­‐M2-­‐1	   expression	   and	   purification	   (~5	  mg/L)	   and	   so	   multiple	   preparations	   of	   protein	   were	   needed.	   	   Small,	  unavoidable	  differences	  between	  preparations,	  such	  as	  contaminant	  levels,	  or	  small	   differences	   in	   pH	   or	   protein	   concentration,	   caused	   difficulties	   in	  reproducing	  crystals	  and	  occasionally	  resulted	  in	  the	  growth	  of	  atypical	  crystal	  forms	  that	  were	  poorly	  diffracting	  (figure	  4.2).	  	  To	  improve	  consistency	  during	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crystallisation	   optimisation,	   a	   number	   of	   freezing	   conditions	   for	   M2-­‐1	   were	  tested.	  	  M2-­‐1	  was	  supplemented	  with	  5	  or	  10	  %	  (v/v)	  DMSO,	  glycerol	  or	  MPD,	  or	  left	  unsupplemented,	  and	  snap-­‐frozen	  in	  liquid	  nitrogen	  before	  storing	  at	  -­‐80	  °C.	   	  After	  a	   few	  days,	  protein	  was	   thawed	  on	   ice	  before	  setting	  up	  known	  crystal	   growth	   conditions.	   	   Unfortunately	   it	   was	   found	   that	   M2-­‐1	   did	   not	  crystallise	   after	   freezing	   with	   or	   without	   cryo-­‐protection,	   and	   so	   batch-­‐to-­‐batch	   variability	   remained	   a	   significant	   problems	   for	   crystallisation	  optimisation.	  	  	  	  
	  
Figure	  4.2	  Atypical	  crystal	  forms.	  	  Batch-­‐to-­‐batch	   variation	   caused	   different,	   poorly	   diffracting	   crystal	   forms	   in	  previously	  successful	  conditions.	  	  	  	  	   A	   commercially	   available	   Additive	   Screen	   (Hampton	   Research)	   was	  used	   in	   96-­‐well	   sitting-­‐drop	   format	   at	   16	   °C,	   based	   on	   the	   best-­‐diffracting	  condition	  so	   far:	  0.1	  M	  Bis-­‐Tris	  propane	  pH	  7,	  0.05	  M	  MgCl2,	  30	  %	  (v/v)	  PEG	  MME	   550.	   	   This	   is	   a	   screen	   consisting	   of	   small	   molecules	   known	   to	   affect	  crystallisation	   by	   altering	   protein	   solubility,	   manipulating	   protein-­‐solvent	  interactions,	  or	  perturbing	  the	  structure	  that	  water	  molecules	  form	  around	  the	  target	   protein.	   	   A	   110	  %	   stock	   solution	   of	   the	  mother	   liquor	  was	  made,	   and	  additives	  added	  to	  a	  10	  %	  concentration.	   	  Crystals	  appeared	  after	  2-­‐3	  days	  in	  almost	   all	   conditions	   and	   several	   additives	   appeared	   to	   visually	   improve	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crystal	   quality,	   including	   10	  mM	  nickel	   chloride	   (figure	   4.3,	   left)	   and	  10	  mM	  TCEP	   hydrochloride,	   a	   reducing	   agent	   (figure	   4.3,	   right).	   	   Both	   of	   these	  additives	   improved	   diffraction	   quality,	   but	   resolution	   was	   not	   improved	  beyond	  3.1	  Å.	  Other	  methods	  of	  improving	  crystal	  quality,	  such	  as	  micro-­‐	  and	  streak-­‐seeding,	  and	   increasing	   crystal	   size	   by	   using	   larger	   volume	   drops,	   did	   not	   improve	  diffraction	   quality	   or	   resolution	   and	   so	   no	   further	   optimisation	   of	   this	  condition	  was	  attempted.	  
	  
Figure	  4.3	  Additive	  screening.	  	  	  Hampton	   Research	   Additive	   Screen	   was	   used	   with	   crystallisation	   condition:	  0.1	  M	  Bis-­‐Tris	  propane	  pH	  7,	  0.05	  M	  MgCl2,	  30	  %	  (v/v)	  PEG	  MME	  550.	  	  Left,	  10	  mM	  nickel	  chloride,	  right,	  10	  mM	  TCEP	  hydrochloride.	  	   	  
4.2.2.2 Wizard	  E1	  Optimisation	  An	  alternative	  diffracting	   condition	   from	   the	   initial	   screening	  was	  optimised.	  	  Crystals	  grown	  in	  Wizard	  E1	  (WE1)	  [0.1	  M	  CAPS	  pH	  10.5,	  30	  %	  (v/v)	  PEG	  400]	  were	   cryo-­‐cooled	  directly	   from	  96-­‐well	  drops	  and	   screened	   for	  diffraction	  at	  Diamond.	   	   Although	   the	   crystals	   were	   smaller	   than	   the	   previous	   condition	  (IG7)	  and	  only	  diffracted	   to	  3.69	  Å	   in	  a	  new	  space	  group	  P422,	  WE1	  crystals	  were	   cubic	   and	   less	   split	   (figure	   4.4,	   left)	   and	   displayed	   higher	   quality	  diffraction	  than	  any	  IG7	  crystal,	  i.e.	  sharper	  spot	  profiles,	  high	  intensity	  spots,	  and	   low	   background	   noise	   (figure	   4.5).	   	   Extensive	  matrix	   optimisation	   of	  %	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PEG,	   pH,	   and	   the	   addition	   of	   salt	   (based	   on	   its	   presence	   in	   the	   previous	   IG7	  condition)	   was	   attempted,	   but	   it	   was	   found	   that	   the	   condition	   could	   not	   be	  translated	   from	   96-­‐well	   sitting	   drop	   to	   24-­‐well	   hanging	   drop.	   	   This	   is	   not	  uncommon,	  as	  factors	  such	  as	  nucleation	  from	  the	  plate	  in	  sitting	  drops	  or	  the	  base	  of	  a	  hanging	  drop,	  and	  differences	  in	  surface	  tension	  due	  to	  the	  shape	  of	  hanging	   vs.	   sitting	   drops,	   can	   be	   parameters	   that	   affect	   crystallisation.	   	   The	  problems	   that	  using	  96-­‐well	   sitting	  drops	   introduces	   are	  difficulty	   in	  picking	  crystals	   due	   to	   the	   curvature	   of	   the	   surface	   in	   which	   the	   drops	   sit,	   and	   a	  limitation	  on	  the	  size	  of	  drops	  that	  can	  be	  set	  up	  (2	  µL)	  which	  can,	  in	  turn,	  limit	  the	  size	  of	  the	  crystals	  grown.	  	  The	  remaining	  crystal	  trials	  were	  set	  up	  in	  96-­‐well	   format,	   both	   with	   the	   robot	   and	   manually.	   	   Some	   increase	   in	   size	   of	  crystals	  and	  resolution	  of	  diffraction	  was	  achieved	  with	  optimisation	  of	  pH;	  a	  single	  crystal	  grown	  in	  0.1	  M	  glycine	  pH	  9.5,	  30	  %	  (v/v)	  PEG	  400,	  diffracted	  at	  12.957	  keV	  to	  a	  maximum	  of	  2.95	  Å	  in	  space	  group	  P21,	  different	  to	  the	  initial	  hit	   in	  P422.	   	  This	  was	  the	  highest	  resolution	  native	  WT	  dataset	  collected	  and	  was	  named	  ‘WT-­‐P21’	  (figure	  4.4,	  right).	  	  Data	  collection	  statistics	  are	  shown	  in	  table	  2,	  section	  4.2.5.	  	   	  	  
	  
Figure	  4.4	  Wizard	  E1	  crystals.	  	  	  Images	   taken	   of	   crystals	   in	   loops	   on	   the	   beamline	   at	   Diamond.	   	   Left,	   crystal	  from	   initial	  Wizard	   screen	  was	   small	   (~30	  µm3)	   and	   cubic,	   and	  diffracted	   to	  3.69	  Å	  in	  P422.	  	  Right,	  crystal	  from	  matrix	  optimisation	  of	  pH	  and	  %	  PEG	  was	  larger	  (~1203	  µm),	  and	  diffracted	  to	  2.95	  Å	  in	  P21.	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Figure	  4.5	  Comparing	  diffraction	  patterns.	  	  (below)	  Comparison	  of	  low	  quality	  diffraction	  from	  Index	  G7,	  top	  image,	  (0.1	  M	  Bis-­‐Tris	   propane	   pH	   7,	   0.05	  M	  MgCl2,	   30	  %	   (v/v)	   PEG	  MME	  550)	  with	   good	  quality	  diffraction	  from	  Wizard	  E1,	  bottom	  image,	  (0.1	  M	  glycine	  pH	  9.5,	  30	  %	  (v/v)	  PEG	  400).	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4.2.3 S58DS61D	  –	  cloning,	  expression	  and	  crystallisation	  	  To	  assess	  the	  possible	  structural	  impact	  of	  phosphorylation	  at	  serines	  58	  and	  61,	   a	   phosphomimetic	   mutant	   ‘S58DS61D’	   was	   synthesised	   to	   replace	   both	  serines	   with	   aspartates,	   thus	   mimicking	   the	   negative	   charge	   of	   this	   post-­‐translational	  modification.	   	  Site	  directed	  mutagenesis	  of	  pGEXM2-­‐1	  was	  used,	  with	   one	   set	   of	   complementary	   mutagenic	   primers	   encoding	   both	   serine	   to	  aspartate	   mutations.	   	   Success	   was	   confirmed	   by	   DNA	   sequencing	   and	   the	  construct	  named	  pGEXM2-­‐1DD.	   	  This	  was	   transformed	   into	  BL21	  (DE3)	  Gold	  cells	   and	   expressed	   with	   the	   same	   protocol	   as	   wild-­‐type.	   	   S58DS61D	   had	   a	  similar	  expression	  and	  purification	  profile	  to	  WT	  with	  comparable	  yields	  and	  purity,	  although	  S58DS61D	  protein	  appeared	  to	  be	  more	  stable	  in	  solution	  as	  it	  was	  amenable	  to	  manipulation	  of	  buffer	  conditions	  and	  concentration	  with	  less	  precipitation	  than	  WT.	  	   Crystallisation	  trials	  with	  S58DS61D	  were	  performed	  as	  for	  WT	  protein:	  initial	   screening	   was	   performed	   with	   commercially	   available	   sparse	   matrix	  screens	   in	  96-­‐well	   sitting	  drops	  with	   the	   automated	   robot	   system,	   at	   several	  temperatures.	   	   Hits	   were	   seen	   in	   many	   of	   the	   same	   conditions	   as	   for	   WT,	  however	  the	  best	  diffracting	  crystals	  were	  from	  a	  unique	  condition:	  0.1	  M	  Tris	  pH	  8.5,	  0.2	  M	  trimethylamine	  N-­‐oxide	  (TMANO),	  20	  %	  (w/v)	  PEG	  MME	  2000.	  	  Crystals	   from	   this	   condition	   were	   picked	   from	   drops	   and	   transferred	   into	   a	  fresh	  drop	  containing	  1:1	  ratio	  of	  mother	  liquor	  to	  cryo-­‐protectant	  solution	  [5	  %	  (v/v)	  of	  each:	  glycerol,	  PEG-­‐400,	  2-­‐Methyl-­‐2,	  4-­‐pentanediol	  (MPD),	  ethylene	  glycol],	   then	  cryo-­‐cooled	   in	   liquid	  nitrogen.	   	  These	  crystals,	  directly	   from	   the	  initial	   screens,	   diffracted	   to	   2.4	   Å	   in	   P21	   with	   a	   higher	   quality	   diffraction	  pattern	  than	  WT	  crystals.	   	  No	   further	  optimisation	  of	  S58DS61D	  crystals	  was	  required	   and	   the	   best	   dataset	   collected	   from	   this	   condition	  was	   named	   ‘DD-­‐P21’.	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4.2.4 Initial	  phasing	  attempts	  	  
4.2.4.1 Molecular	  replacement	  There	  are	  no	  X-­‐ray	  crystal	  structures	  available	  of	  M2-­‐1	  protein	  from	  any	  of	  the	  pneumoviruses,	  nor	  are	  there	  predicted	  to	  be	  any	  homologous	  proteins	  based	  on	  amino	  acid	  sequence,	  and	  so	  there	  was	  no	  appropriate	  structure	  in	  the	  PDB	  to	   use	   as	   a	   search	  model	   for	  molecular	   replacement	  when	   this	   work	   began.	  	  However,	   during	   crystal	   trials	   for	   the	   WT	   M2-­‐1,	   a	   partial	   solution	   NMR	  structure	   of	   M2-­‐1	   residues	   58-­‐177	   was	   published	   (Blondot	   et	   al.,	   2012,	  Dubosclard	   et	   al.,	   2011).	   	   This	   structure	   was	   monomeric,	   as	   it	   lacked	   the	  proposed	  tetramerisation	  domain	  in	  the	  N-­‐terminus.	   	  Attempts	  were	  made	  to	  use	  each	  of	  the	  20	  structures	  from	  the	  PDB,	  in	  turn,	  as	  search	  models	  using	  the	  WT-­‐P21	  dataset	  with	  PHASER	  (McCoy	  et	  al.,	  2007).	  	  The	  structure	  could	  not	  be	  solved	  by	  this	  method. 	   An	  increasingly	  powerful	  option	  for	  structure	  solution	  in	  the	  absence	  of	  a	  suitable	  search	  model	  in	  the	  PDB	  is	  the	  generation	  of	  a	  predicted	  structure.	  	  Robetta	   is	   an	   online	   protein	   structure	   prediction	   server	   that	   takes	   a	   protein	  sequence	  and	  divides	  it	  into	  putative	  domains,	  which	  it	  then	  models	  based	  on	  homologues	   in	   the	   PDB	   or	   ab	   initio	   using	   a	   combination	   of	   basic	   protein	  structure	   principles	   (permissible	   peptide	   bond	   angles,	   helix	   formation	   etc.)	  and	   common	   folds	   found	   in	   the	   PDB.	   	   Robetta	   divided	   M2-­‐1	   into	   a	   domain	  corresponding	   to	   the	  partial	  NMR	  structure,	  which	   it	  modelled	  based	  on	   that	  PDB	  entry,	  and	  a	  domain	  comprising	  the	  remaining	  N-­‐terminal	  residues,	  which	  was	   ab	   initio	   modelled	   but	   failed	   to	   produce	   a	   zinc	   finger-­‐like	   motif	   (figure	  4.6).	   	  None	  of	   the	  Robetta	  models	  were	  capable	  of	  phasing	  our	  X-­‐ray	  data	  by	  molecular	  replacement.	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Figure	  4.6	  Robetta	  structure	  predictions.	  	  	  Two	   examples	   of	   structure	   predictions	   made	   by	   the	   online	   server	   Robetta.	  	  These	  are	  based	  on	  a	  combination	  of	  homology	  modelling	  with	  the	  partial	  NMR	  structure	  and	  ab	  initio	  modelling	  with	  basic	  principles	  of	  protein	  structure.	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4.2.4.2 Experimental	  phasing	  –	  single	  wavelength	  anomalous	  dispersion	  (SAD)	  	  
4.2.4.2.1 Selenomethionine	  	  The	  naturally	  occurring	  sulphur	  atoms	   in	  methionine	  residues	  were	  replaced	  with	   selenium,	   a	   heavier	   atom	   that	   provides	   an	   anomalous	   signal	   when	  selenium-­‐edge	  X-­‐rays	  are	  used.	  	  pGEXM2-­‐1	  was	  retransformed	  into	  B834(DE3)	  cells,	  a	  methionine	  auxotrophic	  strain	  of	  E.	  coli,	  and	  50	  mL	  LB	  medium	  starter	  cultures	   grown	   overnight	   as	   in	   Methods	   2.2.1.7.	   	   Cells	   were	   pelleted	   and	  washed	   3	   times	   in	   sterile	   water,	   resuspended	   in	   1	   mL	   water	   and	   used	   to	  innoculate	   1	   L	   SelenoMet	   Medium	   (a	   premade	   M9	   minimal	   media	  supplemented	  with	  all	  amino	  acids	  except	  methionine;	  Molecular	  Dimensions	  Limited)	   containing	   30	   mg/L	   L-­‐selenomethionine.	   	   Cultures	   were	   grown	   to	  OD600	  0.6-­‐0.8	  and	  induced	  with	  1	  mM	  IPTG	  and	  50	  µM	  ZnSO4	  for	  6	  hours	  at	  37	  
°C,	  as	  per	  the	  manufacturer’s	  protocol.	  	   ‘Semet’	  M2-­‐1	  was	  purified	  as	  per	  wild	  type	  and	  crystal	  trials	  were	  attempted.	  	  This	  protein	  crystallised	  poorly,	  and	  all	  crystals	  that	  were	  obtained	  either	  did	  not	  diffract	  or	  diffracted	  to	  worse	  than	  5	  Å.	   	  
4.2.4.2.2 Naturally-­‐bound	  metal	  atoms	  M2-­‐1	  protein	  contains	  a	  predicted	  Cys3-­‐His1	  zinc	  finger	  motif	  between	  residues	  7	  and	  25	   that	  has	  been	  shown	   to	  coordinate	  one	  atom	  of	   zinc	  per	  monomer.	  	  This	   zinc	   could	   also	   be	   used	   to	   provide	   the	   anomalous	   signal	   for	   phasing	   by	  SAD.	   	   A	   fluorescence	   scan	  was	   used	   to	   determine	   if	   zinc	  was	   present	   in	   the	  crystals	   and	   the	   exact	   wavelength	   of	   the	   zinc	   absorption	   edge	   (figure	   4.7),	  which	  can	  vary	  from	  the	  theoretical	  value	  based	  on	  the	  chemical	  environment	  of	  the	  heavy	  atom.	   	  Zinc	  was	  found	  to	  be	  present	   in	  all	  crystals,	  however	  one	  zinc	   atom	   per	   199	   residues	   did	   not	   provide	   sufficient	   anomalous	   signal	   to	  begin	  an	  initial	  estimate	  of	  phases.	  	   An	  additive	  screen	  used	  to	  optimise	  Wizard	  E1	  crystals	  [0.1	  M	  CAPS	  pH	  10,	   30	  %	   (v/v)	   PEG	   400]	   yielded	  well-­‐diffracting	   crystals	   in	   the	   presence	   of	  0.01	  M	   cadmium	   chloride;	   diffracting	   to	   2.52	   Å	   in	   space	   group	   P422	   (figure	  4.8).	   	   The	  data	  were	  of	  poorer	  quality	   than	  both	   the	  WT-­‐P21	  and	   the	  DD-­‐P21	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datasets	  collected	  previously.	   	  The	  absorption	  edge	   for	  cadmium	  was	  outside	  the	  range	  of	  possible	  fluorescence	  scans	  at	  Diamond,	  however	  there	  remained	  a	   significant	   contribution	   at	   the	   zinc	   edge	   wavelength,	   as	   predicted,	   which	  increased	  the	  magnitude	  of	  the	  anomalous	  signal	  and	  allowed	  phasing	  by	  SAD	  as	  described	  below.	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Figure	  4.7	  Fluorescence	  scan	  of	  zinc	  absorption	  edge.	  	  	  Spectrum	  displaying	  the	  magnitudes	  of	  the	  anomalous	  (f’’)	  and	  dispersive	  (f’)	  components	  of	  scattering	  at	  a	  given	  X-­‐ray	  energy	  (eV).	  	  The	  anomalous	  peak	  is	  at	  9664.13	  eV	  and	  is	  close	  to	  the	  theoretical	  value	  for	  the	  zinc	  K-­‐edge,	  9658.6	  eV.	  
	  
Figure	   4.8.	   Wizard	   E1	   with	   0.01	   M	   cadmium	   chloride,	   crystal	   and	  
diffraction	  pattern.	  	  	  	  The	   crystal	   used	   to	   collect	   dataset	   WT-­‐P422	   at	   the	   zinc	   absorption	   edge	  diffracted	  to	  2.52	  Å	  in	  space	  group	  P422,	  with	  significant	  anomalous	  signal.	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4.2.5 Data	  processing	  	  X-­‐ray	   data	   for	   the	  M2-­‐1	  WT-­‐P422	  crystal	  were	   indexed	   and	   integrated	   using	  iMOSFLM	   (Battye	   et	   al.,	   2011,	   Leslie,	   2006).	   	   Indexing	   is	   the	   process	   of	  assigning	  Miller	   indices	   (hkl)	   to	  each	  reflection	   in	   the	  diffraction	  pattern	  and	  determining	  information	  such	  as	  unit	  cell	  size	  and	  mosaicity.	  	  This	  assignment	  is	   based	  on	   the	  Bravais	   lattice	   class	  observed	   from	   the	   geometric	   location	  of	  reflections,	   and	   must	   be	   manually	   checked	   to	   confirm	   that	   the	   reflections	  predicted	  by	  the	  lattice	  group	  match	  those	  observed	  in	  the	  diffraction	  images.	  	  Integration	   is	   the	   process	   of	   recording	   an	   intensity	   and	   associated	   error	   for	  each	   reflection.	   	   These	   two	   processes	   convert	   the	   dataset	   from	   a	   series	   of	  images	   to	   a	   numerical	   list	   of	   reflection	   intensities.	   	   A	   primitive	   tetragonal	  lattice	  was	  assigned	  with	  unit	  cell	  parameters	  of	  a	  =	  b	  =	  102.28	  Å,	  c	  =	  90.99	  Å,	  α	  =	  b	  =	  γ	  =	  90.00	  °,	  and	  POINTLESS	  used	  to	  confirm	  the	  Laue	  group	  (based	  on	  the	  symmetry	  of	   the	  reflections)	  and	  the	  space	  group	  (using	  systematic	  absences	  in	   the	   diffraction	   pattern	   to	   identify	   screw	   axes).	   	   P422	   was	   assigned	   and	  scored	  as	  the	  only	  probable	  space	  group.	  	  This	  reduced	  data	  was	  then	  scaled	  to	  make	   the	   dataset	   internally	   consistent	   by	   accounting	   for	   variations	   such	   as	  beam	   intensity,	   radiation	   damage,	   and	   detector	   inconsistencies,	   using	   scale-­‐factors	   determined	   by	   comparing	   symmetry	   related	   reflections.	   	   Multiple	  observations	   of	   each	   reflection	   were	   merged	   to	   create	   an	   average	   intensity	  (Ihkl),	  and	  a	  list	  of	  normalised	  structure	  factors	  amplitudes	  (|Fhkl|)	  created	  using	  the	  following	  relationship:	   Ihkl	  ∝ |Fhkl|2 	  Scaling	  and	  merging	  were	  performed	  with	  AIMLESS,	  and	  this	  programme	  also	  outputs	  a	  number	  of	  statistics	  to	  objectively	  assess	  data	  quality:	  Rmerge	   –	   the	   basic	   measure	   of	   internal	   consistency	   that	   assesses	   the	  agreement	   between	   the	   average	   intensity	   of	   a	   reflection,	   and	   each	  individual	  observation	  of	  that	  reflection.	  	  A	  lower	  value	  is	  an	  indication	  of	   higher	   quality,	   however	   Rmerge	   increases	  with	  multiplicity	   and	   so	   is	  not	  always	  an	  accurate	  indicator.	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  Rpim	  –	   the	   ‘precision-­‐indicating	  R-­‐factor’	   is	   like	   the	  Rmerge	   but	   accounts	  for	   multiplicity,	   thus	   reflecting	   the	   increase	   in	   accuracy	   as	   more	  observations	  are	  merged.	  	  Completeness	  –	  the	  number	  of	  unique	  reflections	  as	  a	  percentage	  of	  the	  total	  reflections.	  	  	  	  Multiplicity	   –	   the	   number	   of	   total	   reflections	   divided	   by	   the	   unique	  reflections;	  it	  is	  the	  average	  number	  of	  independent	  measurements	  of	  a	  reflection.	  	  	  	  I/σ(I)	  –	  the	  average	  signal	  to	  noise	  ratio	  of	  the	  intensities.	  	  These	   statistics	   for	   WT-­‐P422	   dataset	   (and	   the	   two	   datasets	   solved	   by	  molecular	   replacement,	   below)	   are	   presented	   in	   table	   2,	   and	   were	   all	  acceptable	  at	  the	  2.52	  Å	  resolution	  cut-­‐off	  that	  was	  chosen.	  	   	  Approximately	  5	  %	   of	   the	   data	   were	   randomly	   selected	   in	   AIMLESS	   to	   be	   omitted	   from	  refinement,	   allowing	   the	  Rfree	   to	   be	  monitored	  during	   refinement	   (see	  4.2.7).	  	  Tests	   for	   twinning	   of	   the	   data,	  where	   two	   or	  more	   lattices	   grow	   together	   so	  that	   their	   unit	   cells	   are	   related	   by	   symmetry,	  were	   also	   performed	   here.	   All	  data	  presented	  in	  this	  thesis	  were	  not	  twinned.	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Data	  set	   WT-­‐P422	   WT-­‐P21	   DD-­‐P21	  Wavelength	  (Å)	   1.2823	   1.2819	   0.9889	  Space	  group	   P422	   P21	   P21	  Cell	  parameters	  (Å,º)	   a	  =	  102.28	  b	  =	  102.28	  c	  =	  90.99	  
α=	  90.00	  
β	  =	  90.00	  
γ	  =	  90.00	  
a	  =	  91.85	  b	  =	  141.6	  c	  =	  141.7	  
α=	  90.00	  
β	  =	  96.14	  
γ	  =	  90.00	  
a	  =	  89.68	  b	  =	  141.60	  c	  =	  142.16	  
α	  =	  90.00	  
β	  =	  93.92	  
γ	  =	  90.00	  Total	  reflections	   884975	  (49270)	   1135690	  (62535)	   840458	  (34707)	  Unique	  reflections	   16695(1565)	   75535	  (4385)	   138151	  (6792)	  Resolution	  shells	  (Å)	   	  	   	  	   	  	  Low	   45.74-­‐2.61	   140.88-­‐3.01	   78.12-­‐2.44	  High	   2.61-­‐2.52	   3.01-­‐2.95	   2.44–2.40	  
Rmerge,	  %	   9.6	  (64.7)	   19.1	  (138.4)	   9.8	  (60.1)	  Rpim,	  %	   1.8(16.1)	   7.4	  (55.2)	   6.5	  (44.1)	  Completeness,	  %	   98.9	  (91.2)	   99.5	  (98.2)	   100	  (99.5)	  Multiplicity	   30	  (6.0)	   15.0	  (14.3)	   6.1	  (5.1)	  
I/σ(I)	   14.8	  (3.8)	   14.4	  (2.3)	   11.1	  (2.4)	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4.2.6 SAD	  Phasing	  	  Phasing	   of	   the	   M2-­‐1	   WT-­‐P422	   data	   was	   carried	   out	   with	   PHENIX	   AutoSol	  (Adams	  et	  al.,	  2010)	  using	  the	  single-­‐wavelength	  anomalous	  dispersion	  (SAD)	  method.	   	  AutoSol	  is	  an	  automated	  structure	  solution	  pipeline	  that	  combines	  a	  series	   of	   programs	   to	   identify	   potential	   heavy-­‐atom	   sites,	   calculate	  experimental	   phases,	   and	   build	   an	   initial	   density-­‐modified	   electron	   density	  map.	  	  It	  is	  a	  fast	  way	  to	  try	  multiple	  solutions,	  such	  as	  different	  possible	  heavy	  atom	  sites,	  related	  space	  groups,	  or	  opposing	  ‘handed’	  structures.	  	  For	  the	  WT-­‐P422	  dataset,	  AutoSol	  first	  used	  HySS	  (Hybrid	  Substructure	  Search)	  to	  identify	  all	   possible	   locations	   of	   anomalous	   scatterers	   through	   a	   combination	   of	  Patterson	  methods	   (see	   Introduction	   1.5.4).	   	   Then	   for	   each	   potential	   heavy-­‐atom	   substructure	   a	   set	   of	   reference	   phases	   (φA)	   for	   the	   heavy	   atoms	   was	  calculated,	  as	   their	   location,	  structure	   factor	  amplitude	  and	  phase	  are	  related	  through	  the	  electron-­‐density	  equation.	  	  Initial	  phases	  for	  the	  rest	  of	  the	  protein	  (φP)	  were	  estimated	  with	  PHASER,	  using	  the	  relationship:	  φP	  =	  φA	  +	  α	  where	  α	   is	   the	  shift	   in	  phase	  from	  heavy	  atom	  phase	  to	  protein	  phase,	  and	   is	  related	   to	   the	   anomalous	   difference	   and	   heavy	   atom	   structure	   factor	  magnitude	   (Dauter	   et	   al.,	   2002).	   	   Using	   these	   initial	   protein	   phases	   electron	  density	   maps	   were	   built	   and	   statistically	   density	   modified	   with	   RESOLVE,	  which	   works	   to	   increase	   the	   probability	   of	   an	   electron	   density	   map	   being	  correct	   by	   incorporating	   prior	   knowledge,	   such	   as:	   non-­‐crystallographic	  symmetry	   averaging	   from	   symmetry	   of	   heavy	   atoms	   in	   the	   substructure;	  solvent	   flattening,	   by	   subtracting	   the	   mean	   solvent	   density	   from	   the	   whole	  map	   and	   masking	   the	   protein	   region	   based	   on	   knowledge	   of	   the	   unit	   cell	  solvent	   content;	   histogram	   matching,	   where	   the	   density	   distribution	   of	   the	  map	  is	  modified	  until	  it	  fits	  the	  pattern	  expected	  for	  a	  protein	  structure.	  	  Electron	   density	   maps	   built	   using	   phase	   estimates	   from	   different	  substructure	  solutions	  were	  scored	  based	  on	  a	  number	  of	  quality-­‐assessment	  criteria:	   skew	  of	   the	  electron	  density	   (i.e.	  density	  next	   to	  density	  and	  solvent	  next	  to	  solvent),	  regions	  of	  connected	  density,	  contiguous	  flat	  solvent,	  R-­‐factor	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for	   density	   modification	   (difference	   between	   calculated	   and	   observed	  structure	   factors).	   	   The	   most	   likely	   solution	   resulted	   in	   a	   map	   with	   two	  monomers	   per	   asymmetric	   unit	   (AU)	   that	   combined	   with	   their	   symmetry	  mates	   to	   form	   two	   tetramers	   in	   the	   unit	   cell.	   	   This	   was	   in	   line	   with	   the	  Matthews	   coefficient	   (VM),	   which	   predicts	   the	   most	   probable	   content	   of	   the	  asymmetric	   unit	   based	   on	   protein	   molecular	   weight	   and	   estimated	   solvent	  content;	   50	   ±10	   %	   for	   most	   proteins	   in	   the	   PDB.	   	   Four	   heavy	   atoms	   were	  identified	   in	   the	   substructure,	  which	  were	   later	   confirmed	   as	   two	   cadmiums	  coordinated	  in	  the	  Cys3-­‐His1	  zinc	  finger	  motifs,	  and	  two	  zinc	  atoms	  bound	  at	  a	  surface	  exposed	  site	  on	  M2-­‐1	  as	  an	  artefact	  of	  crystallisation.	  	  	  	  	  
4.2.7 Model	  building	  and	  refinement	  	  A	   preliminary	   structure	   was	   auto-­‐built	   into	   the	   density-­‐modified	   map	   by	  BUCCANEER	  (Cowtan,	  2006).	  	  This	  programme	  finds	  possible	  Cα	  positions	  and	  then	   extends	   these	   into	   chain	   fragments	   by	   laterally	   adding	   more	   Cα	  candidates	   whilst	   obeying	   Ramachandran	   constraints.	   	   These	   fragments	   are	  gradually	  joined	  and	  side	  chains	  assigned	  according	  to	  the	  sequence	  provided.	  	  This	  model	  was	  sufficient	  to	  see	  that	  the	  solution	  was	  correct,	  as	  some	  major	  features	  such	  as	  α-­‐helices	  had	  been	  auto-­‐built,	  however	  there	  was	  no	  density	  apparent	   for	   the	  C-­‐terminal	  residues	  175-­‐194,	  or	  residues	  52-­‐67,	  resulting	   in	  an	  incomplete	  chain.	  	  	  	   The	   preliminary	   model	   was	   improved	   by	   manual	   building	   in	   COOT	  (Emsley	  and	  Cowtan,	  2004),	  where	  the	  protein	  chain	  was	  modified	  residue	  by	  residue	  to	   improve	  both	  its	   fit	   in	  the	  electron	  density,	  and	  properties	  such	  as	  bond	   lengths	   and	   torsion	   angles.	   	   This	   process	   used	   two	   types	   of	   electron	  density	   maps:	   a	   maximum	   likelihood	   map,	   which	   shows	   the	   current	   best	  estimate	   of	   electron	  density	   for	   the	   structure	  whilst	   accounting	   for	   errors	   in	  the	  phases,	  and	  attempts	   to	   limit	  any	  potential	  model	  bias;	  a	  difference	  map,	  which	   estimates	   the	   difference	   between	   the	   true	   structure	   and	   the	   current	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model,	  and	  highlights	  areas	  of	  positive	  or	  negative	  density	  where	  atoms	  should	  be	  added	  or	  removed,	  respectively.	  	  	  Manual	   building	   was	   followed	   by	   model	   refinement	   in	   REFMAC5	  (Murshudov	   et	   al.,	   2011),	   where	   the	   difference	   between	   observed	   and	  calculated	  structure	  factor	  amplitudes	  (Rcryst)	  was	  minimised	  by	  improving	  the	  atomic	   positions	   in	   the	   model.	   	   This	   was	   achieved	   by	   providing	   additional	  information	  in	  the	  form	  of	  chemical	  restraints,	  such	  as	  preferred	  bond	  lengths,	  angles	   and	   torsions,	   towards	   which	   refinement	   is	   weighted	   at	   lower	  resolutions,	  such	  as	  those	  presented	  in	  this	  thesis.	   	  Refinement	  also	  improves	  the	   isotropic	   B-­‐factor	   of	   atoms,	   a	   measurement	   of	   the	   degree	   of	   movement	  around	   the	   atomic	   position	   in	   the	   model.	   	   This	   process	   of	   minimising	   Rcryst	  improved	   the	   calculated	  phases,	  which	  were	   then	  used	   to	  build	  an	   improved	  electron	  density	  map	  (and	  the	  model	  that	  fits	  it)	  in	  an	  iterative	  cycle.	  	  	  The	  progress	  of	  refinement	  was	  assessed	  by	  calculating	  the	  Rcryst	  for	  the	  5	  %	  of	  data	  omitted	  after	  scaling:	  the	  Rfree.	  	  This	  measures	  how	  well	  the	  current	  model	   can	   predict	   the	   measured	   intensities	   in	   the	   5	   %	   of	   unrefined	   data.	  	  General	   ‘rules	   of	   thumb’	   aim	   to	   have	   Rcrys	  below	   10	  %	   of	   the	   resolution,	   i.e.	  <0.25	  or	  25	  %	  at	  2.5	  Å,	  and	  Rfree	  and	  Rcryst	  should	  not	  deviate	  by	  more	  than	  5-­‐7	  %.	  	  However	  these	  statistics	  are	  often	  poorly	  representative	  of	  the	  true	  quality	  of	   the	   structure,	   which	   should	   be	   determined	   by	   examining	   the	   electron	  density	   itself	   and	   biophysical	   factors	   such	   as:	   root-­‐mean-­‐square	   deviation	  (rmsd)	  bond	   lengths	   (<0.02	  Å)	   and	   rmsd	  bond	  angles	   (1-­‐2	   °),	   the	  number	  of	  amino	   acids	   residing	   in	   the	   ‘preferred’	   region	   of	   a	   Ramachandran	   plot,	   and	  steric	  clashes	  between	  residues	  and/or	  solvent	  molecules.	  	  Refinement	   of	   the	   WT-­‐P422	   dataset	   become	   unstable	   after	   several	  cycles,	   i.e.	  Rcryst	  and	  Rfree	  began	  to	  diverge,	  and	  no	   further	   improvement	  of	  R-­‐factors	   could	  be	  achieved,	   likely	  due	   to	   the	   relatively	  poor	  quality	  diffraction	  images	  that	  lead	  to	  poor	  electron	  density.	  	  Refinement	  of	  this	  dataset	  was	  not	  completed	  and	  statistics	  are	  presented	  in	  table	  3.	  	  Despite	  this,	  the	  model	  was	  assessed	   using	   the	   MolProbity	   server	   (Chen	   et	   al.,	   2010),	   which	   outputs	   a	  series	  of	  scores	  that	  assess	  the	  quality	  of	   the	  model	  based	  on	  the	  biophysical	  criteria	  described	  above.	   	  The	  WT-­‐P422	  model	  had	  a	  MolProbity	  score	   in	   the	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90th	   percentile	   of	   PDB	   structures;	   this	   takes	   into	   account	   sidechain	   clashes,	  whether	  sidechains	  are	  in	  preferable	  rotomers,	  and	  analysis	  of	  Ramachandran	  outliers,	  and	  normalises	  these	  scores	  to	  the	  resolution	  of	  the	  structure.	  	  Figure	  4.9	   shows	  Ramachandran	  plots	   for	  glycines	   (right)	  and	  all	  other	  amino	  acids	  (left),	  with	  favoured	  regions	  in	  pale	  blue	  and	  allowed	  regions	  in	  dark	  blue.	  	  The	  two	  outliers,	  glycine	  18	  on	  both	  monomers	  in	  the	  AU,	  are	  shown	  in	  green	  and	  their	   location	  within	   the	   zinc	   finger	  motif	   (resides	  7-­‐25)	   likely	  explains	   their	  unfavourable	   orientation,	   as	   this	   region	   will	   be	   constrained	   by	   the	   zinc-­‐coordinating	  residues.	  	  	  The	  MolProbity	  analysis	  suggested	  that	  although	  the	  refinement	  of	  WT-­‐P422	  was	   incomplete,	   it	   was	   a	   suitable	  model	   for	  molecular	   replacement	   of	  higher	  quality	  datasets.	  	  	  
	  
Figure	  4.9	  	  Ramachandran	  plots	  for	  WT-­‐P422	  model.	  	  	  Plots	   of	   phi	   and	  psi	   Cα	   backbone	   angles	   are	   the	   output	   from	   the	  MolProbity	  server	  analysis.	  	  Right,	  glycine,	  Left,	  all	  other	  amino	  acids.	  	  Light	  blue,	  favoured	  region,	  Dark	  blue,	  allowed	  region.	  	  Outliers	  are	  shown	  in	  green	  and	  labelled.	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Data	  set	   	   WT-­‐P422	   WT-­‐P21	   DD-­‐P21	  Resolution	  shells	  (Å)	  	  Low	   45.74-­‐2.61	   140.88-­‐3.01	   78.12-­‐2.44	  High	   2.61-­‐2.52	   3.01-­‐2.95	   2.44–2.40	  
Rcryst,	  %	   21.12	   20.54	   20.36	  Rfree	  ,	  %	   26.15	   25.46	   23.78	  VM	  (Å3/Da)	   2.69	   2.59	   2.53	  Mol.	  per	  AU	   2	   16	   16	  Reflections	  working	  set	   15849	   71711	   131263	  Free	   R-­‐value	   set	   (no.	   of	  reflections)	   5.1%	  (845)	   5.0%	  (3795)	   5.0%	  (6851)	  RMSD	  bond	  lengths,	  Å	   0.013	   0.013	   0.015	  RMSD	  bond	  angles,	  º	   1.459	   1.523	   1.579	  No.	  of	  atoms	  used	  in	  refinement	  Non-­‐hydrogen	  atoms	   2669	   21688	   21997	  Protein	  atoms	   2604	   21494	   21586	  Metal	  atoms	   4	   16	   16	  Water	  molecules	   61	   178	   395	  Mean	  B-­‐factor,	  Å2	   	   	   	  Total	   71.8	   69.4	   50.2	  Protein	  atoms	   72.3	   69.8	   50.5	  Metal	  atoms	   49.5	   44.4	   27.61	  Water	  molecules	   53.7	   38.5	   39.3	  Ramachandran	  plot	  statistics,	  %	  Preferred	  region	   96.49	   94.42	   96.21	  Allowed	  region	   2.88	   4.54	   3.15	  Outliers	   0.64	   1.04	   0.63	  	  	  
Table	  3	  Refinement	  statistics.	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4.2.8 Molecular	  replacement	  of	  other	  datasets	  	  Two	  previously	  described	  datasets	  were	  indexed,	  integrated	  and	  scaled	  as	  for	  the	  WT-­‐P422	  data	  (see	  4.2.5):	  WT-­‐P21	  data	  (see	  4.2.2.2)	  0.1	  M	  glycine	  pH	  9.5,	  30	  %	  (v/v)	  PEG	  400,	  diffracted	  to	  maximum	  of	  2.95	  Å	  in	  space	  group	  P21,	  and	  phosphomimetic	  DD-­‐P21	  (see	  4.2.3)	  0.1	  M	  Tris	  pH	  8.5,	  0.2	  M	  trimethylamine	  N-­‐oxide	  (TMANO),	  20	  %	  (w/v)	  PEG	  MME	  2000,	  diffracted	  to	  2.4	  Å	  in	  space	  group	  P21.	  	  For	  both	  datasets,	  16	  monomers	  (corresponding	  to	  four	  tetramers)	  were	  found	  in	  the	  AU.	  	  Data	  collection	  statistics	  are	  presented	  in	  table	  2.	  	  	  A	  monomer	  from	  the	  M2-­‐1	  WT-­‐P422	  model	  was	  used	  to	  solve	  the	  M2-­‐1	  WT-­‐P21	  and	  M2-­‐1	  DD-­‐P21	  X-­‐ray	  datasets	  via	  molecular	  replacement	  (MR)	  using	  PHASER	  (McCoy	  et	  al.,	  2007).	   	  Molecular	  replacement	  works	  by	  manipulating	  the	  model	  molecule,	  an	  M2-­‐1	  monomer	  from	  WT-­‐P422	  in	  this	  instance,	  into	  the	  same	  orientation	  and	  location	  in	  the	  unit	  cell	  as	  the	  unknown	  molecule.	  	  This	  is	  achieved	   by	   correlating	   intra-­‐	   and	   inter-­‐molecular	   vectors	   in	   the	   Patterson	  maps	  of	  both	  molecules.	  	  Translation	  function	  Z-­‐scores	  (TFZ)	  for	  both	  datasets,	  a	   statistic	  used	   to	  assess	   the	  probability	  of	   a	  molecular	   replacement	   solution	  being	  correct,	  were	   considerably	  above	   the	  acceptable	   cut-­‐off	  of	  8.	   	  Once	   the	  orientation	  and	  position	  of	  the	  unknown	  molecule	  are	  known,	  the	  phases	  from	  the	  model	   can	  be	   applied	   to	   the	   structure	   factor	   amplitudes	  of	   the	  unknown	  protein	  to	  build	  an	  electron	  density	  map.	  Maps	  were	  built	  in	  this	  way	  for	  WT-­‐P21	  and	  DD-­‐P21,	  and	  the	  structures	  were	  fully	  refined	  as	  described	  in	  4.2.7,	  with	  cycles	  of	  manual	  building	  in	  COOT	  and	   refinement	   in	   REFMAC5.	   	   16	   zinc	   atoms	   were	   identified	   per	   AU,	   as	  expected,	  and	  no	  cadmium	  as	  none	  was	  present	  in	  the	  mother	  liquor	  for	  either	  of	   these	   datasets.	   	   Automatically	   generated	   non-­‐crystallographic	   symmetry	  restraints	  were	  used	  during	  refinement,	  to	  restrain	  all	  16	  copies	  of	  M2-­‐1	  in	  the	  AU	  to	  the	  average	  atomic	  position.	  	  	  Refinement	   statistics	   are	   presented	   in	   table	   3.	   	   Although	   the	  Ramachandran	   statistics	   for	  WT-­‐P21	  did	   not	   suggest	   that	   this	  model	   of	  M2-­‐1	  was	   significantly	   better	   than	   the	   WT-­‐P422	   model,	   the	   Rcryst	   and	   Rfree	   were	  slightly	   improved	   and	   the	   electron	   density	   map	   was	   deemed	   to	   be	   visibly	  
Chapter	  4:	  Determining	  the	  X-­‐ray	  crystal	  structure	  of	  M2-­‐1	  
147	  
better	   defined	   (figure	   4.10).	   	   Density	   for	   residues	   52-­‐67,	   which	   had	   been	  unresolved	   in	   the	  WT-­‐P422	  model,	  was	   seen	   in	  2	  of	  16	  molecules	   in	   the	  AU.	  	  Statistics	   for	   DD-­‐P21,	   the	   phosphomimetic	   mutant	   S58DS61D,	   were	  significantly	  better	   than	  either	  WT	  dataset,	  with	  a	  smaller	  deviation	  between	  Rcryst	   and	   Rfree,	   a	   lower	   Rfree	   of	   23.78	   %,	   lower	   mean	   B-­‐factors,	   and	   fewer	  Ramachandran	  outliers.	  	  	  
	  
	  
Figure	  4.10	  Comparison	  of	  electron	  density	  maps.	  	  	  Electron	   density	   (blue;	   contoured	   to	   2.0	   rmsd)	   and	   structure	   models	   are	  shown	  for	  the	  original	  SAD-­‐phased	  WT-­‐P422	  dataset	  (top;	  yellow	  model)	  and	  for	   the	   molecular	   replaced	   WT-­‐P21	   dataset	   (bottom;	   green).	   	   The	   WT-­‐P21	  density	   and	   model	   are	   in	   closer	   agreement	   than	   for	   WT-­‐P422,	   which	   has	  poorly	  resolved	  sidechains.	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4.2.9 The	  Structure	  PDB	  codes	  are	  as	  follows:	  WT-­‐P422,	  4c3d;	  WT-­‐P21,	  4c3b,	  DD-­‐P21,	  4c3e.	  	  
4.2.9.1 M2-­‐1	  monomer	  The	  X-­‐ray	   crystal	   structure	   of	   RSV	  WT	  M2-­‐1	  was	   solved	   by	   the	   SAD	  method	  followed	   by	   molecular	   replacement	   into	   a	   higher	   quality	   dataset,	   to	   a	  maximum	  resolution	  of	  2.52	  Å,	   and	   is	   the	   first	   example	  of	   a	   full-­‐length	  M2-­‐1	  structure	   from	  any	  pneumovirus.	  M2-­‐1	  crystallised	  as	  a	   tetramer	   in	  all	   space	  groups,	  however	  a	  monomeric	  view	  of	  the	  crystal	  structure	  is	  shown	  in	  figure	  4.11	  for	  simplicity.	  	  M2-­‐1	  forms	  four	  distinct	  regions	  linked	  by	  unstructured	  or	  flexible	  sequences,	  these	  are	  (N	  to	  C	  terminus):	  the	  zinc	  finger	  region	  (residues	  7-­‐25)	   and	   tetramerisation	   helix	   (residues	   32-­‐49),	   which	   extend	   on	   an	   N-­‐terminal	   arm	   and	   are	   linked	   via	   a	   flexible	   loop	   (residues	   52-­‐67)	   to	   the	   core	  domain	   (residues	   69-­‐172),	   a	   globular	   α-­‐helical	   fold.	   	   An	   additional	   region	   is	  comprised	   of	   the	   C-­‐terminal	   20	   residues,	   which	   were	   not	   resolved	   in	   any	  dataset	  as	  they	  are	  unstructured	  (Tran	  et	  al.,	  2009).	  	  Figure	  4.11	  A)	  shows	  the	  structure	  of	  monomeric	  M2-­‐1	  with	  the	  above	  regions	  in	  different	  colours,	  and	  also	   numbers	   the	   helices	   α1	   to	   α7.	   	   The	   flexible	   loop	   region	   linking	   the	  tetramerisation	  helix	  and	  the	  core	  domain	  was	  poorly	  resolved,	  only	  showing	  density	  in	  2	  out	  of	  16	  molecules	  in	  the	  WT-­‐P21	  dataset,	  and	  this	  is	  reflected	  in	  the	  high	  B-­‐factors	  for	  this	  region	  (figure	  4.11	  B).	   	  All	  monomer	  figures	  shown	  here	   are	   of	   a	   monomer	   from	   the	   WT-­‐P21	   dataset,	   containing	   well-­‐defined	  density	  for	  this	  region.	  	  	  
Figure	  4.11	  The	  monomer	  representation	  of	  M2-­‐1	  crystal	  structure.	  	  	  (below)	  One	  monomer	  is	  shown	  from	  the	  crystallised	  tetramer	  for	  simplicity.	  	  
A)	  N	  and	  C	   termini	  are	   labelled	   (N	  and	  C,	   respectively),	  and	   the	   three	  helical	  regions	   are	   coloured	   as	   follows:	   zinc	   finger,	   purple	   (residues	   7-­‐25);	   the	  tetramerisation	   helix,	   pale	   pink	   (residues	   32-­‐49);	   the	   core	   domain,	   pink	  (residues	   69-­‐172).	   	   Unstructured	   regions	   are	   shown	   in	   grey.	   	   Helices	   are	  numbered	  α1	  (tetramerisation	  helix)	  through	  to	  α7.	  	  B)	  ‘Worm’	  representation	  of	  monomer	  where	  width	  is	  proportional	  to	  B-­‐factor.	  











4.2.9.2 Tetrameric	  organisation	  of	  M2-­‐1	  M2-­‐1	  crystallised	  as	  a	   tetramer	  –	   the	  proposed	  physiologically	  active	   form	  of	  M2-­‐1	  and	  the	  only	  oligomer	  purified	  by	  size	  exclusion	  chromatography	  in	  this	  work	  (figure	  4.12).	  	  All	  tetramer	  figures	  shown	  here	  were	  built	  in	  PISA	  with	  the	  flexible	   loop-­‐containing	  monomer	  described	  above,	   in	  order	  to	  present	  a	   full-­‐length	   tetramer	   and	   ensure	   that	   surface	   representations	   of	   the	   protein	  were	  more	  appropriate.	  	  PISA	  is	  an	  online	  server	  that	  uses	  criteria	  such	  as	  Gibbs	  free	  energy	  of	  formation,	  interface	  size,	  and	  hydrogen	  bonding	  to	  predict	  the	  buried	  surface	  area	  and	  probability	  of	  stability	  for	  higher	  order	  assemblies,	  allowing	  inferences	  about	  biological	  relevance	  to	  be	  made.	  	  It	  is	  imperative	  that	  analyses	  like	  these	  are	  performed	  on	  crystal	  structures	  to	  help	  to	  distinguish	  between	  artefactual	   contacts	   as	   a	   result	   of	   crystallisation,	   and	   biologically	   relevant	  interactions.	   	  The	  agreement	  between	  PISA	  and	  the	  oligomeric	  status	  of	  M2-­‐1	  in	   solution,	  both	   in	   this	  work	  and	   in	  previous	  publications,	   strongly	   suggests	  that	  the	  tetrameric	  form	  crystallised	  here	  is	  physiologically	  relevant.	  	  	  The	   packing	   of	   the	   tetramerisation	   helix	   (α1)	   appears	   to	   drive	  oligomerisation	  by	  burying	  a	  set	  of	  hydrophobic	  residues	  	  (L36,	  L43,	  I46,	  M50	  are	   all	   on	   one	   face	   of	   the	   helix)	   within	   a	   four-­‐helix	   bundle	   (figure	   4.13).	  	  Residues	  from	  a	  single	  protomer	  contact	  all	  neighbouring	  protomers	  forming	  a	  very	   stable	   tetrameric	   structure.	   	   Further	   stabilisation	   of	   the	   tetrameric	  arrangement	  of	  M2-­‐1	  is	  provided	  by	  the	  Cys3-­‐His1	  zinc	  finger	  motif	  (Fig.	  4.12	  A,	  inset),	  which	   interacts	  mainly	  with	   the	  N-­‐terminal	   face	  of	   the	  core	  domain	  of	  an	  adjacent	  protomer,	   increasing	  the	  buried	  surface.	   	  PISA	  analysis	  estimated	  the	   total	   buried	   surface	   area	   in	   the	   tetramer	   as	   12,320	   Å2	   with	   a	   predicted	  change	   in	   Gibbs	   free	   energy	   of	   formation	   (ΔGform)	   of	   -­‐135	   kcal/mol	   upon	  tetramer	   formation,	   implying	   spontaneous,	   exothermic	   formation	   of	   an	  extremely	   stable	   tetramer.	   	  A	  homotetramer	  of	  M2-­‐1	  was	  predicted	   to	  be	   its	  only	   probable	   form	   and	   explains	  why	   no	   other	   oligomers	  were	   ever	   seen	   in	  solution	  during	  protein	  purification.	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The	  zinc	  finger	  motif	  is	  visualised	  here	  for	  the	  first	  time	  and	  appears	  to	  be	   non-­‐canonical,	   with	   no	   structurally	   similar	   folds	   found	   using	   the	   DALI	  server.	  	  However,	  a	  sequence	  search	  of	  the	  PDB	  suggests	  that	  the	  zinc	  finger	  of	  tristetraprolin	  (TTP)/Nup475,	  (a	  mammalian	  RNA	  processing	  factor)	  is	  related	  and	  appears	  to	  recognise	  zinc	  in	  a	  similar	  fashion.	  	  The	  M2-­‐1	  zinc	  finger	  is	  able	  to	  bind	  cadmium	  in	  addition	  to	  zinc,	  as	  evidenced	  by	  the	  presence	  of	  cadmium	  at	  this	  location	  within	  WT-­‐P422	  crystals,	  which	  contributed	  to	  the	  anomalous	  signal.	   	   In	  the	  context	  of	  the	  tetramer,	  the	  four	  zinc	  fingers	   lie	  on	  the	  surface,	  and	  this	  raises	  the	  possibility	  that	  they	  may	  also	  participate	  in	  RNA	  binding.	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Figure	  4.12	  Tetrameric	  crystal	  structure	  of	  RSV	  M2-­‐1.	  	  	  (above)	  A)	  N-­‐terminal	  and	  B)	  side	  views	  of	  the	  M2-­‐1	  tetramer	  are	  shown	  with	  monomers	  highlighted	  in	  different	  colours.	  	  The	  zinc	  finger	  is	  shown	  inset	  in	  A)	  with	  zinc	  atoms	  in	  grey.	   	  The	  side	  view	  highlights	  the	   interlocking	  protomers	  as	  the	  zinc	  finger	  motif	  extends	  through	  the	  tetramer	  to	  contact	  the	  N-­‐terminal	  face	  of	  the	  adjacent	  protomer.	  	  
Figure	  4.13	  Tetramerisation	  via	  a	  four-­‐helix	  bundle.	  	  	  (below)	  Helix	  α1	  mediates	  tetramerisation	  by	  forming	  a	  four-­‐helix	  bundle	  that	  buries	  hydrophobic	   residues	  L36,	  L43,	   I46,	  M50	  on	  all	   four	  helices.	  Top,	   side	  view,	   Bottom,	   top-­‐down	   view.	   	   Hydrophobic	   residues	   are	   coloured	   green,	  graduating	  from	  light	  to	  dark	  from	  N-­‐	  to	  C-­‐terminus	  of	  helix	  α1.	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4.2.10 Electrostatics	  	  Given	   the	  RNA-­‐binding	   nature	   of	   RSV	  M2-­‐1	   protein,	   the	   electrostatic	   surface	  potential	   of	   the	   tetramer	  was	   analysed.	   	   Figure	  4.14	   (left,	  A,	  B	   and	  C)	   shows	  surface	  representations	  of	  the	  WT	  protein	  colour-­‐coded	  blue	  to	  red	  according	  to	   charge	   (positive	   to	   negative,	   respectively),	   which	   was	   calculated	   using	   a	  programme	   called	   Adaptive	   Poisson-­‐Boltzmann	   Solver	   (APBS).	   	   Areas	   of	  positive	   charge	   are	   traditionally	   linked	   to	   electrostatic	   interactions	  with	   the	  negative	   phosphate	   groups	   of	   nucleic	   acids.	   	   This	   analysis	   shows	   extensive,	  contiguous	  surfaces	  of	  blue	  positive	  charge	  that	  cover	  the	  N-­‐terminal	  (A)	  and	  C-­‐terminal	  (B)	  faces,	  and	  additionally	  wrap	  around	  the	  side	  face	  (C),	  suggesting	  that	   the	   region	   of	   M2-­‐1	   involved	   in	   RNA	   binding	   may	   encompass	   a	   large	  number	  of	  residues.	  	  The	  sideview	  of	  the	  tetramer	  also	  shows	  areas	  of	  negative	  charge	   (red).	   	   The	  M2-­‐1	   tetramer	   does	   not	   possess	   an	   obvious	   RNA-­‐binding	  cleft	  or	  channel;	   the	  N-­‐	  and	  C-­‐terminal	  surfaces	  are	  relatively	   flat,	  which	  may	  explain	   why	   the	   bacterially-­‐derived	   RNA	   was	   removed	   from	   M2-­‐1	   during	  purification	  with	  relative	  ease.	  	  The	  extensive	  positive	  charge	  of	  the	  tetramer	  is	  also	  consistent	  with	  the	  high	  pI	  of	  M2-­‐1,	  9.1.	  	  Tracts	  of	  negative	  charge,	  in	  red,	  crossed	  over	   the	  C-­‐terminal	   surface	   (figure	  4.14	  B,	   left)	  and	  corresponded	   to	  the	  surface-­‐exposed	  flexible	  loop	  region	  resolved	  in	  the	  WT-­‐P21	  structure.	  	  	  	  
4.2.11 S58DS61D	  	  M2-­‐1	   protein	   is	   phosphorylated	   at	   serines	   58	   and	   61	   in	   the	   context	   of	   viral	  infection.	   	  The	  WT-­‐P21	  M2-­‐1	  crystal	  structure	  revealed	   that	   these	  sites	   lie	  on	  the	  flexible	  loop	  connecting	  the	  tetramerisation	  helix	  to	  the	  core	  domain.	  	  The	  location	  of	  these	  residues	  on	  a	  mobile,	  surface-­‐exposed	  region	  suggested	  they	  might	  be	  involved	  in	  regulating	  the	  conformation	  of	  the	  loop,	  or	  of	  global	  M2-­‐1	  structure.	   	   The	   X-­‐ray	   crystal	   structure	   of	   the	   M2-­‐1	   mutant	   S58DS61D	   was	  solved	  from	  DD-­‐P21	  data,	  by	  molecular	  replacement	  with	  a	  monomer	  from	  the	  WT-­‐P422	   structure	   (see	   4.2.8).	   	   However,	   the	   structure	   of	   this	   mutant	   was	  
Chapter	  4:	  Determining	  the	  X-­‐ray	  crystal	  structure	  of	  M2-­‐1	  
156	  
identical	  to	  WT	  M2-­‐1	  in	  all	  respects	  (figure	  4.14	  right,	  A,	  B	  and	  C),	  except	  for	  the	  increase	  in	  negative	  charge	  at	  residues	  58	  and	  61	  expected	  from	  a	  serine	  to	  aspartate	  mutation	   (figure	   4.14	   B),	   suggesting	   that	   phosphorylation	   at	   these	  sites	   does	   not	   induce	   conformational	   change	   in	   M2-­‐1.	   	   The	   flexible	   loop	  (residues	   52-­‐67)	  was	   poorly	   resolved	   in	   the	  DD-­‐P21	   dataset,	   suggesting	   that	  the	   position	   of	   the	   loop	  was	   not	   stabilised	   by	  mimicking	   phosphorylation	   at	  serines	  58	  and	  61.	  	  	  	  	  
Figure	  4.14	  Surface	  representation	  of	  electrostatic	  potential.	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WT S58DS61D 
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4.2.12 Comparison	  with	  other	  structures	  	  
4.2.12.1 M2-­‐1	  NMR	  structure	  Blondot	   et	   al	   (2012)	   expressed	   truncated	  monomeric	   M2-­‐1	   and	   determined	  the	   solution	   NMR	   structure,	   comprising	   residues	   58-­‐177	   (M2-­‐158-­‐177),	   which	  consequently	   omitted	   the	   N-­‐terminal	   arm	   and	   zinc	   finger	   motif,	   the	  tetramerisation	   helix,	   part	   of	   the	   flexible	   loop	   containing	   phosphorylatable	  residues	   S58	   and	   S61,	   and	   also	   the	   unstructured	   C-­‐terminus	   (Introduction	  figure	  1.9)	  (Blondot	  et	  al.,	  2012,	  Dubosclard	  et	  al.,	  2011).	  	  Superposition	  of	  the	  partial	   NMR	   structure	   with	   the	   full-­‐length	   crystal	   structure	   described	   here	  (figure	  4.15,	  left)	  shows	  highly	  similar	  arrangement	  of	  α-­‐helices	  2	  to	  7	  (rmsd	  of	  1.26	  Å	  over	  the	  93	  residues	  of	  the	  core	  α-­‐helices),	  demonstrating	  that	  the	  core	  domain	   of	   M2-­‐1	   is	   capable	   of	   independently	   folding	   into	   an	   RNA-­‐	   and	   P-­‐binding	  domain	   in	   the	   absence	   of	   the	   tetramerisation	  helix	   or	   the	   omitted	  N	  and	  C-­‐terminal	  regions.	   	  The	  superposition	  also	  shows	  that	  N-­‐terminus	  of	  the	  NMR	  model	  is	  unstructured,	  whereas	  this	  region	  forms	  part	  of	  the	  flexible	  loop	  in	  our	  crystal	  structure	  and	  contains	  some	  helical	  elements.	   	  Surprisingly,	  we	  were	  unable	   to	   use	   the	  NMR	   core	   structure	   as	   a	   search	  model	   for	  molecular	  replacement	  of	  our	  X-­‐ray	  diffraction	  data.	  	  
4.2.12.2 Ebola	  virus	  VP30	  protein	  Functional	   similarities	   have	   been	   drawn	   between	   the	   RSV	  M2-­‐1	   protein	   and	  the	  VP30	  protein	  of	  Ebola	  virus	  (EBOV)	  from	  the	  family	  Filoviridae,	  which	  are	  also	  members	   of	   the	   order	  Mononegavirales.	   	   Both	   are	   Cys3-­‐His1	   zinc	   finger-­‐containing	   polymerase	   co-­‐factors	   essential	   for	   viral	   transcription	   but	  dispensable	   for	   replication,	   and	   both	   are	   functionally	   regulated	   by	   dynamic	  phosphorylation	  at	  conserved	  N-­‐terminal	  sites.	  	  However,	  they	  are	  proposed	  to	  function	  at	  different	  stages	  of	  transcription:	  VP30	  is	  required	  for	  transcription	  initiation,	   a	   role	   that	   has	   been	   discounted	   for	   M2-­‐1	   (Collins	   et	   al.,	   1996),	  whereas	   M2-­‐1	   is	   required	   for	   antitermination,	   promoting	   both	   inter	   and	  intragenic	   polymerase	   processivity.	   	   Additionally,	   VP30	   is	   hexameric	   in	  solution.	   	   Comparison	   between	   the	   VP30	   C-­‐terminal	   domain	   (only	   residues	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142-­‐272	   out	   of	   288	   have	   been	   resolved)	   and	   the	   M2-­‐158-­‐177	   NMR	   structure	  have	  previously	  demonstrated	  similarities	  (Blondot	  et	  al.,	  2012),	  however	  here	  we	  show	  superposition	  of	  EBOV	  VP30	  with	  our	  full-­‐length	  M2-­‐1	  X-­‐ray	  crystal	  structure	  (rmsd	  2.75	  Å	  over	  the	  central	  61	  Cαs),	  which	  allows	  a	  more	  complete	  alignment	  due	  to	  the	  inclusion	  of	  the	  full	  M2-­‐1	  protein	  (figure	  4.15,	  right).	  	  The	  superposition	  shows	  that,	  in	  particular,	  helices	  3,	  6	  and	  7	  align	  well	  with	  M2-­‐1,	  whilst	   there	   are	   minor	   shifts	   in	   orientation	   of	   helices	   4	   and	   5.	   	   Helix	   2	   is	  considerably	  shifted	  in	  VP30,	  however	  this	  may	  align	  better	  with	  M2-­‐1	  in	  the	  presence	  of	  the	  VP30	  N-­‐terminus,	  including	  its	  zinc	  finger	  domain.	   	  VP30	  also	  contains	  an	  additional	  helix	  at	  its	  C-­‐terminus	  that	  has	  no	  homologue	  in	  M2-­‐1.	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Figure	  4.15	  Superposition	  of	  M2-­‐158-­‐177	  NMR	  structure	  and	  EBOV	  VP30	  C-­‐
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4.2.12.3 Tristetraprolin/Nup475	  Comparisons	   between	   the	   non-­‐canonical	   zinc	   finger	  motifs	   of	   RSV	  M2-­‐1	   and	  TTP/Nup475	  have	  been	  made	   in	   several	  previous	  publications,	   based	  on	   the	  assumption	  that	  their	  similar	  sequences	  would	  cause	  them	  to	  coordinate	  zinc	  in	  a	  similar	  manner:	  by	  3	  cysteines	  and	  1	  histidine.	   	  Nup475	  has	  tandem	  Cys-­‐X8-­‐Cys-­‐X5-­‐Cys-­‐X3-­‐His	  type	  zinc	  finger	  motifs,	  and	  M2-­‐1	  has	  a	  single	  Cys-­‐X7-­‐Cys-­‐X5-­‐Cys-­‐X3-­‐His	   type.	   	  Whilst	  no	  structurally	  similar	   folds	  were	   found	  using	   the	  DALI	  server,	  including	  that	  of	  Nup475,	  a	  least-­‐squares	  superposition	  of	  the	  two	  motifs	   reveals	   that	   although	   there	   is	  minimal	   secondary	   structure	   similarity,	  the	  overall	  disk-­‐like	  fold	  of	  the	  zinc	  finger	  is	  very	  similar	  (figure	  4.16).	  	  Nup475	  has	  also	  been	  purified	  as	  a	  tetramer	  (Cao,	  2004),	  and	  the	  short	  helix-­‐turn	  at	  the	  C-­‐terminus	  of	  the	  partial	  NMR	  structure	  may	  indicate	  that	  this	  region	  forms	  a	  longer	   helix	   analogous	   to	   the	   tetramerisation	   helix	   α1	   of	   M2-­‐1,	   in	   the	   full	  length	  Nup475	  protein.	  In	   the	   original	  WT-­‐P422	   data	   phased	   using	   SAD,	   the	  M2-­‐1	   zinc	   finger	  coordinated	   cadmium	   from	   the	   crystallisation	   condition,	   not	   zinc	   as	   in	   the	  other	   two	  datasets.	   	  Cadmium	  has	  no	  known	  physiological	  role	   in	   the	  human	  body,	  and	  its	  presence	  at	  anything	  other	  than	  trace	  concentration	  is	  considered	  toxic.	  	  This	  is	  likely	  due	  to	  the	  established	  ability	  of	  Cd	  ions	  to	  displace	  zinc	  in	  zinc	   finger	   motifs:	   in	   the	   context	   of	   cellular	   transcription	   factors	   such	   as	  Nup475,	  this	  has	  been	  proposed	  to	  interfere	  with	  gene	  expression	  by	  altering	  nucleic	   acid	   binding	   affinity	   (Michalek	   et	   al.,	   2012).	   	  Whilst	  we	   observed	   no	  structural	   difference	   between	   coordinating	   zinc,	   atomic	   radius	   0.74	   Å,	   and	  cadmium,	   0.95	   Å,	   and	   have	   not	   attempted	   to	   investigate	   the	   functional	  implications	   of	   this	   displacement	   here,	   it	   is	   of	   note	   that	   the	   coordination	   of	  cadmium	  by	  zinc	   fingers	  has	  been	  shown	   in	  a	  physiological	  context	   for	  other	  proteins,	  and	  may	  not	  represent	  a	  solely	  artefactual	  event.	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Figure	  4.16	  Superposition	  of	  zinc	  finger	  domains	  from	  M2-­‐1	  and	  Nup475.	  Superposition	   of	   M2-­‐1	   crystal	   structure	   (blue)	   and	   Nup475	   NMR	   structure	  (red)	   was	   by	   a	   least	   squares	   fit	   of	   the	   Cαs	   from	   the	   three	   cysteines	   and	   1	  histidine	  of	  the	  motif.	  	  Both	  proteins	  have	  an	  unstructured	  N-­‐terminus,	  with	  a	  disk-­‐like	   Cys3-­‐His1	   zinc	   finger	   coordinating	   one	   atom	   of	   zinc	   per	   monomer.	  	  The	  Nup475	   structure	   terminates	  before	   a	  possible	  helix	   equivalent	   to	  α1	   in	  M2-­‐1	  at	  the	  C-­‐terminus	  of	  this	  motif.	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4.3 CHAPTER	  SUMMARY	  
This	   chapter	   presents	   the	   crystallisation	   and	   structure	   solution	   of	   RSV	  M2-­‐1	  protein	  –	  the	  first	  X-­‐ray	  crystal	  structure	  of	  M2-­‐1	  from	  any	  pneumovirus.	  	  Wild	  type	   M2-­‐1	   was	   experimentally	   phased	   using	   cadmium	   and	   zinc	   atoms	   to	   a	  maximum	  resolution	  of	  2.52	  Å.	  	  Phosphomimetic	  M2-­‐1,	  S58DS61D,	  was	  solved	  by	   molecular	   replacement	   to	   2.4	   Å.	   	   All	   three	   structures	   determined	   in	   this	  work,	   outlined	   in	   tables	   1	   and	   2,	  were	   the	   same	  with	   the	   exception	   of	   their	  surface	   charge	   distribution	   and	   small	   differences	   in	   side	   chain	   orientation.	  	  During	   this	   project,	   a	   partial	   solution	   NMR	   structure	   of	   M2-­‐1	   core	   domain	  (residues	  58-­‐177)	  was	  published.	   	  The	   full-­‐length	  M2-­‐1	  structure	  we	  present	  here	  is	  largely	  in	  agreement	  with	  the	  NMR	  structure,	  which	  suggests	  the	  core	  is	  able	  to	   independently	   fold	   into	  a	  compact	  domain	  without	   influence	  of	  either	  N-­‐terminal	  or	  C-­‐terminal	  regions.	  	   The	   crystal	   structure	   confirms	   that	   M2-­‐1	   forms	  many	   of	   the	   features	  that	   had	   been	   predicted	   in	   the	   literature,	   such	   as	   a	   zinc	   finger	   motif	  coordinating	   one	   atom	   of	   zinc/cadmium	   per	   monomer,	   an	   oligomerisation	  region,	  and	  a	  globular	  α-­‐helical	  domain.	  	  What	  this	  crystal	  structure	  reveals	  for	  the	  first	  time	  is	  the	  extended	  nature	  of	  the	  M2-­‐1	  monomer,	  with	  the	  zinc	  finger	  projecting	  away	  from	  the	  core	  on	  an	  N-­‐terminal	  arm,	  and	  the	  structural	  basis	  behind	   the	   ‘tight’	   tetramer	   formation	   seen	   in	   solution:	   the	   extensive	  oligomerisation	   interface	   mediated	   by	   the	   four-­‐helix	   bundle	   and	   the	   zinc	  finger,	  which	  contacts	  the	  adjacent	  protomer.	   	  The	  extensive	  contact	  made	  by	  the	   zinc	   finger	   is	   consistent	   with	   the	   essential	   role	   of	   this	   motif	   in	   M2-­‐1	  function,	   and	  suggests	   it	  plays	  an	   important	   role	   in	  preserving	   the	   structural	  integrity	   of	   the	   tetramer.	   	   Other	   virus-­‐encoded	   tetramers	   are	   known	   to	   use	  similar	   four-­‐helix	  bundles	   to	  drive	  oligomerisation,	  with	  prominent	  examples	  being	   the	   influenza	   A	   virus	   M2	   ion	   channel	   and	   the	   P	   protein	   of	   the	  paramyxovirus	  Sendai	  virus.	  	  	  	   This	   is	   only	   the	   second	   structure	   of	   a	   zinc	   finger	   motif	   coordinating	  cadmium	   in	   the	   PDB,	   and	   is	   the	   first	   crystal	   structure:	   	   a	   solution	   NMR	  structure	   of	   the	   ‘classic’	   Cys₂-­‐His₂	   zinc	   finger	   from	   Arabidopsis	   thaliana	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SUPERMAN	  protein,	  shows	  a	  conformational	  change	  when	  zinc	  is	  displaced	  by	  cadmium	  (Malgieri	  et	  al.,	  2011).	   	  We	  saw	  no	  such	  change	  in	  our	  M2-­‐1	  crystal	  structures,	   however	   the	   two	   zinc	   fingers	   are	   from	   different	   classes	   and	  may	  respond	  differently	  to	  alternative	  cations.	  	  Equally,	  it	  may	  be	  that	  outside	  of	  the	  physical	  constraints	  that	  crystallisation	  can	  impose,	  the	  M2-­‐1	  zinc	  finger	  motif	  may	   also	   undergo	   a	   conformational	   change	  when	   coordinating	   cadmium.	   	   In	  either	   case,	   the	   structure	   presented	   here	   provides	   new	   and	   interesting	  information	  to	  the	  growing	  field	  of	  zinc	  finger-­‐mediated	  cadmium	  toxicity.	  	  The	   tight	   tetramer	   formation	   displayed	   in	   our	   structure	   suggests	   that	  M2-­‐1	  is	  not	  capable	  of	  forming	  alternative	  higher	  order	  oligomers,	  and	  this	  is	  consistent	  with	  our	  observation	  that	  no	  higher	  order	  species	  can	  be	  detected	  in	  solution	  by	  either	  gel	  filtration	  or	  mass	  spectrometry.	  	  M2-­‐1	  has	  recently	  been	  proposed	   to	   perform	   a	   role	   in	   virion	   assembly,	   forming	   a	   matrix-­‐like	   layer	  surrounding	   the	   RNP	   within	   the	   mature	   virus	   particle	   (Liljeroos,	   2013).	  	  However,	   our	   results	   are	   not	   consistent	   with	   this	   role,	   as	   M2-­‐1	   does	   not	  possess	   the	   necessary	   architecture	   needed	   to	   generate	   a	   large	   two-­‐dimensional	  planar	  lattice.	   	  Also	  inconsistent	  with	  a	  role	  for	  M2-­‐1	  as	  a	  matrix	  layer,	   is	   its	   relatively	   low	   abundance	   within	   purified	   virus	   particles	  (Radhakrishnan	   et	   al,	   2010),	   which	   suggests	   it	   is	   a	  minor	   component	   of	   the	  virion.	  	  However,	  we	  cannot	  rule	  out	  the	  possibility	  that	  alternative	  oligomeric	  forms	   of	  M2-­‐1	   exist	   in	   the	   context	   of	   viral	   infection,	   with	   radically	   different	  functions	   as	   has	   recently	   been	   shown	   for	   the	   Ebola	   VP40	   matrix	   protein	  (Bornholdt	  et	  al,	  2013).	  	   The	   electrostatic	   surface	   potential	   of	   the	   M2-­‐1	   tetramer	   allows	  speculation	   over	   regions	   involved	   in	   RNA	   binding,	   a	   known	   function	   of	   this	  protein.	  	  Extensive,	  continuous,	  positively	  charged	  regions	  cover	  all	  three	  faces	  of	  the	  structure.	  	  The	  lack	  of	  an	  apparent	  RNA-­‐binding	  cleft	  supports	  the	  theory	  that	   RNA	   binding	   by	  M2-­‐1	   is	   electrostatically,	   not	   sequence,	   driven	   and	   that	  this	  is	  reflected	  in	  a	  lack	  of	  sequence	  specificity.	  	   The	  X-­‐ray	  crystal	  structure	  of	  a	   phosphomimetic	   M2-­‐1	   mutant	   did	   not	   reveal	   a	   global,	   or	   local,	  conformational	  change	  in	  response	  to	  increased	  negative	  charge	  at	  serines	  58	  and	   61,	   although	   the	   poorly	   defined	   electron	   density	   for	   the	   flexible	   loop	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means	   we	   cannot	   rule	   out	   a	   shift	   in	   equilibrium	   between	   multiple	  conformations	  of	  this	  region.	  	  The	  discovery	  that	  negatively	  charged	  phospho-­‐serines	  58	  and	  61	  reside	  on	  a	  flexible	  loop	  that	  lies	  over	  the	  positively	  charged	  surface	   of	   the	   C-­‐terminal	   face,	   suggests	   that	   regulation	   of	   binding	   (RNA	   or	  otherwise)	  to	  this	  surface	  could	  be	  regulated	  by	  disrupting	  the	  positive	  charge	  with	   phosphorylation	   at	   these	   sites.	   	   Both	   the	   concept	   of	   RNA-­‐binding	  specificity,	  and	  the	  role	  phosphorylation	  might	  play	  in	  this,	  are	  investigated	  in	  Chapter	  5	  of	  this	  thesis.	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5 CHAPTER	  5:	  UNDERSTANDING	  M2-­‐1	  RNA	  BINDING	  AND	  THE	  ROLE	  
OF	  PHOSPHORYLATION	  	  
	  
5.1 CHAPTER	  INTRODUCTION	  
RSV	  M2-­‐1	  was	   first	  described	  as	  an	  RNA-­‐binding	  protein	  after	  a	   reduction	   in	  electrophoretic	  mobility	  upon	  addition	  of	  RNA	  was	  observed	  in	  gel-­‐retardation	  assays	  (Cuesta	  et	  al.,	  2000),	  and	  after	  the	  coimmunoprecipitation	  of	  a	  diffusely	  migrating	   RNase	   A-­‐sensitive	   species	   at	   the	   top	   of	   gels	   analysing	   inorganic	  [33P]phosphate-­‐labelled	  M2-­‐1	  (Cartee	  and	  Wertz,	  2001).	  	  The	  specificity	  of	  this	  RNA	   binding,	   and	   its	   relevance	   to	   the	   RSV	   lifecycle,	   has	   been	   continually	  debated	  since	  these	  original	  publications:	  	  M2-­‐1	  has	  been	  proposed	  to	  bind	  to	  long	   RNAs	   (>700	   nts)	   with	   no	   sequence	   specificity,	   short	   RNAs	   (<80	   nts)	  containing	  the	  antigenomic	  leader	  sequence,	  RSV-­‐specific	  mRNAs,	  A-­‐rich	  RNAs,	  and	  with	  no	  sequence	  specificity	  at	  all.	  	  Each	  of	  these	  suggestions	  carries	  with	  it	   implications	  for	  the	  RNA	  species	  targeted	  and	  thus	  the	  mechanism	  of	  M2-­‐1	  antitermination	   activity,	   e.g.	   association	   with	   the	   genome	   vs.	   mRNA.	   	   This	  chapter	   presents	   the	   interrogation	   of	   M2-­‐1	   RNA-­‐binding	   specificity,	   and	   the	  residues	   of	   the	   protein	   that	   are	   involved,	   using	   a	   fluorescence	   polarisation	  anisotropy	  (FPA)	  assay	  and	  a	  range	  of	  both	  RNAs	  and	  mutant	  M2-­‐1	  proteins.	  	  	  	   The	  principle	  of	  FPA	  is	  that	  when	  a	  fluorescently	  labelled	  molecule	  (e.g.	  RNA)	  is	  excited	  by	  polarised	  light,	  the	  fluorophore	  emits	  light	  with	  a	  degree	  of	  polarisation	  that	  is	  inversely	  proportional	  to	  the	  ‘tumbling	  rate’	  of	  the	  labelled	  molecule.	   	  For	  example,	  a	  small	   labelled	  RNA	  has	  a	  high	  tumbling	  rate	  due	  to	  rapid	  Brownian	  motion	   in	   solution,	  which	  will	   result	   in	  depolarisation	  of	   the	  emitted	   light	  as	   the	   fluorophore	  reorients	  during	  the	   lifetime	  of	   its	  excitation	  (~4	  nanoseconds	  for	  fluorescein,	  used	  here);	  if	  the	  small	  labelled	  RNA	  is	  bound	  to	  a	   larger	  protein	  molecule,	   this	   complex	  will	  have	  a	   slower	  rate	  of	   rotation	  and	  the	  emitted	  light	  will	  still	  be	  polarised	  to	  an	  extent	  (figure	  5.1).	  	  Binding	  of	  M2-­‐1	  to	  a	  range	  of	  3’-­‐fluorescein-­‐labelled	  RNAs	  was	  assessed	  in	  this	  way,	  with	  higher	  polarisation	  values	  indicating	  binding.	  




Figure	  5.1	  Fluorescence	  polarisation	  anisotropy.	  (Top)	  Small	  3’-­‐fluorescently-­‐tagged	  RNAs	  have	  quick	  rotation,	  or	  tumbling,	   in	  solution	   and	   so	   emitted	   fluorescence	   is	   depolarised	   by	   the	   rapid	   motion.	  	  (Bottom)	  Binding	  of	  a	   larger	  protein	  (e.g.	  M2-­‐1)	  to	  the	  RNA	  slows	  the	  rate	  of	  tumbling,	  and	  so	  emitted	  fluorescence	  is	  depolarised	  less	  i.e.	  it	  maintains	  more	  polarisation.	  	  	   	  This	  chapter	  also	  investigates	  the	  effect	  of	  M2-­‐1	  phosphorylation	  on	  its	  RNA-­‐binding	   ability.	   	   Whilst	   data	   suggests	   that	   ablation	   of	   M2-­‐1	  phosphorylation	   reduces	   its	   transcription	   antitermination	   efficiency	   in	   the	  context	  of	  the	  established	  minigenome	  system	  (Cartee	  and	  Wertz,	  2001),	  there	  is	   little	   concrete	   evidence	   for	   phosphorylation	   having	   either	   a	   positive	   or	  negative	  effect	  on	  M2-­‐1	  RNA	  binding:	  Cartee	  et	  al	   found	   that	  mutating	  either	  serine	  58	  or	  61	  to	  alanine	  had	  no	  effect	  on	  coimmunoprecipitation	  of	  RNA	  from	  mammalian	   tissue	  culture;	  Cuesta	  et	  al	   suggest	   that	  phosphorylation	  reduces	  the	  RNA-­‐binding	  capacity	  of	  M2-­‐1,	  however	  they	  present	  no	  primary	  data	  and	  incorrectly	  reported	  the	  phosphorylation	  sites	  as	  threonine	  56	  and	  serine	  58	  	  (Cuesta	  et	  al.,	  2000);	  Tran	  et	  al	  saw	  no	  effect	  on	  binding	  of	  yeast	  tRNA	  to	  M2-­‐1	  protein	  that	  had	  been	  in	  vitro	  phosphorylated	  whilst	  GST-­‐tagged	  and	  bound	  to	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glutathione	  sepharose	  (Tran	  et	  al.,	  2009).	   	  These	  publications	  either	   focus	  on	  ablation	  of	  phosphorylation,	  or	  use	  techniques	  that	  are	  poorly	  representative	  of	   M2-­‐1	   in	   the	   virus	   life	   cycle.	   	   Here,	   we	   demonstrate	   that	   mimicking	  phosphorylation	   reduces	   the	   RNA-­‐binding	   affinity	   of	   M2-­‐1	   for	  multiple	   RNA	  sequences,	  and	  discuss	  how	  this	   links	   to	   the	   location	  of	  serines	  58	  and	  61	  as	  revealed	   by	   our	   X-­‐ray	   crystal	   structure	   in	   Chapter	   4.	   	   This	   chapter	   also	  summarises	   data	   produced	   by	   our	   collaborators	   in	   Jean-­‐François	   Eléouët’s	  group	   for	   the	   publication	   “Crystal	   structure	   of	   the	   essential	   M2-­‐1	  antiterminator	   of	   HRSV	   and	   consequences	   of	   dynamic	   phosphorylation”	   –	  under	   review,	   where	   it	   was	   shown	   that	   both	   mimicking	   and	   ablating	  phosphorylation	  of	  M2-­‐1	  in	  the	  minigenome	  system	  has	  a	  deleterious	  effect	  on	  M2-­‐1-­‐dependent	  expression.	  	  	  	  	  	  	  	  	  	  
5.2 RESULTS	  
5.2.1 Confirmation	  of	  M2-­‐1	  RNA	  binding	  
To	  confirm	  that	  bacterially-­‐expressed,	  RNA-­‐free	  M2-­‐1	  produced	  as	  in	  Chapter	  3	  was	  capable	  of	  binding	  synthetic	  RNAs,	  10	  µM	  M2-­‐1	  protein	  was	   incubated	  with	  10	  µM	  leader	  RNA	  [a	  3’-­‐fluorescein	  44	  nucleotide	  RNA	  representing	  the	  3’	  genomic	   leader	  sequence,	   see	  Appendix	   II]	  and	  analysed	  by	  nanoESI	   time-­‐of-­‐flight	   mass	   spectrometry.	   	   Figure	   5.2	   shows	   a	   comparison	   of	   a	   protein-­‐only	  spectrum	   (top)	   with	   that	   of	   the	   M2-­‐1	   tetramer	   bound	   to	   RNA	   (bottom),	  demonstrating	  an	  increase	  in	  mass:charge	  ratio	  (m/z)	  that	  suggests	  M2-­‐1	  was	  bound	  to	  2	  RNAs	  (44mer	  RNA	  ~14,960	  Da).	   	  M2-­‐1	  protein	  was	  not	  observed	  binding	   to	   any	   other	   number	   of	   RNAs	   in	   these	   analyses,	   although	   a	   small	  amount	   of	   an	   undecipherable	   higher-­‐order	   species	   (m/z	   >8000)	   was	   seen	  (data	   not	   shown)	   which	   could	   be	   RNA-­‐mediated	   aggregation.	   	   A	   low	  signal:noise	   ratio,	   shown	   by	   the	   low	  m/z	   background	   peaks	   and	   the	   poorly	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Figure	  5.2	  Mass	  spectrometric	  analysis	  of	  M2-­‐1	  RNA	  binding.	  	  	  NanoESI-­‐TOF	   MS	   was	   used	   to	   confirm	   that	   bacterially-­‐expressed,	   RNA-­‐free	  M2-­‐1	  was	  capable	  of	  binding	  3’-­‐fluorescein-­‐tagged	  synthetic	  RNAs.	  	  Top,	  M2-­‐1	  only	   spectrum	   shows	   an	  RNA-­‐free	  M2-­‐1	   tetramer;	   peaks	  with	  19,	   20	   and	  21	  charges	  are	   labelled	  and	  give	  a	  mass	  of	  90,538.80	  Da.	   	  Bottom,	  M2-­‐1	  +	  RNA	  spectrum	  shows	  an	  RNA-­‐bound	  tetramer	  with	  a	  mass	  of	  120,210.99	  Da;	  44mer	  RNA	   ~14,960	   Da,	   therefore	   this	   species	   is	   M2-­‐1	   bound	   to	   2	   RNAs.	   	   Poor	  signal:noise	   is	   evidenced	   by	   background	   peaks	   at	   the	   low	   m/z	   end	   of	   the	  spectrum	  and	  broad	  peaks	  of	  interest.	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Figure	  5.3	  RNA	  binding	  of	  Bunyamwera	  nucleocapsid	  protein.	  	  	  A	  typical	  binding	  isotherm	  for	  BUNV	  N	  protein,	  used	  as	  a	  known	  RNA-­‐binder	  to	  establish	   the	   FPA	   assay.	   Full	   details	   of	   this	  work	   are	   outlined	   in	   Ariza	   et	   al.	  2013.	  	  	  
5.2.2 Assay	  development	  
A	   fluorescence	   polarisation	   anisotropy	   assay	  was	   developed	   in	   96-­‐	   and	   384-­‐well	   plate	   format	   for	   determining	   RNA	   binding	   affinity	   of	   M2-­‐1	   to	   various	  sequences.	   	   To	   establish	   the	   technique,	   a	   known	   RNA-­‐binder	   from	   previous	  work	  in	  our	  group,	  the	  nucleocapsid	  protein	  (N)	  of	  Bunyamwera	  virus	  (BUNV),	  was	  used	  with	   its	  cognate	  RNA	  [a	  3’Fl	  48	  nucleotide	  RNA	  representing	  the	  5’	  terminus	  of	  the	  BUNV	  S	  segment	  antigenome]	  (Ariza	  et	  al.,	  2013).	   	  Binding	  of	  BUNV	  N	  protein	  was	  achieved	  using	  the	  method	  outlined	  in	  Methods	  2.2.14.3	  (figure	  5.3,	  above)	  and	  so	  this	  method	  was	  applied	  to	  M2-­‐1	  protein.	  	  3’-­‐Fl	  RNA	  had	  low	  intrinsic	  polarisation	  in	  the	  absence	  of	  M2-­‐1	  protein,	  and	  a	  titration	  of	  M2-­‐1	  with	  no	  RNA	  showed	  a	  consistent	  level	  of	  polarisation	  equivalent	  to	  that	  of	  buffer	  only	   controls.	   	   For	   initial	  M2-­‐1	  RNA	  binding	   tests,	  plates	  were	   read	  after	   equilibrating	   at	   room	   temperature	   for	   30	   minutes,	   and	   then	   again	   the	  
Chapter	  5:	  Understanding	  M2-­‐1	  RNA	  binding	  and	  the	  role	  of	  phosphorylation	  
171	  
following	   day.	   	   Values	   at	   both	   timepoints	   were	   the	   same,	   and	   so	  M2-­‐1-­‐RNA	  interactions	  were	  deemed	  to	  have	  equilibrated	  after	  30	  minutes.	  	   	  
5.2.3 Assessing	  sequence	  specificity	  of	  RNA	  binding	  	  
5.2.3.1 Longer	  RNAs	  (44	  nucleotides)	  The	   44mer	   leader	   RNA,	   used	   in	   the	   mass	   spectrometric	   analysis	   described	  above,	   was	   tested	   for	   binding	   to	  M2-­‐1	   in	   the	   FPA	   assay	   in	   addition	   to	   a	   44	  nucleotide	   RNA	   representing	   the	  M/SH	   gene	   junction,	   including	  M	   gene	   end	  and	  SH	  gene	  start	  sequences	  (see	  Appendix	  II).	   	  Neither	  of	  these	  RNAs	  bound	  to	  M2-­‐1	   in	  this	  assay,	  possibly	  due	  to	  the	  aggregation	  effect	  suggested	  by	  the	  mass	   spectrometry,	   or	   due	   to	   the	   ‘propeller	   effect’	  where	   the	   rotation	  of	   the	  fluorophore	  and	  the	  rotation	  of	   the	  RNA-­‐protein	  complex	  become	  uncoupled,	  as	  a	  considerable	  proportion	  of	  the	  RNA	  is	  not	  in	  contact	  with	  the	  protein.	  	  	  
5.2.3.2 Shorter	  RNAs	  ≤13	  nucleotides	  A	   panel	   of	   short	   RNAs,	   13	   nucleotides	   or	   less,	   were	   selected	   to	   analyse	   the	  specificity	  of	  M2-­‐1	  RNA	  binding	   in	   light	  of	  our	   results	  with	   the	  44mer	  RNAs.	  	  These	   included	  cis-­‐acting	  signals	   from	  the	  RSV	  genome,	  sequences	  present	   in	  RSV	  mRNAs,	  polyG,	  A,	  U	  or	  C	  homo-­‐oligomeric	  sequences,	  and	  other	  non-­‐viral	  RNAs	   of	   unrelated	   sequence,	   all	   of	   which	   were	   tagged	   at	   their	   3’	   ends	   with	  fluorescein	  (Fl)	   (see	   figure	  5.5	  A	   for	  sequences).	   	  Figure	  5.4	  A	  shows	  binding	  isotherms	  typical	  of	   the	  data	  collected	  and	  represents	   the	  highest	  and	   lowest	  affinity	  RNAs	  tested	  here.	  	  All	  data	  were	  fitted	  using	  logistic	  regression	  to	  an	  R-­‐square	   value	   >	   0.98	  with	  Hill	   coefficients	   in	   the	   range	   of	   0.5-­‐0.9,	  which	  may	  suggest	  some	  negative	  cooperativity	  of	  RNA	  binding,	  however	  further	  analysis	  of	  this	  was	  beyond	  the	  scope	  of	  this	  thesis.	  Of	   the	   four	   homo-­‐oligomeric	   RNAs,	   polyA	   RNA	   was	   bound	   with	   the	  highest	   affinity	   (figure	   5.4	   B).	   Binding	   of	   polyU	   and	   C	   RNAs	   could	   not	   be	  saturated	  at	  available	  protein	  concentrations	  and	  consequently	  data	  could	  not	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be	   accurately	   fitted;	   suggested	   Kds	   of	   >	   1	  mM	   are	   based	   on	   an	   extrapolated	  estimate	   of	   the	  100	  %	  RNA	  bound	  protein	   concentration.	   	   In	   contrast,	   polyG	  RNA	  showed	  no	  binding	  to	  M2-­‐1	  (data	  not	  shown),	  whereas	  a	  polyU	  RNA	  with	  an	   inserted	   single	   G	   nucleotide,	   ‘g8mer’,	   showed	   significantly	   higher	   binding	  affinity	  than	  the	  unmodified	  polyU.	  We	   next	   wanted	   to	   examine	  M2-­‐1	   binding	   to	   RSV-­‐specific	   sequences.	  	  M2-­‐1	  possesses	  transcription	  antitermination	  activity	  at	  gene	  ends,	  and	  as	  the	  termination	  event	   is	  signalled	  by	  the	  conserved	  gene	  ends	  alone,	  we	  chose	  to	  focus	   our	   analysis	   on	   the	   binding	   of	  M2-­‐1	   to	  RNAs	   bearing	   these	   sequences.	  	  Two	  gene	  end	  signals	  were	  selected,	  SH	  and	  F,	  and	  corresponding	  genome	  and	  mRNA	  sense	  oligonucleotides	  representing	  these	  sequences	  were	  synthesized	  and	  tested	  in	  binding	  assays.	  	  For	  both	  gene	  ends,	  significantly	  higher	  binding	  affinities	  were	  recorded	  for	  the	  mRNA	  sense	  RNAs	  (figure	  5.5	  B)	  compared	  to	  their	  genomic	  sense	  reverse	  complement,	  consistent	  with	  a	  preference	   for	  A-­‐rich	  sequences.	   	  Although	  this	   is	  difficult	   to	  see	   in	   the	  bar	  chart	  of	   figure	  5.5,	  the	   table	   in	   5.5	   B	   presents	   the	   statistical	   analysis	   that	   confirmed	   this	  significance.	  	  In	  addition,	  we	  observed	  a	  higher	  binding	  affinity	  for	  SH	  than	  for	  F	   gene	   end	   sequences,	   in	   both	   senses,	   despite	   their	   similarity	   in	   ‘A’	   content	  (figure	  5.5	  B).	  	  One	  possible	  explanation	  is	  that	  M2-­‐1	  not	  only	  has	  a	  preference	  for	   A-­‐rich	   sequences,	   but	   that	   the	   spacing	   of	   adenosine	   nucleotides	   is	  important:	  the	  genomic	  sense	  A-­‐rich	  region	  of	  the	  gene	  ends	  for	  F	  (3’-­‐AAUAUA-­‐5’)	  and	  SH	  (3’-­‐AAUUAA-­‐5’)	  vary	  in	  their	  arrangement,	  but	  not	  their	  ‘A’	  content.	  Following	  on	  from	  this	  finding,	  we	  examined	  the	  binding	  of	  M2-­‐1	  to	  the	  conserved	   RSV	   gene	   start	   sequence	   responsible	   for	   transcription	   initiation.	  	  This	   sequence	   in	   genome	   sense	   is	   highly	   pyrimidine	   rich,	   possessing	   only	   a	  single	  A-­‐residue	   in	   its	  entire	   length,	   and	   the	  binding	  affinity	  of	   this	  RNA	  was	  the	   lowest	   of	   any	   RSV-­‐specific	   RNAs	   tested	   (figure	   5.5	   A).	   	   Other	   non-­‐viral	  RNAs	   tested	   included	  oligonucleotides	   control	  1	  and	  control	  2	   (figure	  5.5	  A),	  both	  of	  which	  are	  low	  in	  ‘A’	  nucleotide	  content,	  and	  exhibited	  correspondingly	  low	  binding	  affinities.	  All	   sequence	   analysis	   of	   RNA	   binding	   presented	   in	   this	   chapter	   is	  summarised	   in	   figure	   5.5	   A.	   	   Taken	   together,	   these	   data	   indicate	   that	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Figure	  5.4	  RNA	  binding	  isotherms	  for	  various	  sequences.	  	  	  
























T-Test P-value,  
F vs. SH 
F (genome) 
UCAAUAUAUUUUG 1.68 ±0.03 0.000787 genome	  =	  0.000476	  




CAAAAUAUAUUGA 0.86 ±0.04 
SH (genome) 
UCAAUUAAUUUUU 0.92 ±0.04 0.000829	  
 SH (mRNA) 
AAAAAUUAAUUGA 0.48 ±0.02 
	  
	  
Figure	  5.5	  Sequence	  specificity	  of	  M2-­‐1	  RNA	  binding.	  	  
A)	  Chart	  of	  Kds	  for	  all	  RNAs	  tested	  and	  a	  table	  of	  their	  sequences.	  Genome	  and	  mRNA	  labels	  indicate	  the	  sense	  of	  the	  RNA	  in	  the	  context	  of	  viral	  life	  cycle.	  GS,	  gene	   start.	  B)	   Table	   comparing	   affinities	   for	   SH	   and	   F	   gene	   end	   sequence	   in	  both	   mRNA	   and	   genome	   sense.	   	   Unpaired,	   2-­‐tailed	   Student’s	   T-­‐tests	   were	  performed	   for	   mRNA	   vs	   genome	   sequences,	   and	   for	   F	   vs.	   SH	   gene	   end	  sequences.	  	  All	  p-­‐values	  were	  significant	  to	  p	  <	  0.01.	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5.2.4 Residues	  involved	  in	  RNA	  binding	  	  To	  examine	  the	  contribution	  of	  specific	  M2-­‐1	  residues	  towards	  RNA	  binding,	  a	  panel	   of	   M2-­‐1	   mutants	   was	   created	   using	   site	   directed	   mutagenesis	   (see	  Appendix	  I	  for	  primer	  sequences),	  and	  expressed	  as	  full	  length	  tetrameric	  GST-­‐M2-­‐1	   in	   bacterial	   cells.	   	   Mutants	   were	   expressed,	   purified	   and	   cleaved	   from	  GST	  as	  per	  WT	  M2-­‐1,	  although	  size	  exclusion	  chromatography	  (SEC)	  was	  not	  used	   to	  allow	   for	  higher	   throughput:	  binding	  of	  pre-­‐	   and	  post-­‐SEC	  M2-­‐1	  was	  found	   to	  be	   comparable,	   however	  all	   affinities	  presented	  here	  are	   relative	   to	  WT	  produced	  in	  parallel,	  in	  the	  same	  manner	  as	  the	  mutants.	  	  	  Single	  and	  double	  mutants	  were	  selected	  based	  on	  the	  full-­‐length	  M2-­‐1	  tetramer	  electrostatic	  surface	  model	  (Chapter	  4,	  figure	  4.14)	  and	  consideration	  of	   previously	   examined	   M2-­‐1	   residues	   within	   the	   monomer	   core	   region	  (Blondot	   et	   al,	   2012).	   	  Residues	  directly	   contributing	   to	   the	   zinc	   finger	  motif	  were	  not	  selected	  as	  these	  mutants	  have	  been	  shown	  to	  misfold	  and	  aggregate	  (Jean-­‐François	   Eléouët,	   personal	   communication).	   	   The	   positively	   charged	  residues	  selected	   for	  alteration	  were	   located	   in	  both	   the	  core	  and	  N-­‐terminal	  regions,	  and	  were	  mutated	  to	  either	  alanine	  (to	  negate	  charge)	  or	  aspartate	  (to	  reverse	  the	  charge).	  	  Figure	  5.6	  A	  shows	  a	  surface	  representation	  of	  M2-­‐1	  with	  all	   mutants	   tested	   in	   the	   FPA	   assay	   highlighted	   in	   yellow	   on	   one	   monomer	  (dark	  grey).	  	  	  Mutants	  were	   tested	   for	   their	  binding	   to	  our	  highest	  affinity	  sequence	  described	  above,	  the	  SH	  mRNA	  sense	  gene	  end.	  The	  data	  were	  expressed	  as	  the	  fold	  change	  in	  Kd	  relative	  to	  WT	  (figure	  5.6	  B),	  and	  asterisks	  indicate	  statistical	  significance.	   	   Of	   the	   panel	   of	   mutants	   tested,	   only	   K19AR20A	   exhibited	  essentially	  unchanged	  RNA	  binding	  affinity.	   	  All	  others	   resulted	   in	   significant	  loss	   of	   RNA	   binding	   affinity,	   including	   K92A,	   K92D,	   K150A,	   R150D,	   R151D,	  K150AR151A	  and	  K159A.	  	  These	   findings	   confirm	   Blondot	   et	   al	   (2012),	   which	   found	   that,	  qualitatively,	  K92,	  K150	  and	  R151	  were	  the	  residues	  essential	  for	  the	  binding	  of	   GST-­‐M2-­‐158-­‐177	   to	   yeast	   tRNA.	   	   Our	   structure	   revealed	   that	   N-­‐terminal	  arginine	   residues	   R3	   and	   R4	   also	   contributed	   to	   the	   positively	   charged	   N-­‐
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terminal	   face,	   and	   FPA	   analysis	   of	   the	   R3AR4A	   double	   mutant	   shows	   these	  residues	  also	  significantly	   influence	  RNA	  binding,	   implying	  the	  M2-­‐1	  residues	  that	   participate	   in	   RNA	   binding	   are	   not	   solely	   confined	   to	   the	   main	   basic	  cluster	   of	   the	   core.	   	   We	   saw	   no	   significant	   difference	   between	   mutating	  selected	   positively	   charged	   residues	   to	   alanine	   (uncharged)	   or	   aspartate	  (negatively	   charged),	   unlike	   in	   previous	   studies	   where	   introducing	   negative	  charge	   increased	   the	   loss	   of	   RNA	   binding	   affinity	   relative	   to	   neutralising	  positive	  charge	  (Blondot	  et	  al.,	  2012).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  




Figure	  5.6	  Identification	  of	  M2-­‐1	  residues	  involved	  in	  RNA	  binding.	  	  	  
A)	  A	  tilted	  side	  view	  surface	  representation	  of	  M2-­‐1	  tetramer	  highlighting	  all	  residues	   tested	   in	   the	  FPA	  RNA	  binding	  assay,	   including	   the	  phosphomimetic	  mutations	  described	  below.	  	  B)	  Bar	  chart	  comparing	  the	  binding	  affinity	  of	  M2-­‐1	   mutants,	   which	   is	   expressed	   as	   the	   fold	   change	   in	   Kd	   relative	   to	   WT.	  	  Asterisks	  indicate	  statistical	  significance,	  where	  p	  <	  0.01	  with	  an	  unpaired,	  2-­‐tailed	  Student’s	  T-­‐test.	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5.2.5 Phosphorylation	  and	  RNA	  binding	  	  Figure	  5.6	  A	  also	  highlights	  the	  phosphomimetic	  mutant,	  S58DS61D,	  that	  was	  crystallised	  and	  the	  structure	  solved	  in	  Chapter	  4.	  	  The	  location	  of	  S58	  and	  S61	  adjacent	   to	   the	   positively	   charged	   surface	   of	   the	   C-­‐terminal	   core,	   raised	   the	  possibility	   that	   increased	   negative	   charge	  would	   reduce	   RNA	   binding	   due	   to	  electrostatic	   repulsion	   of	   the	   RNA	   phosphate	   backbone.	   	   The	   role	   of	  phosphorylation	   in	   M2-­‐1	   RNA	   binding	   was	   investigated	   by	   comparing	   the	  binding	   of	   this	   mutant	   and	   WT	   M2-­‐1	   (unphosphorylated	   in	   this	   system)	   to	  various	  RNA	  sequences	  in	  the	  FPA	  assay.	  Analysis	   of	   this	   mutant	   with	   the	   SH	   mRNA	   sense	   gene	   end	   RNA,	  revealed	   a	   significantly	   reduced	   RNA	   binding	   ability	   compared	   to	   the	  unphosphorylated	  WT	  M2-­‐1	  (figure	  5.7	  A),	  confirming	  that	  the	  altered	  negative	  charge	  density	  conferred	  by	  mimicking	  phosphorylation	  significantly	  affected	  the	  ability	  of	  S58DS61D	  to	  bind	  RNA.	  	  We	  also	  tested	  the	  RNA	  binding	  ability	  of	  this	   mutant	   with	   other	   RNAs	   of	   differing	   lengths	   and	   nucleotide	   sequences.	  These	   results	   showed	   that	   phosphomimetic	   mutant	   S58DS61D	   consistently	  demonstrated	   a	   statistically	   significant	   reduction	   in	   affinity	   of	   approximately	  2-­‐fold	   across	   all	   RNAs	   tested	   (figure	   5.7	   B).	   	   This	   finding	   supports	   the	  conclusion	   that	   the	  negative	   charge	  density	  at	   residues	  58	  and	  61	   influences	  the	   ability	   of	  M2-­‐1	   to	   bind	   RNA,	   and	   suggests	   that	   phosphorylation	   of	  M2-­‐1	  during	   RSV	   infection	  would	   similarly	   reduce	   binding	   affinity	   to	   target	   RNAs,	  which	  may	  consequently	  affect	  its	  processivity	  function.	  	  	  	  	  	  	  	  	  	  







Figure	   5.7	   RNA	   binding	   affinity	   of	   the	   phosphomimetic	   mutant	  
S58DS61D.	  	  	  
A)	  Comparison	  of	  the	  affinity	  of	  S58DS61D	  for	  SH	  gene	  end	  (mRNA)	  relative	  to	  WT.	  	  B)	  Binding	  of	  S58DS61D	  to	  a	  number	  of	  RNA	  sequences,	  tested	  with	  WT	  M2-­‐1	  in	  section	  5.2.3.2.	  	  The	  Kds	  for	  WT	  and	  S58DS61D	  are	  compared	  here.	  	  P-­‐values	   (asterisk	   in	  A)	  are	   from	  unpaired,	   two-­‐tailed	  Student’s	  T-­‐tests,	   and	  all	  indicate	  statistical	  significance,	  where	  p	  <	  0.01.	  	  	  
RNA (Fl-3’-5’) WT Kd (µM) S58DS61D Kd (µM) T-Test P-value,  
WT vs. S58DS61D 
polyA 
AAAAAAAA 
3.38 ±0.1 10.95 ±0.2 0.0000009 
GS (genome)  
CCCCGUUUAU 
12.59 ±0.7 28.59 ±0.9 0.0033492 
control 1 
AAUAGAUGUUC 
7.29 ±0.3 14.47 ±0.8 0.0000245 
SH (mRNA) 
AAAAAUUAAUUGA 
0.48 ±0.02 0.776 ±0.02 0.0096107 
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5.2.6 M2-­‐1	  antitermination	  in	  minigenome	  system	  	  To	   analyse	   the	   effect	   of	   both	   RNA	   binding	  mutants	   and	   phosphorylation	   on	  transcriptional	   antitermination	   activity	   of	   M2-­‐1,	   the	   phenotypes	   of	   our	  mutants	  were	  assessed	  in	  the	  context	  of	  the	  well-­‐established	  RSV	  minigenome	  system	  (Yu	  et	  al.,	  1995,	  Hardy	  and	  Wertz,	  1998).	  	  This	  work	  was	  performed	  by	  our	   collaborators	   in	   Jean-­‐François	   Eléouët’s	   group	   (Institut	   National	   de	   la	  Recherche	  Agronomique,	   Jouy-­‐en-­‐Josas,	  France),	  as	   featured	  in	  their	  previous	  M2-­‐1	  publications	  (Tran	  et	  al.,	  2009,	  Blondot	  et	  al.,	  2012).	  	  Briefly,	  this	  reverse	  genetics	   system	   requires	   T7	   RNA	   polymerase-­‐expressing	   mammalian	   cells,	  either	  by	  recombinant	  vaccinia	   infection	  or	  by	  using	  the	  stable	  cell	   line,	  BSR-­‐T7/5.	   	   These	   are	   co-­‐transfected	   with	   a	   truncated	   substitute	   genome	  (containing	  two	  transcriptional	  units	  separated	  by	  a	  native	  gene	  junction,	  and	  flanked	   by	   the	   leader	   and	   trailer	   regions	   required	   for	   replication	   and	  transcription)	   and	   the	   support	   plasmids	   encoding	   the	   N,	   P,	   L	   and	   M2-­‐1	  proteins	  under	  T7	  promoter	  control	  –	  the	  four	  proteins	  that	  are	  necessary	  and	  sufficient	  for	  transcription	  and	  replication	  of	  the	  minigenome.	  	  	  For	   this	  work,	   the	  downstream	  transcriptional	  unit	  was	  replaced	  with	  the	   firefly	   luciferase	   gene	   (Tran	   et	   al.,	   2009),	   the	   expression	   of	   which	   is	  absolutely	   dependent	   on	   functional	   M2-­‐1	   expression.	   	   Site	   directed	  mutagenesis	  of	  the	  M2-­‐1	  support	  plasmid	  was	  used	  to	  assess	  the	  impact	  of	  our	  panel	  of	  RNA	  binding	  mutants,	  discussed	  above.	  	  	  	  	  
5.2.6.1 RNA	  binding	  and	  antitermination	  The	   panel	   of	   mutants	   that	   were	   incorporated	   in	   our	   FPA	   assay,	   described	  above,	  were	   tested	   to	   compare	   their	  M2-­‐1	   antitermination	   and	   RNA	   binding	  abilities	  (figure	  5.8).	   	  Mutant	  R3AR4A,	  which	  possessed	  reduced	  RNA	  binding	  activity,	   also	   exhibited	   a	   significant	   loss	   of	   luciferase	   expression	   (<20	   %	   of	  WT),	   thus	   identifying	   the	   corresponding	   residues	   as	   critical	   for	   M2-­‐1	  transcriptional	   antitermination.	   	   Interestingly,	   single	   mutants	   R3A	   and	   R4A	  showed	   similar	   minigenome	   activity	   to	   that	   of	   WT	   M2-­‐1,	   possibly	   because	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altering	   the	   charge	   on	   these	   single	   residues	   was	   insufficient	   to	   significantly	  disrupt	   the	   ligand	   binding	   capability	   of	   the	   extensive	   positive	   charge	   on	   the	  M2-­‐1	   N-­‐terminal	   face.	   Alteration	   of	   positively	   charged	   residues	   K19AR20A,	  which	   resulted	   in	   no	   significant	   change	   in	   RNA	   binding	   activity,	  correspondingly	  resulted	  in	  essentially	  unchanged	  luciferase	  expression	  in	  the	  replicon	   assay,	   suggestive	   of	   no	   role	   in	   antitermination.	   	  M2-­‐1	  mutants	  with	  alterations	   at	   core	   residues	   K150,	   R151	   and	   K159	   also	   showed	  minigenome	  activities	   that	   reflected	   their	   RNA	   binding	   abilities:	   double	   mutant	  K150AR151A	   that	   exhibited	   approximately	   40	  %	  RNA	  binding	   ability	   of	  WT,	  showed	  a	  comparable	  reduction	  in	  luciferase	  expression,	  while	  mutant	  K159A	  exhibited	   both	   RNA	   binding	   and	   luciferase	   expression	   of	   between	   60-­‐80	   %	  compared	  to	  WT	  M2-­‐1.	  	  Taken	   together,	   our	   results	   showed	   a	   consistent	   trend;	   mutants	   with	  reduced	   RNA	   binding	   ability	   showed	   a	   corresponding	   reduction	   in	  minigenome	  activity,	   further	  emphasising	   the	   importance	  of	  RNA	  binding	   for	  M2-­‐1	  antitermination	  function.	  	  	  	  
5.2.6.2 Phosphorylation	  and	  antitermination	  To	  better	  understand	  the	  role	  of	  phosphorylation	  in	  M2-­‐1	  antitermination,	  the	  minigenome	   assay	   was	   used	   to	   compare	   the	   antitermination	   activity	   of	  previously	   described	   phosphomimetic	   mutant	   S58DS61D	   and	   a	  phosphoablatant	   mutant,	   S58AS61A	   –	   electrostatically	   equivalent	   to	  bacterially-­‐expressed	   WT	   M2-­‐1,	   which	   was	   not	   phosphorylated.	   	   These	  mutants	   represent	   forms	  of	  M2-­‐1	   that	   are	   either	  maximally	   charged	   (DD)	  or	  uncharged	  (AA)	  at	  residues	  58	  and	  61,	  and	  in	  contrast	  to	  the	  WT	  M2-­‐1	  in	  this	  system	   these	   charge	   states	   are	   not	   interchangeable.	   	   Consequently,	   these	  mutants	   are	   not	   directly	   comparable	   to	   the	   panel	   of	   RNA	   binding	   mutants	  described	   above,	   as	   the	   RNA	   binding	  mutants	   were	   still	   capable	   of	   dynamic	  phosphorylation.	  Both	   mutants	   AA	   and	   DD	   resulted	   in	   significantly	   diminished	  antitermination	   activity	   (figure	   5.8):	   phosphoablatant	   S58AS61A	   exhibiting	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<20	  %	  WT	  activity;	  phosphomimetic	  S58DS61D	  exhibiting	  ~45	  %	  WT	  activity.	  	  These	   results	   imply	   that	   during	   RSV	   infection	   unphosphorylated	   (ie.	  uncharged)	   and	   phosphorylated	   (i.e.	   charged)	   M2-­‐1	   variants	   would	   possess	  different	   antitermination	   activities,	   and	   that	   a	   homogenous	   population	   of	  either	   state	   is	   suboptimal.	   	   This	   suggests	   that	   the	   increased	   antitermination	  function	   exhibited	   by	   WT	   M2-­‐1	   in	   the	   minigenome	   system	   depends	   on	   its	  switchable	  charge	  state,	  which	  can	  be	  achieved	  by	  reversible	  phosphorylation	  of	  the	  WT	  serine	  residues.	  
Figure	  5.8	  Minigenome	  activity	  of	  RNA	  and	  phosphorylation	  mutants.	  	  Top,	   a	   histogram	   of	   M2-­‐1-­‐dependent	   luciferase	   activity	   relative	   to	   WT	  (dynamically	  phosphorylated	  in	  this	  system).	  	  Bottom,	  anti-­‐M2-­‐1	  western	  blot	  confirming	  expression	  of	  all	  mutants.	  	  Lane	  order	  is	  the	  same	  as	  the	  histogram	  above.	   	   Non-­‐specific	   binding	   resulted	   in	   two	   higher	  molecular	  weight	   bands	  suspected	   to	   be	   tubulin	   and	   RSV	   N	   protein.	   	   Work	   performed,	   and	   figure	  provided,	  by	  Jean-­‐François	  Eléouët	  and	  his	  group.	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5.3 CHAPTER	  SUMMARY	  
M2-­‐1	   is	  an	  RNA	  binding	  protein	  and	  abrogation	  of	   this	  ability	   coincides	  with	  loss	  of	  viral	  polymerase	  processivity,	  indicating	  RNA	  binding	  is	  critical	  to	  M2-­‐1	  transcriptional	   antitermination	   function	   (Blondot	   et	   al.,	   2012).	   	   To	   better	  understand	  how	  RNA	  binding	  affinity	  and	  specificity	  may	   influence	   the	  mode	  of	   action	   of	   M2-­‐1	   in	   promoting	   polymerase	   processivity,	   we	   quantitatively	  determined	  the	  binding	  affinity	  of	  bacterially-­‐expressed	  full-­‐length	  tetrameric	  RSV	  M2-­‐1	  protein	  to	  a	  variety	  of	  viral	  and	  non-­‐viral	  RNA	  oligonucleotides	  using	  fluorescence	  polarisation	  anisotropy	  (FPA).	  	  	  	   This	   work	   presents	   further	   evidence	   for	   the	   suggestion	   that	   M2-­‐1	  protein	  has	  a	  preference	  for	  A-­‐rich	  RNA	  sequences	  and,	  in	  particular,	  the	  gene	  end	   sequences	   of	   RSV.	   	   Given	   the	   high	   adenosine	   content	   of	   3’	  mRNA	   sense	  gene	  end	  sequences,	  and	  the	  exposed	  nature	  of	  nascent	  viral	  mRNA	  compared	  with	  the	  encapsidated	  viral	  genome,	  it	  is	  tempting	  to	  speculate	  that	  viral	  mRNA	  is	  also	  the	  more	  likely	  target	  for	  M2-­‐1.	  	  This	  idea	  is	  notionally	  supported	  by	  the	  observation	   that	   transcription	   termination	   signals	   are	   ignored	   by	   the	   RSV	  polymerase	   during	   replication	   as	   it	  moves	   along	   the	   genomic	   RNP	   template,	  likely	   as	   a	   result	   of	   the	   concurrent	   encapsidation	   of	   the	   newly	   synthesized	  replication	   product	   by	   the	   N	   protein	   (Cowton,	   McGivern	   and	   Fearns,	   2006).	  This	   role	   of	   N	   may	   be	   partially	   recapitulated	   by	   M2-­‐1	   during	   transcription	  through	  its	  interaction	  with	  specific	  sequences	  within	  the	  nascent	  mRNA.	  	  Our	  data	   also	   present	   a	   difference	   in	   RNA	   binding	   preference	   of	   M2-­‐1	   for	   the	  various	  gene	  end	  sequences	  of	  RSV.	   	  Although	  only	   two	  such	  sequences	  have	  been	  studied	  here	  and	  a	  full	  panel	  of	  gene	  ends	  is	  required	  for	  further	  analysis,	  our	  data	  suggest	  that	  differential	  binding	  to	  gene	  end	  cis-­‐acting	  signals	  may	  be	  responsible	  for	  the	  previously	  observed	  variation	  in	  sensitivity	  to	  M2-­‐1	  of	  the	  gene	   junctions	   (Hardy	   et	   al.,	   1999).	   	   This	   is	   in	   contrast	   to	   the	   findings	   of	  Blondot	  et	  al,	  who	  saw	  no	  distinction	  between	  the	  binding	  affinity	  of	  M2-­‐158-­‐177	  for	   either	   F	   or	   SH	   gene	   end	   sequences,	   however	   the	   truncated	   monomeric	  nature	   of	   their	   protein	   leads	   us	   to	   believe	   that	   our	   results	   are	   more	  representative	  of	  M2-­‐1	  in	  the	  context	  of	  viral	  infection.	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   The	   position	   of	   the	   surface	   responsible	   for	   the	   critical	   M2-­‐1:RNA	  interaction	  that	  was	  defined	  on	  the	  core	  domain	  by	  Blondot	  et	  al,	  can	  now	  be	  visualised	  in	  the	  context	  of	  the	  complete	  tetramer	  (figure	  5.9).	  	  This	  previously	  assigned	  surface	  is	  shown	  in	  blue	  and	  many	  of	  its	  residues	  (K92,	  K150,	  R151)	  have	   been	   confirmed	   in	   this	   chapter	   to	   be	   involved	   in	   RNA	   binding	   in	   the	  context	   of	   full	   length	  M2-­‐1	   tetramer.	   	   The	   surface	   corresponds	   to	   an	   area	   of	  positive	  charge	  on	  the	  side	  face	  of	  the	  tetramer	  that	  can	  now	  be	  seen	  to	  extend	  across	  both	  N-­‐	  and	  C-­‐terminal	  faces;	  the	  extension	  of	  positive	  charge	  combined	  with	   the	   identification	   of	   residues	   outside	   of	   this	   previously	   defined	   surface,	  such	   as	   R3,	   R4	   and	   R126	   (shown	   in	   pink	   in	   figure	   5.9),	   points	   to	   the	  involvement	   of	   considerably	   larger	   surface	   of	   the	  M2-­‐1	   tetramer	   in	   its	   RNA	  binding	   capability,	   including	  a	   critical	   contribution	   to	   the	  N-­‐terminal	  binding	  surface	  made	  by	  each	  adjacent	  monomer	  within	   the	   tetramer.	   	  Residues	   that	  were	   identified	   as	   playing	   important	   roles	   in	   RNA	   binding	   also	   exhibited	  correspondingly	   reduced	   levels	   of	   transcriptional	   antitermination	   in	   the	  context	   of	   the	   minigenome	   system	   when	   mutated	   to	   alanine,	   further	  confirming	  the	  critical	  role	  of	  RNA	  binding	  in	  M2-­‐1	  function.	  	  Figure	  5.9	  also	  highlights	  an	   interesting	  and	  novel	   finding	  revealed	  by	  our	  crystal	  structures:	  The	  sites	  of	  phosphorylation,	  serines	  58	  and	  61,	  are	  in	  close	  proximity	  to	  the	  proposed	  RNA	  binding	  surface,	  leading	  to	  the	  possibility	  of	   their	   involvement	   in	   the	   regulation	   of	   RNA	   binding	   and,	   consequently,	  antitermination	   activity	   of	   M2-­‐1.	   	   A	   combination	   of	   FPA	   and	   minigenome	  analysis	  allowed	  interrogation	  of	  the	  possible	  effects	  of	  M2-­‐1	  phosphorylation	  on	   its	   RNA	   binding	   and	   antitermination	   activity,	   respectively,	   using	  phosphomimetic	   and	   phosphoablatant	   mutants.	   The	   consequence	   of	  preventing	  phosphorylation	  at	  either	  S58	  or	  S61	  was	  previously	  shown	  to	  be	  a	  significant	   reduction	   in	   transcription	   antitermination	   efficiency	   (Cartee	   and	  Wertz,	  2001),	  however	  neither	  this	  publication	  nor	  any	  other	  published	  study	  has	   investigated	   the	   phenotype	   of	   fully	   phosphorylated	   M2-­‐1.	   	   Here	   we	   not	  only	  confirm	  that	  complete	  abrogation	  of	  phosphorylation	  at	  both	  these	  sites,	  as	  exhibited	  by	  mutant	  S58AS61A,	  profoundly	  inhibits	  antitermination,	  but	  we	  also	   show	   that	   mimicking	   phosphorylation	   at	   these	   residues	   by	   using	   the	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phosphomimetic	   S58DS61D	   M2-­‐1	   mutant	   also	   significantly	   reduces	  antitermination	  activity.	  	  These	  results	  show	  that	  the	  antitermination	  ability	  of	  M2-­‐1	  protein	  is	  highest	  for	  the	  WT,	  suggesting	  that	  dynamic	  phosphorylation	  is	  essential	  for	  efficient	  M2-­‐1	  antitermination	  function.	  To	  correlate	  these	  antitermination	  phenotypes	  to	  a	  loss	  of	  RNA	  binding	  affinity,	   bacterially-­‐expressed	   phosphomimetic	   and	   WT	   (intrinsically	  unphosphorylated	   in	   this	   system)	  proteins	  were	   compared	   in	   the	  FPA	  assay.	  	  The	   data	   demonstrated	   that	   although	   unphosphorylated	   M2-­‐1	   had	   lower	  antitermination	   activity,	   it	   was	   capable	   of	   binding	   RNA	   with	   higher	   affinity	  than	   phosphomimetic	   M2-­‐1.	   	   Whilst	   a	   comparison	   with	   a	   heterogeneous	  population	   of	   M2-­‐1	   containing	   both	   charge	   states	   is	   required	   to	   truly	  understand	   the	   involvement	   of	   phosphorylation	   in	   RNA	  binding,	   data	   in	   this	  chapter	  suggest	  that	  phosphorylation	  may	  not	  simply	  regulate	  RNA	  binding	  of	  M2-­‐1;	   rather	   phosphorylation	   may	   also	   be	   involved	   in	   regulating	   M2-­‐1	  interactions	   with	   other	   ligands,	   such	   as	   the	   viral	   P	   protein	   or	   as	   yet	  undiscovered	  host	  factors.	  	  	  	  	  	  In	  summary,	  this	  chapter	  has	  confirmed	  the	  RNA	  binding	  preference	  of	  full	  length	  tetrameric	  M2-­‐1	  for	  A-­‐rich	  sequences,	  which	  are	  strongly	  suggested	  to	  be	  the	  gene	  end	  sequences	  at	  the	  3’	  end	  of	  nascent	  viral	  mRNAs.	   	  We	  have	  defined	  the	  RNA	  binding	  surface	  in	  the	  context	  of	  tetrameric	  M2-­‐1	  and	  suggest	  the	  involvement	  of	  additional	  residues,	  including	  several	  in	  the	  N-­‐terminus	  of	  the	  protein.	  	  Phosphomimetic	  M2-­‐1	  has	  decreased	  RNA	  binding	  affinity	  across	  a	  range	  of	  sequences,	  relative	  to	  unphosphorylated	  wild	  type,	  but	  both	  charge	  states	  show	  lower	  antitermination	  activity	  than	  WT;	  dynamic	  phosphorylation	  of	  M2-­‐1	  protein	  is	  required	  for	  efficient	  antitermination	  in	  the	  context	  of	  viral	  transcription	  and	  replication.	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Figure	  5.9	  Defining	  the	  RNA	  binding	  surface	  of	  M2-­‐1.	  	  	  A	   surface	   representation	   of	   the	  M2-­‐1	   tetramer,	   shown	   as	   a	   C-­‐terminal	   (left)	  and	  tilted	  side	  view	  (right),	  with	  one	  monomer	  coloured	  grey	  for	  clarity.	   	  The	  previously	  outlined	  RNA	  binding	  surface,	  as	  defined	  by	  NMR	  using	  M2-­‐158-­‐177,	  is	   shown	   in	   blue	   and	   includes	   residues	  K92,	  K150,	  R151	   and	  K159	   tested	   in	  this	   chapter.	   	   Additional	   residues	   identified	   in	   this	   study	   (R3,	   R4,	   S58,	   S61,	  R126)	   are	   highlighted	   in	   pink.	   	   Some	   residues	   are	   labelled	   for	   orientation	  purposes.	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6 CHAPTER	  6:	  DISCUSSION	  
6.1 THE	   X-­‐RAY	   CRYSTAL	   STRUCTURE	   OF	   RSV	   M2-­‐1	   PROVIDES	   NEW	  
UNDERSTANDING	   OF	   THE	   FUNCTIONAL	   IMPLICATIONS	   OF	   ITS	  
ORGANISATION	  
	  The	   high-­‐resolution	   crystal	   structures	   we	   present	   here	   reveal	   new	   and	  important	  insights	  into	  the	  structure	  and	  function	  of	  the	  full	  length	  RSV	  M2-­‐1	  in	  its	  biologically	  relevant	  tetrameric	  form.	  	  These	  structures	  identify	  multiple	  elements	   that	   drive	   oligomerisation,	   including	   a	   four-­‐helix	   bundle	   and	   non-­‐canonical	   zinc	   finger	   that	   interacts	   with	   adjacent	   monomers	   within	   the	  assembled	   tetramer.	   	  We	  pinpoint	   the	   location	  of	   residues	  essential	   for	  M2-­‐1	  mediated	   antitermination,	   and	   define	   the	   location	   of	   regions	   responsible	   for	  critical	   M2-­‐1:RNA	   interactions	   on	   the	   tetramer	   surface.	   We	   also	   provide	   a	  structural	  and	  functional	  interrogation	  of	  critical	  phosphorylated	  residues	  S58	  and	   S61,	   known	   to	   play	   essential	   roles	   in	   M2-­‐1	   polymerase	   processivity	  activity.	  	  	  	   Whilst	  the	  crystal	  structure	  outlined	  in	  this	  thesis	  is	  in	  close	  agreement	  with	   the	   partial	   solution	   NMR	   structure	   of	   monomeric	   M2-­‐158-­‐177	   that	   was	  published	   during	   this	   project	   (Blondot	   et	   al.,	   2012),	   the	   full-­‐length	   nature	   of	  our	   protein	   provides	   previously	   unknown	   information	   about	   the	   quaternary	  organisation	   of	   M2-­‐1,	   which	   is	   essential	   for	   understanding	   functional	  interrogation	  in	  a	  physiologically	  relevant	  context.	   	  Equally,	  it	  is	  reassuring	  to	  note	   the	   similarity	   between	   NMR	   and	   crystal	   structures,	   as	   the	   possible	  irrelevance	   of	   crystalline	   protein	   compared	   to	   protein	   in	   solution	   (as	   with	  NMR)	  is	  often	  cited	  as	  a	  disadvantage	  of	  X-­‐ray	  crystallography.	  	  	  Oligomerisation	  of	  M2-­‐1	  to	  form	  a	  stable	  tetramer	  has	  previously	  been	  inferred	   from	  cross-­‐linking	  experiments	  and	  measurements	  of	  hydrodynamic	  volume.	  	  We	  have	  confirmed	  that	  M2-­‐1	  is	  indeed	  a	  homo-­‐tetramer	  and	  that	  this	  organisation	   is	   strongly	   favoured;	   it	   is	   driven	   primarily	   by	   the	   long	  tetramerisation	   helix	   α1	   forming	   a	   four-­‐helix	   bundle	   stabilised	   by	   clustered	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hydrophobic	  residues.	  	  The	  formation	  of	  a	  zinc	  finger	  domain,	  critical	  for	  M2-­‐1	  antitermination	  and	  correct	  folding,	  is	  confirmed	  here	  for	  the	  first	  time	  and	  the	  structure	   shows	   it	   extends	   on	   the	   N-­‐terminal	   arm	   and	   interacts	   with	   an	  adjacent	   protomer,	   further	   stabilising	   the	   tetramer.	   	   The	   involvement	   of	   the	  zinc	   finger	   in	   conformational	   stability	   explains	   its	   indispensability	   for	   M2-­‐1	  function,	   which	   was	   not	   previously	   understood	   given	   its	   apparent	   lack	   of	  involvement	   in	   RNA	   binding	   or	   phosphorylation	   (Hardy	   and	   Wertz,	   2000,	  Cartee	  and	  Wertz,	  2001).	  	  The	  only	  other	  mononegavirus	  protein	  with	  known	  similar	  function	  to	  M2-­‐1	   is	   VP30	   from	   the	   Ebola	   virus	   (EBOV).	   	   Both	  M2-­‐1	   and	   VP30	   influence	  transcription,	   interact	   with	   multiple	   components	   of	   the	   viral	   RNA	   synthesis	  machinery,	   possess	   related	   zinc	   finger	   motifs,	   and	   are	   modified	   by	   dynamic	  phosphorylation.	   	   It	   was	   hoped	   that	   revealing	   the	   structural	   similarities	  between	   VP30	   and	   full-­‐length	   M2-­‐1	   might	   point	   to	   similar	   mechanisms	   of	  regulation,	   however	   the	   data	   presented	   here	   serve	   more	   to	   highlight	   the	  functional	   differences	   between	   M2-­‐1	   and	   VP30,	   than	   to	   confirm	   their	  similarities;	  the	  loss	  of	  negative	  charge	  through	  phosphoablation	  at	  M2-­‐1	  S58	  and	   S61	   dramatically	   reduces	   productive	   transcription,	   whereas	   for	   VP30	  phosphoablation	  increases	  transcription	  in	  a	  minigenome	  system	  (Biedenkopf	  et	  al.,	  2013).	  	  Comparison	  of	  the	  VP30	  model	  with	  the	  known	  functions	  of	  M2-­‐1	  is	  complicated	  by	  the	  multiple	  binding	  partners	  of	  VP30	  within	  the	  polymerase	  complex	   (VP35,	  N,	  L	  and	  RNA),	   in	  contrast	   to	  M2-­‐1,	  which	  has	  only	  2	  known	  associates	  (RNA	  and	  P).	  	  Furthermore,	  here	  we	  show	  that	  the	  ability	  of	  M2-­‐1	  to	  bind	  RNA	  is	  both	  modulated	  by	  phosphorylation,	  and	  is	  a	  critical	  determinant	  of	   antitermination	   function,	   whereas	   for	   VP30	   no	   such	   association	   has	   been	  made.	   	   Although	   it	   may	   seem	   unlikely	   that	   two	   proteins	   sharing	   such	  considerable	   structural	   similarity	  would	   perform	   different	   functions	   in	  what	  are,	  otherwise,	  two	  highly	  conserved	  lifecycle-­‐strategies,	  M2-­‐1	  protein	  already	  has	  precedent	  for	  such	  an	  occurrence:	  in	  contrast	  to	  the	  M2-­‐1	  protein	  of	  RSV,	  human	  metapneumovirus	  M2-­‐1	  protein	   is	  not	  essential	   to	   the	   lifecycle	  of	   the	  virus	   nor	   is	   it	   required	   for	   the	   complete	   and	   efficient	   transcription	   of	   viral	  mRNAs	  despite	   considerable	   sequence	   identity	   (Buchholz	  et	  al.,	  2005).	   	  Thus	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the	  differences	  in	  RSV	  M2-­‐1	  and	  EBOV	  VP30	  function,	  despite	  their	  structural	  similarities,	   may	   be	   as	   a	   result	   of	   the	   binding	   partners	   they	   mediate	   their	  function	   through,	   rather	   than	   a	   fundamental	   difference	   in	   their	   modes	   of	  action.	  	  	  
6.2 AN	   EXTENSIVE	   AREA	   OF	   M2-­‐1	   SURFACE	   MEDIATES	  
ELECTROSTATICALLY-­‐DRIVEN	   RNA	   BINDING	   OF	   A-­‐RICH	  
SEQUENCES	  
	  The	   surface	   of	   the	  M2-­‐1	   tetramer	   is	   covered	   in	   extensive	   regions	   of	   positive	  charge,	  classically	  associated	  with	  binding	  to	  nucleic	  acid.	  	  Our	  data	  describe	  a	  number	   of	   positively	   charged	   residues	   whose	   mutation	   to	   an	   uncharged	  residue	  results	  in	  a	  reduction	  in	  RNA	  binding	  affinity	  of	  M2-­‐1.	  	  These	  residues	  not	   only	   feature	   in	   the	   RNA	   binding	   region	   previously	   assigned	   by	   NMR	  chemical	  shifts,	  a	  region	  which	  can	  now	  be	  mapped	  to	  the	  side	  face	  of	  the	  M2-­‐1	  tetramer,	  but	  are	  also	  present	  on	  the	  N-­‐	  and	  C-­‐terminal	  faces	  on	  the	  protein.	  	  	  	  Binding	   of	   RNA	   to	  M2-­‐1	  was	   recently	   found	   to	   be	  mutually	   exclusive	  from	  the	  M2-­‐1:P	   interaction,	  due	  to	  partially	  overlapping	   interaction	  surfaces	  (Blondot	  et	  al.,	  2012,	  Tran	  et	  al.,	  2009).	   	  Our	  structure	  of	  the	  full	   length	  M2-­‐1	  tetramer,	  onto	  which	  the	  P	  and	  RNA	  binding	  surfaces	  can	  be	  mapped,	  further	  supports	   this	   exclusivity	   as	   the	   regions	   in	   question	   remain	   sufficiently	   close	  that	  binding	  of	  a	  ligand	  to	  one	  would	  sterically	  hinder	  the	  other.	  	  M2-­‐1	  has	  also	  recently	  been	  shown	  to	  bind	  P	  with	  a	  1:1	  stoichiometry	  at	  high	  affinity	  (Kd	  in	  the	  low	  nM	  range)	  with	  each	  M2-­‐1	  tetramer	  binding	  a	  P	  tetramer	  (Esperante	  et	  al.,	   2012).	   	   Although	   no	   high-­‐resolution	   structure	   of	   RSV	   P	   is	   currently	  available,	  the	  large	  hydrodynamic	  volume	  of	  the	  P	  tetramer	  (elutes	  as	  500	  kDa	  tetramer	  despite	  mass	  spectrometry	  confirmation	  of	  mass	  as	  125	  kDa)	  and	  the	  overlap	  of	  P	  and	  RNA	  binding	  sites	  would	  further	  support	  the	  exclusivity	  of	  P	  and	  RNA	  binding.	  	  The	  interaction	  between	  P	  and	  M2-­‐1	  has	  been	  proposed	  to	  recruit	   M2-­‐1	   to	   the	   polymerase	   complexes	   during	   transcription,	   and	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abrogation	  of	  P-­‐binding	  causes	  relocalisation	  (by	  immunofluorescence)	  of	  M2-­‐1	   from	  the	   locations	  of	  viral	   transcription	  and	  replication	   in	   transfected	  cells	  (Blondot	  et	  al.,	  2012).	  	  Given	  the	  low	  affinity	  RNA	  binding	  presented	  here,	  it	  is	  interesting	  to	  speculate	  how	  the	  strong	  M2-­‐1:P	  interaction	  could	  be	  disrupted	  by	   RNA,	   as	   would	   be	   necessary	   to	   permit	   interaction	   with	   RNA	   for	  transcriptional	   antitermination.	   	   An	   alternative	   possibility	   is	   that	   the	  M2-­‐1:P	  interaction	   is	  disrupted	  by	   the	  phosphorylation	  of	  P	  at	   threonine	  108,	  which	  has	  been	  shown	  to	  prevent	  the	  P:M2-­‐1	  interaction	  (Asenjo	  et	  al,	  2003).	  Considering	  the	  lack	  of	  an	  obvious	  RNA	  binding	  cleft	  or	  solvent-­‐exposed	  aromatic	  residues	  that	  could	  stack	  against	  nucleotide	  bases,	  and	  the	  extensive	  surfaces	  of	  positive	  charge	  described	  above,	  it	  seems	  likely	  that	  RNA	  binding	  of	  M2-­‐1	   is	   electrostatically	   driven	   rather	   than	   by	   the	   recognition	   of	   a	   specific	  sequence.	   	  This	   is	   supported	  by	   the	   relatively	   low	  affinities	  presented	   in	   this	  work	   (0.48-­‐33	  µM)	   and	   in	   previous	   publications	   (Blondot	   et	   al,	   2.5	   to	   >600	  
µM),	  which	  point	  to	  a	  preference	  for	  A-­‐rich	  RNAs	  but	  no	  obvious	  preference	  for	  a	   particular	   viral	   sequence.	   	   Our	   RNA	   binding	   data	   suggested	   a	   slight	  preference	  for	  the	  mRNA	  sense	  gene	  end	  cis-­‐acting	  signals,	  in	  agreement	  with	  the	   high	   ‘A’	   content	   of	   these	   sequences	  within	   the	   nascent	   viral	  mRNAs.	   	   In	  addition,	  the	  variability	  of	  these	  sequences	  between	  genes	  may	  account	  for	  the	  apparent	  lack	  of	  sequence	  specificity	  of	  M2-­‐1;	  it	  must	  be	  capable	  of	  recognising	  all	  gene	  end	  signals	  despite	  their	  conservation	  amounting	  only	  to	  a	  A-­‐G-­‐U-­‐U/A-­‐A	  sequence,	  followed	  by	  a	  1-­‐4	  nucleotide	  variable	  region	  and	  a	  4-­‐6	  polyA	  tract.	  	  The	   conservation	   of	   only	   small	   elements	   of	   the	   gene	   end	   signals	   may	   also	  support	   the	   idea	   that	   gene	   end-­‐like	   sequences,	   only	   containing	   some	  characteristics	  of	   these	   sequences	   such	  as	  a	  polyA	   tract,	  may	  be	   the	  cause	  of	  premature	  polymerase	   transcription	   termination	  within	  genes	  and	   that	  M2-­‐1	  must	   be	   flexible	   enough	   to	   recognise	   these	   too,	   for	   its	   intragenic	  antitermination	  function.	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6.3 THE	  ROLE	  OF	  PHOSPHORYLATION	  	  The	  role	  of	  M2-­‐1	  phosphorylation	  has	  long	  been	  debated,	  although	  it	  is	  known	  to	  be	  required	  for	  antitermination	  function	  (Cartee	  and	  Wertz,	  2001).	   	   In	  this	  work,	   we	   have	   not	   only	   confirmed	   the	   identification	   of	   the	   phosphorylation	  sites	  as	  serines	  58	  and	  61,	  but	  we	  suggest	  that	   it	   is	  dynamic	  phosphorylation	  that	   is	  required	  by	  M2-­‐1;	  homogenous	  populations	  of	  either	  phosphomimetic	  or	   phosphoablatant	   M2-­‐1	   protein	   have	   suboptimal	   antitermination	   activity	  relative	  to	  wild	  type,	  with	  phosphoablatant	  M2-­‐1	  being	  the	  most	  deleterious	  to	  transcription	   of	   a	   minigenome.	   	   In	   contrast,	   analysis	   of	   the	   RNA	   binding	  abilities	   of	   these	   charge	   states	   (S58DS61D	   phosphomimetic,	   and	   bacterially-­‐expressed	   WT	   phosphoablatant)	   revealed	   that	   unphosphorylated	   M2-­‐1	   had	  higher	   RNA	   binding	   affinity	   across	   a	   range	   of	   sequences	   than	   the	  phosphomimic.	   	   This	   suggests	   that	   phosphorylation	   is	   not	   simply	   regulating	  the	  binding	  of	  RNA	  to	  M2-­‐1,	  although	  it	  is	  clearly	  impacting	  on	  this	  interaction,	  nor	  is	  it	  affecting	  the	  sequence	  specificity	  of	  RNA	  binding,	  as	  we	  saw	  the	  same	  pattern	   of	   affinity	   for	   different	   sequences	   with	   phosphomimetic	   and	  unphosphorylated	   protein.	   	   The	   consistent	   two-­‐fold	   reduction	   in	   binding	  affinity	  of	  mutant	  S58DS61D	  across	  all	  RNAs	  tested	  is	  likely	  due	  to	  electrostatic	  effects,	   as	   residues	   S58	   and	   S61	   are	   in	   close	   proximity	   to	   the	   RNA	   binding	  cluster	   on	   the	   tetramer	   surface,	   and	   increased	   negative	   charge	   would	   be	  expected	  to	  reduce	  RNA	  binding	  affinity	  –	  although	  the	  less	  deleterious	  effect	  on	   antitermination	   of	   mimicking	   charge	   compared	   with	   a	   lack	   of	   charge,	  suggests	   that	   an	   effect	   on	   RNA	   binding	   is	   not	   the	   primary	   role	   of	  phosphorylation	  in	  regulating	  antitermination	  of	  M2-­‐1.	  One	   possibility	   is	   that	   phosphorylation	   of	  M2-­‐1	   could	   be	   regulating	   a	  currently	  undiscovered	  interaction	  with	  a	  viral	  protein	  or	  host	  cell	  factor.	   	  To	  determine	   if	   the	  regulation	  of	  such	  an	   interaction	   is	   through	   the	   induction	  of	  structural	   rearrangement	   that	   exposes	   a	   new	   binding	   surface,	   the	   crystal	  structures	  of	  WT	  and	  S58DS61D	  M2-­‐1	  protein	  were	  compared.	  	  The	  full	  length	  M2-­‐1	  tetramer	  structure	  revealed	  the	  position	  of	  S58	  and	  S61	  on	  a	  negatively	  charged	  flexible	  loop	  that	  lies	  across	  the	  positively	  charged	  C-­‐terminal	  face	  of	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each	   monomer,	   raising	   the	   possibility	   that	   altered	   charge	   resulting	   from	  phosphorylation	   could	   shift	   its	   position,	   exposing	   an	   alternative	   binding	  surface.	  	  However,	  our	  data	  showed	  that	  the	  altered	  negative	  charge	  density	  of	  the	   loop	  had	  no	  detectable	  effect	  on	  its	  position	  or	  any	  other	  M2-­‐1	  structural	  element.  This	   finding	  does	  not	  rule	  out	   the	  regulation	  of	  such	  an	   interaction	  via	  electrostatic	  effects	  in	  the	  existing	  surfaces	  presented	  by	  our	  structure,	  but	  more	  work	   is	   required	   to	   fully	   identify	   the	   binding	  partners	   of	  M2-­‐1;	  RSV	   is	  known	  to	  require	  a	  number	  of	  host	  cell	  proteins	  for	  poorly-­‐described	  roles	  in	  its	  virus	  lifecycle,	  such	  as	  actin	  and	  HSP90	  (Radhakrishnan	  et	  al.,	  2010),	  and	  an	  interaction	  of	  these	  proteins	  with	  M2-­‐1	  itself	  cannot	  be	  discounted.	  	  	  Although	  there	  is	  extensive	  precedent	  for	  the	  use	  of	  aspartate	  mutation	  to	  mimic	  the	  negative	  charge	  imparted	  by	  a	  phosphorylation	  event,	  there	  is	  the	  possibility	   that	   our	   mutants	   do	   not	   adequately	   reflect	   the	   post-­‐translational	  modification	  in	  vivo.	  	  There	  have	  been	  published	  incidences	  where	  two	  charged	  residues	  were	  required	  to	  mimic	  phosphorylation,	  or	  where	  aspartate	  mutants	  have	  activity	  more	   like	   the	  unphosphorylated	   form	  (reviewed	   in	  Pearlman	  et	  al.,	   2011).	   	   However	   the	   substitution	   of	   serines	   for	   aspartates	   successfully	  mimics	   phosphorylation	   in	   the	   majority	   of	   cases,	   and	   Pearlman	   et	   al	   even	  suggest	   that	   the	   mutation	   of	   aspartate/glutamate	   residues	   to	   phospho-­‐serines/tyrosines	  is	  how	  many	  regulatory	  phosphorylation	  sites	  have	  evolved.	  	  	  
6.4 A	  MODEL	  OF	  M2-­‐1	  FUNCTION	  	  Taking	   the	   available	   evidence	   together,	   we	   propose	   that	   M2-­‐1	   may	  preferentially	  bind	  nascent	  mRNAs	  as	   they	  are	  being	   transcribed:	   the	  3’	  viral	  mRNA	   contains	   the	   gene	   end	   consensus	   transcription	   termination	   signal,	  which	  is	  A-­‐rich	  by	  virtue	  of	  the	  U-­‐tract	  that	   is	  a	  conserved	  genomic	  gene	  end	  feature.	   	   Recognition	   of	   this	   region	  of	  RNA	  by	  M2-­‐1	  may	  be	  what	   allows	   the	  polymerase	   to	   read-­‐through	   these	   cis-­‐acting	   signals,	   a	   function	   that	   could	   be	  performed	  by	  the	  nucleocapsid	  protein	  during	  the	  concurrent	  encapsidation	  of	  replication.	   	   How	   RNA	   binding	   of	   M2-­‐1	   translates	   to	   an	   effect	   on	   the	   viral	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polymerase	   is	   unknown,	   but	   it	   could	   be	   mediated	   through	   the	   M2-­‐1:P	  interaction	  or	  the	  predicted	  (although	  not	  proven)	  interaction	  of	  M2-­‐1	  with	  the	  polymerase	   itself.	   	   In	   addition,	  we	  propose	   that	  RNA	   sequences	   that	   possess	  conserved	  gene	  end	  characteristics	  may	  also	  arise	  sporadically	  within	  the	  body	  of	  a	   transcript,	  and	  the	  binding	  of	  M2-­‐1	  to	  these	  sequences	   in	  nascent	  mRNA	  may	  account	   for	   intragenic	  antitermination.	   	   It	   is	  of	  note	   that	   the	  majority	  of	  transcription	   antiterminators	   in	   bacterial	   systems	   bind	   sequences	   within	  nascent	   mRNAs,	   and	   act	   by	   preventing	   formation	   of	   cis-­‐acting	   secondary	  structure	   termination	   signals	   that	   are	   consequently	   ignored	   by	   the	  transcribing	   polymerase	   (Greenblatt	   et	   al.,	   1993).	   	   Possibly	   the	   best	  understood	   virus-­‐encoded	   processivity	   factor	   is	   HIV	   Tat,	   which	   through	  binding	   to	   the	   TAR	   element	   in	   nascent	  mRNA,	   serves	   to	   recruit	   kinases	   that	  modify	  the	  C-­‐terminal	  domain	  of	  RNA	  pol	  II	  to	  modify	  its	  processivity.	  	  In	  light	  of	  the	  encapsidated	  state	  of	  the	  RSV	  genome	  in	  contrast	  to	  naked	  RSV	  mRNAs,	  it	   seems	   likely	   that	  M2-­‐1	  may	  mediate	   its	   antitermination	   through	   a	   similar	  mechanism.	  The	   discovery	   presented	   here,	   that	   dynamic	   phosphorylation	   is	  required	  for	  M2-­‐1	  transcriptional	  antitermination	  function,	  poses	  an	  important	  question:	   Why	   should	   the	   ability	   to	   dynamically	   switch	   between	   different	  charged	  states	  be	  critical	   to	  overall	  M2-­‐1	  function?	   	  One	  possible	  explanation	  for	  this	  requirement	  is	  that	  M2-­‐1	  function	  is	  a	  multi-­‐step	  process,	  at	  least	  one	  of	  which	  requires	  the	  uncharged	  state	  and,	  conversely,	  at	  least	  one	  other	  step	  requires	   M2-­‐1	   in	   the	   charged,	   phosphorylated	   state.	   	   In	   the	   context	   of	   viral	  infection,	   this	   could	   equate	   to	   the	   reversible	   binding	   of	   RNA	   or	   P	   protein	  ligands,	  which	  consequently	  allow	  recycling	  of	  various	   forms	  of	  M2-­‐1	   into	  or	  away	  from	  the	  transcribing	  polymerase	  complex.	  	  Transient	  binding	  of	  M2-­‐1	  to	  a	   host	   factor	   is	   another	   possibility,	   as	   several	   other	   viruses	   of	   the	   order	  
Mononegavirales	   require	   cellular	   binding	   partners	   for	   transcription	   and	  replication,	   such	   as	   the	   paramyxovirus	   Sendai	   virus	   whose	   polymerase	  interacts	  with	  tubulin	  to	  promote	  processivity,	  and	  human	  parainfluenza	  virus	  type	  3	  whose	   ribonucleocapsids	  bind	  beta-­‐catenin	   (an	   actin-­‐binding	  protein)	  as	  a	  transcriptional	  activator	  (Collins	  and	  Crowe	  Jr,	  2007).	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6.5 FUTURE	  DIRECTIONS	  	  The	  crystal	  structure	  presented	  here	  provides	  the	  opportunity	  for	  the	  phasing	  of	   future	   X-­‐ray	   diffraction	   data	   by	   molecular	   replacement,	   such	   as	   the	  structures	  of	  other	  M2-­‐1	  proteins	  within	  the	  subfamily	  Pneumovirinae	  or	  RSV	  M2-­‐1	   co-­‐crystallised	   with	   some	   of	   the	   ligands	   discussed	   in	   this	   thesis.	   	   In	  particular,	  a	  crystal	  structure	  of	  M2-­‐1	  bound	  to	  an	  mRNA	  sense	  gene	  end	  RNA	  sequence	  would	  provide	  essential	  confirmation	  of	  the	  residues	  involved	  in	  the	  interaction	   and	  would	   allow	   further	   inferences	   to	   be	  made	   about	   how	  M2-­‐1	  performs	   its	   functions.	   	   Equally	   useful	   would	   be	   a	   M2-­‐1:P	   co-­‐crystallisation	  experiment,	   however	   the	   large	   size	   of	   such	   a	   complex	   will	   make	   this	  technically	   challenging,	   and	   truncated	   domains	   predicted	   to	   interact	  may	   be	  more	  easily	  achievable.	  	  	  	   The	   role	   of	   phosphorylation	   in	   M2-­‐1	   function	   suggested	   here	   is	  speculative,	  and	  further	   investigation	   is	  required	  to	  understand	  this	  essential	  process.	   	   Structural	   studies	   with	   in	   vitro	   phosphorylated	   M2-­‐1	   protein	   are	  necessary	  to	  discount	  a	  conformational	  role	  for	  this	  modification.	  	  The	  possible	  regulation	   of	   RNA	   binding	   by	   phosphorylation	   should	   be	   examined	   more	  closely,	  possibly	  by	  repeating	  the	  mutational	  analysis	  performed	  in	  this	  thesis	  but	  with	   both	   S58AS61A	   and	   S58DS61D	  mutations	   coupled	   to	   possible	   RNA	  binding	  mutants,	  to	  determine	  if	  the	  effect	  of	  negating	  positive	  charge	  at	  these	  residues	   is	   phosphorylation	   dependent.	   	   Another	   possible	   avenue	   of	  investigation	  is	  a	  proteomic	  study	  comparing	  the	  potential	  host	  factor	  binding	  partners	  of	  phosphorylated	  vs.	  unphosphorylated	  M2-­‐1,	  using	  GST	  pull-­‐down	  assays	  coupled	  to	  mass	  spectrometric	  analysis.	  	   There	   remains	   a	   considerable	   amount	   of	   work	   to	   be	   done	   with	   this	  exciting	  RSV	  protein,	  as	  much	  remains	  poorly	  understood	  about	  the	  role	  of	  M2-­‐1	  in	  the	  virus	  life	  cycle,	  how	  it	  performs	  its	  functions,	  and	  how	  these	  functions	  are	  regulated.	  	  We	  believe	  that	  the	  research	  presented	  here	  makes	  a	  significant	  contribution	  to	  the	  fundamental	  knowledge	  of	  M2-­‐1	  molecular	  biology,	  and	  not	  only	  paves	  the	  way	  for	  further	  structure-­‐guided	  investigation	  of	  M2-­‐1	  function,	  but	  allows	  reinterpretation	  of	  previous	  data	  in	  a	  new	  and	  informative	  light.	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APPENDIX	   II	   -­‐	   ADDITIONAL	   RNA	   SEQUENCES	   FOR	   FLUORESCENCE	  
POLARISATION	  
	  
Name Sequence 5’-3’ 
Le 
ACGCGAAAAAAUGCGUACAACAAACUUGCAUAAACCAAAA
AAAU-Fl  (44) 
M/SH 
AAUGAUUAUUUGCCCCAUGUGUAUAUUUUUUAUUAACUUA
UUUG-Fl  (44) 	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APPENDIX	  III	  –	  M2-­‐1	  SEQUENCES	  
RSV	  A2	  strain	  M2-­‐1	  nucleotide	  sequence	  	  Start	  codon,	  stop	  codon	  	  ATGTCACGAAGGAATCCTTGCAAATTTGAAATTCGAGGTCATTGCTTAAATGGTAAGAGGTGTCATTTTAGTCATAATTATTTTGAATGGCCACCCCATGCACTGCTTGTAAGACAAAACTTTATGTTAAACAGAATACTTAAGTCTATGGATAAAAGTATAGATACCTTATCAGAAATAAGTGGAGCTGCAGAGTTGGACAGAACAGAAGAGTATGCTCTTGGTGTAGTTGGAGTGCTAGAGAGTTATATAGGATCAATAAACAATATAACTAAACAATCAGCATGTGTTGCCATGAGCAAACTCCTCACTGAACTCAATAGTGATGATATCAAAAAGCTGAGGGACAATGAAGAGCTAAATTCACCCAAGATAAGAGTGTACAATACTGTCATATCATATATTGAAAGCAACAGGAAAAACAATAAACAAACTATCCATCTGTTAAAAAGATTGCCAGCAGACGTATTGAAGAAAACCATCAAAAACACATTGGATATCCATAAGAGCATAACCATCAACAACCCAAAAGAATCAACTGTTAGTGATACAAATGACCATGCCAAAAATAATGATACTACCTAA	  
	  
RSV	   A2	   strain	   M2-­‐1	   amino	   acid	   sequence	   and	   secondary	   structure	  
alignment	  	  MSRRNPCKFEIRGHCLNGKRCHFSHNYFEWPPHALLVRQNFMLNRILKSMDKSIDTLSEISGAAELDRTEEYALGVVGVLESYIGSINNITKQSACVAMSKLLTELNSDDIKKLRDNEELNSPKIRVYNTVISYIESNRKNNKQTIHLLKRLPADVLKKTIKNTLDIHKSITINNPKESTVSDTNDHAKNNDTT	  	  
